Scientific Program Committee
Scientific Program Committee Scientific Program Committee
CR I 2OO8 15th Conference on Retroviruses and Opportunistic p Infections Pocket Program February 25 -28, 2007 Los Angeles Convention Center Los Angeles, California, US February 3-6, 2008 Hynes Convention Center Boston, MA, US
- Page 2: Scientifi c Program Committee Mario
- Page 6: vi General Information CROI 2008 20
- Page 10: x Conference Supporters CROI 2008 T
- Page 14: Sunday February 3 Sessions Session
- Page 18: Monday February 4 Sessions Session
- Page 22: Monday February 4 Sessions Session
- Page 26: Monday February 4 Sessions Session
- Page 30: Monday February 4 Sessions Session
- Page 34: Tuesday February 5 Sessions Session
- Page 38: Tuesday February 5 Sessions Session
- Page 42: Tuesday February 5 Sessions Session
- Page 46: Tuesday February 5 Sessions Session
- Page 50: Wednesday February 6 Sessions Sessi
CR I<br />
2OO8<br />
15th Conference on Retroviruses<br />
and Opportunistic p<br />
Infections<br />
Pocket<br />
<strong>Program</strong><br />
February 25 -28, 2007<br />
Los Angeles Convention Center<br />
Los Angeles, California, US<br />
February 3-6, 2008<br />
Hynes Convention Center<br />
Boston, MA, US
Scientifi c <strong>Program</strong> <strong>Committee</strong><br />
Mario Stevenson, PhD, Chair<br />
Univ of Massachusetts Med Sch,<br />
Worcester, US<br />
John W Mellors, MD, Vice Chair<br />
Univ of Pittsburgh, PA, US<br />
Elaine J Abrams, MD<br />
Columbia Univ, Mailman Sch of Publ<br />
Hlth, New York, NY, US<br />
Constance A Benson, MD<br />
Univ of California, San Diego Antiviral<br />
Res Ctr, US<br />
Susan P Buchbinder, MD<br />
San Francisco Dept of Publ Hlth, CA, US<br />
Dennis R Burton, PhD<br />
The Scripps Res Inst, La Jolla, CA, US<br />
Andrew Carr, MD<br />
St Vincent’s Hosp, Sydney, Australia<br />
Ellen G Chadwick, MD<br />
Northwestern Univ, Feinberg Sch of<br />
Med, Chicago, IL, US<br />
Richard E Chaisson, MD<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
John M Coffin, PhD<br />
Tufts Univ, Boston, MA, US<br />
Judith S Currier, MD, MSc<br />
Univ of California, Los Angeles, US<br />
Kevin M De Cock, MD<br />
World Hlth Org, Geneva, Switzerland<br />
Wafaa El-Sadr, MD, MPH<br />
Columbia Univ, Harlem Hosp Ctr, New<br />
York, NY, US<br />
Courtney V Fletcher, PharmD<br />
Univ of Nebraska Med Ctr, Omaha, US<br />
Dana H Gabuzda, MD<br />
Dana-Farber Cancer Inst, Boston, MA,<br />
US<br />
Francisco Gonzalez-Scarano, MD<br />
Univ of Pennsylvania, Philadelphia, US<br />
Community Liaison Subcommittee<br />
Beatrice H Hahn, MD<br />
Univ of Alabama at Birmingham, US<br />
James G Hakim, MBChB<br />
Univ of Zimbabwe Coll of Hlth Sci,<br />
Harare<br />
Scott M Hammer, MD<br />
Columbia Univ, Coll of Physicians &<br />
Surgeons, New York, NY, US<br />
Sharon L Hillier, PhD<br />
Univ of Pittsburgh, Magee-Womens<br />
Res Inst, PA, US<br />
David D Ho, MD<br />
Aaron Diamond AIDS Res Ctr, The<br />
Rockefeller Univ, New York, NY, US<br />
Harold W Jaffe, MD<br />
Univ of Oxford, UK<br />
Richard A Koup, MD<br />
Vaccine Res Ctr, NIAID, NIH,<br />
Bethesda, MD, US<br />
Nathaniel R Landau, PhD<br />
New York Univ Sch of Med, NY, US<br />
Norman L Letvin, MD<br />
Beth Israel Deaconess Med Ctr,<br />
Boston, MA, US<br />
Michael H Malim, DPhil<br />
King’s Coll London Sch of Med, UK<br />
Julio S G Montaner, MD<br />
St Paul’s Hosp and Univ of British<br />
Columbia, Vancouver, Canada<br />
Douglas D Richman, MD<br />
Univ of California, San Diego, US<br />
Robert T Schooley, MD<br />
Univ of California, San Diego, US<br />
Melissa A Sordyl, MBA<br />
Conference Secretariat, Alexandria,<br />
VA, US<br />
Amalio Telenti, MD, PhD<br />
Univ of Lausanne, Switzerland<br />
David Thomas, MD<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
Michael Marco, MPH<br />
Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, New York, NY, US<br />
Lina Sheth, MPH<br />
Asian & Pacific Islander Wellness Ctr, San Francisco, CA, US<br />
Nelson R Vergel, MBA<br />
Res Access Network, Houston, TX, US<br />
CROI Message Center<br />
617-954-2594<br />
3rd Level<br />
General Sessions Balcony<br />
Breakout Rooms Ballroom A<br />
Ballroom B/C<br />
Balcony<br />
302-304<br />
311<br />
312<br />
Speaker Services Room 300<br />
2 nd Level<br />
General Sessions Auditorium<br />
Breakout Room Auditorium<br />
Media Center 207<br />
CyberCafé Hall C<br />
Posters 200-504 Hall D<br />
Plaza Level<br />
Registration Main Lobby<br />
Message Center Main Lobby<br />
First Aid Main Lobby<br />
Computer Lab/ 100<br />
Poster Drop-Off<br />
Meeting Headquarters 102<br />
Coat Check 107<br />
Posters 505-773 Hall A<br />
Posters 774-1084 Hall B<br />
300<br />
Speaker<br />
Services<br />
100<br />
Computer<br />
Lab<br />
Dining<br />
Lounge<br />
The Hynes Convention Center<br />
900 Boylston St, Boston, MA 02115 • 617-954-2000<br />
Balcony<br />
Balcony<br />
Auditorium<br />
Message Center<br />
Main<br />
Lobby<br />
Registration<br />
Balcony<br />
Boylston Street<br />
Entrance<br />
First<br />
Aid<br />
Ballroom B/C<br />
Ballroom A<br />
302-304 312<br />
207<br />
Media Ctr<br />
Hall A<br />
Posters 505-773<br />
107<br />
Coat<br />
Check<br />
Hall C<br />
102<br />
Headquarters<br />
3 rd LEVEL<br />
208<br />
Press Conf<br />
2 nd LEVEL<br />
Entrance from Prudential Center<br />
and Copley Place Mall<br />
PLAZA LEVEL<br />
311<br />
Hall D<br />
Posters 200-504<br />
Hall B<br />
Posters 774-1084
iv<br />
General Information CROI 2008 2007<br />
INTRODUCTION<br />
The 15 th Conference on Retroviruses and Opportunistic Infections<br />
(CROI) is a research meeting created to provide a forum for basic<br />
scientists, clinical investigators, and global health researchers to present,<br />
discuss, and critique their investigations into the epidemiology and<br />
biology of human retroviruses and the diseases they produce with the<br />
ultimate goal of translating laboratory and clinical research into progress<br />
against the AIDS epidemic.<br />
To support the goals of the meeting and the preferences of the<br />
scientific community the conference serves, the <strong>Scientific</strong> <strong>Program</strong><br />
<strong>Committee</strong> has limited registration to researchers actively participating<br />
as investigators in basic science or clinical studies of retroviral diseases<br />
and their complications and clinician-teachers (full-time academic faculty<br />
members responsible for HIV/AIDS training and research programs).<br />
Preference will be accorded to doctoral and professional degree level<br />
researchers/clinicians. In addition, a limited number of slots have<br />
been reserved for press, AIDS treatment and prevention community<br />
educators, and senior clinical development personnel from industry who<br />
have product development planning responsibilities.<br />
At the conclusion of CROI 2008, attendees will again be polled<br />
to determine their programmatic and logistical preferences for future<br />
conferences. The CME Worksheet and/or Conference Evaluation<br />
should be completed (online at www.retroconference.org) no later than<br />
March 6, 2008. The <strong>Scientific</strong> <strong>Program</strong> <strong>Committee</strong> welcomes your<br />
opinions on how to continue to improve the conference. The committee<br />
will use the survey results to determine the venue and policies for future<br />
meetings, so your feedback is important.<br />
ABBREVIATIONS AND ICONS USED IN THE PROGRAM<br />
International Scholarship Awardee<br />
(a listing appears in the <strong>Program</strong> & Abstracts book)<br />
Young Investigator Awardee<br />
(a listing appears in the <strong>Program</strong> & Abstracts book)<br />
LB Late Breaker Abstract Presentation<br />
CME<br />
Workshop Oral Abstracts<br />
Plenary Poster Discussion<br />
Symposium Poster Abstracts<br />
Session will be Webcast<br />
Session will be Podcast<br />
Session is eligible for CME credit<br />
AMERICANS WITH DISABILITIES ACT<br />
Each participating hotel is in compliance to some degree with the<br />
Americans with Disabilities Act. Special services (e.g., wheelchairaccessible<br />
transportation and sign interpreters for the hearing impaired)<br />
are available if requested in advance. Should you require assistance on<br />
site, please visit the Headquarters Office located on the Plaza Level in<br />
Room 102.<br />
BADGES<br />
All registered meeting attendees, after showing photo identification, will<br />
be issued a meeting badge when they pick up their registration materials<br />
onsite and will be required to wear their badge at all official functions.<br />
Due to enhanced security measures, attendees will need to present<br />
their badges for admittance into the convention center at all times. In<br />
the event of a lost badge, the attendee will be required to pay another<br />
registration fee, in order for their badge to be reissued.<br />
CROI 2008 2007 General Information<br />
CHILD CARE<br />
Due to the professional nature of this meeting, children are not allowed<br />
in sessions, poster halls, or the Welcome Reception, so please plan<br />
accordingly. Child care arrangements can usually be made through<br />
the hotel concierge. Alternatively, the Boston Convention and<br />
Visitors Bureau has suggested the daycare center Parents in a Pinch<br />
(617-739-5437 phone).<br />
CONFERENCE COURTESIES<br />
In consideration of all meeting attendees:<br />
• Make sure all cell phones and pagers are silent (in the off position or<br />
in vibrate mode) in session rooms; kindly step out of the room prior to<br />
answering or initiating a cell phone call.<br />
• Refrain from photography in sessions and the poster hall (as a<br />
reminder, all sessions will be available online).<br />
• In keeping with the scientific nature of the conference, and to ensure<br />
a productive meeting experience, no disruptions and/or protests are<br />
allowed.<br />
• The Hynes Convention Center is a smoke-free facility. Individuals who<br />
wish to smoke should do so outside of the entrance to the building.<br />
CONTINUING MEDICAL EDUCATION (CME) CREDITS CME<br />
CROI 2008 has been planned and implemented in accordance with the<br />
Essential Areas and policies of the Accreditation Council for Continuing<br />
Medical Education through the joint sponsorship of the Conference on<br />
Retroviruses and Opportunistic Infections and University of California,<br />
San Diego School of Medicine. The University of California, San Diego<br />
School of Medicine is accredited by the ACCME to provide continuing<br />
medical education for physicians. The University of California, San<br />
Diego School of Medicine designates this educational activity for a<br />
maximum of 27 AMA PRA Category 1 Credits . Physicians should<br />
only claim credit commensurate with the extent of their participation<br />
in the activity.<br />
To be eligible for CME credit, registrants must complete the CME<br />
Worksheet and Conference Evaluation (online at www.retroconference.<br />
org) no later than March 6, 2008. Your badge number will be required to<br />
access the forms. CME certificates will be mailed after June 1, 2008.<br />
Session participants must disclose to the program audience any<br />
financial interest or other relationship with the manufacturer(s) of any<br />
commercial product(s) and/or provider(s) of commercial services related<br />
to the content of their presentations. The <strong>Program</strong> <strong>Committee</strong> does not<br />
view the existence of these interests or commitments as implying bias or<br />
decreasing the value of speakers’ participation in CME programming.<br />
For the list of authors who have nothing to disclose and those who<br />
have disclosed that either they or their departments have received<br />
support from the commercial parties, please see the CME Disclosures<br />
Addendum.<br />
California Assembly Bill 1195 requires continuing medical education<br />
activities with patient care components to include curriculum in the subjects of<br />
cultural and linguistic competency. It is the intent of the bill, which went into<br />
effect on July 1, 2006, to encourage physicians and surgeons, CME providers in<br />
the state of California, and the Accreditation Council for Continuing Medical<br />
Education to meet the cultural and linguistic concerns of a diverse patient<br />
population through appropriate professional development. The planners, speakers<br />
and authors of this CME activity have been encouraged to address issues relevant<br />
in the topic area. In addition, a variety of resources are available that address<br />
cultural and linguistic competency, some of which are included in your syllabus<br />
or handout materials. Additional resources and information about AB1195 can<br />
be found on our website at http://cme.ucsd.edu.<br />
v
vi<br />
General Information CROI 2008 2007 CROI 2008 2007 General Information<br />
MEALS<br />
Complimentary continental breakfast and morning coffee breaks will<br />
be available to conference registrants in Hall C (to the rear of the<br />
auditorium overflow seating on the 2 nd Level).<br />
Complimentary afternoon refreshments will be available to conference<br />
registrants in Poster Halls A and B (Plaza Level) and Poster Hall D<br />
(2 nd Level).<br />
Attendees are on their own for lunch during the hours of 12 noon to<br />
1 pm each day. Below is a list of food service options located in the<br />
Convention Center or within a short walking distance.<br />
At the Convention Center<br />
Coffee House and Cafe (Plaza Level across from Registration):<br />
In Copley Plaza and Prudential Center<br />
• Au Bon Pain<br />
• California Pizza Kitchen<br />
• Legal Sea Foods<br />
• PF Chang’s China Bistro<br />
• The Cheesecake Factory<br />
• The Terrace Food Court includes Gourmet India, Boston Chowda,<br />
Panda Express, Pizzeria Regina, Sakkio Japan, Qdoba Mexican<br />
Grill, and more<br />
WEBCASTS AND PODCASTS<br />
www.retroconference.org<br />
Plenaries, symposia, scientific overviews, and oral abstract sessions will<br />
be Webcast and Podcast. In addition, electronic versions of abstracts and<br />
posters from CROI 2008 as well as Webcasts, abstracts, and posters from<br />
previous meetings (CROI 1994-2007) will be available online.<br />
WELCOME RECEPTION<br />
Sunday, February 3, 6-8 pm, Halls C and D<br />
A Welcome Reception will immediately follow the Opening Plenaries.<br />
There will be large screens available for football fans to enjoy the Super<br />
Bowl while socializing with colleagues.<br />
WI-FI ACCESS<br />
CROI will be offering complimentary wireless connectivity within the<br />
Hynes Convention Center. Coverage in the facility includes CROI<br />
general session and breakout rooms, poster halls, registration area, and<br />
CyberCafé. No additional equipment is required beyond the wireless<br />
access card already installed in a client device (Wi-Fi enabled laptop,<br />
PDA, or telephone).<br />
Offices<br />
& Services<br />
Boston Information,<br />
Restaurant<br />
Reservations and<br />
Pre-/Post-<br />
Conference<br />
Activities<br />
617-954-2597<br />
Coat & Baggage<br />
Check<br />
Computer Lab &<br />
Poster Drop-off<br />
617-954-2611<br />
Location Hours of Operation Information<br />
Main Lobby<br />
Plaza Level<br />
107<br />
Plaza Level<br />
100<br />
Plaza Level<br />
CyberCafé Hall C<br />
2 nd Level<br />
Media Center<br />
617-954-2604<br />
Meeting<br />
Headquarters<br />
617-954-2599<br />
Message Center<br />
617-954-2594<br />
Registration &<br />
Housing<br />
617-954-2595<br />
Speaker Services<br />
617-954-2610<br />
207<br />
2 nd Level<br />
102<br />
Plaza Level<br />
Main Lobby<br />
Plaza Level<br />
Main Lobby<br />
Plaza Level<br />
300<br />
3 rd Level<br />
Saturday 12 n-5 pm<br />
Sunday 9 am-7 pm<br />
Monday 9 am-7 pm<br />
Tuesday 9 am-7 pm<br />
Wednesday 9 am-7 pm<br />
Sunday 7 am-8:30 pm<br />
Monday 7 am-7:15 pm<br />
Tuesday 7 am-7:15 pm<br />
Wednesday 7 am-6:30 pm<br />
Saturday 12 n-5 pm<br />
Sunday 7-9 am, 1-6 pm<br />
Monday 7 am-6 pm<br />
Tuesday 8 am-6 pm<br />
Wednesday 8 am-6 pm<br />
Saturday 12 n-5 pm<br />
Sunday 7 am-8 pm<br />
Monday 7 am-7 pm<br />
Tuesday 7 am-7 pm<br />
Wednesday 7 am-7 pm<br />
Sunday 8 am-8 pm<br />
Monday 8 am-6:30 pm<br />
Tuesday 8 am-6:30 pm<br />
Wednesday 8 am-6:30 pm<br />
Saturday 12 n-5 pm<br />
Sunday 7 am-6 pm<br />
Monday 7 am-6 pm<br />
Tuesday 8 am-6 pm<br />
Wednesday 8 am-6 pm<br />
Saturday 12 n-5 pm<br />
Sunday 7 am-6 pm<br />
Monday 7 am-6 pm<br />
Tuesday 8 am-6 pm<br />
Wednesday 8 am-6 pm<br />
Saturday 12 n-5 pm<br />
Sunday 7 am-6 pm<br />
Monday 7 am-6 pm<br />
Tuesday 8 am-6 pm<br />
Wednesday 8 am-6 pm<br />
Saturday 12 n-5 pm<br />
Sunday 8 am-6 pm<br />
Monday 8 am-6 pm<br />
Tuesday 8 am-6 pm<br />
Wednesday 8 am-5 pm<br />
For maps, information on local<br />
attractions, restaurant<br />
reservations, and to make<br />
reservations for tours and other<br />
Boston recreational activities,<br />
visit the Boston Convention and<br />
Visitors Bureau kiosk.<br />
Coat & Baggage Check service is<br />
complimentary.<br />
Computers are available for<br />
attendees to view webcasts,<br />
search the abstracts and posters,<br />
and check email. This location is<br />
also where electronic versions of<br />
posters may be submitted for<br />
placement on the CROI web site.<br />
The Host Genomics Hands-on<br />
Computer Workshop is<br />
scheduled on Sunday 10 am-1<br />
pm.<br />
Computers will be available for<br />
attendees to view webcasts,<br />
search the abstracts and<br />
posters, and check email. In<br />
addition, Wi-Fi service will be<br />
available throughout the<br />
convention center.<br />
Pre-registered journalists<br />
should pick up press kits and<br />
convene for daily press<br />
conferences in the Media<br />
Center. There is no on-site<br />
press registration.<br />
To contact staff and <strong>Program</strong><br />
<strong>Committee</strong> members or for lostand-found<br />
items, please go to<br />
the Meeting Headquarters.<br />
Voice and text messages may<br />
be left for attendees at the<br />
Message Center.<br />
Pre-registered attendees<br />
should pick up conference<br />
materials including badges,<br />
<strong>Program</strong> & Abstracts, and<br />
Addenda during registration<br />
hours. There is no on-site<br />
registration.<br />
Speakers should bring their<br />
presentation (in MS Power Point<br />
only) to the Speaker Services<br />
Room on a disk or drive at least 4<br />
hours prior to presentation. CROI<br />
supports both MacIntosh and PC<br />
platforms. The Speaker Services<br />
Room will be equipped with<br />
workstations, and an art director<br />
and AV technicians will be<br />
available to assist speakers.<br />
vii
viii<br />
Hotel Information CROI 2007 2008<br />
Map<br />
Key<br />
Hotels<br />
1 Boston Back Bay Hilton<br />
40 Dalton St<br />
Boston, MA 02115<br />
617-236-1100<br />
2 Boston Marriott Copley Place<br />
110 Huntington Ave<br />
Boston, MA 02116<br />
617-236-5800<br />
3 Boston Park Plaza<br />
50 Park Plaza at Arlington St<br />
Boston, MA 02116<br />
617-426-2000<br />
4 Fairmont Copley Place<br />
138 St James Ave<br />
Boston, MA 02116<br />
617-267-5300<br />
5 Sheraton Boston<br />
39 Dalton St<br />
Boston, MA 02199<br />
617-236-2000<br />
6 Taj Boston<br />
15 Arlington St<br />
Boston, MA 02116<br />
617-536-5700<br />
Newbury Street<br />
7 Westin Copley Place<br />
10 Huntington Ave<br />
Boston, MA 02116<br />
617-262-9600<br />
Beacon Street<br />
Hynes Convention<br />
Center 2<br />
1<br />
5<br />
Back<br />
Bay<br />
Commonwealth Ave<br />
Boyston Street<br />
Huntington Ave<br />
7<br />
Clarendon Street<br />
4<br />
Back Bay<br />
South End<br />
Columbus Ave<br />
St James Ave<br />
Distance<br />
to Convention Center<br />
1 block<br />
cross the street into the Sheraton, which<br />
is connected to the convention center<br />
3 minute walk<br />
2 blocks<br />
connected via enclosed sky bridge<br />
5 minute walk<br />
8 blocks<br />
4 blocks to the Copley Square Mall,<br />
the remainder inside mall<br />
15 minute walk<br />
Or take the T green line, 2nd stop<br />
(T vouchers available to hotel guests)<br />
3 blocks<br />
cross the street to the Westin,<br />
through the enclosed sky bridge and<br />
the remainder inside mall<br />
9 minute walk<br />
connected to the convention center<br />
1 minute walk<br />
7 blocks<br />
4½ blocks to the Copley Square Mall,<br />
the remainder inside the mall<br />
15 minute walk<br />
Or take the T green line, 2 nd stop<br />
(T vouchers available to hotel guests)<br />
3 blocks<br />
connected via enclosed sky bridge<br />
8 minute walk<br />
6<br />
Arlington<br />
Massachusetts Turnpike<br />
3<br />
Arlington Street<br />
Rates*<br />
*scholarship<br />
rates are half off<br />
the general rate<br />
$148<br />
$168<br />
$114<br />
$168<br />
$153<br />
$188<br />
$168<br />
CROI 2008 2007 Travel and Ground Transportation Information<br />
TRAVEL AND GROUND TRANSPORTATION<br />
Boston Logan International Airport to downtown Boston is<br />
approximately 4 miles and can take up to 30 minutes by car depending<br />
on traffic.<br />
Taxi Service<br />
Available 24 hours a day and service to all of New England. All areas<br />
within 12 mile radius of downtown Boston are charged a metered rate.<br />
Taxi fare from the airport is approximately $25-$30. Taxi fare from the<br />
train station is approximately $15–$20.<br />
Shuttle Service<br />
Discounts have been arranged with Star Shuttle (from Boston Logan to<br />
downtown) at a rate of $10 one way, $20 round trip (regular $15/$25) by<br />
mentioning convention code 703 to the shuttle driver.<br />
• Toll-free number for Star Shuttle is 877-970-STAR (7827).<br />
• Option of pre-paying for shuttle service at http://www.<br />
starshuttleboston.com/.com in the reservation option by entering the<br />
convention code 703.<br />
Amtrak<br />
Discounts have been arranged with Amtrak and are available from<br />
January 3 through February 9. For reservations, call Amtrak<br />
at 800-872-7245 or contact your local travel agent and refer to<br />
convention fare code X69R-93. This discount cannot be accessed via<br />
the internet.<br />
Back Bay Station<br />
145 Dartmouth St<br />
Boston, MA 02116<br />
This station is located in downtown Boston and can be accessed<br />
through the Copley Place Mall via the Prudential Center.<br />
Amtrak South Station<br />
Atlantic Ave & Summer St<br />
Boston, MA 02110<br />
This station is approximately 2–3 miles from downtown Boston<br />
and can take up to 20 minutes by car depending on traffic.<br />
MBTA (Mass Bay Transportation Authority) aka the “T”<br />
Runs daily service on buses, trains, and trolleys throughout Boston.<br />
T-stations can be identified by a black “T” on a white circular sign.<br />
Charlie cards can be bought at booths at each station. Purchase 1 and 7<br />
Day Passes at the Visitor Information Center on Boston Common. For<br />
transport from Logan Airport to Hynes Convention Center or hotels,<br />
there are 3 options:<br />
• Closest stop to the Taj, Marriott, Westin, and Fairmont - Take the<br />
Blue Line to State Street, transfer to the Orange Line and get off at<br />
Back Bay.<br />
• Closest stop to the Hilton, Sheraton and Convention Center - Take<br />
the Blue Line to Government Center, transfer to the Green Line and<br />
get off at Hynes Convention Center.<br />
• Closest stop to the Park Plaza - Take the Blue Line to Government<br />
Center, transfer to the Green Line and get off at Arlington.<br />
The cost is $2.00 one way.<br />
Hertz<br />
Discounts on car rental have been arranged with Hertz and are<br />
available from January 28 through February 13. For reservations, call<br />
Hertz in the US and Canada at 800-654-2240 or outside these areas at<br />
405-749-4434. You or your travel agent may make your reservations by<br />
phone or on line at hertz.com. To receive the discounted rates listed on<br />
the CROI website, refer to CV #04040002.<br />
ix
x<br />
Conference Supporters CROI 2008<br />
The 15 th Conference on Retroviruses and Opportunistic Infections<br />
acknowledges and appreciates the support of the companies listed<br />
below. Their support is integral to the success of the CROI scholarship<br />
programs.
CROI 2008 Session 1<br />
j Sunday, 9 am-1:40 pm; Room 302-304<br />
Session 1–Workshop CME<br />
<strong>Program</strong> <strong>Committee</strong> Workshop for New<br />
Investigators and Trainees<br />
The purpose of this workshop is to educate and engage new investigators and<br />
trainees, to spark interest in the field, to provide opportunities for interaction<br />
among trainees and faculty, and to orient trainees to the science being<br />
presented at the conference.<br />
Presentations during the <strong>Program</strong> <strong>Committee</strong> Workshop will be geared<br />
toward new trainees (e.g., graduate students, postdoctoral fellows, and<br />
physician fellows) and new investigators (both international and domestic)<br />
who have been conducting active research in the field for less than 3 years.<br />
The lunch presentation is limited to awardees from the young investigator,<br />
international scholar, and community educator programs. Other CROI<br />
registrants may attend the workshop (on a space available basis). No preregistration<br />
is required.<br />
The workshop format is designed to be interactive. Each presenter will<br />
provide a state-of-the-art summary of a research area being covered at<br />
the conference and then outline the top 3-5 research issues in their field.<br />
The floor will then be open for questions from the audience and panel<br />
discussion.<br />
9-9:10 am<br />
Opening Comments<br />
John Mellors<br />
Univ of Pittsburgh, PA, US<br />
9:10-9:40 am<br />
1a<br />
Cellular and Viral Factors in HIV-host<br />
Cell Interplay<br />
Mario Stevenson<br />
Univ of Massachusetts Med Sch, Worcester, US<br />
9:40-10:10 am<br />
1b<br />
New Insights into Immunopathogenesis<br />
and Vaccine Design<br />
Rick Koup<br />
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US<br />
10:30-11 am<br />
1c<br />
Genomics–a Door to a New Biology<br />
Amalio Telenti<br />
Univ of Lausanne, Switzerland<br />
11-11:30 am<br />
1d<br />
Pharmacologic Contributions to Therapeutic<br />
Success with Antiretroviral Agents<br />
Courtney Fletcher<br />
Univ of Nebraska Med Ctr, Omaha, US<br />
11:30 am-12:30 pm (Ballroom A)<br />
1e<br />
Special Luncheon for Young Investigators,<br />
International Scholars and Community Educators<br />
The Early AIDS Epidemic in the US:<br />
Views from Atlanta and Hollywood<br />
Harold Jaffe<br />
Univ of Oxford, UK<br />
12:30-1 pm<br />
1f<br />
The State of ART—Current and Future<br />
Constance Benson<br />
Univ of California, San Diego, US<br />
1-1:30 pm<br />
1g<br />
HIV/AIDS–Where Is It Going and<br />
What Does It Mean?<br />
Kevin De Cock<br />
World Hlth Org, Geneva, Switzerland<br />
1:30-1:40 pm<br />
Closing Comments<br />
Scott Hammer<br />
Columbia Univ Coll of Physicians and Surgeons, New York, NY, US<br />
<strong>Program</strong> 1<br />
Sunday<br />
February 3 Sessions
Sunday<br />
February 3 Sessions<br />
Session 2 CROI 2008<br />
k Sunday, 10 am-1 pm; Room 100 (Computer Lab)<br />
Session 2–Workshop<br />
Host Genomics Hands-on Computer Workshop<br />
The purpose of this workshop is to engage investigators in the emerging field<br />
of host genome analysis (candidate gene and genome-wide analyses). This<br />
workshop can accommodate 30 participants on a first-come, first-served basis.<br />
No pre-registration is required.<br />
The workshop will be a hands-on, interactive short course, with an<br />
introduction to some of the search and analysis tools the host genome<br />
databases provide. Participants will explore ways the database tools can<br />
facilitate a study by working through a hypothetical research problem. The<br />
faculty will answer questions about how the database might be usefully<br />
applied to the work of those attending the workshop. The course will include<br />
a series of short presentations that will introduce several database tools.<br />
Attendees will each have a computer terminal available, and there will be time<br />
for working through example problems and queries.<br />
Convener:<br />
Amalio Telenti<br />
Univ of Lausanne, Switzerland<br />
I Introduction<br />
Defining Phenotypes for Host Genetic and<br />
Genomic Studies<br />
Jacques Fellay<br />
Duke Univ, Durham, NC, US<br />
II PLINK<br />
Samuel Deutsch<br />
Univ of Geneva Med Sch, Switzerland<br />
III WGAviewer<br />
IV Covariantes and Strategies for Stratification<br />
Control<br />
Dongliang Ge<br />
Duke Univ, Durham, NC, US<br />
2 15th Conference on Retroviruses and Opportunistic Infections<br />
CME<br />
c Sunday, 2-4 pm; Auditorium<br />
Session 3–Symposium CME<br />
Scale-up of HIV Prevention and Treatment in the<br />
Developing World<br />
Conveners:<br />
James Hakim, Univ of Zimbabwe,<br />
Coll of Hlth Sci, Harare<br />
Marie Laga, Inst of Tropical Med, Antwerp,<br />
Belgium<br />
2<br />
Implementing Circumcision for HIV Prevention in<br />
Sub-Saharan Africa<br />
Bertran Auvert* 1 , E Marseille 2 , and J Kahn 2<br />
1 INSERM U687, Univ of Versailles, and Hosp Ambroise Pare,<br />
France and 2 Philip R Lee Inst for Hlth Policy Studies, Univ of<br />
California, San Francisco, US<br />
3<br />
Scale-up of HIV Testing in Africa<br />
Elizabeth Marum<br />
Global AIDS Prgm, CDC, Atlanta, GA, US<br />
4<br />
ART in Africa: Beyond the Roll-out<br />
Gary Maartens<br />
Univ of Cape Town, South Africa<br />
5<br />
Prevention of Cervical Cancer in the HAART Era<br />
Silvia Franceschi<br />
Intl Agency for Res on Cancer, Lyon, France<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
the prevention and treatment of HIV infection and its complications in the<br />
developing world. It is assumed participants are familiar with the magnitude<br />
and basic epidemiology of HIV/AIDS in Sub-Saharan Africa. At the<br />
completion of the session, participants will understand the roles of testing and<br />
circumcision in HIV prevention, strategies for prevention of cervical cancer,<br />
and the challenges of implementing HIV treatment in the developing world.
CROI 2008 Session 4<br />
e Sunday, 4-6 pm; Auditorium<br />
CME<br />
Session 4–Opening Plenaries<br />
Greetings from the <strong>Program</strong> <strong>Committee</strong><br />
Mario Stevenson<br />
Univ of Massachusetts Med Sch, Worcester, US<br />
13th Bernard Fields Memorial Lecture<br />
The Bernard Fields Memorial Lectureship recognizes a scientist whose body<br />
of work has significantly contributed to the understanding of virology and viral<br />
pathogenesis as exemplified by the career of Bernard Fields.<br />
6<br />
Contending with Evolution and Escape by HIV<br />
Douglas Richman<br />
VA San Diego Hlthcare System and Univ of California, San<br />
Diego, US<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
the pathogenesis, treatment, and prevention of HIV disease. It is assumed<br />
participants are familiar with the basic principles and state-of-the-art of<br />
pathogenesis, treatment, and prevention. At the completion of the session,<br />
participants will be knowledgeable about HIV evolution and escape<br />
with regard to the selective pressures of antiretroviral therapy, anatomic<br />
compartmentalization, and the neutralizing antibody response.<br />
2nd N’Galy-Mann Lecture<br />
The N’Galy-Mann lectureship was established in 2006 to recognize<br />
an individual researcher or team who has made important and timely<br />
contributions in epidemiology and clinical research as exemplified by the<br />
collaborative careers of Bosenge N’Galy and Jonathan Mann. The 2008<br />
N’Galy-Mann Lectureship has been awarded to David Serwadda, Nelson<br />
Sewankambo, Ronald Gray, and Maria Wawer from The Rakai Health<br />
Sciences <strong>Program</strong> for their seminal research on HIV transmission.<br />
7<br />
A Population-based Approach to Understanding a Very Clever<br />
Virus: A Brief History of HIV Research and Services in the Rakai<br />
Health Sciences <strong>Program</strong>, Uganda<br />
David Serwadda*<br />
Makerere Univ Sch of Publ Hlth, Kampala,<br />
Uganda<br />
Nelson Sewankambo<br />
Makerere Univ Sch of Med, Kampala,<br />
Uganda<br />
Maria Wawer*<br />
Johns Hopkins Univ Bloomberg Sch of Publ<br />
Hlth, Baltimore, MD, US<br />
Ron Gray<br />
Johns Hopkins Univ Bloomberg Sch of Publ<br />
Hlth, Baltimore, MD, US<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
HIV epidemiology, prevention, and care. It is assumed that participants are<br />
familiar with basic HIV biology and epidemiology. At the completion of the<br />
session, participants will be knowledgeable about the value of longitudinal<br />
population-based research in elucidating HIV and human interactions and<br />
how this serves in the development and testing of HIV prevention and care<br />
strategies.<br />
<strong>Program</strong> 3<br />
Sunday<br />
February 3 Sessions
Monday<br />
February 4 Sessions<br />
Session 5 CROI 2008<br />
i Monday, 8:30-9 am; Auditorium<br />
Session 5–Plenary CME<br />
Morbidity and Mortality in the HAART Era<br />
8<br />
Andrew Phillips<br />
Royal Free and Univ Coll Med Sch, Univ Coll London, UK<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
gaining greater appreciation of the extent of continued morbidity and mortality<br />
occurring during the HAART era, the surprisingly broad spectrum of clinical<br />
disease that might be influenced by HIV infection, and measures that might be<br />
needed to further reduce morbidity and mortality. It is assumed participants in<br />
this session are familiar with basic concepts of HIV progression, such as CD4<br />
count decline and the link between CD4 count level and risk of AIDS, and the<br />
effects of HAART in suppressing viral load and raising the CD4 count, leading<br />
to a reduction in AIDS risk. Participants are further assumed to be broadly<br />
familiar with current guidelines for treating individuals with HIV infection<br />
in developed countries. At the completion of the session, participants should<br />
have greater knowledge of the 3 areas outlined above.<br />
j Monday, 9-9:30 am; Auditorium<br />
Session 6–Plenary CME<br />
Searching the Genome for Determinants<br />
of Response to HIV<br />
9<br />
David Goldstein<br />
Duke Univ, Durham, NC, US<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
how genome-wide association is being applied to study HIV host genetics,<br />
and what has been found with this approach. It is assumed that participants are<br />
familiar with basic genetics, but not with the details of statistical genomics. At<br />
the completion of the session, participants will be knowledgeable about how<br />
genome-wide association studies work, how they are being applied in HIV<br />
genetics, and what new studies are being carried out as part of the CHAVI<br />
program.<br />
4 15th Conference on Retroviruses and Opportunistic Infections<br />
k Monday, 10 -11:45 am; Room 302-304<br />
CME<br />
Session 7–Oral Abstracts<br />
Epidemiology of SIV/HIV Infection and<br />
AIDS-related Malignancies<br />
Moderators:<br />
Marie-Laure Chaix, Hosp Necker, Paris, France<br />
Harold Jaffe, Univ of Oxford, UK<br />
10:00 10 Geographic Distribution of SIV gor in Wild-living<br />
Gorillas from Cameroon<br />
Cecile Neel* 1,2 , F Van Heuverswyn 1 , E Mpoudi Ngole 2 , Y Li 3 ,<br />
B Keele 3 , F Liegeois 1 , C Butel 1 , E Delaporte 1 , B Hahn 3 , and<br />
M Peeters 1<br />
1 UMR145, Inst for Res and Devt, Univ of Montpellier 1, France;<br />
2 PRESICA, Yaounde, Cameroon; and 3 Univ of Alabama at<br />
Birmingham, US<br />
10:15 11 Diagnosis and Monitoring of HIV-1 Group O Infections<br />
in Cameroon<br />
Aurelia Vessiere* 1 , D Rousset 1 , M Leoz 2 , A Depatureaux 2 ,<br />
F Simon 3 , and JC Plantier 2<br />
1 Ctr Pasteur of Cameroon, Yaounde; 2 Hosp Charles Nicolle, Rouen,<br />
France; and 3 Hosp St Louis, Paris, France<br />
10:30 12 New and Old Complex Recombinant HIV-1 Strains<br />
Entering in France among Patients with Primary<br />
Infection in 2004 to 2006: The French ANRS CO06<br />
Primo Cohort Study<br />
P Frange1 , J Galimand1 , M Peeters2 , C Goujard3 , C Deveau4 ,<br />
V Avettand - Fenoel1 , F Souala5 , L Meyer4 , C Rouzioux1 , and<br />
Marie-Laure Chaix* 1<br />
1 2 Ctr Hosp Univ Necker, Paris, France; Inst for Res and Devt,<br />
Montpellier, France; 3Ctr Hosp Univ Bicetre, Le Kremlin-Bicetre,<br />
France; 4INSERM, Le Kremlin Bicetre, France; and 5Ctr Hosp Univ<br />
Pontchaillou, Rennes, France<br />
10:45 13 Recent Phylodynamics of the HIV Epidemic among<br />
MSM in the UK<br />
Gareth Hughes* 1 , A Leigh Brown1 , A Rambaut1 , S Lycett1 , F Lewis2 ,<br />
E Fearnhill3 , and UK Collaborative Group on HIV Drug Resistance<br />
1 2 Univ of Edinburgh, Scotland; Scottish Agricultural Coll, Inverness,<br />
UK; and 3Med Res Council Clinical Trials Unit, London, UK<br />
11:00 14 Changes Over Time in the Risk of Death following<br />
HIV Seroconversion Compared with Mortality in the<br />
General Population<br />
Kholoud Porter* 1 , O Hamouda2 , M Sannes3 , F Boufassa4 ,<br />
A Johnson5 , S Walker1 , and CASCADE Collaboration<br />
1 2 Med Res Council Clinical Trials Unit, London, UK; Robert Koch<br />
Inst, Germany; 3Ulleval Univ Hosp, Oslo, Norway; 4INSERM, Paris,<br />
France; and 5Univ Coll London, UK<br />
11:15 15 Immunodeficiency and Risk of AIDS-defining and Non-<br />
AIDS-defining Cancers: ANRS CO3 Aquitaine Cohort,<br />
1998 to 2006<br />
M Bruyand1,2 , R Thiebaut1,2,3,4 , S Lawson-Ayayi1,2 , P Joly3,4 ,<br />
A Sasco5 , JL Pellegrin2,4 , D Neau2,4 , P Morlat1,2,4 , G Chene1,2,4 ,<br />
Fabrice Bonnet* 1,2,4 , and Groupe d’Epidémiologie Clinique du SIDA<br />
en Aquitaine (GECSA)<br />
1 2 INSERM U593 and CIC-EC7, Bordeaux, France; Ctr Hosp Univ<br />
Bordeaux, France; 3INSERM U875, Bordeaux, France; 4Univ Victor<br />
Segalen, Bordeaux, France; and 5INSERM U897, Bordeaux, France<br />
11:30 16 Insufficient Virus Suppression during HAART Is a<br />
Strong Predictor for the Development of AIDS-related<br />
Lymphoma: German CLINSURV Cohort<br />
Alexander Zoufaly* 1 , HJ Stellbrink2 , M an der Heiden3 ,<br />
C Kollan3 , J van Lunzen1 , O Hamouda3 , and CLINSURV Study Group<br />
1 2 Univ Med Ctr Hamburg-Eppendorf, Germany; IPM Study Ctr,<br />
Hamburg, Germany; and 3Robert Koch Inst, Berlin, Germany
CROI 2008 Session 9<br />
k Monday, 10 am-12:15 pm; Ballroom A<br />
CME<br />
Session 8–Oral Abstracts<br />
Viral Pathogenesis and Immune Surveillance<br />
Moderators:<br />
Amitinder Kaur, New England Primate Res Ctr, Harvard Med Sch, Southborough,<br />
MA, US<br />
David Watkins, Univ of Wisconsin, Madison, US<br />
10:00 18 Patterns of CD8 + Immunodominance May Influence the<br />
Ability of Mamu-B*08 + Macaques to Naturally Control<br />
SIVmac239 Replication<br />
John Loffredo* 1 , A Bean1 , D Beal1 , E Leon1 , S Piaskowski1 ,<br />
S Musani2 , E Rakasz1 , N Wilson1 , D Allison2 , and D Watkins1 1Wisconsin Natl Primate Res Ctr, Univ of Wisconsin, Madison, US<br />
and 2Univ of Alabama at Birmingham, US<br />
10:15 19 CD20 + Cell Depletion Results in Abbreviated Cellmediated<br />
Immune Responses, Higher Viral Set-points and<br />
Shortened Survival in SIV-infected Pigtailed Macaques<br />
Lu-Ann Pozzi*, D Pauley, S Sato, H Knight, D Walsh,<br />
A Carville, W Johnson, S Westmoreland, and S O’Neil<br />
New England Primate Res Ctr, Harvard Med Sch, Southborough,<br />
MA, US<br />
10:30 20 Humoral Immune Responses Have Little Effect on<br />
Controlling Viremia during SIVagm Infection of African<br />
Green Monkeys<br />
Thaidra Gaufin* 1 , M Pattison1 , C Stoulig1 , R Gautam1 , M Barnes1 ,<br />
C Monjure1 , M Marx1 , D Montefiori2 , C Apetrei1 , and I Pandrea1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US and Duke Univ,<br />
Durham, NC, US<br />
10:45 21aLB Experimentally Induced Immune Activation in Natural<br />
Hosts of SIV Results in Significant Increases in Viral<br />
Replication<br />
Ivona Pandrea*, C Coleman, T Gaufin, R Gautam, M Pattison,<br />
C Monjure, A Lackner, and C Apetrei<br />
Tulane Natl Primate Res Ctr, Tulane Univ, Covington, LA, US<br />
11:00 21bLB Depletion of CD8 + T Cells Does Not Change the in vivo Life<br />
Span of Infected Cells during Pathogenic SIV Infection of<br />
Rhesus Macaques<br />
Nichole Klatt* 1,2 , E Shudo3 , A Ortiz1 , J Engram1 , S Gordon1,2 ,<br />
B Lawson2 , J Else2 , J Schmitz4 , A Perelson3 , and G Silvestri1 1 2 Univ of Pennsylvania, Philadelphia, US; Yerkes Natl Primate Res<br />
Ctr, Emory Univ, Atlanta, GA, US; 3Los Alamos Natl Lab, NM, US;<br />
and 4Beth Israel Deaconess Med Ctr, Boston, MA, US<br />
11:15 22 Functionality of HIV-1-specific CD8 + T Cells Is Dependent<br />
on Antigen Load and Sequence Diversification<br />
Hendrik Streeck* 1 , Z Brumme1 , M Anastario2 , K Cohen1 , J Jolin1 ,<br />
G Alter1 , A Meier1 , T Allen1 , B Walker1 , and M Altfeld1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med<br />
Sch, Boston, US and 2 Ctr for Disaster and Humanitarian Assistance<br />
Med, Univ of the Hlth Sci, Bethesda, MD, US<br />
11:30 23 Kinetics of Escape within HLA-restricted CTL Epitopes<br />
in the First Year of HIV Infection Is Consistent with<br />
Early Immunodominant CTL Response Patterns<br />
Zabrina Brumme* 1 , C Brumme1 , H Streeck1 , J Carlson2,3 ,<br />
M Markowitz4 , H Jessen5 , A Kelleher6 , M John7 , D Heckerman2 , and<br />
B Walker1,8 1 2 Partners AIDS Res Ctr, Boston, MA, US; Microsoft Res, Redmond<br />
WA, US; 3Univ of Washington, Seattle, US; 4Aaron Diamond AIDS<br />
Res Ctr, The Rockefeller Univ, New York, NY, US; 5Jessen-Praxis, Berlin, Germany; 6Univ of New South Wales, Sydney, Australia;<br />
7 8 Murdoch Univ, Perth, Australia; and Howard Hughes Med Inst,<br />
Chevy Chase, MD, US<br />
11:45 24 Intracellular Epitope Stability Contributes to HIV<br />
Epitope Hierarchy and Can Be Altered to Modulate<br />
Epitope Presentation<br />
E Lazaro1 , P Stamegna1 , D Heckerman2 , B Walker1,3 , and<br />
Sylvie Le Gall* 1,3<br />
1Massachusetts Gen Hosp, Harvard Med Sch, Boston, US;<br />
2 3 Microsoft Res, Seattle, WA, US; and Howard Hughes Med Inst,<br />
Chevy Chase, MD, US<br />
12:00 25 Mapping Escape Mutations Arising under HLArestricted<br />
CTL Selection Pressure in HIV-1 Gag:<br />
Correlations with Plasma Viral Load and CD4 Count in<br />
Untreated Chronic Infection<br />
Chanson Brumme* 1 , I Tao2 , S Szeto2 , Z Brumme1 , J Carlson3,4 ,<br />
N Frahm1 , R Hogg2,5 , B Walker1,6 , D Heckerman3 , and R Harrigan2,7 1 2 Partners AIDS Res Ctr, Boston, MA, US; BC Ctr for Excellence in<br />
HIV/AIDS, Vancouver, Canada; 3Microsoft Res, Redmond WA, US;<br />
4 5 Univ of Washington, Seattle, US; Simon Fraser Univ, Burnaby,<br />
Canada; 6Howard Hughes Med Inst, Chevy Chase, MD, US; and<br />
7Univ of British Columbia, Vancouver, Canada<br />
k Monday, 10 am-12 noon; Ballroom B/C<br />
CME<br />
Session 9–Oral Abstracts<br />
Prevention Strategies<br />
Moderators:<br />
Myron Cohen, Univ of North Carolina at Chapel Hill, US<br />
Jeanne Marrazzo, Univ of Washington, Harborview Med Ctr, Seattle, US<br />
10:00 26 Comprehensive Pre-clinical Assessment of Microbicide<br />
Safety Using in vitro and Murine Models<br />
Pedro Mesquita*, S Wilson, N Cheshenko, M Keller, B Galen,<br />
and B Herold<br />
Albert Einstein Coll of Med, Bronx, NY, US<br />
10:15 27LB Protective Effect of Vaginal Lactobacillus on Genital<br />
HIV-1 RNA Concentrations: Longitudinal Data from a<br />
US Cohort Study<br />
Jane Hitti* 1 , K Paul1 , K Agnew1 , R Gausman1 , D Lockhart1 , S Cohn2 ,<br />
A Luque2 , and R Coombs1 1 2 Univ of Washington, Seattle, US and Univ of Rochester, NY, US<br />
10:30 28LB Trial of Male Circumcision: Prevention of HSV-2 in Men<br />
and Vaginal Infections in Female Partners, Rakai, Uganda<br />
Aaron Tobian* 1 , D Serwadda2 , T Quinn1,3 , G Kigozi4 , S Reynolds1,3 ,<br />
F Makumbi4 , T Suntoke1 , S Watya5 , M Wawer1 , and R Gray1 1 2 Johns Hopkins Univ, Baltimore, MD, US; Makerere Univ Sch of<br />
Publ Hlth, Kampala, Uganda; 3NIAID, NIH, Bethesda, MD, US;<br />
4 5 Rakai Hlth Sci Prgm, Entebbe, Uganda; and Makerere Univ,<br />
Kampala, Uganda<br />
10:45 29 3-Year Follow-up of Sexual Behavior and HIV<br />
Transmission Risk of Persons Taking ART in Rural<br />
Uganda<br />
Rebecca Bunnell* 1 , J Ekwaru1 , R King1 , S Bechange1 , D Moore2 ,<br />
K Khana1 , W Were1 , A Coutinho3 , J Tappero1 , and J Mermin1 1 2 Global AIDS Prgm, CDC Uganda, Kampala; Univ of California,<br />
San Francisco, US; and 3AIDS Support Org, Kampala, Uganda<br />
11:00 30 Effect of a Novel Behavioral Intervention to Promote<br />
Condom Use among Female Sex Workers along Lagos,<br />
Nigeria–Cotonou, Benin International Border<br />
Olusegun Busari*, O Busari, G Oligbu, and HIV Study Group<br />
Federal Med Ctr, Ido-Ekiti, Nigeria<br />
11:15 31 Serosorting, but Not Seropositioning, Is Associated<br />
with Decreased Risk of HIV Seroconversion in the<br />
EXPLORE Study Cohort<br />
Susan Philip* 1 , D Donnell2 , X Yu2 , E Vittinghoff3 , and S Buchbinder1 1 2 San Francisco Dept of Publ Hlth, CA, US; Statistical Ctr for HIV/<br />
AIDS Res and Prevention, Seattle, WA, US; and 3Univ of California,<br />
San Francisco, US<br />
11:30 32LB HSV-2 Suppressive Therapy for Prevention of HIV<br />
Acquisition: Results of HPTN 039<br />
Connie Celum* 1 , A Wald1 , J Hughes1 , J Sanchez2 , S Reid3 ,<br />
S Delaney-Moretlwe4 , F Cowan5 , J Fuchs6 , B Koblin7 , L Corey8 , and<br />
HPTN 039<br />
1 2 3 Univ of Washington, Seattle, US; Impacta, Lima, Peru; Univ of<br />
Alabama at Birmingham, Ctr for Infectious Disease Res in Zambia,<br />
Lusaka; 4Univ of the Witwatersrand, Johannesburg, South Africa; 5Univ of California, San Francisco, US and Univ of Zimbabwe, Harare; 6San Francisco Dept of Publ Hlth, CA, US; 7New York Blood Ctr, New York,<br />
US; and 8Fred Hutchinson Cancer Res Ctr, Seattle, WA, US<br />
11:45 33LB Trial of Male Circumcision in HIV+ Men, Rakai,<br />
Uganda: Effects in HIV+ Men and in Women Partners<br />
Maria Wawer* 1 , G Kigozi2 , D Serwadda3 , F Makumbi3 , F Nalugoda2 ,<br />
S Watya4 , D Buwembo2 , V Ssempijja2 , L Moulton1 , and R Gray1 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD,<br />
US; 2Rakai Hlth Sci Prgm, Kalisizo, Uganda; 3Makerere Univ Sch of<br />
Publ Hlth, Kampala, Uganda; and 4Makerere Univ Faculty of Med,<br />
Kampala, Uganda<br />
<strong>Program</strong> 5<br />
Monday<br />
February 4 Sessions
Monday<br />
February 4 Sessions<br />
Session 10 CROI 2008<br />
k Monday, 10 am-12 noon; Auditorium<br />
CME<br />
Session 10–Oral Abstracts<br />
New Antiretrovirals and Clinical Trials<br />
Moderators:<br />
Constance Benson, Univ of California, San Diego, US<br />
Patrick Yeni, Hosp Bichat, Paris, France<br />
10:00 34 Structure of HIV-1 CA N in Complex with CAP-1, an<br />
Assembly Inhibitor<br />
Brian Kelly* 1 , S Kyere 2 , I Kinde 2 , C Tang 2 , B Howard 3 ,<br />
H Robinson 4 , W Sundquist 1 , M Summers 2 , and C Hill 1<br />
1 Univ of Utah, Salt Lake City, US; 2 Univ of Maryland, Baltimore,<br />
US; 3 Southern Utah Univ, Cedar City, US; and 4 Brookhaven Natl<br />
Lab, Upton, NY, US<br />
10:15 35 A Prospective, Randomized, Controlled, Open-label Trial<br />
Evaluating the Effect of Therapeutic Drug Monitoring<br />
and Protease Inhibitor Dose Escalation on Viral Load<br />
Responses in Antiretroviral-experienced, HIV-infected<br />
Patients with a Normalized Inhibitory Quotient<br />
Lisa Demeter* 1 , H Jiang2 , L Mukherjee2 , G Morse3 , R DiFrancesco3 ,<br />
K Klingman4 , L Bacheler5 , R DiCenzo3 , A Rinehart6 , M Albrecht7 ,<br />
and the A5146 Study Team<br />
1 2 Univ of Rochester Sch of Med Dentistry, NY, US; Harvard Sch<br />
of Publ Hlth, Boston, MA, US; 3State Univ of New York at Buffalo,<br />
US; 4Div of AIDS, NIAID, NIH Bethesda, MD, US; 5VircoLab Inc,<br />
Durham, NC, US; 6Tibotec Therapeutics, Bridgewater, NJ, US; and<br />
7Beth Israel Deaconess Med Ctr, Boston, MA, US<br />
10:30 36 Re-initiation of ART in the CD4-guided ART<br />
Interruption Group in the SMART Study Lowers Risk<br />
of Opportunistic Disease or Death<br />
Wafaa El-Sadr and SMART Study Group<br />
Harlem Hosp Ctr, Columbia Univ, New York, NY, US<br />
10:45 37 Efficacy and Safety of Once-daily Atazanavir/Ritonavir<br />
Compared to Twice-daily Lopinavir/Ritonavir, Each<br />
in Combination with Tenofovir and Emtricitabinein<br />
ARV-naïve HIV-1-infected Subjects: The CASTLE<br />
Study, 48-week Results<br />
Jean-Michel Molina* 1 , J Andrade-Villanueva2 , J Echevarria3 ,<br />
P Chetchotisakd4 , J Corral5 , N David6 , M Mancini7 , L Percival7 ,<br />
A Thiry7 , and D McGrath7 1 2 Hosp St Louis, Paris, France; Hosp Civil de Guadalajara, Mexico;<br />
3 4 Hosp Natl Cayetano Heredia, Lima, Peru; Khonkaen Univ,<br />
Thailand; 5Hosp Intl Gral de Agudos Oscar Alende, Buenos Aires,<br />
Argentina; 6Brooklyn Med Ctr, Western Cape, South Africa; and<br />
7Bristol-Myers Squibb R&D, Wallingford, CT, US<br />
11:00 38 Safety and Activity of SCH532706, a Small Molecule<br />
Chemokine Receptor 5 Antagonist in HIV-1-infected<br />
Individuals<br />
Sarah Pett* 1 , S Emery1 , K MacRae2 , R Norris2 , M McCarthy3 ,<br />
A Tendlokar3 , J Tseng3 , K Williams2 , and D Cooper1 1Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South<br />
Wales, Australia; 2St Vincent’s Hosp, Sydney, Australia; and<br />
3Schering-Plough Res Inst, Kenilworth, NJ, US<br />
11:15 39LB Vicriviroc, a Next Generation CCR5 Antagonist,<br />
Exhibits Potent, Sustained Suppression of Viral<br />
Replication in Treatment-experienced Adults:<br />
VICTOR-E1 48-week Results<br />
Barry Zingman* 1 , J Suleiman2 , E DeJesus3 , J Slim4 , M McCarthy5 ,<br />
E Lee5 , N Case5 , C Mak5 , and L Dunkle5 1 2 Montefiore Med Ctr, Bronx, NY, US; Brazilmed Assistencia<br />
Medica e Pesquisa, Sao Paolo; 3Orlando Immunology Ctr, FL, US;<br />
4 5 St Michael’s Med Ctr, Newark, NJ, US; and Schering-Plough Res<br />
Inst, Kenilworth, NJ, US<br />
11:30 40LB Virological Correlates Associated with Treatment<br />
Failure at Week 48 in the Phase 3 Study of Maraviroc<br />
in Treatment-naïve Patients<br />
J Heera1 , M Saag2 , P Ive3 , J Whitcomb4 , M Lewis5 ,<br />
L McFadyen5 , J Goodrich1 , H Mayer1 , E van der Ryst5 , and Mike<br />
Westby* 5<br />
1 2 Pfizer Global R&D, New London, CT, US; Univ of Alabama at<br />
Birmingham, US; 3Univ of the Witwatersrand, Johannesburg, South<br />
Africa; 4Monogram Biosci, South San Francisco, CA, US; and<br />
5Pfizer Global R&D, Sandwich, UK<br />
11:45 41 Trends in Second Virologic Failure and Predictors<br />
of Subsequent Mortality among ART-experienced<br />
Patients: North American Experience<br />
Stephen Deeks and North American AIDS Cohort Collaboration on<br />
Res and Design (NA-ACCORD) of the IeDEA<br />
Univ of California, San Francisco, US<br />
6 15th Conference on Retroviruses and Opportunistic Infections<br />
c Monday, 1-4 pm; Poster Hall<br />
Poster Abstracts<br />
(see full session listings starting on page 25)<br />
Session 46. Cellular Co-factors<br />
Session 47. Cellular Restrictions<br />
Session 48. Viral Accesory Genes<br />
Session 57. Factors Impacting Disease Progression<br />
Session 58. Factors Impacting Viral Replication in vivo<br />
Session 59. Studies on Viral Evolution in vivo<br />
Session 67. Therapy and CNS Infection<br />
Session 68. Clinical Developments in Neuropathogenesis<br />
Session 73. Studies on T Cell Responses in Viral Infection<br />
Session 74. Studies on Cytokines and HIV Infection<br />
Session 84. Molecular Epidemiology: The Americas<br />
Session 85. Molecular Epidemiology: Europe<br />
Session 86. Molecular Epidemiology: Africa and Asia<br />
Session 87. Epidemiology and Transmission in Adult Populations<br />
Session 91. Novel PrEP Agents and Evaluation Strategies<br />
Session 95. Pharmacokinetics and Children<br />
Session 96. Response to and Efficacy of ART in Children<br />
Session 97. Resistance after First-line Failure in Children<br />
Session 105. Antiretroviral Pharmacokinetics during Pregnancy<br />
Session 106. Resistance Associated with ART for PMTCT<br />
Session 112. Health Outcomes in Women<br />
Session 113. Infertility in HIV-infected Women<br />
Session 116. Acute HIV/SIV Infection: Characterization of Transmitted Viruses<br />
Session 117. Acute HIV/SIV Infection: Immune Responses<br />
Session 118. Acute HIV Infection: Treatment<br />
Session 119. Acute HIV Infection: Recognition and Correlates of Transmission<br />
Session 127. ART: Treatment-naïve Patients<br />
Session 128. ART: Treatment-experienced Patients<br />
Session 131. Treatment Outcomes in Scale-up <strong>Program</strong>s<br />
Session 135. New Mechanisms of HIV-1 Drug Resistance<br />
Session 142. Viral Rebound and Emergence of Drug Resistance<br />
Session 143. HIV-1 Drug Resistance after First-line Therapy<br />
Session 144. Changing Prevalence of HIV-1 Drug Resistance<br />
Session 145. Impact of Subtype on HIV-1 Drug Resistance<br />
Session 146. Simplified Diagnostics for Resource-limited Settings<br />
Session 147. Evaluation of Serodiagnostic Assays<br />
Session 148. HLA Testing: Refinements and Cost-effectiveness<br />
Session 152. Dyslipidemia: Role of ART and Interventions for Management<br />
Session 153. Lipoatrophy/Lipohypertrophy: Predictors and Interventions<br />
Session 154. Atherosclerosis, Cardiovascular Risk and HIV Infection<br />
Session 169. Hepatitis B Co-infection<br />
Session 170. Hepatitis C Co-infection: Cellular Immune Responses and Pathogenesis<br />
Session 171. Hepatitis C Co-infection: Fibrosis
CROI 2008 Session 12<br />
c Monday, 2-3 pm; Room 311<br />
CME<br />
Session 11–Poster Discussion<br />
(see Session 65 on Wednesday for corresponding Poster Abstracts)<br />
Lymphocyte Depletion in the Gut<br />
Discussants:<br />
Cristian Apetrei, Tulane Natl Primate Res Ctr, Covington , LA, US<br />
Martin Markowitz, Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York,<br />
NY, US<br />
372 HIV Pathogenesis: Viral Blitzkrieg or 10 Years’ War?<br />
Cristian Apetrei* 1 , R Gautam1 , T Gaufin1 , R Ribeiro2 , M Pattison1 ,<br />
M Barnes1 , C Monjure1 , A Perelson2 , G Silvestri3 , and I Pandrea1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Los Alamos Natl Lab,<br />
NM, US; and 3Univ of Pennsylvania, Philadelphia, US<br />
373 Collagen Deposition Limits Immune Reconstitution in the Gut<br />
J Estes 1 , J Brenchley 2 , A Khoruts 3 , J Barthold 3 , C Reilly 3 , G Beilman 3 ,<br />
D Douek 2 , A Haase 3 , and Timothy Schacker* 3<br />
1 NCI-Frederick, MD, US; 2 Vaccine Res Ctr, NIAID, NIH, Bethesda, MD,<br />
US; and 3 Univ of Minnesota, Minneapolis, US<br />
374 Disruption of Intestinal Epithelial Integrity and Increased<br />
Microbial Translocation and Systemic Dissemination in<br />
HIV and SIV Infections Are Linked to Impaired IL-17expressing<br />
Mucosal T Cell Responses<br />
Satya Dandekar*, M Rafatellu, M Macal, S Sankaran, D Verhoeven,<br />
M George, R Santos, and A Baumler<br />
Univ of California, Davis, US<br />
375a Differential Mucosal Pathogenesis of SIV Infection in<br />
Progressing and Long-term Nonprogressing Rhesus<br />
Macaques<br />
Binhua Ling*, M Mohan, T Ooms, A Lackner, P Marx, and R Veazey<br />
Tulane Natl Primate Res Ctr, Covington, LA, US<br />
375b Disturbed Gut Microbiota in HAART-naïve HIV + Adults:<br />
Effect of Intervention with a Specific Prebiotic Oligosaccharide<br />
Mixture<br />
Kaouther Ben Amor* 1 , G Rizzardini 2 , C Torti 3 , T Quirino 4 , M Moroni 2 ,<br />
J Knol 1 , D Bray 5 , A Vriesema 1 , M Clerici 6 , and A Gori 7<br />
1 Numico Res, Wageningen, The Netherlands; 2 Hosp Luigi Sacco, Milan,<br />
Italy; 3 Univ of Brescia, Italy; 4 Hosp Busto Arsizio, Italy; 5 ImmunoClin,<br />
Paris, France; 6 Univ of Milan, Italy; and 7 Hosp San Gerardo, Univ of<br />
Milan-Bicocca, Monza, Italy<br />
376 Functional Analysis of Intestinal Epithelial Cells Isolated by<br />
Laser Dissection from SIV-infected Rhesus Macaques in vivo<br />
Michael George*, S Sankaran, I Grishina, and S Dandekar<br />
Univ of California, Davis, US<br />
377 Microbial Translocation Is a Determinant of Persisting T Cell<br />
Hyperactivation in HIV-infected Patients Failing to Recover<br />
CD4 following Long-term HAART<br />
Giusi Maria Bellistri* 1 , V Pegorer 1 , C Tincati 1 , L Meroni 2 , A Gori 3 ,<br />
A d’Arminio Monforte 1 , and G Marchetti 1<br />
1 San Paolo Hosp, Univ of Milan, Italy; 2 Luigi Sacco Hosp, Univ of Milan,<br />
Italy; and 3 San Gerardo Hosp, Monza, Italy<br />
c Monday, 2-3 pm; Room 312<br />
CME<br />
Session 12–Poster Discussion<br />
(see Session 88 on Tuesday for corresponding Poster Abstracts)<br />
New Approaches to HIV Testing<br />
Discussants:<br />
Susan Buchbinder, San Francisco Dept of Publ Hlth, CA, US<br />
Carlos Del Rio, Emory Univ Ctr for AIDS Res, Atlanta, GA, US<br />
531 Partner Counseling and Referral Outcomes after Acute HIV<br />
Identification in North Carolina<br />
Sandra McCoy* 1 , J Kuruc 1 , C Gay 1 , C Hurt 1 , J Anderson 1 , C Pilcher 2 ,<br />
J Barnhart 3 , J Eron 1 , P Leone 1,3 , and the North Carolina STAT Team<br />
1 Univ of North Carolina at Chapel Hill, US; 2 Univ of California, San<br />
Francisco, US; and 3 North Carolina Dept of Hlth and Human Svcs,<br />
Raleigh, US<br />
532 Acceptance of Routine HIV Testing in Medical Inpatients in<br />
Nigeria: Implications for a New HIV Testing Approach in<br />
Sub-Saharan Africa<br />
Olusegun Busari* 1 , M Nakayima 2 , O Busari 1 , G Oligbu 1 , A Adeyemi 3 ,<br />
L Onigbogi 4 , and HIV Study Group<br />
1 Federal Med Ctr, Ido-Ekiti, Nigeria; 2 AIDS Support Org, Masaka,<br />
Uganda; 3 Hlthmatch Intl, Lagos, Nigeria; and 4 Univ Coll Hosp, Ibadan,<br />
Nigeria<br />
533 Interim Findings from a Multi-site Evaluation of HIV<br />
Testing in Emergency Departments<br />
James Heffelfinger* 1 , R Rothman 2 , H Pollack 3 , J Brown 4 , M Lyons 5 ,<br />
G Almond 6 , P Sullivan 1 , S Barera 7 , and G Williams Torres 7<br />
1 CDC, Atlanta, GA, US; 2 Johns Hopkins Univ, Baltimore, MD, US; 3 Sch<br />
of Social Svc Admin, Ctr for Hlth Admin Studies, Univ of Chicago, IL,<br />
US; 4 George Washington Univ, Washington, DC, US; 5 Univ of Cincinnati<br />
Coll of Med, OH, US; 6 Metropolitan Hosp Ctr, New York, NY, US; and<br />
7 Hlth Res and Ed Trust, Chicago, IL, US<br />
534 Revisiting Expectations from Rapid HIV Test and<br />
Confirmation in the Emergency Department<br />
Rochelle Walensky* 1,2,3 , C Arbelaez 2 , W Reichmann 2 , R Walls 2 , J Katz 2,4 , and<br />
E Losina 1,2,5<br />
1 Massachusetts Gen Hosp, Boston, US; 2 Brigham and Women’s Hosp,<br />
Boston, MA, US; 3 Harvard Med Sch, Boston, MA, US; 4 Harvard Sch of<br />
Publ Hlth, Boston, MA, US; and 5 Boston Univ Sch of Publ Hlth, MA, US<br />
535a Patient Perspectives and Testing Uptake with Abbreviated<br />
versus Standard Pre-test HIV Counseling in the Prenatal<br />
Setting: A Randomized-Controlled, Non-inferiority Trial<br />
Deborah Cohan* 1,2 , E Gomez1,2 , and E Charlebois1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp,<br />
CA, US<br />
535b Using Multiple Rapid HIV Tests at the Point of Care:<br />
Implications for Clinicians Receiving Referrals<br />
Kevin Delaney* 1 , T Knoble2 , J Rurangirwa3 , A Scribner4 , E Hopkins5 ,<br />
B Boyett1 , D White4 , J Haukoos5 , T Dowling2 , and J King3 1 2 CDC, Atlanta, GA, US; HIV Prevention Prgm, City and County of San<br />
Francisco, CA, US; 3Los Angeles County Dept of Hlth, CA, US; 4Highland Hosp, Alameda County Hlth Ctr, Oakland, CA, US; and 5Denver Hlth<br />
Med Ctr, CO, US<br />
<strong>Program</strong> 7<br />
Monday<br />
February 4 Sessions
Monday<br />
February 4 Sessions<br />
Session 13 CROI 2008<br />
c Monday, 2-3 pm; Room 302-304<br />
CME<br />
Session 13–Poster Discussion<br />
(see Session 137 on Tuesday for corresponding Poster Abstracts)<br />
Emerging Patterns of Resistance to New<br />
Antiretrovirals<br />
Discussants:<br />
Victoria Johnson, Univ of Alabama at Birmingham, US<br />
Rob Schuurman, Univ Med Ctr Utrecht, The Netherlands<br />
869 An Enhanced Version of the Trofile HIV Co-receptor<br />
Tropism Assay Predicts Emergence of CXCR4 Use in<br />
ACTG5211 Vicriviroc Trial Samples<br />
Jacqueline Reeves* 1 , D Han 1 , T Wilkin 2 , T Wrin 1 , D Kuritzkes 3 ,<br />
C Petropoulos 1 , J Whitcomb 1 , N Parkin 1 , R Gulick 2 , and E Coakley 1<br />
1 Monogram Biosci, South San Francisco, CA, US; 2 Weill Med Coll of<br />
Cornell Univ, New York, NY, US; and 3 Brigham and Women’s Hosp,<br />
Cambridge, MA, US<br />
870 Emergence in vivo of Vicriviroc Resistance in HIV-1<br />
Subtype C: Role of V3 Loop and Susceptibility to Other<br />
CCR5 Antagonists<br />
Athe Tsibris* 1,2 , M Sagar 2,3 , Z Su 4 , C Flexner 5 , W Greaves 6 , P Skolnik 7 ,<br />
E Coakley 8 , M Subramanian 9 , R Gulick 10 , and D Kuritzkes 2,3<br />
1 Massachusetts Gen Hosp, Boston, US; 2 Harvard Med Sch, Boston, MA,<br />
US; 3 Brigham and Women’s Hosp, Boston, MA, US; 4 Harvard Sch of<br />
Publ Hlth, Boston, MA, US; 5 Johns Hopkins Univ, Baltimore, MD, US;<br />
6 Schering-Plough Res Inst, Kenilworth, NJ, US; 7 Boston Med Ctr, MA,<br />
US; 8 Monogram Biosci, South San Francisco, CA, US; 9 Human Genome<br />
Sci, Rockville, MD, US; and 10 Weill Med Coll of Cornell Univ, New York,<br />
NY, US<br />
871 Changes in V3 Loop Sequence Associated with Failure<br />
of Maraviroc Treatment in Patients Enrolled in the<br />
MOTIVATE 1 and 2 Trials<br />
Marilyn Lewis* 1 , J Mori 1 , P Simpson 1 , J Whitcomb 2 , X Li 3 , D Roberston 1 ,<br />
and M Westby 1<br />
1 Pfizer Global R&D, Sandwich Labs, Kent, UK; 2 Monogram Biosci, South<br />
San Francisco, CA, US; and 3 Faculty of Life Sci, Univ of Manchester, UK<br />
872 Naturally Occurring Polymorphisms in HIV-1 Group M, N,<br />
and O Integrase: Implications for Integrase Inhibitors<br />
John Hackett*, B Harris, V Holzmayer, J Yamaguchi, KC Luk,<br />
C Brennan, G Schochetman, S Devare, and P Swanson<br />
Abbott Diagnostics, Abbott Park, IL, US<br />
873 Development of vircoTYPE HIV-1 Resistance Analysis,<br />
Including Clinical Cutoffs for TMC125, a New NNRTI<br />
Bart Winters* 1 , J Vingerhoets2 , M Peeters2 , J Villacian1 ,<br />
E Van Craenenbroeck1 , and L Bacheler3 1 2 Virco BVBA, Mechelen, Belgium; Tibotec BVBA, Mechelen, Belgium;<br />
and 3VircoLab Inc, Durham, NC, US<br />
874 Characterization of Virologic Failures on Darunavir/<br />
Ritonavir in the Randomized, Controlled, Phase III TITAN<br />
Trial in Treatment-experienced Patients<br />
Sandra De Meyer* 1 , E Lathouwers1 , I Dierynck1 , E De Paepe1 ,<br />
B Van Baelen1 , T Vangeneugden1 , S Spinosa-Guzman1 , G Picchio2 , and<br />
MP de Bethune1 1 2 Tibotec BVBA, Mechelen, Belgium and Tibotec Inc, Yardley, PA, US<br />
8 15th Conference on Retroviruses and Opportunistic Infections<br />
e Monday, 4-6 pm; Room 302-304<br />
CME<br />
Session 14–Oral Abstracts<br />
PMTCT<br />
Moderators:<br />
Grace Aldrovandi, Children’s Hosp Los Angeles and Univ of Southern California, US<br />
Wafaie Fawzi, Harvard Sch of Publ Hlth, Boston, MA, US<br />
4:00 42LB Extended Infant Post-exposure Prophylaxis with<br />
Antiretroviral Drugs Significantly Reduces Postnatal<br />
HIV Transmission: The PEPI-Malawi Study<br />
Taha Taha* 1 , M Thigpen2 , N Kumwenda1 , D Hoover3 , G Kafulafula4 ,<br />
Q Li1 , L Mipando5 , K Nkanaunena5 , M Fowler6 , and L Mofenson7 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore,<br />
MD, US; 2CDC, Atlanta, GA, US; 3Rutgers Univ, Piscataway, NJ,<br />
US; 4Univ of Malawi Coll of Med, Blantyre; 5Johns Hopkins Univ<br />
Coll of Med, Blantyre, Malawi; 6Johns Hopkins Univ Sch of Med,<br />
Baltimore, MD, US; and 7Natl Inst of Child Hlth and Human Devt,<br />
NIH, Bethesda, MD, US<br />
4:15 43 Extended-dose Nevirapine to 6 Weeks of Age for<br />
Infants in Ethiopia, India, and Uganda: A Randomized<br />
Trial for Prevention of HIV Transmission through<br />
Breastfeeding<br />
Jayagowri Sastry* 1,2,3,4 and the SWEN Study Team<br />
1 2 BJ Med Coll, Pune, India; Johns Hopkins Univ, Baltimore, MD,<br />
US; 3Addis Ababa Univ Faculty of Med, Ethiopia; and 4Makerere Univ Sch of Med, Kampala, Uganda<br />
4:30 44 Timing of Infection Is Critical for Nevirapine<br />
Resistance Outcomes among Breastfed Subtype C HIV-<br />
1-infected Infants Exposed t o Extended vs Single-dose<br />
Nevirapine Prophylaxis: The India SWEN Study<br />
Anitha Moorthy* 1 , A Gupta2 , J Sastry3 , V Venkatramani4 ,<br />
R Bhosale4 , V Kulkarni3 , N Gupte3 , C Ziemniak2 , R Bollinger2 , and<br />
D Persaud2 on behalf of the India SWEN Study Team<br />
1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD,<br />
US; 2Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 3BJ Med<br />
Coll and Johns Hopkins Univ, Pune, India; and 4BJ Med Coll, Pune,<br />
India<br />
4:45 45aLB PMTCT of HIV-1 among Breastfeeding Mothers Using<br />
HAART: The Kisumu Breastfeeding Study, Kisumu,<br />
Kenya, 2003-2007<br />
Timothy Thomas* 1 , R Masaba2 , R Ndivo2 , C Zeh1 , C Borkowf3 ,<br />
M Thigpen3 , K De Cock1 , P Amornkul1 , A Greenberg3 , M Fowler3 ,<br />
and Kisumu Breastfeeding Study Team<br />
1 2 3 CDC Kenya, Kisumu; Kenya Med Res Inst, Kisumu; and CDC,<br />
Atlanta, GA, US<br />
5:00 45b The TEmAA ANRS 12109 Phase II Trial, Step 1:<br />
Tolerance and Viral Resistance after Single-dose<br />
Nevirapine and Short-course of Tenofovir Disoproxil<br />
Fumarate and Emtricitabine to Prevent Mother-to-<br />
Child Transmission of HIV-1<br />
Elise Arrive* 1 , ML Chaix2 , E Nerrienet3 , S Blanche4 , C Rouzioux2 ,<br />
J McIntyre5 , P Coffie6 , K Sim7 , D Ekouevi6 , and F Dabis1 1INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor<br />
Segalen, Bordeaux, France; 2Ctr Hosp Univ Necker, Univ Paris<br />
Descartes, Paris, France; 3Inst Pasteur, Phnom Penh, Cambodia;<br />
4 5 Hosp Necker for Sick Children, Paris, France; Univ of the<br />
Witwatersrand, Soweto, South Africa; 6Prgm PACCI, Abidjan Côte<br />
d’Ivoire; and 7Hosp Calmette, Phnom Penh, Cambodia<br />
5:15 46 Duration and Pattern of Breastfeeding and Postnatal<br />
Transmission of HIV: Pooled Analysis of Individual<br />
Data from a West and South African Cohort Study<br />
Renaud Becquet* 1,2,3 , R Bland1,4 , V Leroy2,3 , N Rollins1,5 ,<br />
D Ekouevi2,3,6 , A Coutsoudis5 , F Dabis2,3 , H Coovadia7 ,<br />
R Salamon2,3 , and ML Newell1,8 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu<br />
Natal, Somkhele, South Africa; 2INSERM U593, Bordeaux, France;<br />
3Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen, Bordeaux,<br />
France; 4Univ of Glasgow, UK; 5Univ of KwaZulu Natal, Durban,<br />
South Africa; 6Ctr Hosp Univ of Treichville, Abidjan, Côte d’Ivoire;<br />
7Ctr for HIV/AIDS Networking, Univ of KwaZulu Natal, Durban,<br />
South Africa; and 8Ctr for Pediatric Epi and Biostatistics, Inst of<br />
Child Hlth, Univ Coll London, UK<br />
5:30 47LB Population Pharmacokinetics of Tenofovir in HIV-<br />
1-infected Pregnant Women and Their Neonates:<br />
TEmAA ANRS 12109<br />
Deborah Hirt* 1,2 , S Urien1,2 , E Rey1 , D Ekouevi3 , S Blanche2 ,<br />
G Gray4 , P Coffie3 , K Leang Sim5 , F Dabis6 , and JM Treluyer1,2 1 2 3 Hosp Cochin, France; Univ Paris Descartes, France; Prgm<br />
PACCI, Abidjan, Côte d’Ivoire; 4Univ of the Witwatersrand,<br />
Soweto, South Africa; 5Hosp Calmette, Phnom Penh, Cambodia;<br />
and 6INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor<br />
Segalen, Bordeaux, France
CROI 2008 Session 15<br />
5:45 48 Effectiveness of NNRTI-containing ART in Women<br />
Previously Exposed to a Single Dose of Nevirapine: A<br />
Multi-country Cohort Study<br />
Paul Weidle* 1 , J Stringer 2 , M McConnell 1,3 , J Kiarie 4 ,<br />
T Anekthananon 5 , T Jariyasethpong 6 , D Potter 2 , W Mutsotso 7 ,<br />
C Borkowf 1 , O Bolu 1 , and the NNRTI Response Study Team<br />
1 CDC, Atlanta, GA, US; 2 Univ of Alabama at Birmingham, Ctr<br />
for Infectious Disease Res in Zambia, Lusaka; 3 Thailand Ministry<br />
of Publ Hlth-US CDC Collaboration, Nonthaburi; 4 Kenyatta<br />
Natl Hosp, Univ of Nairobi, Kenya; 5 Siriraj Hos., Mahidol Univ,<br />
Bangkok, Thailand; 6 Rajavithi Hosp, Bangkok, Thailand; and 7 CDC<br />
Kenya, Nairobi<br />
e Monday, 4-6 pm; Ballroom A<br />
Session 15–Symposium CME<br />
Voyages through the Cell: Imaging Viral Traffic<br />
Conveners:<br />
Thomas Hope, Northwestern Univ, Chicago,<br />
IL, US<br />
Marilyn Resh, Memorial Sloan-Kettering<br />
Cancer Ctr, New York, NY, US<br />
49<br />
Pre-integration Complex Transport to the Nucleus<br />
Nathalie Arhel* and P Charneau<br />
Pasteur Inst, Paris, France<br />
50<br />
Live Imaging of Cell-to-Cell Transmission of<br />
Retroviruses<br />
N Sherer, M Lehmann, J Jin, and Walther Mothes*<br />
Yale Univ, New Haven, CT, US<br />
51<br />
Electron Cryotomography of HIV Virions<br />
Grant Jensen<br />
California Inst of Tech, Pasadena, US<br />
52<br />
Electron Tomography of Immunodeficiency Viruses<br />
and Structural Mechanisms of Cellular Entry<br />
Sriram Subramaniam<br />
Ctr for Cancer Res, NCI, NIH, Bethesda, MD, US<br />
Objectives: This session is directed to those interested in learning about<br />
HIV structure, mechanisms of virus entry into cells, and trafficking of virus<br />
particles from cell to cell and from the cytoplasm to the nucleus. The session<br />
will emphasize recent discoveries resulting from the use of state-of-the-art<br />
imaging technologies. It is assumed that participants are familiar with basic<br />
concepts of HIV replication. At the completion of the session, participants will<br />
be knowledgeable about the structure of HIV virus particles, molecular events<br />
that lead to virus entry and trafficking into the nucleus, and host cell factors<br />
that regulate these processes.<br />
<strong>Program</strong> 9<br />
Monday<br />
February 4 Sessions
Monday<br />
February 4 Sessions<br />
Session 16 CROI 2008<br />
e Monday, 4-6 pm; Ballroom B/C<br />
Session 16–Symposium CME<br />
Curbing the US Epidemic<br />
Conveners:<br />
Kenneth Mayer, Brown Univ Sch of Med,<br />
Miriam Hosp, Providence, RI, US<br />
Mary Ann Chiasson, Med and Hlth Res Assn<br />
of New York City, NY, US<br />
53<br />
What’s Driving the US Epidemic in Men Who Have<br />
Sex with Men<br />
Ron Stall*, M Friedman, M Marshal, and S Wisniewski<br />
Univ of Pittsburgh Sch of Publ Hlth, PA, US<br />
54<br />
What’s Driving the US Epidemic among Women<br />
Adaora Adimora<br />
Univ of North Carolina at Chapel Hill, US<br />
55<br />
Prevention for Positives<br />
Simon Rosser<br />
Univ of Minnesota, Minneapolis, US<br />
56<br />
Addressing Substance Abuse<br />
David Vlahov<br />
New York Academy of Med, NY, US<br />
Objectives: This session is directed to clinicians and scientists interested<br />
in prevention of HIV infection in the US. It is assumed that participants<br />
are familiar with the groups at highest risk for HIV/AIDS in the US. At<br />
the completion of the session, participants will be knowledgeable about<br />
prevention strategies for men who have sex with men, women at risk, injection<br />
drug users, and persons already infected with HIV.<br />
10 15th Conference on Retroviruses and Opportunistic Infections<br />
e Monday, 4-6 pm; Auditorium<br />
CME<br />
Session 17–Oral Abstracts<br />
Hepatitis Co-infection<br />
Moderators:<br />
Ray Chung, Massachusetts Gen Hosp, Boston, US<br />
Karine Lacombe, Hosp St Antoine, Paris, France<br />
4:00 57 HIV Entry and Replication in Stellate Cells Promotes<br />
Cellular Activation and Fibrogenesis: Implications for<br />
Hepatic Fibrosis in HIV/HCV Co-infection<br />
Ana Tuyama*, F Hong, A Mosoian, P Chen, B Chen, I Fiel,<br />
A Schecter, M Klotman, and M Bansal<br />
Mt Sinai Sch of Med, New York, NY, US<br />
4:15 58 HIV-related Microbial Translocation, a Mechanism for<br />
Liver Disease<br />
A Balagopal1 , F Philp1 , J Astemborski1 , T Block2 , A Mehta2 , G Kirk1 ,<br />
S Mehta1 , A Cox1 , S Ray1 , and David Thomas* 1<br />
1 2 Johns Hopkins Med Inst, Baltimore, MD, US and Drexel Inst for<br />
Biotech and Virology Res, Doylestown, PA, US<br />
4:30 59 Sustained Long-term Antiviral Maintenance with<br />
Pegylated Interferon in HCV/HIV-co-infected Patients:<br />
Early Viral Response and Effect on Fibrosis in Treated<br />
and Control Subjects<br />
Kenneth Sherman* 1 , J Andersen2 , A Butt3 , Z Goodman4 , T Umbleja2 ,<br />
B Alston6 , M Koziel5 , M Peters7 , M Sulkowski8 , R Chung9 , and<br />
ACTG A5178 Study Team<br />
1 2 Univ of Cincinnati, OH, US; Harvard Sch of Publ Hlth, Boston,<br />
MA, US; 3Univ of Pittsburgh, PA, US; 4Armed Forces Inst of<br />
Pathology, Washington, DC, US; 5Beth Israel Deaconess Med<br />
Ctr, Boston, MA, US; 6NIAID, NIH, Bethesda, MD, US; 7Univ of<br />
California, San Francisco, US; 8Johns Hopkins Univ, Baltimore,<br />
MD, US; and 9Massachusetts Gen Hosp, Boston, US<br />
4:45 60 Sustained Virological Response to Interferon plus<br />
Ribavirin Reduces Liver-related Complications and<br />
Mortality in HIV/HCV-co-infected Patients<br />
Juan Berenguer* 1 , J Alvarez-Pellicer2 , J Lopez Aldeguer3 ,<br />
M Von-Wichman4 , C Quereda5 , J Mallolas6 , J Sanz7 , C Tural8 ,<br />
J Bellon1 , J Gonzalez2 , and the GESIDA 3603 Study Group<br />
1 2 Hosp Gregorio Maranon, Madrid, Spain; Hosp La Paz, Madrid,<br />
Spain; 3Hosp La Fe, Valencia, Spain; 4Hosp Donostia, San<br />
Sebastian, Spain; 5Hosp Ramon y Cajal, Madrid, Spain; 6Hosp Clin,<br />
Barcelona, Spain; 7Hosp Principe de Asturias, Alcala de Henares,<br />
Madrid; and 8Hosp Germans Trías i Pujol, Badalona, Spain<br />
5:00 61LB Hepatitis C Viremia following Sustained Virological<br />
Response to Pegylated Interferon and Ribavarin in<br />
HIV + Men Who Have Sex with Men–Re-infection or<br />
Late Relapse?<br />
Rachael Jones* 1 , D Brown2 , M Nelson1 , S Bhagani2 , M Atkins1 ,<br />
M Danta3 , G Dusheiko2 , O Pybus4 , and D Asboe1 1 2 Chelsea and Westminster NHS Fndn Trust, London, UK; Royal<br />
Free and Univ Coll Med Sch, London, UK; 3Univ of New South<br />
Wales, Sydney, Australia; and 4Univ of Oxford, UK<br />
5:15 62 3 Interlinked Mechanisms of Inhibition of HIV-1<br />
Reverse Transcriptase by the HBV Drug Entecavir<br />
Egor Tchesnokov* 1 , A Obikhod2 , R Schinazi2 , and M Gotte1 1 2 McGill Univ, Montreal, Canada and Emory Univ Sch of Med,<br />
Atlanta, GA, US<br />
5:30 63 The Anti-HIV Activity of Entecavir: Serum HIV RNA<br />
Decreases and Selection of the M184V Mutation Occurs<br />
in both ART-naïve and -experienced HIV/HBV-coinfected<br />
Individuals<br />
Jennifer Audsley* 1,2,3 , J Sasadeusz1,3 , A Mijch1,2 , R Baden4 , J Caro4,5 ,<br />
H Hunter6 , G Matthews7 , S Olender8 , S Lewin1,2,3 , and C Thio9 1 2 Alfred Hosp, Melbourne, Australia; Monash Univ, Melbourne,<br />
Australia; 3CCREID, Univ of Melbourne, Australia; 4Harvard Med<br />
Sch, Boston, MA, US; 5Fenway Community Hlth, Boston, MA, US;<br />
6 7 AID Atlanta, GA, US; Natl Ctr in HIV Epi and Clin Res, Sydney,<br />
Australia; 8Columbia Univ Med Ctr, New York, NY, US; and 9Johns Hopkins Univ Sch of Med, Baltimore, MD, US<br />
5:45 64 MELD is the Best Predictor of Pre-transplant Mortality<br />
in HIV-infected Liver Transplant Candidates<br />
Aruna Subramanian* 1 , M Sulkowski1 , B Barin2 , D Stablein2 ,<br />
M Curry3 , N Nissen4 , L Dove5 , M Roland6 , P Stock7 , and M Ragni8 1 2 Johns Hopkins Univ, Baltimore, MD US; EMMES Corp, Rockville,<br />
MD, US; 3Beth Israel Deaconess Med Ctr, Boston, MA, US;<br />
4 5 Cedars-Sinai Med Ctr, Los Angeles, CA, US; Columbia Univ, New<br />
York, NY, US; 6California Dept of Publ Hlth, Sacramento, US; 7Univ of California, San Fransisco, US; and 8Univ of Pittsburgh, PA, US
CROI 2008 Session 20<br />
i Tuesday, 8:30-9 am; Auditorium<br />
Session 18–Plenary CME<br />
Challenges in Pediatric and Adolescent HIV Care<br />
65<br />
Lynne Mofenson<br />
Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD,<br />
US<br />
Objectives: This session is directed to clinicians and scientists interested<br />
in treatment and management of HIV-infected children and adolescents in<br />
resource-rich and resource-limited settings. It is assumed that participants<br />
are familiar with interventions to prevent mother-to-child HIV transmission,<br />
the principles of ART, and the clinical course of pediatric HIV infection.<br />
At the completion of the session, participants will be knowledgeable about<br />
differences between pediatric and adult HIV infection, factors associated with<br />
response to ART and choice of antiretroviral drugs in children, including<br />
maternal antiretroviral drug exposure, long-term complications of ART in<br />
children, issues related to the aging of infected children into adulthood, and<br />
barriers to treatment of children in resource-limited countries.<br />
j Tuesday, 9-9:30 am; Auditorium<br />
Session 19–Plenary CME<br />
Natural Enhancers and Inhibitors of HIV Infection<br />
66<br />
J Munch 1 , L Standker 2,3 , WG Forssmann 2,3 , and Frank Kirchhoff* 1<br />
1 Univ Clin of Ulm, Germany; 2 VIRO Pharma GmbH & Co,<br />
Hannover, Germany; and 3 Hannover Med Sch, Ctr of Pharma,<br />
Hannover, Germany<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
sexual transmission of HIV/AIDS. It is assumed that participants are familiar<br />
with the basic aspects of HIV entry into target cells. At the completion of<br />
the session, participants will be knowledgeable about the presence of factors<br />
enhancing the infectiousness of HIV in semen, the mechanisms underlying the<br />
enhancement of HIV infection, and the potential relevance of amyloid fibrils<br />
in the transmission of HIV and other viruses.<br />
k Tuesday, 10-11:30 am; Room 302-304<br />
CME<br />
Session 20–Oral Abstracts<br />
Insights into Neuropathogenesis<br />
Moderators:<br />
Paola Cinque, San Raffaele Sci Inst, Milan, Italy<br />
David Clifford, Washington Univ Sch of Med, St Louis, MO, US<br />
10:00 67 Reducing the Prevalence of Primary HIV Brain<br />
Pathology by Antiretrovirals<br />
Ian Everall* 1 , F Vada1 , S Letendre1 , D Lazzaretto1 , B Gelman2 ,<br />
S Morgello3 , E Singer4 , R Ellis1 , E Masliah1 , I Grant1 , and<br />
Natl NeuroAIDS Tissue Consortium and the UCSD HIV<br />
Neurobehavioral Res Ctr<br />
1 2 Univ of California, San Diego, US; Univ of Texas Med Branch,<br />
Galveston, US; 3Mt Sinai Med Ctr, New York, NY, US; and 4Univ of<br />
California, Los Angeles, US<br />
10:15 68 Low-grade Immune Restoration Disease May Limit<br />
Recovery from HIV-associated Neurocognitive<br />
Impairment<br />
Scott Letendre*, R Ellis, L Cysique, M Cherner, S Gibson,<br />
R Heaton, A McCutchan, and the HNRC Group<br />
Univ of California, San Diego, US<br />
10:30 69 Elevated Plasma Endotoxin Associated with Monocyte<br />
Activation and Reduced BDNF in AIDS Patients with<br />
Dementia<br />
Petronela Ancuta* 1 , K Kunstman2 , EY Kim2 , P Autissier3 ,<br />
M Mefford4 , D Stone5 , S Wolinsky2 , and D Gabuzda4 1 2 Univ of Montreal, Canada; Northwestern Univ, Chicago, IL, US;<br />
3 4 Beth Israel Deaconess Med Ctr, Boston, MA, US; Dana-Farber<br />
Cancer Inst, Boston, MA, US; and 5Lemuel Shattuck Hosp, Jamaica<br />
Plain, MA, US<br />
10:45 70 HIV Infection of the Cerebrospinal Fluid of Elite<br />
Controllers<br />
John Probasco*, S Deeks, E Lee, R Hoh, T Liegler, R Price, and<br />
S Spudich<br />
Univ of California, San Francisco, US<br />
11:00 71 Influence of Immunological, Virological, and<br />
Radiological Determinants in the Clinical<br />
Outcome of Patients with Progressive Multifocal<br />
Leukoencephalopathy<br />
A Marzocchetti1 , T Tompkins1 , D Clifford2 , R Gandhi3 , S Kesai4 ,<br />
J Berger5 , D Simpson6 , A DeLuca7 , and Igor Koralnik* 1<br />
1Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA,<br />
US; 2Washington Univ Sch of Med, Seattle, US; 3Massachusetts Gen<br />
Hosp, Harvard Med Sch, Boston, US; 4Brigham and Women’s Hosp,<br />
Boston, MA, US; 5Univ of Kentucky Coll of Med, US; 6Mt Sinai Med<br />
Ctr, New York, NY, US; and 7Catholic Univ, Rome, Italy<br />
11:15 72 Natural Genetic Resistance to Lentiviral CNS Disease:<br />
A Neuroprotective MHC Class I Allele in SIV-infected<br />
Macaques<br />
Joseph Mankowski* 1 , S Queen1 , C Fernandez2 , P Tarwater3 ,<br />
J Karper1 , R Adams1 , and S Kent2 1 2 Johns Hopkins Univ, Baltimore, MD, US; Univ of Melbourne,<br />
Australia; and 3Univ of Texas Hlth Sci Ctr at Houston, Sch of Publ<br />
Hlth, El Paso, US<br />
<strong>Program</strong> 11<br />
Tuesday<br />
February 5 Sessions
Tuesday<br />
February 5 Sessions<br />
Session 21 CROI 2008<br />
k Tuesday, 10-11:30 am; Ballroom A<br />
CME<br />
Session 21–Oral Abstracts<br />
HIV in Women and Children<br />
Moderators:<br />
Linda-Gail Bekker, Desmond Tutu HIV Ctr, Univ of Cape Town, South Africa<br />
Addy Kekitiinwa, Mulago Hosp, Kampala, Uganda<br />
10:00 73 Alternatives to Prolonged Breastfeeding and Incidence<br />
of Pregnancies among HIV-infected Women: The<br />
ANRS 1201-1202 Ditrame Plus Cohort in Abidjan, Côte<br />
d’Ivoire, 2001 to 2005<br />
I Viho1 , R Becquet2,3 , D Ekouevi1,2 , H Brou1 , A Yao1 , F Dabis2,3 ,<br />
C Amani-Bosse1 , A Desgree-du-Lou4 , M Timite-Konan5 ,<br />
Valeriane Leroy* 2,3 , and ANRS 1201-1202 DITRAME PLUS Study<br />
Group<br />
1Natl Agency for AIDS Res Ditrame Plus Project, PACCI<br />
Collaboration, Abidjan, Côte d’Ivoire; 2INSERM U593, Bordeaux,<br />
France; 3Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen,<br />
Bordeaux, France; 4Inst for Res and Devt, UMR 151, Nogent-sur-<br />
Marne, France; and 5Ctr Hosp Univ of Yopougon, Abidjan, Côte<br />
d’Ivoire<br />
10:15 74 Incidence and Determinants of Pregnancy among<br />
Women Receiving ART in Rural Uganda<br />
Jaco Homsy* 1,2 , R Bunnell2 , D Moore2,3 , R King2 , S Malamba2 ,<br />
R Nakityo2 , D Glidden1 , C Likicho2 , J Tappero2 , and J Mermin2 1Inst for Global Hlth, Univ of California, San Francisco, US;<br />
2 3 Global AIDS Prgm, CDC Uganda, Entebbe; and BC Ctr for<br />
Excellence in HIV/AIDS, Vancouver, Canada<br />
10:30 75 Immune Reconstitution Inflammatory Syndrome in<br />
HIV-infected Infants and Young Children Initiating<br />
ART<br />
1 2 3 4 3 Kelly Smith* , L Kuhn , A Coovadia , T Meyers , B Marais ,<br />
G Barry3 , and E Abrams2 1Columbia Univ Coll of Physicians and Surgeons, New York,<br />
NY, US; 2Columbia Univ Mailman Sch of Publ Hlth, New York,<br />
NY, US; 3Coronation Women and Children’s Hosp, Univ of the<br />
Witwatersrand, Johannesburg, South Africa; and 4Chris Hani<br />
Baragwanath Hosp, Univ of the Witwatersrand, Johannesburg,<br />
South Africa<br />
10:45 76 Clinical and Immunological Characteristics of Very<br />
Young Infants with HIV Infection: Children with HIV<br />
Early Antiretroviral Study<br />
Heather Jaspan* 1 , L Myer2 , A Violari3 , S Madhi4 , J Steyn3 ,<br />
R van Niekerk3 , W Stevens3 , and M Cotton1 1Faculty of Hlth Sci, Univ of Stellenbosch, Cape Town, South Africa;<br />
2 3 Univ of Cape Town, South Africa; Univ of the Witwatersrand,<br />
Johannesburg, South Africa; and 4Chris Hani Baragwanath Hosp,<br />
Johannesburg, South Africa<br />
11:00 77LB Randomized, Controlled Trial of 3 Approaches to<br />
Management of HIV-infected Infants<br />
Andrew Prendergast* 1 , F Chonco2 , G Tudor-Williams3 , W Mphatswe2 ,<br />
A Cengimbo2 , C Thobakgale2 , K Dong4 , H Coovadia2 , B Walker4 , and<br />
P Goulder1 1 2 Univ of Oxford, UK; Univ of KwaZulu Natal, Durban, South<br />
Africa; 3Imperial Coll, London, UK; and 4Partners AIDS Res Ctr,<br />
Boston, MA, US<br />
11:15 78LB Safety and Efficacy of Darunavir Co-administered<br />
with Low-dose Ritonavir in Treatment-experienced<br />
Children and Adolescents at Week 24<br />
R Bologna1 , S Rugina2 , P Cahn3 , P Flynn4 , S Blanche5 ,<br />
B Van Baelen6 , R De Greef6 , L Lavreys6 , T Van De Casteele6 , and<br />
Sabrina Spinosa-Guzman* 6<br />
1Hosp de Pediatria “JP Garrahan”, Buenos Aires, Argentina;<br />
2 3 Spitalul Clinic de Boli Infectioase, Constanta, Romania; Fndn<br />
Huesped, Buenos Aires, Argentina; 4St Jude Children’s Res Hosp,<br />
Memphis, TN, US; 5Hosp Necker-Enfants Malades, Paris, France;<br />
and 6Tibotec, Inc, Mechelen, Belgium<br />
12 15th Conference on Retroviruses and Opportunistic Infections<br />
k Tuesday, 10-11:30 am; Ballroom B/C<br />
CME<br />
Session 22–Oral Abstracts<br />
New Mechanisms of Resistance and Virologic<br />
Failure<br />
Moderators:<br />
Bonaventura Clotet, Fndn irsiCaixa, Barcelona, Spain<br />
Karin Metzner, Univ of Erlangen-Nuremberg, Germany<br />
10:00 79 Mechanism by which N348I in HIV-1 Reverse<br />
Transcriptase Confers Dual Zidovudine/Nevirapine<br />
Resistance<br />
Soo-Huey Yap* 1,2 , J Radzio3,4 , N Sluis-Cremer3 , and<br />
G Tachedjian1,5 1 2 Burnet Inst, Melbourne, Australia; Monash Univ, Churchill,<br />
Australia; 3Univ of Pittsburgh Sch of Med, PA, US; 4Univ of<br />
Pittsburgh Grad Sch of Publ Hlth, PA, US; and 5Monash Univ,<br />
Clayton, Australia<br />
10:15 80 Molecular Mechanisms for 3’-Azido-3’-<br />
Dideoxythymidine-resistance Conferred by Mutations<br />
in the Connection and RNase H Domains of HIV-1<br />
Reverse Transcriptase<br />
Jessica Brehm*, N Sluis-Cremer, and J Mellors<br />
Univ of Pittsburgh, PA, US<br />
10:30 81 Connection Domain Mutations N348I and A360V in<br />
HIV-1 RT Selectively Facilitate Excision of AZT by<br />
Improving Access to Transiently Formed RNA/DNA<br />
Hybrids<br />
Maryam Ehteshami*, G Beilhartz, B Scarth, E Tchesnokov, and<br />
M Gotte<br />
McGill Univ, Montreal, Canada<br />
10:45 82 Circumventing Drug Resistance: Using the Substrate<br />
Envelope Hypothesis to Develop Robust Novel HIV-1<br />
Protease Inhibitors<br />
M Nalam1 , A Ali1 , K Reddy1 , M Altman2 , S Chellappan3 , S Anjum1 ,<br />
T Rana1 , M Gilson3 , B Tidor2 , and Celia Schiffer* 1<br />
1 2 Univ of Massachusetts Med Sch, Worcester, US; Massachusetts<br />
Inst of Tech, Cambridge, US; and 3Ctr for Advanced Res in Biotech,<br />
Univ of Maryland, Baltimore, US<br />
11:00 83 Presence of Minor Populations of Y181C Mutants<br />
Detected by Allele-specific PCR and Risk of Efavirenz<br />
Failure in Treatment-naïve Patients: Results of an<br />
ACTG 5095 Case-cohort Study<br />
Roger Paredes* 1,2 , C Lalama3 , H Ribaudo3 , B Schackman4 ,<br />
C Shikuma5 , W Meyer6 , F Giguel1 , K Squires7 , R Gulick4 , and<br />
D Kuritzkes1 1Brigham and Women’s Hosp, Harvard Med Sch, Boston, MA,<br />
US; 2Fndns irsiCaixa and Lluita contra la SIDA, Badalona, Spain;<br />
3 4 Harvard Sch of Publ Hlth, Boston, MA, US; Weill Med Coll of<br />
Cornell Univ, New York, NY, US; 5Univ of Hawaii, Honolulu, US;<br />
6 7 Quest Diagnostics, Baltimore, MD, US; and Jefferson Med Coll,<br />
Philadelphia, PA, US<br />
11:15 84LB Emergence of HIV-1 Drug Resistance among<br />
Breastfeeding Infants Born to HIV-infected Mothers<br />
Taking Antiretrovirals for Prevention of Mother-to-<br />
Child Transmission of HIV: The Kisumu Breastfeeding<br />
Study, Kenya<br />
Clement Zeh* 1 , P Weidle2 , L Nafisa1 , H Musuluma1 , J Okonji1 ,<br />
E Anyango1 , P Bondo1 , R Masaba1 , M Thigpen2 , and T Thomas1 1 2 CDC Kenya, Kisumu and CDC, Atlanta, GA, US
CROI 2008 Session 25<br />
k Tuesday, 10-11:30 am; Auditorium<br />
CME<br />
Session 23–Oral Abstracts<br />
HIV Vaccines<br />
Moderators:<br />
John Mellors, Univ of Pittsburgh, PA, US<br />
Mario Stevenson, Univ of Massachusetts Med Sch, Worcester, US<br />
10:00 85 GeoVax Clade B DNA/MVA HIV/AIDS Vaccine Is<br />
Well Tolerated and Immunogenic when Administered<br />
to Healthy Seronegative Adults (HVTN 065 part A)<br />
Harriet Robinson* 1 , P Goepfert2 , C Hay3 , S Frey4 , W Blattner5 ,<br />
P Wright6 , M Elizaga7 , L Qin7 , B Moss8 , and HVTN 065 Protocol Team<br />
1 2 GeoVax Inc, Atlanta, GA, US; Univ of Alabama at Birmingham,<br />
US; 3Univ of Rochester, NY, US; 4St Louis Univ, MO, US; 5Inst of<br />
Human Virology, Univ of Maryland, Baltimore, US; 6Vanderbilt Univ, Nashville, TN, US; 7Fred Hutchinson Cancer Res Ctr, Seattle,<br />
WA, US; and 8NIAID, NIH, Bethesda, MD, US<br />
10:15 86 Cellular Immune Responses in HIV-1 Uninfected<br />
Adult Tanzanian Volunteers Enrolled in a Phase I/<br />
II Multiclade HIV-1 DNA Plasmid Vaccine (VRC-<br />
HIVDNA016-00-VP)/Adenovirus-5 Vector (VRC-<br />
HIVADV014-00-VP) Boost Vaccine Trial<br />
Alexandra Schuetz* 1,2 , A Haule1 , M Schunk1 , L Maboko1 ,<br />
M Hoelscher1 , M Robb2 , N Michael2 , B Graham3 , J Cox2 , and<br />
M de Souza2,4 1 2 Mbeya Med Res Prgm, Tanzania; US Military HIV Res Prgm,<br />
Rockville, MD, US; 3Vaccine Res Ctr, NIAID, NIH, Bethesda, MD,<br />
US; and 4Armed Forces Res Inst of Med Sci, Bangkok, Thailand<br />
10:30 87 Therapeutic Vaccination with a Replication Defective<br />
Adenovirus Type 5 HIV-1 gag Vaccine in a Prospective,<br />
Double-blinded, Placebo-controlled Trial (ACTG 5197)<br />
Robert Schooley* 1 , H Wang2 , J Spritzler2 , M Lederman3 , D Havlir4 ,<br />
D Kuritzkes5 , C Battaglia6 , C Godfrey7 , M Robertson8 , B Schock9 ,<br />
and AIDS Clinical Trials Group<br />
1 2 Univ of California, San Diego, US; Harvard Sch of Publ Hlth,<br />
Boston, MA, US; 3Case Western Reserve Univ, Cleveland, OH,<br />
US; 4Univ of California, San Francisco, US; 5Partners Hlthcare,<br />
Boston, MA, US; 6Social & Sci Systems, Silver Spring, MD, US; 7Div of AIDS, NIAID, NIH, Bethesda, MD, US; 8Merck Res Labs, North<br />
Wales, PA, US; and 9Frontier Sci and Tech Res Fndn, Amherst,<br />
NY, US<br />
10:45 88LB Efficacy Results from the STEP Study (Merck V520<br />
Protocol 023/HVTN 502): A Phase II Test-of-Concept<br />
Trial of the MRKAd5 HIV-1 Gag/Pol/Nef Trivalent<br />
Vaccine<br />
M Robertson1 , D Mehrotra1 , D Fitzgerald2 , A Duerr3 , D Casimiro1 ,<br />
J McElrath3 , D Lawrence4 and Susan Buchbinder* 5<br />
1 2 Merck Res Labs, West Point, PA, US, GHESKIO, Port-au-Prince,<br />
Haiti; 3HIV Vaccine Trials Network, Seattle, WA, US; 4NIAID, NIH,<br />
Bethesda, MD, US; and 5San Francisco Dept of Publ Hlth, CA, US<br />
11:05 89LB Immunological Characterization of Subjects from the<br />
STEP Study: A Phase IIB Test-of-Concept Trial of the<br />
MRKAd5 HIV-1 Gag/Pol/Nef Trivalent Vaccine<br />
Michael Robertson* 1 , D Casimiro1 , S De Rosa2 , S Dubey1 , L<br />
Kierstead1 , and J McElrath2 1 2 Merck Res Labs, West Point, PA, US and Fred Hutchinson Cancer<br />
Res Ctr, HIV Vaccine Trials Network, Seattle, WA, US<br />
l Tuesday, 11:30 am-12 noon; Auditorium<br />
Session 24–Plenary CME<br />
<strong>Scientific</strong> Obstacles to an Effective HIV Vaccine<br />
91<br />
Ronald Desrosiers<br />
New England Primate Res Ctr, Harvard Med Sch, Boston,<br />
MA, US<br />
Objectives: This session is directed to clinicians, scientists, and administrators<br />
interested in the development of a safe, effective, preventive vaccine for<br />
HIV-1. It is assumed that participants are familiar with the fundamentals<br />
of immunology and the historic role of vaccines in limiting the spread of<br />
viral disease. At the completion of the session, participants will have gained<br />
knowledge of the formidable scientific obstacles that confront development<br />
of an effective AIDS vaccine. They will also have learned of critical questions<br />
currently facing the field, particularly with respect to the degree of emphasis<br />
that should be placed on discovery research versus product development and<br />
clinical testing.<br />
a Tuesday, 12 noon-12:30 pm; Auditorium<br />
Session 25–Plenary CME<br />
AIDS Vaccine at the Crossroads<br />
92<br />
Neal Nathanson<br />
Univ of Pennsylvania Med Ctr, Philadelphia, US<br />
Objectives: This session is directed to clinicians and scientists interested<br />
in the status of AIDS vaccine development. It is assumed that participants<br />
are familiar with HIV infection and the pathogenesis of AIDS, and with the<br />
history of attempts to develop an AIDS vaccine, as well as the general basis<br />
of vaccines against other viral infections. At the completion of the session,<br />
the participants will be knowledgeable about some of the problems with<br />
development of an AIDS vaccine. Also, they will be acquainted with some<br />
of the proposed strategies to make a more effective candidate immunogen to<br />
protect against HIV infection.<br />
<strong>Program</strong> 13<br />
Tuesday<br />
February 5 Sessions
Tuesday<br />
February 5 Sessions<br />
Session 26 CROI 2008<br />
c Tuesday, 1-4 pm; Poster Hall<br />
Poster Abstracts<br />
(see full session listings starting on page 25)<br />
Session 49. New Insights into APOBEC Proteins<br />
Session 50. Viral Replication Cycle: Molecular Studies<br />
Session 51. Viral Envelope: Tropism and Co-receptor Studies<br />
Session 52. Viral Fitness, Evolution and Recombination<br />
Session 60. CTL Studies and Consequences of Immune Escape<br />
Session 61. Factors Influencing CD4 Counts<br />
Session 62. HIV Superinfection and Viral Co-infection<br />
Session 69. Virologic Parameters in NeuroAIDS<br />
Session 70. Studies into Mechanisms of HIV Neuropathogenesis<br />
Session 75. Immune Activation and Lymphocyte Function<br />
Session 76. Studies on Regulatory T Cells<br />
Session 77. Immune Responses and Control of Viremia<br />
Session 88. New Approaches to HIV Testing<br />
Session 92. HIV-1 Prevention for Positives<br />
Session 93. Modeling the Cost-effectiveness and Impact of PrEP on Resistance<br />
Session 98. Complications, Neurodevelopment and ART-related Toxicities in<br />
Children<br />
Session 99. Mycobacterial Disease in Children<br />
Session 100. Prevention, Identification and Treatment of at-Risk and HIV-infected<br />
Adolescents<br />
Session 107. Maternal ART and Feeding Practices: Impact on Infant Outcomes<br />
Session 108. Infant Feeding, PMTCT and Infant Outcome<br />
Session 109. Properties of Breast Milk<br />
Session 114. Influence of Gender on HIV Replication and Viremia<br />
Session 115. HIV Replication, Immune Activation, HIV-2 Co-infection, and<br />
Genital Shedding in Women<br />
Session 123. ART: Novel Approaches I<br />
Session 124. ART: Novel Approaches II<br />
Session 125. Clinical Pharmacology of Reverse Transcriptase Inhibitors<br />
Session 126. Clinical Pharmacology of Protease Inhibitors<br />
Session 132. Switching Therapy/Treatment Failure in Scale-up <strong>Program</strong>s<br />
Session 136. Resistance to New Antiretrovirals<br />
Session 137. Emerging Patterns of Resistance to New Antiretrovirals<br />
Session 138. Minor Drug-resistant Variants: Detection and Clinical Significance<br />
Session 149. Impact of Subtype on HIV Quantification<br />
Session 150. New Diagnostic and Monitoring Tools<br />
Session 155. Hepatic Complications<br />
Session 156. Markers of Inflammation, Immunodeficiency and Complications<br />
Session 157. Changes in Bone Mineral Density<br />
Session 158. Renal Disease<br />
Session 172. Hepatitis C Co-infection: Markers, Outcome and Effect of ART<br />
Session 173. Hepatitis C Co-infection: Treatment<br />
Session 174. Hepatitis Co-infection: Cardiovascular and Malignancy Association<br />
14 15th Conference on Retroviruses and Opportunistic Infections<br />
c Tuesday, 2-3 pm; Room 311<br />
CME<br />
Session 26–Poster Discussion<br />
(see Session 68 on Monday for corresponding Poster Abstracts)<br />
Clinical Developments in Neuropathogenesis<br />
Discussants:<br />
Dennis Kolson, Univ of Pennsylvania, Philadelphia, US<br />
Richard Price, Univ of California, San Francisco, US<br />
391 Changes in Cognition during HAART: Comparison of 2<br />
Different Scoring Systems to Measure Antiretroviral Drug<br />
Efficacy on HIV Dementia<br />
Valerio Tozzi*, P Balestra, M Salvatori, C Vlassi, G Liuzzi, S Menichetti,<br />
M Zaccarelli, S Cerilli, A Antinori, and P Narciso<br />
Natl Inst for Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy<br />
392 CSF Neural Marker Profile Distinguishes AIDS Dementia<br />
Complex from Alzheimer’s Disease<br />
Magnus Gisslen* 1 , K Blennow 1 , B Brew 2 , P Cinque 3 , L Hagberg 1 , R Price 4 ,<br />
and H Zetterberg 1<br />
1 Sahlgrenska Univ Hosp, Gothenburg, Sweden; 2 St Vincent’s Hosp, Univ<br />
of New South Wales, Sydney, Australia; 3 San Raffaele Hosp, Milan, Italy;<br />
and 4 Univ of California, San Francisco, US<br />
393 HIV Protease Inhibitors and Risk of Peripheral Neuropathy<br />
Ronald Ellis* 1 , J Marquie-Beck 1 , P Delaney 1 , T Alexander 1 , D Clifford 2 ,<br />
J McArthur 3 , D Simpson 4 , C Ake 1 , A Collier 5 , B Gelman 6 , and the<br />
CHARTER Group<br />
1 Univ of California, San Diego, US; 2 Washington Univ, St Louis, MO, US;<br />
3 Johns Hopkins Univ, Baltimore, MD, US; 4 Mt Sinai Sch of Med, New<br />
York, NY, US; 5 Univ of Washington, Seattle, US; and 6 Univ of Texas Med<br />
Branch, Galveston, US<br />
394 ART Resistance Influences CSF HIV RNA Levels and<br />
Neuropsychological Performance in HIV-infected Individuals<br />
George Hightower* 1 , S Letendre 1 , M Cherner 1 , S Gibson 1 , R Ellis 1,2 ,<br />
C Ignacio 1 , R Heaton 1 , I Grant 1,2 , D Richman 1,2 , D Smith 1,2 , and San Diego<br />
HIV Neurobehavioral Res Ctr (HNRC) Group<br />
1 Univ of California, San Diego, US and 2 San Diego VA Hlthcare Systems,<br />
CA, US<br />
395 CSF t-τ/p-τ and Amyloid-β 1-42 in HIV Infection<br />
Bruce Brew* 1 , M Gisslen 2 , L Pemberton 1 , P Cinque 3 , L Hagberg 2 , R Price 4 ,<br />
K Blennow 2 , H Zetterberg 2 , and S Spudich 4<br />
1 St Vincent’s Hosp, Sydney Australia; 2 Gothenburg Univ, Sweden; 3 San<br />
Raffaele Hosp, Milan, Italy; and 4 Univ of California, San Francisco, US<br />
396a Comparative Analysis of HIV-specific CD8 + T Cells<br />
in Cerebrospinal Fluid and Peripheral Blood among<br />
Treatment-naïve HIV-immune Controllers<br />
Shanmugalakshmi Sadagopal*, S Lorey, L Barnett, R Basham, L Lebo,<br />
H Erdem, K Haman, M Avison, D Haas, and S Kalams<br />
Vanderbilt Univ, Nashville, TN, US<br />
396b Abnormal CSF Amyloid β42 Levels Link HIV-associated<br />
Cognitive Disease and Alzheimer’s Disease<br />
David Clifford*, J Kauwe, M Teshome, A Shah, M Spinner, J Morris,<br />
D Holtzman, and A Fagan<br />
Washington Univ, St Louis, MO, US
CROI 2008 Session 28<br />
c Tuesday, 2-3 pm; Room 312<br />
CME<br />
Session 27–Poster Discussion<br />
(see Session 133 on Wednesday for corresponding Poster Abstracts)<br />
Risk Factors for Lost-to-Follow-up in Resourcelimited<br />
Settings<br />
Discussants:<br />
Wafaa El-Sadr, Harlem Hosp Ctr, Columbia Univ, New York, NY, US<br />
Charles Gilks, World Hlth Org, Geneva, Switzerland<br />
838 Characteristics of Facilities and <strong>Program</strong>s Delivering HIV<br />
Care and Treatment Services Are Associated with Loss to<br />
Follow-up Rates in <strong>Program</strong>s from 7 Sub-Saharan African<br />
Countries<br />
Denis Nash* 1 , C Korves 1 , S Saito 1 , S Sherman 1 , B Elul 1 , D Hoos 1 ,<br />
V Mugisha 2 , M Sheriff 3 , W El Sadr 1 , and Intl Ctr for AIDS Care and<br />
Treatment Prgms (ICAP)<br />
1 Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; 2 Columbia<br />
Univ, Intl Ctr for AIDS Care and Treatment Prgms, Kigali, Rwanda; and<br />
3 Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, Nairobi,<br />
Kenya<br />
839 Loss to Care and Death before ART: Patients Eligible for<br />
Treatment Who Do Not Make It in Durban, South Africa<br />
Ingrid Bassett* 1,2,3 , B Wang 1 , S Chetty 4 , J Giddy 4 , Z Lu 1 , E Losina 2,3,5 ,<br />
R Walensky 1,2,3,6 , and K Freedberg 1,3,5,6<br />
1 Massachusetts Gen Hosp, Boston, US; 2 Brigham and Women’s Hosp,<br />
Boston, MA, US; 3 Harvard Med Sch, Boston, MA, US; 4 McCord Hosp,<br />
Durban, South Africa; 5 Boston Univ Sch of Publ Hlth, MA, US; and<br />
6 Harvard Sch of Publ Hlth, Boston, MA, US<br />
840 Losses to Follow-up in a Large ART <strong>Program</strong> in Uganda<br />
A Muwanga, Philippa Easterbrook*, P Schaefer, M Wandera, D Okello,<br />
B Castelnuovo, M Kamya, and A Kambugu<br />
Infectious Disease Inst, Kampala, Uganda<br />
841 Loss to Follow-up in Community Clinics in South Africa:<br />
Role of CD4 Count, Gender, and Pregnancy<br />
Bingxia Wang* 1,2 , E Losina 1,3,4 , R Stark 5 , A Munro 5 , R Walensky 1,2,3 ,<br />
M Wilke 5 , D Martin 5 , Z Lu 1 , K Freedberg 1,2,4,6 , and R Wood 7<br />
1 Massachusetts Gen Hosp, Boston, US; 2 Harvard Med Sch, Boston, MA,<br />
US; 3 Brigham and Women’s Hosp, Boston, MA, US; 4 Boston Univ Sch of<br />
Publ Hlth, MA, US; 5 South Africa Catholic Relief Svcs; 6 Harvard Sch of<br />
Publ Hlth, Boston, MA, US; and 7 Univ of Cape Town, South Africa<br />
842 What Becomes of the Defaulters? A Sampling-based<br />
Approach to Determine Outcomes of Patients Who Become<br />
Lost to Follow-up in ART Scale-up <strong>Program</strong>s in Africa<br />
Elvin Geng* 1 , D Bangsberg 1 , N Musinguzi 2 , N Emenyonu 1 , M Bwana 2 ,<br />
D Glidden 1 , C Yiannoutsos 3 , S Deeks 1 , J Martin 1 , and East Africa IeDEA<br />
Consortium<br />
1 Univ of California, San Francisco, US; 2 Mbarara Univ of Sci and Tech,<br />
Uganda; and 3 Indiana Univ, Indianapolis, US<br />
c Tuesday, 2-3 pm; Room 302-304<br />
CME<br />
Session 28–Poster Discussion<br />
(see Session 91 on Monday for corresponding Poster Abstracts)<br />
Novel PrEP Agents and Evaluation Strategies<br />
Discussants:<br />
Walid Heneine, CDC, Atlanta, GA, US<br />
Sharon Hillier, Univ of Pittsburgh, Magee-Womens Res Inst, PA, US<br />
556 An Engineered Bi-functional HIV-1 Neutralizing Protein as<br />
a Potential Microbicide<br />
Vadim Villarroel* 1 , L Lagenaur1,2 , and E Berger1 1 2 NIAID, NIH, Bethesda, MD, US and Osel, Inc, Santa Clara, CA, US<br />
557 Better Protection against HIV-1 Infection in vitro with<br />
Candidate Microbicide Compounds in Combination<br />
Susan Schader* 1,2 , B Scarth2 , S Colby-Germinario1 , J Schachter1 ,<br />
J Nuttall3 , M Gotte2 , and M Wainberg1,2 1 2 McGill Univ AIDS Ctr, Lady Davis Inst, Montreal, Canada; McGill<br />
Univ, Montreal, Canada; and 3Intl Partnership for Microbicides, Silver<br />
Spring, MD, US<br />
558 Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal<br />
Transmission of HIV-1 in Humanized BLT Mice<br />
Paul Denton* 1 , J Estes 2 , Z Sun 1 , F Othieno 1 , D Powell 1 , A Haase 2 , and<br />
V Garcia 1<br />
1 Univ of Texas Southwestern Med Ctr, Dallas, US and 2 Univ of<br />
Minnesota, Minneapolis, US<br />
559a Size-fitting of Intravaginal Rings for Macaques and in vitro<br />
Release Kinetics of Zinc Finger Inhibitors<br />
James Smith* 1 , K Malcolm 2 , E Appella 3 , C McConville 2 , M Schito 3 ,<br />
D Woolfson 2 , R Hayashi 3 , N Lanier 1 , R Otten 1 , and S Butera 1<br />
1 CDC, Atlanta, GA, US; 2 Queen’s Univ of Belfast, Sch of Pharmacy,<br />
Northern Ireland; and 3 NCI, NIH, Bethesda, MD, US<br />
559b Safety and Pharmacokinetic Assessment of 28-Day Anti-HIV<br />
Dapivirine Intravaginal Microbicide Rings<br />
Annalene Nel* 1 , S Smythe 1 , K Young 1 , K Malcolm 2 , Z Rosenberg 1 , and<br />
J Romano 1<br />
1 Intl Partnership for Microbicides, Silver Spring, MD, US and 2 Queen’s<br />
Unive, Belfast, Northern Ireland<br />
560 Topical Application of Fully Recombinant RANTES Analogs<br />
Protect Macaques from Vaginal SHIV Transmission<br />
Ronald Veazey* 1 , M Lederman 2 , B Ling 1 , L Green 1 , E Ribka 1 , D Mosier 3 ,<br />
R Offord 4,5 , and O Hartley 4<br />
1 Tulane Natl Primate Res Ctr, Covington, LA, US; 2 Case Western<br />
Reserve Univ, Cleveland, OH, US; 3 Scripps Res Inst, La Jolla, CA, US;<br />
4 Univ of Geneva, Switzerland; and 5 Mintaka Fndn for Med Res, Geneva,<br />
Switzerland<br />
<strong>Program</strong> 15<br />
Tuesday<br />
February 5 Sessions
Tuesday<br />
February 5 Sessions<br />
Session 29 CROI 2008<br />
c Tuesday, 2-3 pm; Ballroom A<br />
CME<br />
Session 29–Poster Discussion<br />
(see Session 165 on Wednesday for corresponding Poster Abstracts)<br />
TB-associated Immune Reconstitution<br />
Inflammatory Syndrome<br />
Discussants:<br />
Philippa Easterbrook, Infectious Disease Inst, Kampala, Uganda<br />
Andrew Zolopa, Stanford Univ, Palo Alto, CA, US<br />
1006 M. tuberculosis-specific T Cell Expansions and the<br />
Pathogenesis of the HIV-TB-associated Immune<br />
Reconstitution Inflammatory Syndrome<br />
G Meintjes 1 , K Wilkinson 2 , K van Veen 1 , K Rebe 3 , D Pepper 3 ,<br />
K Skolimowska 4 , M Rangaka 1 , R Seldon 1 , G Maartens 5 , and Robert Wilkinson* 1<br />
1 Inst of Infectious Disease and Moleculr Med, Univ of Cape Town, South<br />
Africa; 2 Natl Inst of Med Res, London, UK; 3 GF Jooste Hosp, Manenberg,<br />
South Africa; 4 Imperial Coll London, UK; and 5 Univ of Cape Town, South<br />
Africa<br />
1007 Biomarkers of Immune Activation Are Predictors of HIV<br />
Immune Reconstitution Inflammatory Syndrome<br />
David Boulware* 1 , D Meya 2 , T Bergemann 1 , I Vlasova 1 , A Kambugu 2 ,<br />
K McAdam 2 , E Janoff 3 , and P Bohjanen 1<br />
1 Univ of Minnesota, Minneapolis, US; 2 Infectious Disease Inst, Makerere<br />
Univ, Kampala, Uganda; and 3 Univ of Colorado Hlth Sci Ctr, Denver, US<br />
1008 Immunologic Markers as Predictors of TB-associated<br />
Immune Reconstitution Inflammatory Syndrome in HIV<br />
and TB Co-infected Persons in Thailand<br />
Hong Van Tieu* 1 , J Ananworanich 2 , A Avihingsanon 3,4 ,<br />
W Apateerapong 2 , S Sirivichayakul 4,5 , S Klongugkara 6 , B Boonchokchai 2 ,<br />
U Siangphoe 2 , S Hammer 1 , and W Manosuthi 6<br />
1 Columbia Univ Coll of Physicians and Surgeons, New York, NY, US;<br />
2 South East Asia Res Collaboration with Univ of Hawaii, Bangkok,<br />
Thailand; 3 HIV Netherlands Australia Thailand Res Collaboration,<br />
Bangkok; 4 Thai Red Cross AIDS Res Ctr, Bangkok; 5 Chulalongkorn<br />
Univ, Bangkok, Thailand; and 6 Bamrasnaradura Infectious Diseases Inst,<br />
Nonthaburi, Thailand<br />
1009 High Rates of Drug-resistant TB among Patients with<br />
Suspected TB Immune Reconstitution Inflammatory<br />
Syndrome in South Africa<br />
Kevin Rebe* 1,2 , G Meintjes 1,2 , M Rangaka 1 , D Pepper 2 , C Morroni 1 ,<br />
G Maartens 1 , and R Wilkinson 1,2,3<br />
1 Univ of Cape Town, South Africa; 2 GF Jooste Hosp, Manenberg, South<br />
Africa; and 3 Imperial Coll, London, UK<br />
16 15th Conference on Retroviruses and Opportunistic Infections<br />
e Tuesday, 4-6 pm; Room 302-304<br />
Session 30–Symposium CME<br />
The Emerging Science of HIV Prevention in Women<br />
Conveners:<br />
Sharon Hillier, Univ of Pittsburgh, Magee-<br />
Womens Res Inst, PA, US<br />
Renee Ridzon, Bill and Melinda Gates Fndn,<br />
Seattle, WA, US<br />
93<br />
Vaginal Flora, Co-infections, and Immune Cells<br />
in the Genital Mucosa: Implications for HIV<br />
Transmission<br />
Rupert Kaul, Univ of Toronto, Canada<br />
94<br />
Impact of Hormonal Contraception on HIV<br />
Acquisition, Cervico-Vaginal Viral Shedding, and<br />
Disease Progression<br />
Elizabeth Stringer<br />
Univ of Alabama at Birmingham, Lusaka, Zambia<br />
95<br />
Genital Compartmentalization of Orally and<br />
Topically Administered Antiretrovirals<br />
Angela Kashuba<br />
Univ of North Carolina at Chapel Hill, US<br />
96<br />
Microbicides: Rapid Evolution since 2000<br />
Quarraisha Abdool Karim<br />
Columbia Univ, NY, New York, US and Univ of Kwazulu Natal,<br />
Durban, South Africa<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
gender-specific issues related to genital distribution of antiretrovirals, immune<br />
cells in the genital tract, the effect of female reproductive hormones on HIV,<br />
and new biomedical HIV prevention options for women. It is assumed that<br />
participants are familiar with risk factors for HIV transmission to women. At<br />
the completion of the session, participants will be knowledgeable about the<br />
effect of the vaginal ecology on immune cells in the female reproductive tract,<br />
the influence of contraceptives on HIV susceptibility and disease progression,<br />
the pharmacokinetics of orally and vaginally administered antiretrovirals in the<br />
female genital tract, and ongoing research in topical microbicides.
CROI 2008 Session 32<br />
e Tuesday, 4-6:15 pm; Ballroom A<br />
CME<br />
Session 31–Oral Abstracts<br />
HIV Molecular Biology and Host Cell Interactions<br />
Moderators:<br />
Alan Engelman, Dana-Farber Cancer Inst, Boston, MA, US<br />
Dana Gabuzda, Dana-Farber Cancer Inst, Boston, MA, US<br />
4:00 97 Early Interactions of Fluorescently Labeled HIV with<br />
the Female Genital Tract<br />
Scott McCoombe* 1 , A Trull1 , M McRaven1 , N Byers1 ,<br />
M Anderson1 , J Kowalski1 , M Dinh1 , R Veazey2 , and T Hope1 1 2 Northwestern Univ, Chicago, IL, US and Tulane Natl Primate Res<br />
Ctr, Covington, LA, US<br />
4:15 98 Identification of LEDGF/p75 PWWP Domain Amino<br />
Acids Residues Critical for Chromatin Binding and<br />
HIV-1 Infection<br />
Michelle Shun*, F Di Nunzio, and A Engelman<br />
Dana-Farber Cancer Inst, Boston, MA, US<br />
4:30 99 Host-specific Adaptation of the HIV-1/SIVcpz Gag<br />
Matrix Protein<br />
Frederic Bibollet-Ruche* 1 , J Decker1 , J Easlick1 , B Keele1 , Y Li1 ,<br />
J Takehisa1 , M Krauss1 , G Shaw1 , P Sharp2 , and B Hahn1 1 2 Univ of Alabama at Birmingham, US and Univ of Edinburgh, UK<br />
4:45 100 Vpr Binds to DCAF1 and to DDB1 to Mediate Its<br />
Biological Functions in a Species-specific Interaction<br />
Yoshiyuki Hakata* and N Landau<br />
New York Univ Sch of Med, New York, US<br />
5:00 101 The Role of Human Staufen in the Intracellular<br />
Trafficking of Unspliced HIV-1 RNA<br />
Nan Yan* and J Lieberman<br />
Immune Disease Inst, Boston, MA, US and Harvard Med Sch,<br />
Boston, MA, US<br />
5:15 102 Identification of a Novel ESCRT-I Subunit and Other<br />
ESCRT-I Binding Factors Required for Efficient HIV-1<br />
Release<br />
Virginie Sandrin* 1 , E Morita1 , MA Karren1 , S Gygi2 , S Morham3 ,<br />
and W Sundquist1 1 2 Univ of Utah, Salt Lake City, US; Harvard Med Sch, Boston, MA,<br />
US; and 3Myriad Genetics Inc, Salt Lake City, UT, US<br />
5:30 103 Role of GGA and Arf Proteins in HIV-1 Assembly and<br />
Release<br />
A Joshi1 , J Bonifacino2 , and Eric Freed* 1<br />
1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US and Natl Inst<br />
of Child Hlth and Human Devt, NIH, Bethesda, MD, US<br />
5:45 104a Modulation of Viral Assembly and Virion Release by Vpu<br />
John Guatelli* 1,2 , D Goff1 , and N Van Damme2 1 2 Univ of California, San Diego, US and VA Hlthcare System, San<br />
Diego, CA, US<br />
6:00 104bLB Identification of Host Proteins Required for HIV<br />
Infection through a Functional Genomic Screen<br />
Abraham Brass* 1,2,3 , D Dykxhoorn3,4 , Y Benita3 , N Yan3,4 , A Engelman5 ,<br />
R Xavier3 , J Lieberman3,4 , and S Elledge2,3 1 2 Massachusetts Gen Hosp, Boston, US; Brigham and Women’s<br />
Hosp, Boston, MA, US; 3Harvard Med Sch, Boston, MA, US;<br />
4 5 Immune Disease Inst, Boston, MA, US; and Dana-Farber Cancer<br />
Inst, Boston, MA, US<br />
e Tuesday, 4-6 pm; Ballroom B/C<br />
Session 32–Symposium CME<br />
Aging and AIDS<br />
Conveners:<br />
Amy Justice, Yale Univ Sch of Med, New<br />
Haven, CT, US<br />
Michael Lederman, Case Western Reserve<br />
Univ, Sch of Med, Cleveland, OH, US<br />
105<br />
Immune Exhaustion in Aging and AIDS: Parallel<br />
Mechanisms and Possible Solutions<br />
Rita Effros<br />
David Geffen Sch of Med, Univ of California, Los Angeles, US<br />
106<br />
The Effect of Aging on Human Pharmacology<br />
Charles Flexner<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
107<br />
Contributions of Age-related Morbidities<br />
William Powderly<br />
Univ Coll Dublin, Ireland<br />
108<br />
Epidemiology of HIV, including Response to ART, in<br />
Older Populations<br />
Bruno Ledergerber<br />
Univ Hosp Zurich, Switzerland<br />
Objectives: This session is directed to clinicians and researchers interested<br />
in the immunopathogenesis of HIV infection and aging and in the clinical<br />
management of HIV infection in older individuals. The session will describe<br />
the effects of aging on the normal immune system and the interactions between<br />
the effects of aging and of HIV infection on immune function.; identify<br />
changes in drug metabolism and pharmacodynamics with age; list strategies<br />
for overcoming the challenges in managing diseases of aging in the context of<br />
HIV infection; and enable the participant to recognize the effect of aging on<br />
response to treatment with ART. It is assumed that participants are familiar<br />
with basic HIV-related immunology and management of HIV disease. At the<br />
completion of the session, participants will be able to identify the challenges of<br />
managing HIV infection in an aging population, the complex interrelationships<br />
between management of HIV disease and of diseases of aging, and will<br />
understand some of the immunologic issues that underlie changes due to aging<br />
and their effect on HIV and its complications.<br />
<strong>Program</strong> 17<br />
Tuesday<br />
February 5 Sessions
Tuesday<br />
February 5 Sessions<br />
Session 33 CROI 2008<br />
e Tuesday, 4-6 pm; Auditorium<br />
Session 33–Symposium CME<br />
Targeting TB: New Opportunities and Challenges<br />
Conveners:<br />
Richard Chaisson, Johns Hopkins Univ Sch<br />
of Med, Baltimore, MD, US<br />
Betina Durovni, Dept of Publ Hlth, Rio de<br />
Janeiro, Brazil<br />
109<br />
How Can <strong>Scientific</strong> Advances Contribute to TB<br />
Control<br />
William Bishai<br />
Johns Hopkins Univ Sch of Med, Baltimore, MD, US<br />
110<br />
Prospects for New Drugs for TB<br />
Timothy Sterling<br />
Vanderbilt Univ Sch of Med, Nashville, TN, US<br />
111<br />
Concurrent Management of TB and HIV<br />
Stephen Lawn<br />
Univ of Cape Town, South Africa and London Sch of Hygiene &<br />
Tropical Med, UK<br />
112<br />
Confronting the Catastrophe of M/XDR TB<br />
Gerald Friedland and TF CARES<br />
Yale Univ, New Haven, CT, US<br />
Objectives: This session is directed to clinicians and scientists interested<br />
in controlling TB and TB/HIV co-infection, using new tools and strategies.<br />
It is assumed that participants are familiar with the natural history and<br />
clinical manifestations of TB and TB/HIV, as well as with conventional<br />
treatment paradigms. At the completion of the session, participants with be<br />
knowledgeable about scientific advances in TB genomics, new drugs in the<br />
pipeline for treating and preventing TB, special challenges in co-managing<br />
TB and HIV disease, and the prospects for controlling multi-drug resistance<br />
(MDR) and extremely drug-resistant (XDR) TB.<br />
18 15th Conference on Retroviruses and Opportunistic Infections
CROI 2008 Session 36<br />
i Wednesday, 8:30-9 am; Auditorium<br />
Session 34–Plenary CME<br />
Advances in the Management of Treatmentexperienced<br />
Patients: A 2 nd Wave of HAART<br />
113<br />
Sharon Walmsley<br />
Univ of Toronto, Canada<br />
Objectives: This session is directed to clinicians and scientists interested<br />
in the current clinical management of persons living with HIV who have<br />
developed resistant viruses. It is assumed that participants are familiar with<br />
the major classes of antiretroviral agents and their mechanism of action. At the<br />
completion of the session, participants will be knowledgeable about the goal<br />
of maximal viral suppression in treatment-experienced patients, and the role<br />
of new agents within existing classes and new targets for ART to help achieve<br />
this goal.<br />
j Wednesday, 9-9:30 am; Auditorium<br />
Session 35–Plenary CME<br />
New Insights into Retrovirus-Host-cell<br />
Interactions<br />
114<br />
Paul Bieniasz<br />
Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New<br />
York, NY, US<br />
Objectives: This session is directed to clinicians and scientists interested<br />
in retrovirus-host interactions, in particular how host cells mount a defense<br />
against retrovirus infection and how HIV-1 has evolved strategies to evade<br />
or counteract these host defenses. It is assumed that participants are familiar<br />
with the basic features of HIV-1 and its replication cycle. At the completion<br />
of the session, participants will be knowledgeable about concepts associated<br />
with intrinsic and innate cellular defenses that inhibit the HIV-1 replication<br />
cycle, about a newly discovered cellular inhibitor called “tetherin” that blocks<br />
the release of HIV-1 and other virus particles from infected cells, and how an<br />
HIV-1 accessory gene antagonizes the function of this antiviral molecule.<br />
k Wednesday, 10 am-12 noon; Room 302-304<br />
CME<br />
Session 36–Oral Abstracts<br />
New Insights into Mechanisms of Viral<br />
Pathogenicity<br />
Moderators:<br />
Satya Dandekar, Univ of California, Davis, US<br />
Ivona Pandrea, Tulane Natl Primate Res Ctr, Covington, LA, US<br />
10:00 115 Preferential Loss of Th17 CD4 T Cells in the<br />
Gastrointestinal Tract of HIV-infected Individuals but<br />
Not SIV-infected Sooty Mangabeys<br />
Barbara Cervasi* 1 , J Brenchley2 , M Paiardini1 , S Gordon1 ,<br />
A Asher2 , I Frank1 , J Else3 , D Douek2 , and G Silvestri1 1 2 Univ of Pennsylvania, Philadelphia, US; Vaccine Res Ctr, NIAID,<br />
NIH, Bethesda, MD, US; and 3Yerkes Natl Primate Res Ctr, Emory<br />
Univ, Atlanta, GA, US<br />
10:15 116 Preferential Loss of Th17 T Cells at Mucosal Sites<br />
Predicts AIDS Progression in Simian Immunodeficiency<br />
Virus-infected Macaques<br />
Valentina Cecchinato* 1 , C Trindade1 , JM Heraud1 , A Laurence2 ,<br />
J Brenchley3 , E Tryniszewska1,4 , D Venzon1 , D Douek3 , J O’Shea2 ,<br />
and G Franchini1 1 2 NCI, NIH, Bethesda, MD, US; Natl Inst of Arthritis and<br />
Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, US;<br />
3 4 NIAID, NIH, Bethesda, MD, US; and Med Univ of Bialystok,<br />
Poland<br />
10:30 117LB Primary SIV Infection Causes Rapid Loss of the Balance<br />
between TH17 and T Regulatory Cell Populations in<br />
Pathogenic Infection of Non-human Primates<br />
David Favre* 1 , S Lederer2 , B Kanwar1 , ZM Ma3 , S Proll2 , Z Kasakow1 ,<br />
C Miller3 , M Katze2 , and J McCune1 1 2 Univ of California, San Francisco, US; Univ of Washington,<br />
Seattle, US; and 3Univ of California, Davis, US<br />
10:45 118 SIVrcm, a Unique CCR2-tropic Virus, Selectively<br />
Depletes Memory CD4 + T Cells in Pigtailed Macaques<br />
Due to Rapid Co-receptor Expansion in vivo<br />
Rajeev Gautam*, T Gaufin, I Butler, A Gautam, C Monjure,<br />
M Barnes, M Pattison, P Marx, I Pandrea, and C Apetrei<br />
Tulane Natl Primate Res Ctr, Covington, LA, US<br />
11:00 119 Bacterial DNA Are Measurable in Plasma of HIVinfected<br />
Patients and Are Diminished by ART<br />
Wei Jiang* 1 , K Haley1 , S Sieg1 , M Lederman1 , A Aasher2 ,<br />
D Douek2 , and J Brenchley2 1 2 Case Western Reserve Univ, Cleveland, OH, US and Vaccine Res<br />
Ctr, NIAID, NIH, Bethesda, MD, US<br />
11:15 120 Evidence for Persistent Viral Replication in Lymph<br />
Node and GALT of ARV-treated Persons<br />
Timothy Schacker* 1 , M Stevenson2 , J Brenchley3 , D Douek3 , and<br />
A Haase1 1 2 Univ of Minnesota, Minneapolis, US; Univ of Massachuesetts,<br />
Boston, US; and 3Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US<br />
11:30 121 HIV-1 Rebound during ART Interruption Is Associated<br />
with a Preferential Depletion of CD4 + T Cells from the<br />
Gastrointestinal Tract<br />
Saurabh Mehandru* 1,2 , M Poles1,3 , K Tenner-Racz4 , M LaRoche1 ,<br />
K Rodriguez1 , T Evering1 , D Castor1 , A Lloyd1 , P Racz4 , and<br />
M Markowitz1 1Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York,<br />
NY, US; 2Mt Sinai Sch of Med, New York, NY, US; 3New York Univ<br />
Sch of Med, New York, US; and 4Bernhard Nocht Inst for Tropical<br />
Med, Hamburg, Germany<br />
11:45 122 Syndecan-3 Is a Dendritic Cell-specific Attachment<br />
Receptor for HIV-1<br />
L De Witte1 , M Bobardt2 , T Geijtenbeek1 , and Philippe Gallay* 2<br />
1 2 VU Univ Med Ctr, Amsterdam, The Netherlands and Scripps Res<br />
Inst, La Jolla, CA, US<br />
<strong>Program</strong> 19<br />
Wednesday<br />
February 6 Sessions
Wednesday<br />
February 6 Sessions<br />
Session 37 CROI 2008<br />
k Wednesday, 10-11:45 am; Ballroom A<br />
CME<br />
Session 37–Oral Abstracts<br />
Epidemiology of HIV Infection and Scale-up of ART<br />
in Developing Countries<br />
Moderators:<br />
Kevin De Cock, World Hlth Org, Geneva, Switzerland<br />
Dorothy Mbori-Ngacha, Global AIDS Prgm, CDC Kenya, Nairobi<br />
10:00 123 Determinants for HIV Acquisition among Adults in<br />
Uganda: A Population-based, Nationally Representative<br />
Study<br />
Wolfgang Hladik* 1 , J Musinguzi2 , A Opio2 , W Kirungi2 , J Ekwaru1 ,<br />
F Kaharuza1 , R Downing1 , R Bunnell1 , and J Mermin1 1 2 CDC Uganda, Entebbe and AIDS Control Prgm, Ministry of Hlth,<br />
Kampala, Uganda<br />
10:15 124 Measuring the Force of the HIV Epidemic in a Rural<br />
Area of South Africa: The Africa Centre<br />
Till Barnighausen* 1,2 , ML Newell1,3 , F Tanser1 , C Mbizana1 ,<br />
C Wallrauch1 , G Cooke1,4 , Z Gqwede1 , and K Herbst1 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal,<br />
Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA,<br />
US; 3Inst of Child Hlth, Univ Coll London, UK; and 4Imperial Coll,<br />
London, UK<br />
10:30 125 Utility of Routine Viral Load, CD4 Cell Count, and<br />
Clinical Monitoring among HIV-infected Adults in<br />
Uganda: A Randomized Trial<br />
Alex Coutinho* 1 , J Mermin2,3 , J Ekwaru2 , W Were2 , R Bunnell2,3 ,<br />
F Kaharuza2 , L Alexander2 , P Solberg2 , J Tappero2 , and D Moore2,4 1 2 TASO and Infectious Disease Inst, Kampala, Uganda; CDC<br />
Uganda, Entebbe; 3CDC Kenya, Nairobi; and 4Univ of British<br />
Columbia, Vancouver, Canada<br />
10:45 126 Long-term CD4 Response to Potent ART among ARTnaïve<br />
Patients in Several Low-income Countries<br />
Denis Nash* 1 , M Katyal1 , M Brinkhof2 , S Tuboi3 , P Braitstein4 ,<br />
E Balestre5 , M May6 , E Sprinz7 , N Kumarasamy8 , M Egger2 , and<br />
the Antiretroviral Therapy in Low Income Countries (ART-LINC)<br />
Collaboration of IEDEA<br />
1Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US;<br />
2 3 4 Univ of Berne, Switzerland; Univ of Pittsburgh, PA, US; Indiana<br />
Univ Sch of Med, Indianapolis, US; 5Univ Victor Segalen, Bordeaux,<br />
France; 6Univ of Bristol, UK; 7Federal Univ of Rio Grande do Sul,<br />
Porte Alegre, Brazil; and 8YRGCARE, Chennai, India<br />
11:00 127 Evaluation of Clinical and Immunologic Outcomes from<br />
the National ART <strong>Program</strong> in Rwanda, 2004 to 2005<br />
Francois Ndamage* 1 , D Lowrance1,2,3 , A Rukundo1 , E Kayirangwa4 ,<br />
F Ndagije2 , D Hoover5 , J Hanson6 , W Lo7 , A Ayaba4 , and T Ellerbrock3 1Treatment and Res on AIDS Ctr, Ministry of Hlth, Kigali, Rwanda;<br />
2Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms,<br />
Kigali, Rwanda; 3Global AIDS Prgm, CDC, Atlanta, GA, US;<br />
4 5 Global AIDS Prgm, CDC Rwanda, Kigali; Rutgers Univ, New<br />
Brunswick, NJ, US; 6Global AIDS Prgm, CDC Namibia, Windhoek;<br />
and 7Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms,<br />
New York, NY, US<br />
11:15 128 Early Detection of Effect on Adult Mortality of a<br />
Government ART <strong>Program</strong> in Rural KwaZulu Natal,<br />
South Africa<br />
Till Barnighausen* 1,2 , G Cooke1,3 , K Herbst1 , A Kany Kany1 , and<br />
ML Newell1,4 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal,<br />
Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA,<br />
US; 3Imperial Coll, London, UK; and 4Univ Coll London, UK<br />
11:30 129LB High HIV Prevalence among Males in Discordant<br />
Partnerships in a Full Access Door–Door VCT<br />
<strong>Program</strong> in Rural Uganda<br />
E Tumwesigye* 1 , S Asiimwe1 , E Muganzi1 , M Achom2 , D Kabatesi2 ,<br />
and J Tappero2 1 2 Integrated Community Based Initiatives and CDC Uganda<br />
20 15th Conference on Retroviruses and Opportunistic Infections<br />
k Wednesday, 10-11:45 am; Ballroom B/C<br />
CME<br />
Session 38–Oral Abstracts and <strong>Scientific</strong> Overview<br />
Drug Delivery, Interactions and Genetic Variability<br />
Moderators:<br />
Giovanni Di Perri, Univ of Turin, Italy<br />
Courtney Fletcher, Univ of Nebraska Med Ctr, Omaha, US<br />
10:00 131 Low Tenofovir Concentrations in Cerebrospinal Fluid<br />
Brookie Best* 1 , S Letendre 1 , P Koopmans 2 , D Clifford 3 , A Collier 4 ,<br />
B Gelman 5 , J McArthur 6 , D Simpson 7 , E Capparelli 1 , R Ellis 1 , and the<br />
CHARTER Group<br />
1 Univ of California, San Diego, US; 2 Radboud Univ Nijmegen Med<br />
Ctr, The Netherlands; 3 Washington Univ, St Louis, MO, US; 4 Univ<br />
of Washington, Seattle, US; 5 Univ of Texas Med Branch, Galveston,<br />
US; 6 Johns Hopkins Univ, Baltimore, MD, US; and 7 Mt Sinai Sch of<br />
Med, New York, NY, US<br />
10:15 132 Drug Interaction between Antimalarial Drugs and<br />
Lopinavir/Ritonavir<br />
Polina German* 1 , S Parikh 2 , J Lawrence 2 , N Lindegardh 3 ,<br />
P Rosenthal 2 , D Havlir 2 , E Charlebois 2 , G Dorsey 2 , and F Aweeka 1<br />
1 Univ of California, San Francisco, Sch of Pharmacy, US; 2 San<br />
Francisco Gen Hosp, Univ of California, US; and 3 Faculty of<br />
Tropical Med, Mahidol Univ, Bangkok, Thailand<br />
10:30 133 Genetic Variation in Accessory Metabolic Pathways<br />
Is Associated with Extreme Efavirenz Exposure in<br />
Individuals with Impaired CYP2B6 Function<br />
Julia di Iulio* 1 , M Rotger1 , R Lubomirov1 , L Decosterd1 , CB Eap2 ,<br />
and A Telenti1 1 2 Univ Hosp Ctr, Univ of Lausanne, Switzerland and Cery Hosp,<br />
Lausanne, Switzerland<br />
10:45 134 Long-acting TMC278, a Parenteral Depot Formulation<br />
Delivering Therapeutic NNRTI Concentrations in<br />
Preclinical and Clinical Settings<br />
Gerben van ‘t Klooster* 1 , R Verloes1 , L Baert1 , F van Velsen1 ,<br />
MP Bouche2 , K Spittaels1 , J Leempoels3 , P Williams1 , G Kraus1 , and<br />
P Wigerinck1 1 2 Tibotec BVBA, Mechelen, Belgium; Johnson & Johnson Pharma<br />
R&D, Beerse, Belgium; and 3Johnson & Johnson Pharma R&D,<br />
Merksem, Belgium<br />
11:00 135LB Maraviroc Pharmacokinetics in Blood Plasma, Genital<br />
Tract Fluid and Tissue in Healthy Female Volunteers<br />
J Dumond1 , Kristine Patterson* 1 , A Pecha1 , R Werner1 , E Andrews2 ,<br />
B Damle2 , R Tressler2 , J Worsley3 , K Boggess1 , and A Kashuba1 1 2 Univ of North Carolina at Chapel Hill, US; Pfizer Inc, New York,<br />
NY, US; and 3Pfizer Global R&D, Sandwich, Kent, UK<br />
11:15 136<br />
The Evolution of Therapeutic Drug Monitoring in<br />
ART<br />
Giovanni Di Perri* and S Bonora<br />
Univ of Turin, Italy
CROI 2008 Session 39<br />
k Wednesday, 10 am-12 noon; Auditorium<br />
CME<br />
Session 39–Oral Abstracts<br />
Cardiovascular Risk, Mortality and TB<br />
Complicating HIV Infections<br />
Moderators:<br />
Ian Sanne, Univ of the Witwatersrand, Johannesburg, South Africa<br />
Christine Wanke, Tufts Univ Sch of Med and Tufts–New England Med Ctr, Boston,<br />
MA, US<br />
10:00 139 Elevated Levels of Interleukin-6 and D-dimer Are<br />
Associated with an Increased Risk of Death in Patients<br />
with HIV<br />
Lewis Kuller and SMART Study Group<br />
Univ of Pittsburgh, PA, US<br />
10:15 140 HIV Activates Markers of Cardiovascular Risk in a<br />
Randomized Treatment Interruption Trial: STACCATO<br />
Alexandra Calmy* 1 , A Nguyen1 , F Montecucco1 ,<br />
A Gayet-Ageron1 , F Burger1 , F Mach1 , A Carr2 , S Ubolyam3 ,<br />
B Hirschel1 , and J Ananworanich3,4 for the STACCATO Study Team<br />
1 2 Geneva Univ Hosp, Switzerland; St Vincent’s Hosp, Sydney,<br />
Australia; 3HIV Netherlands Australia Thailand Res Collaboration,<br />
Bangkok; and 4South East Asia Res Collaboration with Hawaii,<br />
Bangkok, Thailand<br />
10:30 141 Age- and Sex-specific Death Rates in ART-naïve<br />
Patients with CD4 Count above 350 cells/mm3 Compared with the General Population<br />
Rebecca Lodwick* 1 , K Porter2 , C Sabin1 , B Ledergerber3 ,<br />
A Cozzi-Lepri1 , P Khaykin4 , A Mocroft1 , L Jacobson5 , S de Wit6 ,<br />
A Phillips1 , and Study Group on Death Rates at High CD4 Count in<br />
Antiretroviral-naïve Patients<br />
1 2 Univ Coll London, UK; Med Res Council Clinical Trials Unit,<br />
London, UK; 3Univ Hosp Zurich, Switzerland; 4JW Goethe Univ,<br />
Frankfurt, Germany; 5Johns Hopkins Univ, Baltimore, MD, US; and<br />
6St Pierre Univ Hosp, Brussels, Belgium<br />
10:45 142 Immediate vs Deferred ART in the Setting of Acute<br />
AIDS-related Opportunistic Infection: Final Results of<br />
a Randomized Strategy Trial, ACTG A5164<br />
Andrew Zolopa* 1 , J Andersen2 , L Komarow2 , A Sanchez3 ,<br />
C Suckow4 , I Sanne5 , E Hogg6 , W Powderly7 , and ACTG A5164<br />
Study Team<br />
1 2 Stanford Univ, Palo Alto, CA, US; Statistical and Data Analysis<br />
Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Univ of Southern<br />
California, Los Angeles, US; 4Frontier Sci & Tech Res Fndn,<br />
Buffalo, NY, US; 5Univ of the Witswatersrand, Johannesburg, South<br />
Africa; 6Social & Sci Systems, Silver Spring, MD, US; and 7Univ Coll Dublin, Ireland<br />
11:00 143 Exogenous Re-infection with Multidrug- and<br />
Extensively Drug-resistant TB among TB/HIV<br />
Co-infected Patients in Rural South Africa<br />
J Andrews1 , Neel Gandhi* 2 , P Moodley3 , S Shah2 , L Bohlken3 ,<br />
T Moll4 , M Pillay3 , G Friedland1 , W Sturm3 , and Tugela Ferry Care<br />
and Res Collaboration<br />
1 2 Yale Univ Sch of Med, New Haven, CT, US; Albert Einstein Coll of<br />
Med, Bronx, NY, US; 3Nelson R Mandela Sch of Med, Durban, South<br />
Africa; and 4Philanjalo and Church of Scotland Hosp, Tugela Ferry,<br />
South Africa<br />
11:15 144 HIV Infection and Drug-resistant TB in Ukraine: A<br />
Threatening Convergence of 2 Epidemics?<br />
I Dubrovina1 , K Miskinis2 , S Lyepshina3 , Y Yann4 , H Hoffmann5 ,<br />
R Zaleskis6 , P Nunn7 , and Matteo Zignol* 7<br />
1 2 WHO, Project Office, Donetsk, Ukraine; WHO, Country Office,<br />
Kiev, Ukraine; 3Donetsk State Med Univ, Ukraine; 4Donetsk TB<br />
Reference Lab, Ukraine; 5Inst of Microbio and Lab Med, Asklepios<br />
Fachkliniken München-Gauting, Germany; 6WHO, European<br />
Regional Office, Copenhagen, Denmark; and 7WHO Headquarters,<br />
Geneva, Switzerland<br />
11:30 145 The Influence of TB on Early Mortality in the Themba<br />
Lethu Clinical Cohort, Johannesburg, South Africa<br />
Daniel Westreich* 1 , S Badal-Faesen2 , B Malope2 , D Rubel2 ,<br />
Z Akiy2 , P MacPhail2 , A Van Rie1 , and I Sanne2 1Univ of North Carolina at Chapel Hill, Sch of Publ Hlth, US and<br />
2Univ of the Witwatersrand, Johannesburg, South Africa<br />
11:45 146LB Effects of 18-Month Physiological GH Replacement in<br />
Relatively GH-deficient Patients with HIV Lipodystrophy<br />
J Lo, S You, B Canavan, J Liebau, G Beltrani, P Koutkia, H Lee, and<br />
Steven Grinspoon*<br />
Massachusetts Gen Hosp, Boston, US<br />
c Wednesday, 1-4 pm; Poster Hall<br />
Poster Abstracts<br />
(see full session listings starting on page 25)<br />
Session 53. HIV-1 Macrophage Studies<br />
Session 54. Co-infection: Virus/Virus Interactions<br />
Session 55. Viral Reservoirs<br />
Session 56. Viral Transmission: Molecular Studies<br />
Session 63. Studies on Elite Controllers and Exposed Uninfected<br />
Session 64. Studies of Non-progressive Infection<br />
Session 65. Lymphocyte Depletion in the Gut<br />
Session 66. Monocyte/Macrophage Studies<br />
Session 71. Co-infection with HCV<br />
Session 72. PML and JC Virus<br />
Session 78. B Cell and Immunoglobulin Studies<br />
Session 79. Studies on NK and Plasmacytoid Dendritic Cells<br />
Session 80. HIV Vaccines: Induction of Neutralizing Antibodies and Responses<br />
Session 81. HIV Vaccines: Induction of Cellular Immune Responses<br />
Session 82. HIV Vaccines: Novel Viral Vectors<br />
Session 83. HIV Vaccines: Clinical Trials<br />
Session 89. Expanding HIV Testing<br />
Session 90. Behavioral Risk in HIV Infection<br />
Session 94. Preclinical and Clinical Studies of Topical and Oral PrEP<br />
Session 101. Special Considerations in Laboratory Studies for Children<br />
Session 102. Transmission and Diagnosis of HIV Infection in Infants and Children<br />
Session 103. Immune Response in Children<br />
Session 104. Viral and Host Factors Associated with Pediatric Disease Progression<br />
Session 110. Risk, Timing and Viral Genetics of MTCT<br />
Session 111. Co-infections during Pregnancy<br />
Session 120. Immune-Based Therapies: Cytokines<br />
Session 121. Immune-Based Therapies: Therapeutic Vaccines<br />
Session 122. Immune-Based Therapies: Novel Approaches<br />
Session 129. ART: Adherence<br />
Session 130. HIV Care in Different Settings<br />
Session 133. Risk Factors for Lost-to-Follow-up in Resource-limited Settings<br />
Session 134. Complications in Resource-limited Settings<br />
Session 139. New Resistance Technologies<br />
Session 140. HIV-1 Drug Resistance: Genital Shedding and Recombination<br />
Session 141. HIV-2 Drug Resistance<br />
Session 151. Diagnosis and Monitoring Using Dried Specimens<br />
Session 159. Impact on Cardiac Function<br />
Session 160. Hypersensitivity Reactions: Other Drug Toxicities<br />
Session 161. in vitro and Animal Studies of Metabolic Toxicity<br />
Session 162. ART Toxicity in Resource-limited Settings<br />
Session 163. TB Screening and Diagnostics<br />
Session 164. HIV/TB Co-infection<br />
Session 165. TB-associated Immune Reconstitution Inflammatory Syndrome<br />
Session 166. Cryptococcal and Herpesvirus Infections<br />
Session 167. Infectious Complications<br />
Session 168. Malignancies<br />
<strong>Program</strong> 21<br />
Wednesday<br />
February 6 Sessions
Wednesday<br />
February 6 Sessions<br />
Session 40 CROI 2008<br />
c Wednesday, 2-3 pm; Room 311<br />
CME<br />
Session 40–Poster Discussion<br />
(see Session 49 on Tuesday for corresponding Poster Abstracts)<br />
New Insights into APOBEC Proteins<br />
Discussants:<br />
Francois Clavel, Hosp Bichat, Paris, France<br />
Welkin Johnson, New England Primate Res Ctr, Harvard Med Sch, Southborough,<br />
MA, US<br />
229 Deamination in 3D: Intra- and Intersegmental Transfer of<br />
APOBEC3G Cytidine Deaminase<br />
Roni Nowarski*, M Kotler, and E Britan<br />
Hebrew Univ, Hadassah Med Sch, Jerusalem, Israel<br />
230 APOBEC3G’s Cytoplasmic Localization Is Actively<br />
Regulated but Not Required for HIV-1 Restriction<br />
Mark Stenglein* and R Harris<br />
Univ of Minnesota, Minneapolis, US<br />
231 Enzymatically Active APOBEC3G Is Required for Efficient<br />
Inhibition of HIV-1<br />
E Miyagi, S Opi, H Takeuchi, M Khan, R Goila-Gaur, S Kao, and<br />
Klaus Strebel*<br />
NIH, Bethesda, MD, US<br />
232 Distinct Packaging Mechanisms of Human Cytidine<br />
Deaminase APOBEC3 Proteins into HIV-1 Virions<br />
Lindi Tan*, T Wang, and X Yu<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
233 Effect of Impaired Processivity of HIV-1 Reverse<br />
Transcriptase on the G-to-A Mutation Rate Induced by<br />
APOBEC-3G/-3F<br />
Stefanie Knoepfel*, P Rauch, N Salisch, K Allers, P Huelsmann, and<br />
K Metzner<br />
Univ of Erlangen-Nuremberg, Germany<br />
234 Protein Kinase A-mediated Phophorylation of APOBEC3G<br />
Antagonizes Its Degradation by Vif<br />
Kotaro Shirakawa*, A Takaori-Kondo, T Izumi, K Io, M Matsui, and<br />
T Uchiyama<br />
Kyoto Univ, Japan<br />
22 15th Conference on Retroviruses and Opportunistic Infections<br />
c Wednesday, 2-3 pm; Room 312<br />
CME<br />
Session 41–Poster Discussion<br />
(see Session 84 on Monday for corresponding Poster Abstracts)<br />
Molecular Epidemiology: The Americas<br />
Discussants:<br />
Beatrice Hahn, Univ of Alabama at Birmingham, US<br />
Andrew Leigh Brown, Univ of Edinburgh, Scotland<br />
505 HIV-1 Transmission Dynamics in Quebec in the HAART Era<br />
Bluma Brenner* 1 , M Roger 2 , D Moisi 1 , J Cox 3 , JP Routy 1 , M Wainberg 1 , and<br />
Quebec PHI Study Group<br />
1 McGill AIDS Ctr, Jewish Gen Hosp, Montreal, Canada; 2 Ctr Hosp Univ<br />
Montreal, Canada; and 3 Quebec Agency of Publ Hlth and Social Svcs,<br />
Canada<br />
506 Tracking Molecular Epidemiology of HIV-1 in Mexico:<br />
Emergence of BG Intersubtype Recombinant<br />
Eduardo Vazquez-Valls* 1 , M Escoto-Delgadillo 1 , R Carabez-Hernandez 2 ,<br />
and B Torres-Mendoza 2<br />
1 UMAE Specialties Hosp, Western Biomed Res Ctr, Mexican Inst of Social<br />
Security, Guadalajara and 2 Univ Hlth Sci Ctr, Univ of Guadalajara,<br />
Mexico<br />
507 Evolutionary Dynamics of HIV-1 BF and CB Recombinants<br />
in South America<br />
Elcio Leal* 1 , L Martins 2 , M Janini 1 , and R Diaz 1<br />
1 Federal Univ of Sao Paulo, Brazil and 2 Grad Sch of Agriculture and Life<br />
Sci, Univ of Tokyo, Japan<br />
508 A Foothold for Subtype C in the Americas: Risk Factors<br />
Associated with Subtype C and Non-Subtype C HIV<br />
Infection among HIV Testing Clients in South Brazil<br />
Oliver Bacon* 1 , R da Silva de Souza 2 , K Page Shafer 1 , R Diaz 3 , V Debastiani 4 ,<br />
G Preussler 5 , M Leticia Ikeda 6 , N Barcellos 7 , W Steward 1 , and C Pilcher 1<br />
1 Univ of California, San Francisco, US; 2 Univ de Caxias do Sul, Rio<br />
Grande, Brazil; 3 Paulista Sch of Med, Federal Univ of Sao Paulo, Brazil;<br />
4 Ambulatorio de DST/AIDS, Caxias do Sul, Rio Grande do Sul, Brazil;<br />
5 Svc de Assistencia Especializado, Ctr de Saude Vila dos Comercarios,<br />
Rio Grande do Sul, Brazil; 6 Svc Especializado de DST/AIDS Herbert de<br />
Souza, Rio Grande do Sul, Brazil; and 7 Hosp Sanatorio Partenon, Rio<br />
Grande do Sul, Brazil<br />
509 Timing the Introduction of HIV-1 Subtype C in Brazil<br />
Gonzalo Bello*, R Lorete, M Guimaraes, C Bittencourt Passaes, and<br />
M Morgado<br />
Oswaldo Cruz Inst, Fiocruz, Rio de Janeiro, Brazil
CROI 2008 Session 43<br />
c Wednesday, 2-3 pm; Room 302-304<br />
CME<br />
Session 42–Poster Discussion<br />
(see Session 107 on Tuesday for corresponding Poster Abstracts)<br />
Maternal ART and Feeding Practices: Impact on<br />
Infant Outcomes<br />
Discussants:<br />
Elaine Abrams, Columbia Univ, Mailman Sch of Publ Hlth, New York, NY, US<br />
Francois Dabis, Univ Victor Segalen, Bordeaux, France<br />
636 18-Month HIV-free Survival by Infant Feeding Practices<br />
in Children of HIV-infected Women in South Africa: The<br />
Vertical Transmission Study<br />
Nigel Rollins* 1 , R Becquet 2,3,4 , R Bland 2,5 , A Coutsoudis 1 , H Coovadia 6 , and<br />
ML Newell 2,7<br />
1 Univ of KwaZulu Natal, Durban, South Africa; 2 Africa Ctr for Hlth and<br />
Population Studies, Univ of KwaZulu Natal, Somkhele, South Africa;<br />
3 INSERM U593, Bordeaux, France; 4 Inst for Publ Hlth, Epi and Devt,<br />
Univ Victor Segalen, Bordeaux, France; 5 Univ of Glasgow, UK; 6 Ctr for<br />
HIV/AIDS Networking, Univ of KwaZulu Natal, Durban, South Africa;<br />
and 7 Ctr for Pediatric Epi and Biostatistics, Inst of Child Hlth, Univ Coll<br />
London, UK<br />
637 Risk Factors for Mother-to-Child Transmission of HIV-1<br />
from Breastfeeding in a Randomized Clinical Trial in<br />
Botswana: The Mashi Study<br />
Roger Shapiro* 1 , L Smeaton 2 , S Lockman 3 , I Thior 4 , R Rossenkhan 4 ,<br />
C Wester 4 , L Stevens 4 , J Leidner 2 , J Makhema 4 , and M Essex 5<br />
1 Beth Israel Deaconess Med Ctr, Boston, MA, US; 2 Harvard Sch of Publ<br />
Hlth, Ctr for Biostatistics in AIDS Res, Boston, MA, US; 3 Brigham and<br />
Women’s Hosp, Boston, MA, US; 4 Botswana Harvard Sch of Publ Hlth<br />
AIDS Initiative Partnership for HIV Res and Ed, Gaborone; and 5 Harvard<br />
Sch of Publ Hlth, Boston, MA, US<br />
638 HIV-free Survival at 12 Months among Children Born to<br />
HIV-infected Women Receiving Antiretrovirals from 34 to<br />
36 Weeks of Pregnancy<br />
Isabelle de Vincenzi* and the Kesho Bora Study Group<br />
WHO, Geneva, Switzerland<br />
639 Decrease in HIV-1 Mother-to-Child Transmission in Women<br />
Receiving Postnatal HAART: 12-Month Follow-up Data<br />
M Marazzi 1 , L Palombi 2 , G Liotta 2 , P Germano 3 , N Abdul Majid 4 , I Zimba 4 ,<br />
A Doro Altan 2 , G Bortolot 3 , and Karin Nielsen-Saines* 5<br />
1 LUMSA Univ, Rome, Italy; 2 Univ of Tor Vergata, Rome, Italy; 3 DREAM<br />
Prgm, Community of St Egidio, Italy; 4 Benfica Hlth Ctr, Maputo,<br />
Mozambique; and 5 David Geffen Sch of Med, Univ of California, Los<br />
Angeles, US<br />
640 Comparison of Adverse Fetal Outcomes in HIV-1-infected<br />
Antiretroviral- naïve Pregnant Women Who Have<br />
Received Combivir and Either Nevirapine or Nelfinavir for<br />
Prevention of Mother-to-Child Transmission Antenatally<br />
Rose Masaba* 1 , R Ndivo 1 , I Nyangau 1 , K Achola 1 , C Zeh 2 , M Thigpen 3 ,<br />
P Weidle 3 , and T Thomas 2<br />
1 Kenya Med Res Inst, Kisumu; 2 CDC Kenya, Kisumu; and 3 CDC, Atlanta,<br />
GA, US<br />
641 Low Birth Weight with Nevirapine-based ART in Abidjan,<br />
Côte d’Ivoire: The ANRS Ditrame Plus Cohort and MTCT-<br />
Plus Initiative, 2001 to 2007<br />
Didier Koumavi Ekouevi* 1,2 , B Tonwe-Gold 1,3 , R Becquet 1 , P Coffie 1,2 ,<br />
P Toure 3 , V Leroy 1 , I Viho 2 , S Blanche 4 , F Dabis 1 , and E Abrams 5<br />
1 INSERM U593, Inst for Publ Hlth, Epi and Devt, Bordeaux, France;<br />
2 Natl Agency for AIDS Res Ditrame Plus Project, Abidjan, Côte d’Ivoire;<br />
3 ACONDA, NGO, Abidjan, Côte d’Ivoire; 4 Hosp Necker, Paris France;<br />
and 5 MTCT-Plus Initiative, New York, NY, US<br />
e Wednesday, 4-6 pm; Ballroom A<br />
Session 43–Symposium CME<br />
Accessory Proteins and Intrinsic Resistance<br />
Conveners:<br />
Ned Landau, New York Univ, NY, US<br />
Aine McKnight, Barts and The London Sch<br />
of Med and Dentistry, UK<br />
147<br />
Vif and APOBEC: What We Know<br />
Xiao-Fang Yu<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
148<br />
The Role of Vpu in Retrovirus Particle Release<br />
Paul Spearman<br />
Emory Univ Sch of Med, Atlanta, GA, US<br />
149<br />
Genetic Variation in TRIM5α and Related Genes<br />
Sara Sawyer* 1 , M Emerman 2 , and H Malik 2<br />
1 Univ of Texas, Austin, US and 2 Fred Hutchinson Cancer Res Ctr,<br />
Seattle, WA, US<br />
150<br />
HIV Vpr Protein as a Mediator of Ubiquitylation<br />
Carlos de Noronha*, X Wen, L Casey, J Sharifi, and K Duus<br />
Albany Med Coll, NY, US<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
HIV molecular biology, viral accessory genes, mechanisms of intracellular<br />
resistance to viruses and co-evolution of viruses and hosts. It is assumed that<br />
participants are familiar with basic cell and molecular biology, and the HIV<br />
genome and replication cycle. At the completion of the session participants<br />
will be knowledgeable about the HIV Vif, Vpr, and Vpu accessory proteins<br />
and about the APOBEC3 and Trim-5a host restriction factors.<br />
<strong>Program</strong> 23<br />
Wednesday<br />
February 6 Sessions
Wednesday<br />
February 6 Sessions<br />
Session 44 CROI 2008<br />
e Wednesday, 4-6 pm; Ballroom B/C<br />
Session 44–Symposium CME<br />
Frontiers in Vaccine Research<br />
151<br />
Advances in Vaccines Scaffolds<br />
Bill Schief<br />
Univ of Washington, Seattle, US<br />
Conveners:<br />
David Ho, Aaron Diamond AIDS Res Ctr,<br />
The Rockefeller Univ, New York, NY, US<br />
Lynn Morris, Natl Inst for Communicable<br />
Diseases, Johannesburg, South Africa<br />
152<br />
Lessons Learned from HIV-1 Envelope Glycoprotein<br />
Immunogenicity Analysis<br />
M Forsell 1,2 , B Dey 1 , A Moerner 3 , G Voss 4 , R Thorstensson 3 ,<br />
P Kwong 1 , G Shaw 5 , J Mascola 1 , G Karlsson Hedestam 2,3 , and<br />
Richard Wyatt* 1<br />
1 Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US; 2 Karolinska<br />
Inst, Stockholm, Sweden; 3 Swedish Ctr for Infectious Disease<br />
Control, Solna; 4 GlaxoSmithKline, Rixensart, Belgium; and<br />
5 Univ of Alabama at Birmingham, US<br />
153<br />
Identification and Characterization of Transmitted<br />
and Early Founder Viruses in Primary HIV-1 Infection<br />
B Keele 1 , E Giorgi 2,3 , J Salazar-Gonzalez 1 , F Gao 4 , R Swanstrom 5 ,<br />
M Busch 6 , B Haynes 4 , B Korber 2,7 , B Hahn 1 , and George Shaw* 1<br />
1 Univ of Alabama at Birmingham, US; 2 Los Alamos Natl Lab,<br />
NM, US; 3 Univ of Massachusetts, Amherst, US; 4 Duke Univ,<br />
Durham, NC, US; 5 Univ of North Carolina at Chapel Hill, US;<br />
6 Blood Systems Res Inst, San Francisco, CA, US; and 7 Santa Fe<br />
Inst, NM, US<br />
154<br />
Attenuated SIV Models and Protection from<br />
Pathogenic Heterologous Challenges<br />
James Hoxie* 1 , A Jordan1 , B Haggarty1 , J Romano1 , M Piatak2 ,<br />
J Lifson2 , D Montefiori3 , M Marsh4 , and P Fultz5 1 2 Univ of Pennsylvania Sch of Med, Philadelphia, US; NCI-<br />
Frederick, MD, US; 3Duke Univ, Durham, NC, US; 4Univ Coll<br />
London, UK; and 5Univ of Alabama at Birmingham, US<br />
Objectives: This session is directed to clinicians and scientists interested in<br />
immunology and vaccine development. It is assumed that participants are<br />
familiar with basic HIV biology, acute infection, principles of cellular and<br />
humoral immunology, and how antibodies recognize foreign antigens. At the<br />
completion of the session, participants will be knowledgable about how HIV<br />
evades the early immune response to HIV during acute infection, animals<br />
models of vaccine-induced protection against disease progression, problems<br />
associated with eliciting neutralizing antibodies against HIV, and some of the<br />
promising strategies to overcome these roadblocks. In particular, the promise<br />
and limitations of rational vaccine design, and how those such vaccines are<br />
evaluated, will be better understood.<br />
24 15th Conference on Retroviruses and Opportunistic Infections<br />
e Wednesday, 4-6 pm; Auditorium<br />
Session 45–Symposium CME<br />
Individualizing Patient Management<br />
Conveners:<br />
Elly Katabira, Makerere Univ, Kampala,<br />
Uganda<br />
Caroline Sabin, Royal Free and Univ Coll<br />
Med Sch, London, UK<br />
155<br />
Optimizing Patient Management in Resource-limited<br />
Settings<br />
Jonathan Mermin<br />
CDC Kenya, Nairobi<br />
156<br />
Individualizing Patient Management: Host Genetics<br />
Jacques Fellay<br />
Duke Univ, Durham, NC, US<br />
157<br />
Individualized Management of Therapy: Virologic<br />
Complications<br />
Carlo-Federico Perno<br />
Univ of Rome Tor Vergata, Italy<br />
158<br />
Individualized Management of Therapy: The Issue<br />
of Complications<br />
Jennifer Hoy<br />
Alfred Hosp, Monash Univ, Melbourne, Australia<br />
Objectives: This session is directed to clinicians and scientists interested<br />
in gaining an understanding of the optimal management of HIV-infected<br />
patients. The session will address this issue in a global context. It is assumed<br />
that participants are familiar with natural history of HIV infection and basic<br />
principles of HIV management. At the completion of the session, participants<br />
will be able to identify key host-related factors, virological consideration,<br />
and patient complications that determine outcome of HIV/AIDS. Participants<br />
will also gain a better understanding of individual management strategies in<br />
resource-limited settings.
CROI 2008 Session 48<br />
b Monday, 1-4 pm; Hall D<br />
Session 46–Poster Abstracts<br />
Cellular Co-factors<br />
200 Visualization of the HIV Host Protein Interaction Network<br />
Jonathan Dickerson* 1 , J Pinney1 , R Ptak2 , W Fu2 , B Sanders-Beer2,3 , and<br />
D Robertson1 1 2 Univ of Manchester, UK; Southern Res Inst, Frederick, MD, US; and<br />
3Bioqual, Inc, Rockville, MD, US<br />
201 ADAM10: A Cellular Metalloprotease Required at or Just<br />
Prior to HIV Integration<br />
B Friedrich1 , J Murray2 , D Rubin3 , T Hodge2 , and William O’Brien* 1<br />
1 2 Univ of Texas Med Branch, Galveston, US; Zirus, Buford, GA, US; and<br />
3VA Tennessee Valley Hlthcare System and Vanderbilt Univ, Nashville, US<br />
202 Transient Knockdown of the Von Hippel Lindau Binding<br />
Protein 1 in HeLaP4 Cells Enhances HIV-1 Replication<br />
Wannes Thys*, F Christ, J De Rijck, and Z Debyser<br />
Katholieke Univ Leuven, Flanders, Belgium<br />
203 Activator Protein 1 Synergizes with NF-κB to Activate Latent<br />
HIV Provirus Transcription following T Cell Receptor<br />
Activation<br />
Joseph Hokello*, YK Kim, R Pearson, and J Karn<br />
Case Western Reserve Univ, Cleveland, OH, US<br />
204 Overexpression of NF90 or Its Mutants Together with Its<br />
N-ter Region, Decrease Rev Export Activity and HIV-1<br />
Replication<br />
Claudia Patino* 1 , X Zapata1 , G St Laurent2 , A Kumar2 ,<br />
D Hernandez-Verdun3 , and S Urcuqui-Inchima1 1 2 Univ de Antioquia, Colombia; George Washington Univ, Washington,<br />
DC, US; and 3UMR 7592, Univ Paris VI and VII, France<br />
205 The Receptor Tyrosine Kinase RON Represses HIV-1<br />
Transcription by Targeting RNA Polymerase II Processivity<br />
A Klatt1 , Z Zhang2 , P Kalantari1 , P Hankey1 , D Gilmour1 , and<br />
Andrew Henderson* 3<br />
1 2 Penn State Univ, Univ Park, US; Fox Chase Cancer Ctr, Philadelphia,<br />
PA, US; and 3Boston Univ Sch of Med, MA, US<br />
206 Dominant Negative Cyclin T1 Protein That Inhibits HIV<br />
Transcription by Specifically Degrading Tat<br />
Julie Jadlowsky* 1 , K Fujinaga1 , M Nojima1 , M Geyer2 , and<br />
T Okamoto3 1 2 Case Western Reserve Univ, Cleveland, OH, US; Max-Planck-Inst for<br />
Molecular Physiology, Dortmund, Germany; and 3Nagoya City Univ<br />
Graduate Sch of Med Sci, Japan<br />
207 PRMT6 Fine-tunes Localization Patterns of HIV-1 Proteins<br />
Tat and Rev<br />
Rita Schildknecht*, C Invernizzi, S Colby-Germinario, K Dahl,<br />
J Martinez, B Spira, B Brenner, and M Wainberg<br />
McGill Univ AIDS Ctr, Montreal, Canada<br />
208 Roles for IST1 in VPS4 Regulation and HIV-1 Budding<br />
Monika Bajorek*, E Morita, J Skalicky, M Babst, and W Sundquist<br />
Univ of Utah, Salt Lake City, US<br />
209 Functional Role of Alix in HIV-1 Replication<br />
Ken Fujii*, U Munshi, S Ablan, and E Freed<br />
NCI-Frederick, MD, US<br />
210 Structure of Yeast Vps4p by Electron Microscopy and X-ray<br />
Crystallography<br />
Malgorzata Gonciarz* 1 , Z Yu2 , F Whitby1 , C Kieffer1 , G Jensen2 ,<br />
W Sundquist1 , and C Hill1 1 2 Univ of Utah, Salt Lake City, US and California Inst of Tech, Pasadena,<br />
US<br />
211 Role of Kinases of the PIKK Family in Retroviral Replication<br />
Y Yang, V Guen, and Lionel Berthoux*<br />
Univ of Quebec, Trois-Rivieres, Canada<br />
b Monday, 1-4 pm; Hall D<br />
Session 47–Poster Abstracts<br />
Cellular Restrictions<br />
212 APOBEC3G Protein Expression in Blood Resting and<br />
Activated CD4 + and CD8 + T Cells: Its Effect on Susceptibility<br />
to HIV Infection and Progression<br />
H Oliva1 , Montserrat Plana* 1 , A Lopez1 , J Martinez-Navio2 , R Franco2 ,<br />
J Miro1 , F Garcia1 , J Gatell1 , N Navaratnam3 , and T Gallart1 1 2 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain; Faculty of Bio, Univ of<br />
Barcelona, Spain; and 3Med Res Council, Hammersmith Hosp, London,<br />
UK<br />
213 Target Cell APOBEC3C Can Induce Limited G-to-A<br />
Mutation in HIV-1<br />
K Bourara1 , T Liegler2 , and Robert Grant* 1,2<br />
1Gladstone Inst of Virology and Immunology, San Francisco, CA, US and<br />
2Univ of California, San Francisco, US<br />
214 Determinants of HIV-1 Vif Regulation of APOBEC3 Proteins<br />
Anna Maria Niewiadomska*, W Zhang, and XF Yu<br />
Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US<br />
215 The Anti-HIV-1 Potency of APOBEC1 Cytidine Deaminase<br />
from Small Animal Species<br />
Terumasa Ikeda* 1 , T Ohsugi 2 , T Kimura 1 , S Matsushita 3 , Y Maeda 1 ,<br />
S Harada 1 , and A Koito 1<br />
1 Grad Sch of Med Sci, Kumamoto Univ, Japan; 2 Ctr for Animal Resources<br />
and Devt, Kumamoto Univ, Japan; and 3 Ctr for AIDS Res, Kumamoto<br />
Univ, Japan<br />
216 A Single Amino Acid of the HIV-2 Capsid Determines Its<br />
Replication in the Presence of Cynomolgus Monkey and<br />
Human TRIM5α<br />
Haihan Song* 1 , E Nakayama1 , M Yokoyama2 , H Sato2 , J Levy3 , and<br />
T Shioda1 1 2 Res Inst for Microbial Diseases, Osaka Univ, Japan; Natl Inst of<br />
Infectious Diseases, Tokyo, Japan; and 3Univ of California, San<br />
Francisco Sch of Med, Cancer Res Inst, US<br />
217 Analysis of the Role of Cytoplasmic Bodies in TRIM5α<br />
Restriction<br />
Cindy Danielson*, E Campbell, M McRaven, and T Hope<br />
Northwestern Univ, Chicago, IL, US<br />
218 Using a Restriction-deficient Cell Line in the Search for<br />
Cellular Proteins Important for TRIM5α Activity<br />
Julie Berube*, A Bouchard, and L Berthoux<br />
Univ of Quebec, Trois-Rivieres, Canada<br />
b Monday, 1-4 pm; Hall D<br />
Session 48–Poster Abstracts<br />
Viral Accessory Genes<br />
219 Co-variation Networks in HIV-1 Nef Sequences from<br />
Phylogenetic and Mixtures Analysis<br />
Art Poon* 1 , R Harrigan2 , and S Frost1 1 2 Univ of California, San Diego, US and BC Ctr for Excellence in HIV/<br />
AIDS, Vancouver, Canada<br />
220 Nef Proteins Derived from HIV-1 Subtypes C and F Fail to<br />
Up-regulate Invariant Chain Cell Surface Expression<br />
Gabriela Turk* 1 , P Benaroch2 , and H Salomon1 1Natl Reference Ctr for AIDS, Univ of Buenos Aires, Argentina and<br />
2INSERM U653, Inst Curie, Paris, France<br />
221 Nucleo-cytoplasmic Transport of Vpx Play a Critical Role in<br />
HIV-2/SIV Replication in Non-dividing Cells<br />
P Singhal1 , P Rajendra Kumar1 , and Sundarasamy Mahalingam* 1,2<br />
1Ctr for DNA Fingerprinting and Diagnostics, Hyderabad, India and<br />
2Indian Inst of Tech Madras, Chennai<br />
222 CTIP2 Inhibits HIV-1 Vpr-induced Cell Cycle Arrest by<br />
Repressing p21WAF1 Gene Expression<br />
Stella Suzanne* 1 , T Cherrier1 , C Marban1 , B Samah2 , R Mukerjee3 ,<br />
C Schwartz1 , S Zeichner4 , D Aunis1 , C Van Lint5 , and O Rohr1 1 2 INSERM U575, Univ Strasbourg 1, France; CEA, Fontenay aux Roses,<br />
France; 3Ctr for Neurovirology and Cancer Bio, Coll of Sci and Tech,<br />
Temple Univ, Philadelphia, PA, US; 4NCI, NIH, Bethesda, MD, US; and<br />
5Inst for Molecular Bio and Med, Univ of Bruxelles, Gosselies, Belgium<br />
223 Functional Properties of Naturally Occurring Truncated<br />
Forms of HIV-1 Vif<br />
Mohammad Khan* 1 , R Goila-Gaur1 , N Choudry2 , E Miyagi1 , S Kao1 ,<br />
and K Strebel1 1 2 NIAID, NIH, Bethesda, MD, US and Univ of Maryland, US<br />
224 HIV-1 Vif Causes G2 Cell Cycle Arrest via the p53 Pathway<br />
Taisuke Izumi*, A Takaori-Kondo, K Shirakawa, K Io, M Matsui, and<br />
T Uchiyama<br />
Kyoto Univ, Japan<br />
225 Genetic Patterns Associated with Functional Adaptation of<br />
Nef to Down-regulate MHC-I and Evade CTL<br />
Martha Lewis*, P Lee, A Rusmevichientong, L Hultin, and O Yang<br />
David Geffen Sch of Med, Univ of California, Los Angeles, US<br />
226 HIV-1-mediated Cell Cycle Arrest and Apoptosis in Human<br />
CD4 + T Cells Is Independent of HIV-1 Env and Vpr<br />
Alicja Dabrowska*, N Kim, and A Aldovini<br />
Children’s Hosp Boston, MA, US<br />
227 Importance of SIVmac239 Vpr Induced Cell Cycle Arrest for<br />
Disease Progression<br />
Sandra Mueller* 1,2 , B Scholz3 , S Weiler4 , N Stolte-Leeb5 ,<br />
C Stahl-Hennig5 , B Fleckenstein3 , S Lang6 , and German Competence<br />
Network on HIV/AIDS<br />
1 2 Univ Hosp Erlangen, Germany; German Competence Network on<br />
HIV/AIDS; 3Inst of Clinical and Molecular Virology, Univ Hosp<br />
Erlangen, Germany; 4Univ of Erlangen, Germany; 5German Primate Ctr,<br />
Goettingen; and 6Yale Univ Sch of Med, New Haven, CT,US<br />
228 Vpr-mediated Inhibition of IL-12 and Disruption of<br />
Upstream Signaling Receptors CD14, TLR4, and the<br />
Glucocorticoid Receptor<br />
Fiona Frappier* 1,2 , J Boucher1,2 , A O’Connor1,2 , and J Angel1,2 1 2 Univ of Ottawa, Canada and Ottawa Hlth Res Inst, Canada<br />
<strong>Program</strong> 25<br />
Poster Listings
Poster Litings<br />
Session 49 CROI 2008<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 49–Poster Abstracts<br />
(see Session 40 on Wednesday for corresponding Poster Discussion)<br />
New Insights into APOBEC Proteins<br />
229 Deamination in 3D: Intra- and Intersegmental Transfer of<br />
APOBEC3G Cytidine Deaminase<br />
Roni Nowarski*, M Kotler, and E Britan<br />
Hebrew Univ, Hadassah Med Sch, Jerusalem, Israel<br />
230 APOBEC3G’s Cytoplasmic Localization Is Actively<br />
Regulated but Not Required for HIV-1 Restriction<br />
Mark Stenglein* and R Harris<br />
Univ of Minnesota, Minneapolis, US<br />
231 Enzymatically Active APOBEC3G Is Required for Efficient<br />
Inhibition of HIV-1<br />
E Miyagi, S Opi, H Takeuchi, M Khan, R Goila-Gaur, S Kao, and<br />
Klaus Strebel*<br />
NIH, Bethesda, MD, US<br />
232 Distinct Packaging Mechanisms of Human Cytidine<br />
Deaminase APOBEC3 Proteins into HIV-1 Virions<br />
Lindi Tan*, T Wang, and X Yu<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
233 Effect of Impaired Processivity of HIV-1 Reverse<br />
Transcriptase on the G-to-A Mutation Rate Induced by<br />
APOBEC-3G/-3F<br />
Stefanie Knoepfel*, P Rauch, N Salisch, K Allers, P Huelsmann, and<br />
K Metzner<br />
Univ of Erlangen-Nuremberg, Germany<br />
234 Protein Kinase A-mediated Phophorylation of APOBEC3G<br />
Antagonizes Its Degradation by Vif<br />
Kotaro Shirakawa*, A Takaori-Kondo, T Izumi, K Io, M Matsui, and<br />
T Uchiyama<br />
Kyoto Univ, Japan<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 50–Poster Abstracts<br />
Viral Replication Cycle: Molecular Studies<br />
235 Dimerization of HIV-1 Spliced RNA in vitro<br />
Lucile Sinck* 1 , D Richer1 , J Howard2 , M Alexander2 , D Purcell2 ,<br />
R Marquet1 , and JC Paillart1 1 2 Inst of Molecular and Cellular Bio, CNRS, Strasbourg, France and Univ<br />
of Melbourne, Parkville, Australia<br />
236 Equine Infectious Anemia Virus Entry Occurs through<br />
Clathrin-mediated Endocytosis<br />
Melinda Brindley* and W Maury<br />
Univ of Iowa, Iowa City, US<br />
237 Changes to the HIV Long Terminal Repeat and to HIV<br />
Integrase Differentially Affect HIV Integrase Assembly,<br />
Activity, and the Binding of Strand Transfer Inhibitors<br />
Ira Dicker* 1 , H Samanta1 , Z Li1 , Y Hong2 , Y Tian2 , J Banville1 ,<br />
R Remillard1 , M Walker1 , D Langley1 , and M Krystal1 1 2 Bristol-Myers Squibb, Wallingford, CT, US and Bristol-Myers Squibb,<br />
Princeton, NJ, US<br />
238 Examination of HIV Integration Sites in Quiescent CD4<br />
T Cells: Implications for Viral Mechanisms of Infection and<br />
Gene Therapy<br />
Dimitrios Vatakis*, S Kim, G Bristol, S Chow, and J Zack<br />
David Geffen Sch of Med, Univ of California, Los Angeles, US<br />
239 TRBP Directs HIV-1 mRNA to Polysomes for Efficient<br />
Translation<br />
S Campbell1 , F Fangsi Ke1 , J Waters1 , H Christensen1 , J Howard1 ,<br />
M Alexander1 , A Gatignol2 , and Damian Purcell* 1<br />
1 2 Univ of Melbourne, Parkville, Australia and McGill Univ, Lady Davis<br />
Inst for Med Res, Montreal, Canada<br />
240 The Effect of Episomal Overexpression of the HIV Wild Type<br />
NC Protein on the Viral Particle Formation<br />
Seonhee Kim*, S Jang, and J You<br />
Catholic Univ of Korea, Sch of Med, Seoul, South Korea<br />
26 15th Conference on Retroviruses and Opportunistic Infections<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 51–Poster Abstracts<br />
Viral Envelope: Tropism Co-receptor Studies<br />
241 Selection of Replication-competent Strains of Simian<br />
Immunodeficiency Virus Which Are Deficient in Sites for<br />
Carbohydrate Attachment<br />
Elizabeth Stansell* and R Desrosiers<br />
New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US<br />
242 A Single Residue in the HIV-1 Envelope V3 Domain<br />
Modulates Exposure of the CD4 Binding Site<br />
Rebecca Lynch* 1 , R Rong1 , W Honnen2 , J Mulenga3 , S Allen1 ,<br />
J Blackwell1 , A Pinter2 , S Gnanakaran4 , and C Derdeyn1 1 2 Emory Univ, Atlanta, GA, US; Univ of Med and Dentistry of New<br />
Jersey, New Jersey Med Sch, Newark, US; 3Zambia Blood Transfusion<br />
Svc, Lusaka; and 4Los Alamos Natl Lab, NM, US<br />
243 Functional Analysis of Intracellular Targeting Motifs within<br />
HIV-1 Envelope Cytoplasmic Domain<br />
Sushma Bhakta*, E Hunter, P Spearman, and N Tsurutani<br />
Emory Univ, Atlanta, GA, US<br />
244 Cross-reactive HIV-neutralizing Human Monoclonal<br />
Antibody Recognizes Novel Conformational Epitope on gp41<br />
and Lacks Reactivity against Self-antigens<br />
Mei-Yun Zhang* 1,2 , B Vu1 , M Alam3 , R Ruprecht4 , G Quinnan5 , S Jiang6 ,<br />
D Montefiori7 , C Broder5 , B Haynes3 , and D Dimitrov1 1 2 3 NCI-Frederick, MD, US; SAIC-Frederick MD, US; Human Vaccine<br />
Inst, Durham, NC, US; 4Dana-Farber Cancer Inst, Boston, MA, US;<br />
5 6 Uniformed Svcs Univ of the Hlth Sci, Bethesda, MD, US; Lindsley F<br />
Kimball Res Inst, New York Blood Ctr, NY, US; and 7Duke Univ Med Ctr,<br />
Durham, NC, US<br />
245 Genotypic and Phenotypic Analysis of HIV-1 env Gene<br />
Populations in Subjects with Dual or Mixed Entry<br />
Phenotypes<br />
Milloni Patel* 1,2 , G Schnell1,2 , M Pagan1,2 , and R Swantrom1,2 1 2 Univ of North Carolina at Chapel Hill, US and Ctr For AIDS Res, Univ<br />
of North Carolina at Chapel Hill, US<br />
246 Characterization of V2 and V3 Envelope Determinants and<br />
their Correlation with Co-receptor Usage from a Cohort of<br />
East London Patients Infected with HIV-1 Clade CRF02_AG<br />
Ronald D’Amico* 1,2 , H Dreja2 , K Aubin3 , C Orkin4 , J Hand4 , C DeSouza4 ,<br />
M Dittmar2 , and A McKnight2 1 2 London Sch of Hygiene and Tropical Med, UK; Barts and the London,<br />
Queen Mary’s Univ, UK; 3Wohl Virion Ctr, Univ Coll London, UK; and<br />
4St Bartholomew’s Hosp, London, UK<br />
247 X4-tropic and Dualtropic Subtype C Biological Clones from<br />
Syncytia Inducing Isolates<br />
Elizabeth Johnston White*, B McColgan, S Kassaye, and D Katzenstein<br />
Stanford Univ, Palo Alto, CA, US<br />
248 Variation in HIV-1 R5 Macrophage-tropism Correlates<br />
with Sensitivity to Reagents that Block Envelope: CD4<br />
Interactions<br />
P Peters1 , M Duenas-DeCamp1 , M Sullivan1 , R Brown2 ,<br />
C Ankghuambom2 , K Luzuriaga1 , J Robinson3 , D Burton4 , J Ball2 , and<br />
Paul Clapham* 1<br />
1 2 Univ of Massachusetts Med Sch, Worcester, US; Univ of Nottingham,<br />
UK; 3Tulane Univ Med Ctr, New Orleans, LA, US; and 4Scripps Res Inst,<br />
La Jolla, CA, US<br />
249 HIV-1 Viruses with Different Co-receptor Tropisms Are Not<br />
Highly Compartmentalized in the Peripheral Blood<br />
William Ince*, P Harrington, K Dang, G Schnell, J Eron, C Burch, and<br />
R Swanstrom<br />
Univ of North Carolina at Chapel Hill, US<br />
250 Low CCR5 Expression Levels on Primary CD4 +<br />
Lymphocytes Are a Major Obstacle to CCR5-mediated<br />
Infection by R5X4 Viruses<br />
Lamorris Loftin*, L Wang, Y Yi, J Isaacman-Beck, M Kienzle, and<br />
R Collman<br />
Univ of Pennsylvania, Philadelphia, US<br />
251 The gp41 Transmembrane Subunit of HIV-1 Envelope<br />
Influences CD4 Receptor-dependent Virus Entry<br />
Jonathan Toma*, S Fransen, T Wrin, J Whitcomb, N Parkin,<br />
C Petropoulos, and W Huang<br />
Monogram Biosci, South San Francisco, CA, US<br />
252 Susceptibility of Human Prostate to HIV-1 Infection<br />
Anna le Tortorec1 , AP Satie1 , H Denis1 , L Havard2 , N Rioux-Leclercq2 ,<br />
A Ruffault2 , B Jegou1 , and Nathalie Dejucq-Rainsford* 1<br />
1 2 INSERM U625, Rennes, France and Ctr Hosp Univ Regional<br />
Pontchaillou, Rennes, France
CROI 2008 Session 55<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 52–Poster Abstracts<br />
Viral Fitness, Evolution and Recombination<br />
253 Molecular Characterization of SIV in Wild Gorillas<br />
gor<br />
Jun Takehisa* 1 , M Kraus1 , Y Li1 , R Rudicell1 , B Keele1 , J Decker1 ,<br />
E Bailes2 , P Sharp3 , M Peeters4 , and B Hahn1 1 2 3 Univ of Alabama at Birmingham, US; Univ of Nottingham, UK; Univ of<br />
Edinburgh, Scotland; and 4Univ of Montpellier, France<br />
254 Generation of in vivo Intersubtype BG Recombinants<br />
of HIV-1 and Analysis of Intersubtype Breakpoints:<br />
Comparison to BG Recombinants Generated in vivo<br />
Mercedes Munoz-Nieto* 1 , L Perez-Alvarez1 , M Pinilla1 , Y Vega1 ,<br />
E Delgado1 , V Garcia1 , M Sierra1 , M Thomson1 , C Miralles2 , and<br />
R Najera1 1 2 Inst Salud Carlos III, Madrid, Spain and Hosp Xeral-Cies, Vigo,<br />
Pontevedra, Spain<br />
255 Immune-driven HIV-1 Recombination and Loss of Control<br />
following Superinfection<br />
Hendrik Streeck* 1 , B Li1 , A Poon2 , A Schneidewind1 , A Gladden1 ,<br />
K Power1 , B Walker1 , M Altfeld1 , S Frost2 , and T Allen1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch,<br />
Boston, US and 2Univ of California, San Diego, US<br />
256 Identifying the Important HIV-1 Recombination Breakpoints<br />
John Archer* 1 , J Pinney1 , J Fan1 , E Simon-Loriere2 , E Arts3 ,<br />
M Negroni2 , and D Robertson1 1 2 3 Univ of Manchester, UK; Pasteur Inst, Paris, France; and Case<br />
Western Reserve Univ, Cleveland, OH, US<br />
257 Molecular Characterization of Recombinant CCR5- and<br />
CXCR4-utilizing HIV-1 Subtype C gp120<br />
Katherine Michler*, W Stevens, M Papathanasopoulos, and<br />
A Capovilla<br />
Univ of the Witwatersrand Med Sch, Johannesburg, South Africa<br />
258 A New Algorithm to Detect HIV-1 Intra-patient Recombinant<br />
Sequences and Investigate the Role of Recombination in the<br />
Emergence of CXCR4-using Viral Variants<br />
M Salemi1 , R Gray1 , J Sleasman2 , S Koch1 , and Maureen Goodenow* 1<br />
1 2 Univ of Florida, Gainsville, US and Univ of South Florida, St<br />
Petersburg, US<br />
259 Meta-evolutionary Analysis of Selection on HIV and Other<br />
Viruses: Functional and Subtype Correlates<br />
Sergei Kosakovsky Pond* 1 , C Woelk1 , A Poon1 , S Pillai2,3 , D Richman1,4 ,<br />
and S Frost1 1 2 Univ of California, San Diego, US; Univ of California, San Francisco,<br />
US; 3VAMC, San Francisco, CA, US; and 4VA San Diego Hlthcare<br />
System, La Jolla, CA, US<br />
260 Analysis of HIV-1 CA Residues under Positive Selective<br />
Pressure<br />
Angela Ciuffi*, K Zhang, M Munoz, R Martinez, and A Telenti<br />
Inst of Microbio, Univ Hosp Ctr and Univ of Lausanne, Switzerland<br />
261 Models of Neutralization and Sequence Variation in HIV-1<br />
Selene Zarate* 1 , D Richman2,3 , J Overbaugh4,5 , and S Frost2 1 2 Univ Autonoma de la Ciudad de Mexico, Mexico City; Univ of<br />
California, San Diego, US; 3VA Hlthcare System, San Diego, CA,<br />
US; 4Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; and 5Univ of<br />
Washington, Seattle, US<br />
262 Construction of Replication-competent Chimeric HIV-1<br />
Reporter Viruses to Study Fitness Costs of Mutations in Non-<br />
Clade B Contexts<br />
Markus Bickel*, M Lewis, A Ali, and O Yang<br />
Univ of California, Los Angeles, US<br />
263 Differential Evolution of HIV-1 Reverse Transcriptase in<br />
Treatment-naïve Female Genital Tract and Plasma<br />
Uma Shanmugasundaram*, N Kumarasamy, K Murugavel, S Solomon,<br />
and P Balakrishnan<br />
YRGCARE, Voluntary Hlth Svcs, Chennai, India<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 53–Poster Abstracts<br />
HIV-1 Macrophage Studies<br />
264 Visualization of HIV-1 Gag Trafficking to the Virological<br />
Synapse in Living Infected Macrophages<br />
K Gousset1 , S Ablan1 , L Coren2 , D Ott2 , and Eric Freed* 1<br />
1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US and SAIC-<br />
Frederick and NCI-Frederick, MD, US<br />
265 Galectin-1 Increases Transfer of HIV-1 from Macrophages to<br />
CD4 + T Cells<br />
Simon Mercier*, C St-Pierre, M Ouellet, M Tremblay, and S Sato<br />
Laval Univ, Canada<br />
266 Links between Cellular Factors Expressed during Monocyte<br />
Differentiation and Productive HIV-1 Replication<br />
Irena Kadiu* 1 , T Wang1 , M Ricardo-Dukelow2 , J Schlautman1 ,<br />
P Ciborowski1 , and H Gendelman1 1 2 Univ of Nebraska Med Ctr, Omaha, US and Univ of Hawaii at Manoa,<br />
Honolulu, US<br />
267 HIV-1 Replication Is Enhanced by Macrophage Migration<br />
Inhibitory Factor<br />
Eduardo Regis* 1 , V Barreto-de-Souza1 , L Leng2 , R Bucala2 , M Bozza3 ,<br />
and D Bou-Habib1 1 2 Oswaldo Cruz Inst, Fiocruz, Rio de Janeiro, Brazil; Yale Univ Sch of<br />
Med, New Haven, CT, US; and 3Federal Univ of Rio de Janeiro, Brazil<br />
268 Entry Co-receptor Use and Fusion Inhibitor T20 Sensitivity<br />
of Dual-tropic R5X4 HIV-1 in Primary Macrophage<br />
Infection<br />
Yanjie Yi*, L Loftin, L Wang, S Ratcliffe, J Issacman-Beck, and<br />
R Collman<br />
Univ of Pennsylvania Sch of Med, Philadelphia, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 54–Poster Abstracts<br />
Co-infection: Virus/Virus Interactions<br />
269 HIV Post-entry Inhibition by Non-structural GBV-C Proteins<br />
Susan Jung*, R Muller, N Donhauser, B Fleckenstein, and H Reil<br />
Univ Hosp, Erlangen, Germany<br />
270 E2, a Novel and Potent HIV Entry Inhibitor Derived from the<br />
Non-pathogenic GBV-C—Characterization of the Detailed<br />
Mechanism<br />
Kristin Hanel*, S Jung, B Fleckenstein, and H Reil<br />
Univ Hosp Erlangen, Germany<br />
271 Establishment of a Cord Blood Lymphocytes-based Cell<br />
Culture System to Study GBV-C and HIV in vitro<br />
Susan Jung*, S Weber, B Fleckenstein, and H Reil<br />
Univ Hosp Erlangen, Germany<br />
272 Interference between HSV-2 and HIV-1 in Co-infected<br />
Human Lymphoid Tissue ex vivo<br />
Christophe Vanpouille*, A Lisco, JC Grivel, A Biancotto,<br />
B Brichacek, and L Margolis<br />
NIH, Bethesda, MD, US<br />
273 GBV-C Infection Is Associated with Less T Cell Activation<br />
in Recently HIV-1-infected Subjects and Is Independent of<br />
HIV-1 Viral Load<br />
Maria Teresa Maidana Giret* 1 , T Silva1 , E Levi2 , H Tomiyama1 ,<br />
K Bassichetto3 , A Nishiya4 , E Sabino4 , R Palacios1 , and E Kallas1 1 2 Federal Univ of Sao Paulo, Brazil; Inst of Tropical Diseases of Sao<br />
Paulo, Brazil; 3Publ Hlth Dept of Sao Paulo, Brazil; and 4Blood Ctr of<br />
Sao Paulo, Brazil<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 55–Poster Abstracts<br />
Viral Reservoirs<br />
274 Phylodynamic Analysis of SIV Populations in Lymphoid<br />
Tissues Reveals the Central Role of the Gut-associated<br />
Lymphoid Tissue as a Reservoir during Suppressive ART<br />
Thomas Ndolo* 1 , M Syvanen1 , J Pan1 , D Verhoeven1 , C Bedford2 ,<br />
R Donovan2 , and S Dandekar1 1 2 Univ of California, Davis, US and California Dept of Hlth Svcs,<br />
Richmond, US<br />
275 HIV-1 Transmission from Infected Dendritic Cells and<br />
Infection of Primary CD4 + T Lymphocytes in the Presence of<br />
Entry Inhibitors Targeting Co-receptors or gp41<br />
Jose Este* 1,2 , I Clotet1 , B Bosch1 , M Fernandez-Figueras2 , R Pena1 ,<br />
M Bofill1 , and B Clotet1,2 1 2 Fndn irsiCaixa, Spain and Hosp Germans Trials i Pujol, Badalona, Spain<br />
276 Different Activation Stimuli Induce Differential<br />
Sequestration of HIV-1 in Human Dendritic Cells<br />
Morgan Reuter*, H Yu, and D McDonald<br />
Case Western Reserve Univ, Cleveland, OH, US<br />
277 A Novel Model for the Establishment of HIV Latency<br />
in Primary CD4 + Cells Demonstrates Epigenetic<br />
Transcriptional Shutdown Due to Chromatin Restrictions<br />
Mudit Tyagi* and J Karn<br />
Case Western Reserve Univ Sch of Med, Cleveland, OH, US<br />
278 CCL2 Enhances Permissiveness of Resting CD4 + T Cells to<br />
Infection with X4-tropic HIV-1<br />
Grant Campbell* and S Spector<br />
Univ of California, San Diego, US<br />
279 HIV-1 Tat Association with Cellular Promoters in Human<br />
Immature Dendritic Cells<br />
Nayoung Kim*, S Kukkonen, and A Aldovini<br />
Children’s Hosp Boston, MA, US<br />
<strong>Program</strong> 27<br />
Poster Listings
Poster Litings<br />
Session 55<br />
280a Latent/Persistent HIV-1 Infection Is Most Likely to Develop<br />
in Minimally Activated Bystander CD4 T Cells<br />
Paula Soto*, V Terry, and C Spina<br />
Univ of California, San Diego and VA San Diego Hlthcare System, US<br />
280b HIV-1 Replicates Locally in Sub-compartments of Female<br />
Genital Tract<br />
MariaPia De Pasquale* 1 , L Sutton2 , J Ingersoll3 , A Caliendo3 ,<br />
J Kurpewski1 , S Chapman1 , S Cu-Uvin1 , and R D’Aquila2 1 2 Brown Univ, Providence, RI, US; Vanderbilt Univ, Nashville, TN, US;<br />
and 3Emory Univ, Atlanta, GA, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 56–Poster Abstracts<br />
Viral Transmission: Molecular Studies<br />
281 Visualization of HIV Interaction with Adult Human Foreskin<br />
Explants<br />
Minh Dinh* 1 , S McCoombe2 , M McRaven2 , N Byers2 , and T Hope2 1Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US and<br />
2Northwestern Univ, Chicago, IL, US<br />
282 The DCIR Lectin, a New Receptor Involved in the<br />
Transmission of HIV-1 from Dendritic Cells to CD4 + T Cells<br />
Alexandra Lambert*, C Gilbert, and M Tremblay<br />
Ctr Hosp of Laval Univ, Canada<br />
283 The Evolutionary History of the CD209 (DC-SIGN) Family in<br />
Human and Non-human Primates<br />
Millan Ortiz*, K Zhang, and A Telenti<br />
Inst of Microbio, Univ of Lausanne, Switzerland<br />
284 Single Variant Transmission Predominates in HIV-1 Subtype<br />
C Infection, with Multiple Variant Transmission Associated<br />
with Increased Genital Inflammatory Cytokines<br />
Carolyn Williamson* 1 , M Abrahams1 , F Treurnicht1 , C Seioghe1 ,<br />
JA Passmore1 , N Wood1 , K Mlisana2 , B Hahn3 , S Abdool Karim2 , and the<br />
CAPRISA002 Study and the Ctr for HIV/AIDS Vaccine Immunology<br />
Consortium<br />
1 2 Univ of Cape Town, South Africa; Univ of KwaZulu Natal, Durban,<br />
South Africa; and 3Univ of Alabama at Birmingham, US<br />
285 Transmission of Simian Immunodeficiency Virus by<br />
Plasma Collected Prior to Detectable Viremia, and Relative<br />
Infectivity of Ramp-up versus Chronic Stage Plasma<br />
ZM Ma1 , M Piatak2 , L Fritts1 , D Lu1 , J Lifson2 , M Busch3 , and<br />
Christopher Miller* 1<br />
1California Natl Primate Res Ctr and Ctr for Comparative Med, Univ of<br />
California, Davis, US; 2SAIC-Frederick and NCI-Frederick, MD, US; and<br />
3Blood Systems Res Inst and Univ of California, San Francisco, US<br />
286 Mucosally Transmissible R5 SHIV-2873Nip Encoding<br />
env from a Child with Rapid Progression of HIV Clade C<br />
Infection: A Tool for Vaccine Development<br />
Siddappa Nagadenahalli* 1,2 , R Song1,2 , A Chenine1,2 , R Grisson1,2 ,<br />
V Karmor1 , C Wood3 , G Bhat4 , R Amara5 , F Novembre5 , and R Ruprecht1,2 1 2 Dana-Farber Cancer Inst, Boston, MA, US; Harvard Med Sch, Boston,<br />
MA, US; 3Nebraska Ctr for Virology and Sch of Biological Sci, Univ<br />
of Nebraska, Lincoln, US; 4Univ Teaching Hosp, Lusaka, Zambia; and<br />
5Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US<br />
287 Uptake and Intracellular Behavior of HIV-1 in Human<br />
Hepatoma Cells Leading to Virus Recycling and Transfer to<br />
T Cells<br />
Remi Fromentin*, R Lodge, M Tremblay, and D Leclerc<br />
Infectious Disease Res Ctr, Quebec, Canada<br />
288 Nuclear Receptor Ligands Inhibit HIV-1 cis- and transinfection<br />
Timothy Hanley* and G Viglianti<br />
Boston Univ Sch of Med, MA, US<br />
289 Characterization of a Novel Mechanism of an Envelope<br />
Glycoprotein-independent HIV-1 Capture and Transmission<br />
Mediated by Mature Dendritic Cells<br />
Nuria Izquierdo-Useros* 1 , I Erkizia-Jauregi1 , J Blanco1 , R Wiley2 ,<br />
E Newton2 , J Archer2 , S Hatch2 , B Clotet1 , J Martinez-Picado1 , and<br />
R Gummuluru2 1 2 Fndn irsiCaixa, Badalona, Spain and Boston Univ Sch of Med, MA, US<br />
290 Cell-type and Envelope/Virion Dependence of Galectin-1mediated<br />
Enhancement of HIV-1 Infection<br />
Patrick Hong*, J Fulcher, and B Lee<br />
David Geffen Sch of Med, Univ of California, Los Angeles, US<br />
291 Mechanism of Human Defensins 5- and 6-mediated<br />
Enhancement of HIV-1 Infectivity<br />
A Rapista1 , W Lu2 , and Theresa Chang* 1<br />
1 2 Mt Sinai Sch of Med, New York, NY, US and Univ of Maryland Biotech<br />
Inst, Baltimore, US<br />
28 15th Conference on Retroviruses and Opportunistic Infections<br />
CROI 2008<br />
292 Cell-to-cell HIV Transmission Targets CD45RO + CD4 T Cells<br />
through LFA-1-dependent and -independent Mechanisms<br />
Isabel Puigdomenech*, M Massanella, N Izquierdo-Useros, M Curriu,<br />
R Ruiz-Hernandez, M Bofill, J Martinez-Picado, M Juan, B Clotet, and<br />
J Blanco<br />
Fndn irsiCaixa, Hosp Univ Germans Trias i Pujol, Spain<br />
293 Impact of TLR2, 4, 5, 7, and 9 Stimulations on Dendritic Cell<br />
HIV-1 Infection and Transfer to CD4 + T Cells<br />
Sandra Thibault*, M Tardif, and M Tremblay<br />
Infectious Diseases Res Ctr, Quebec, Canada<br />
294 Phylogenetic Clustering of HIV-1 from Acutely Infected<br />
Individuals Does Not Reflect a Higher per-Act Transmission<br />
Probability<br />
Erik Volz* and S Frost<br />
Univ of California, San Diego AIDS Vaccine Res Ctr, US<br />
b Monday, 1-4 pm; Hall D<br />
Session 57–Poster Abstracts<br />
Factors Impacting Disease Progression<br />
295 Identification of an IL-7RA Risk Allele for Rapid Progression<br />
to AIDS: Results of a Genomic IL-7/IL-7RA Study in the<br />
GRIV Cohort<br />
Sophie Limou* 1,2,3 , C Coulonges1 , H Do2 , A Vasilescu2 , T Labib1,3 , I Gut2 ,<br />
JD Lelievre3 , Y Levy3 , and JF Zagury1,3 1 2 Conservatoire Natl des Arts et Metiers, Paris, France; CEA, Evry,<br />
France; and 3Hosp Henri Mondor, INSERM U84, Creteil, France<br />
296 CCL3L1 Variable Gene Copy Number Influence on the<br />
Susceptibility to HIV-1/AIDS among Estonian Intravenous<br />
Drug Users<br />
Maarja Sadam*, K Huik, R Avi, T Karki, K Ruutel, and I Lutsar<br />
Inst of Microbio, Univ of Tartu, Estonia<br />
297 Interferon-γ Genotype (874T>A) Is Associated with CCR5<br />
Expression in HIV + Patients<br />
N Liptrott, B Chandler, S Khoo, D Back, and Andrew Owen*<br />
Univ of Liverpool, UK<br />
298 Use of a Dually Inducible Cell Line Reveals Distinct Patterns<br />
of CD4 and CCR5 Usage among Laboratory and Primary<br />
HIV-1 and SIV Strains<br />
Samantha Johnston* 1 , M Lobritz2 , S Nguyen1 , C Garibay1 , B Ank1 ,<br />
Y Bryson1 , E Arts2 , T Chou1 , and B Lee1 1 2 Univ of California, Los Angeles, US and Case Western Reserve Univ,<br />
Cleveland, OH, US<br />
299 Lack of Effect of Short Viremic Episodes in LPS Plasma<br />
Levels in Chronically HIV-1-infected Subjects<br />
Emmanouil Papasavvas* 1 , M Pistilli1 , A Hancock1 , G Reynolds1 ,<br />
A Mackiewicz1 , C Gallo2 , J Kostman2,3 , K Mounzer2 , J Shull2 , and<br />
L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US; Philadelphia Field Initiating Group<br />
for HIV Trials, PA, US; and 3Univ of Pennsylvania, Philadelphia, US<br />
300 Reduction in the Absolute Number of Myeloid Dendritic<br />
Cells and Plasmacytoid Dendritic Cells in HIV Infection<br />
Correlates with Disease Progression<br />
Meera Singh*, M Thakar, S Suregaonkar, M Ghate, and R Paranjape<br />
Natl AIDS Res Inst, Pune, India<br />
301 Role of TLR in HIV-1 Pathogenesis<br />
Beda Brichacek*, A Biancotto, Y Kiselyeva, C Vanpouille, A Lisco,<br />
J Grivel, and L Margolis<br />
NIH, Bethesda, MD, US<br />
302 Alternative pre-mRNA Splicing and Expression of ILT4 in<br />
HIV-1 Chronic Infection<br />
Danlei Mou*, M Lichterfeld, K Williams, D Kavanagh, H Duong,<br />
B Walker, and X Yu<br />
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US<br />
304 Micro-RNA of Host and HIV Origin Play a Major Role in the<br />
Pathogenesis of HIV Infection and Its Control<br />
Zvi Bentwich* 1,2 , E Meiri2 , A Levy2 , O Carmi1 , and Y Shemer1 1 2 Ben Gurion Univ Faculty of Hlth Sci, Beer Sheba, Israel and Rosetta<br />
Genomics Inc, Rehovot, Israel<br />
305 Chemokine Receptor Gene (CCR5 and CCR2) Haplotypes as<br />
Risk Factors for HIV-1 Acquisition and Pathogenesis<br />
Rakhi Malhotra* 1 , W Song1 , I Brill1 , D Chanda2 , J Mulenga2 , S Allen2,3 ,<br />
E Hunter3 , J Tang1 , and R Kaslow1 1 2 Univ of Alabama at Birmingham, US; Rwanda-Zambia HIV-1 Res<br />
Group, Lusaka; and 3Emory Univ, Atlanta, GA, US<br />
306 Viroverse: A Research Database and Bioinformatics Analysis<br />
Framework<br />
Brandon Maust* 1 , W Deng1 , J Stoddard1 , Z Frazier2 , M Guerquin1 ,<br />
G Learn1 , R Samudrala1 , R Bumgarner1 , and J Mullins1 1 2 Univ of Washington, Seattle, US and Univ of Southern California, Los<br />
Angeles, US
CROI 2008 Session 60<br />
307a HIV-specific B Cells Are Enriched in a Dysfunctional Memory<br />
B Cell Compartment in HIV-infected Viremic Individuals<br />
Susan Moir*, J Ho, A Malaspina, W Wang, A DiPoto, M O’Shea,<br />
G Roby, J Arthos, TW Chun, and A Fauci<br />
NIAID, NIH, Bethesda, MD, US<br />
307b KIR/HLA Genotypes that Inhibit NK Cell Activation Are<br />
Associated with Protection against HIV-1 Disease Progression<br />
Wim Jennes* 1 , S Verheyden2 , C Demanet2 , O Tossou3 , B Vuylsteke1 , and<br />
L Kestens1 1 2 Inst of Tropical Med, Antwerp, Belgium; Univ Hosp Brussels, Belgium;<br />
and 3Project RETRO-CI, Abidjan, Côte d`Ivoire<br />
307c Severe Primary Sexually Transmitted HIV Infection Due to<br />
Dual-tropic HIV-1<br />
J Dalmau1 , M Puertas1 , M Azuara2 , A Marino3 , N Izquierdo-Useros1 ,<br />
M Buzon1 , R Paredes1 , C Rodrigo2 , Bonaventura Clotet* 1,2 , and<br />
J Martinez-Picado1,4 1 2 Fndn irsiCaixa, Badalona, Spain; Hosp Univ Germans Trias i Pujol,<br />
Badalona, Spain; 3Hosp Arquitecto Marcide, El Ferrol, Spain; and<br />
4ICREA, Barcelona, Spain<br />
b Monday, 1-4 pm; Hall D<br />
Session 58–Poster Abstracts<br />
Factors Impacting Viral Replication in vivo<br />
308 Increased Levels of APOBEC3G mRNA in Highly Exposed<br />
Persistently Seronegative Individuals and Individuals with<br />
Long Term Low Viral Loads<br />
Joel Vazquez-Perez*, R Hernandez, C Ormsby, and G Reyes-Teran<br />
Natl Inst of Respiratory Diseases, Mexico City, Mexico<br />
309 Levels of APOBEC3G and APOBEC3F mRNA Increase Post<br />
HIV-1 Infection Associated with Low Viral Set-point<br />
Nzovu Ulenga* 1 , A Dieng Sarr1 , S Thakore-Meloni1 , JL Sankale1 ,<br />
G Eisen1 , A Gueye-NDiaye2 , S MBoup2 , and P Kanki1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US and Cheikh Anta Diop Univ,<br />
Dakar, Senegal<br />
310 Viral Replication is Sustained by Short-lived Infected Cells in<br />
SIVagm-infected African Green Monkeys<br />
Ivona Pandrea* 1 , R Ribeiro2 , R Gautam1 , T Gaufin1 , C Monjure1 ,<br />
M Pattison1 , G Silvestri3 , M Miller4 , A Perelson2 , and C Apetrei1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Los Alamos Natl<br />
Lab, NM, US; 3Univ of Pennsylvania, Philadelphia, US; and 4Gilead Sci,<br />
Foster City, CA, US<br />
311 Evolution in HIV-1 gag and env Is Differentially Associated<br />
with Viral Load and the Immune Response at Different<br />
Times in Infection<br />
Anne Piantadosi* 1,2 , B Chohan1,2 , D Panteleeff1 , Z Jalalian-Lechak1 ,<br />
J Baeten2 , and J Overbaugh1 1 2 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US and Univ of<br />
Washington, Seattle, US<br />
312 Genome-wide HLA-associated Selection in HIV-1 and<br />
Protein-specific Correlations with Viral Load: An ACTG<br />
5142 Study<br />
M John1 , D Heckerman2 , L Park1 , S Gaudieri1 , A Chopra1 , J Carlson2 ,<br />
I James1 , D Nolan1 , R Haubrich3 , Simon Mallal* 1 , and ACTG 5142 Study<br />
Team<br />
1Ctr for Clinical Immunology and Biomed Statistics, Murdoch Univ, Royal<br />
Perth Hosp, Australia; 2Microsoft Res, Redmond WA, US; and 3Antiviral Res Ctr, San Diego, CA, US<br />
313 Contribution of NK Cells to the Control of Primary SIV<br />
Infection in Rhesus Monkeys<br />
Elisa Choi*, N Letvin, K Reimann, and Ctr for HIV/AIDS Vaccine<br />
Immunology (CHAVI)<br />
Beth Israel Deaconess Med Ctr, Boston, MA, US<br />
314 Higher Frequencies of γ δ T Cells Are Associated with<br />
Undetectable Plasma Viral Loads in HIV-2 Infections<br />
N Zheng1,2 , J McElrath1,2 , S Sow3 , A Mesher1 , S Hawes1 , J Stern1 ,<br />
Geoffrey Gottlieb* 1 , S De Rosa1,2 , and N Kiviat1 1 2 Univ of Washington, Seattle, US; Fred Hutchinson Cancer Res Ctr,<br />
Seattle, WA, US; and 3Univ of Dakar, Senegal<br />
315 HIV-1-induced Activation of CD4 + T Cells Creates New Targets<br />
for HIV-1 Infection in Human Lymphoid Tissue ex vivo<br />
Angelique Biancotto* 1 , JC Grivel1 , I Hirsch2 , C Vanpouille1 , A Lisco1 ,<br />
and L Margolis1 1Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US and<br />
2INSERM UMR 599, Marseille, France<br />
316 Alloantigen Exposure Alters the Susceptibility to Cellassociated<br />
Mucosal FIV Challenge<br />
Surender Kumar*, S Leavell, B Assogba, and M Burkhard<br />
Ohio State Univ, Columbus, US<br />
317 WFDC1/ps20 Is a Novel Innate Immunomodulatory Signature<br />
Protein of HIV permissive CD4 + CD45RO + Memory T Cells<br />
that Promotes Infection by Up-regulating CD54 Integrin<br />
Expression and Is Elevated in HIV-1 Infection<br />
Raymond Alvarez*, J Reading, P Easterbrook, and A Vyakarnam<br />
King’s Coll London, UK<br />
318 Foreskin Langerhans’ Cell Density of HIV Infected and<br />
Uninfected Men in Rakai, Uganda<br />
Kristine Johnson* 1 , J Taube 1 , R Sharma 1 , A Rabkin 2 , D Serwadda 3 ,<br />
G Kigozi 3 , S Watya 3 , M Wawer 3,4 , R Gray 3,4 , and T Quinn 1,5<br />
1 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 2 Stanford Univ,<br />
Palo Alto, CA, US; 3 Rakai Hlth Sci Prgm, Kalisizo, Uganda; 4 Johns<br />
Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; and<br />
5 NIAID, NIH, Bethesda, MD, US<br />
b Monday, 1-4 pm; Hall D<br />
Session 59–Poster Abstracts<br />
Studies on Viral Evolution in vivo<br />
319 Nonlinear Accumulation of Genetic Diversity in HIV-1<br />
Infection<br />
Mary Kearney* 1 , F Maldarelli 1 , W Shao 1 , E Daar 2 , J Margolick 3 ,<br />
V Boltz 1 , J Mellors 4 , J Coffin 5 , and S Palmer 1<br />
1 NCI-Frederick, MD, US; 2 Univ of California, Los Angeles AIDS Inst, US;<br />
3 Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US;<br />
4 Univ of Pittsburgh, PA, US; and 5 Tufts Univ, Boston, MA, US<br />
320 Sequence Conservation and Viral Fitness in Circulating<br />
HIV-1 Sequences<br />
Morgane Rolland* 1 , L Heath 1 , W Deng 1 , D Heckerman 2 , and J Mullins 1<br />
1 Univ of Washington Sch of Med, Seattle, US and 2 Machine Learning and<br />
Applied Statistics Group, Microsoft Res, Redmond, WA, US<br />
321 Increasing Mutations in HIV-1 DNA from Sputum vs<br />
Peripheral Blood during Effective ART<br />
Thor Wagner* 1,2 , N Tobin 3 , J McKernnan 2 , K Mohan 2 , A Melvin 1,2 ,<br />
M Xu 1,2 , G Learn 1 , J Mullins 1 , and L Frenkel 1,2<br />
1 Univ of Washington, Seattle, US; 2 Children’s Hosp and Regional Med Ctr,<br />
Seattle, WA, US; and 3 Santa Clara Valley Med Ctr, San Jose, CA, US<br />
322 High Viral Load and Weak Humoral Immunity, but Not<br />
Target Cell Availability, Are Factors Driving X4 Virus<br />
Evolution and Emergence in Rhesus Macaques<br />
Amy Li*, SH Ho, V Sahi, and C Cheng-Mayer<br />
Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US<br />
323 Envelope Modifications over the Course of Infection Confer a<br />
Greater Ability to Utilize the CCR5 Receptor<br />
A Fellows1 , A Kamat1 , B Kwambana1 , J Overbaugh2 , and Manish Sagar* 1<br />
1 2 Brigham and Women’s Hosp, Cambridge, MA, US and Fred Hutchinson<br />
Cancer Res Ctr, Seattle, WA, US<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 60–Poster Abstracts<br />
CTL Studies and Consequences of Immune Escape<br />
324 Transmission of HIV-1 CTL Escape Variants Provides HLAmismatched<br />
Recipients with a Survival Advantage<br />
Denis Chopera* 1 , Z Woodman1 , M Mlotshwa2 , D Martin1 , C Seoighe1 ,<br />
D Assis de Rosa2 , K Mlisana3 , S Abdool Karim3 , C Gray2 , and<br />
C Williamson1 1 2 Univ of Cape Town, South Africa; Natl Inst for Communicable Diseases,<br />
Johannesburg, South Africa; and 3Univ of KwaZulu Natal, Durban, South<br />
Africa<br />
325 Long-term Stability of Compensated CD8 Escape Mutations<br />
following HIV Transmission to HLA-Mismatched Individuals<br />
Arne Schneidewind*, B Li, A Gladden, R Allgaier, E Rosenberg,<br />
B Walker, and T Allen<br />
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch,<br />
Boston, US<br />
326 HIV-1 CTL Escape Mutation Contribute to Dendritic<br />
Cell Dysfunction by Increasing pMHC Class I Binding to<br />
Inhibitory Myelomonocytic Receptors<br />
Huang Jinghe*, M Lichterfeld, D Kavanagh, K Williams, T Miura,<br />
F Pereyra, A Trocha, R Gandhi, B Walker, and X Yu<br />
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Univ Ctr for<br />
AIDS Res, Boston, US<br />
327 Dense Networks of Correlated Substitutions Accompany<br />
Adaptations to HLA-restricted CTL Epitopes<br />
Jonathan Carlson* 1,2 , Z Brumme3 , C Brumme3 , L Swenson4 , S Szeto4 ,<br />
I Tao4 , C Kadie1 , B Walker3,5 , R Harrigan4 , and D Heckerman1 1 2 Microsoft Res, Redmond, WA, US; Univ of Washington, Seattle, US;<br />
3 4 Partners AIDS Res Ctr, Boston, MA, US; BC Ctr for Excellence in HIV/<br />
AIDS, Vancouver, Canada; and 5Howard Hughes Med Inst, Chevy Chase,<br />
MD, US<br />
328 CTL Escape Mutations within the HIV-1 Nef HLA-<br />
B8-restricted CTL Epitope FL8 Correlate with Disease<br />
Progression in HLA-B8 Patients<br />
Katja Maurer*, E Harrer, A Goldwich, K Eismann, S Bergmann,<br />
M Schmitt-Haendle, B Spriewald, S Mueller, and T Harrer<br />
Univ Erlangen-Nuremberg, Germany<br />
<strong>Program</strong> 29<br />
Poster Listings
Poster Litings<br />
Session 60 CROI 2008<br />
329 Antiviral Efficacy of a CTL Immune Response Focused on<br />
Conserved HIV-1 Segments<br />
Morgane Rolland* 1 , W Deng1 , C Rousseau1 , H Coovadia2 , K Bishop2 ,<br />
P Goulder3,4 , B Walker2,3 , C Brander3 , and J Mullins1 1 2 Univ of Washington, Seattle, US; Doris Duke Med Res Inst, Univ<br />
of KwaZulu Natal, Durban, South Africa; 3Partners AIDS Res Ctr,<br />
Massachusetts Gen Hosp, Harvard Med Sch, Charlestown, US; and 4Univ of Oxford, UK<br />
330 Discordant Neutralization of HIV by CTL Targeting Core<br />
and Envelope Proteins<br />
Huabiao Chen* 1,2 , A Trocha1,2 , F Pereyra1 , T Miura1,2 , M Brockman1,2 ,<br />
B Julg1 , B Baker1 , A Rothchild1 , B Block1 , and B Walker1,2 1 2 Massachusetts Gen Hosp, Harvard Med Sch, Boston, US and Howard<br />
Hughes Med Inst, Chevy Chase, MD, US<br />
331 Antigenic Escape of SIVmac239 in a SIVmac239-Infected Rhesus<br />
Macaque in vivo with an Unusually High-titer Neutralizing<br />
Antibody Response<br />
Shuji Sato*, E Yuste, H Sanford, A Lauer, E Chang, R Desrosiers, and<br />
W Johnson<br />
New England Primate Res Ctr, Harvard Med Sch, Southborough, MA, US<br />
332 Viral Escape from a Novel HLA-C0102-restricted<br />
Immunodominant Gag CTL Epitope in HIV-1 Subtype<br />
CRF01_AE-infected Thai Patients<br />
Supranee Buranapraditkun* 1 , P Chatkulkawin1 , R Allgaier2 ,<br />
SI Lorenzen1 , P Thantiworasit1 , P Pitakpolrat1 , S Sirivichayakul1 ,<br />
B Walker2 , T Allen2 , and K Ruxrungtham1 1 2 Chulalongkorn Univ, Bangkok, Thailand and Partners AIDS Res Ctr,<br />
Boston, MA, US<br />
333 HIV-1 Escape Driven by HLA-B*13 CD8 T Cell Responses<br />
Targeting p15 Gag Is Associated with Fitness Cost and<br />
Modification of the Gag-Pol Frameshift Stem-loop<br />
Julia Prado*, I Honeyborne, and P Goulder<br />
Univ of Oxford, UK<br />
334 HLA-B Alleles Selecting Multiple Escape Mutations in Gag<br />
Are Associated with Reduced Viremia<br />
Philippa Matthews* 1 , A Prendergast1 , A Leslie1 , R Payne1 ,<br />
H Crawford1 , C Rousseau2 , T Ndung’u3 , B Walker3,4 , D Heckerman5 , and<br />
P Goulder1,3,4 1 2 3 Univ of Oxford, UK; Univ of Washington, Seattle, US; Univ of KwaZulu<br />
Natal, Durban, South Africa; 4Harvard Univ, Boston, MA, US; and<br />
5Microsoft Res, Redmond, WA, US<br />
335 Accumulation of CTL Escape Variants and HLA-driven<br />
Convergence of Viral Subtypes<br />
Dario Alberto Dilernia* 1 , L Lourtau2 , L Jones1,3 , G Turk1 ,<br />
M Gomez-Carrillo1 , C Bautista4 , J Benetucci5 , M Losso2 , P Cahn6 , and<br />
H Salomon1 1 2 Argentinean Reference Ctr for AIDS, Buenos Aires; Hosp Gen de<br />
Agudos “Jose Maria Ramos Mejia”, Buenos Aires, Argentina; 3Estacion de Fotobiologia Playa Union, Buenos Aires, Argentina; 4Assn Benefica<br />
PRISMA, Lima, Peru; 5Hosp de Enfermedades Infecciosas “Francisco<br />
J Muniz”, Buenos Aires, Argentina; and 6Hosp Gen de Agudos “Juan A<br />
Fernandez”, Buenos Aires, Argentina<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 61–Poster Abstracts<br />
Factors Influencing CD4 Counts<br />
336 CD4 Loss Rate in Untreated Chronic HIV-1 Infection May<br />
Be Better Predicted by PD-1 than HIV RNA and CD38<br />
M Holm, F Pettersen, and Dag Kvale*<br />
Ulleval Univ Hosp, Univ of Oslo, Norway<br />
337 Maintenance of Proliferative PD-1 low Memory CD8 + T Cells<br />
Specific for Eradicated Virus in HIV-1 Patients with High<br />
CD4 Count<br />
Ai Kawana-Tachikawa*, M Motose, T Odawara, T Fuji, and A Iwamoto<br />
Inst of Med Sci, Univ of Tokyo, Japan<br />
338 Decline in Regulatory T Cells Is Associated with Generalized<br />
Immune Activation during HIV Disease Progression<br />
Andrew Prendergast*, P Klenerman, and P Goulder<br />
Univ of Oxford, UK<br />
339 Differential Expression of Genes Associated with Apoptosis<br />
Predicts CD4 Decline after Interruption of ART in ACTG<br />
A5170<br />
Maryanne Vahey* 1 , Z Wang2 , Z Su3 , A Krambrink3 , D Skiest4 , and<br />
D Margolis5 1 2 Walter Reed Army Inst of Res, Washington, DC, US; Henry M Jackson<br />
Fndn, Rockville, MD, US; 3Harvard Sch of Publ Hlth, Boston, MA, US;<br />
4 5 Baystate Med Ctr, Springfield, MA, US; and Univ of North Carolina at<br />
Chapel Hill, US<br />
340 Plasma IL-7 Levels Do Not Evolve in Parallel to CD4 + Counts<br />
at Early Stages of HIV Infection<br />
Jose Benito*, M Lopez, S Lozano, J Gonzalez-Lahoz, and V Soriano<br />
Hosp Carlos III, Madrid, Spain<br />
30 15th Conference on Retroviruses and Opportunistic Infections<br />
341 HIV-1 Proviral Hypermutation Associates with Decline in<br />
CD4 Count in HIV-infected Kenyan Women<br />
Allison Land* 1 , B Ball1 , M Luo1 , R Pilon2 , P Sandstrom2 , J Embree1 ,<br />
C Wachihi3 , J Kimani3 , and F Plummer1,4 1 2 Univ of Manitoba, Winnipeg, Canada; Publ Hlth Agency of Canada,<br />
Ottawa; 3Univ of Nairobi, Kenya; and 4Publ Hlth Agency of Canada,<br />
Winnipeg<br />
342 Non-invasive in vivo Imaging of CD4 Cells in SHIV-infected<br />
Rhesus Monkeys<br />
Michele Di Mascio* 1 , C Paik2 , J Carrasquillo3 , JS Maeng2 , S Srinivasula4 ,<br />
M Catalfamo1 , Y Nishimura1 , K Reimann5 , M Martin1 , and C Lane1 1 2 NIAID, NIH, Bethesda, MD, US; Warren G Magnuson Clinical Ctr,<br />
NIH, Bethesda, MD, US; 3Memorial Sloan Kettering Cancer Ctr, New<br />
York, NY, US; 4SAIC-Frederick, MD, US; and 5Beth Israel Deaconess<br />
Med Ctr, Boston, MA, US<br />
343 The Frequency and Clinical Implications of a Discordant<br />
CD4 Count and CD4 Percentage<br />
M Gompels1 , Caroline Sabin* 2 , A Phillips2 , D Dunn3 , and the UK<br />
Collaborative HIV Cohort (CHIC) Study<br />
1 2 North Bristol NHS Trust, UK; Royal Free and Univ Coll Med Sch,<br />
London, UK; and 3Med Res Council Clinical Trials Unit, London, UK<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 62–Poster Abstracts<br />
HIV Superinfection and Viral Co-infection<br />
344 Transmission of HIV-1 in Seroconcordant Couples<br />
Mary Campbell* 1 , G Gottlieb1 , K Wong1 , S Hawes1 , T Lampinen2 ,<br />
N Kiviat1 , and J Mullins1 1 2 Univ of Washington, Seattle, US and Univ of British Columbia,<br />
Vancouver, Canada<br />
345 Estimate of the Frequency of HIV-1 Co-infection in vivo<br />
Igor Rouzine* 1 , E Gubankova1 , M Kearney2 , S Palmer2 , F Maldarelli2 , and<br />
J Coffin1 1 2 Tufts Univ, Boston, MA, US and HIV Drug Resistance Prgm, NCI-<br />
Frederick, MD, US<br />
346 Down Regulation of β-Chemokines Production in Human T<br />
Cell Leukemia/Lymphoma Virus Type 2 Subtype 2a-infected<br />
Subjects, Regardless of HIV-1 or HCV Infections<br />
I Olah1 , A Brito1 , L Fukumori1 , J Smid2 , A Oliveira2 , A Duarte1 , and<br />
Jorge Casseb* 1,2<br />
1 2 Sao Paulo Univ, Sch of Med, Brazil and Inst of Infectious Diseases, Sao<br />
Paulo, Brazil<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 63–Poster Abstracts<br />
Studies on Elite Controllers and Exposed Uninfected<br />
347 Longitudinal Measurements of Ultra-sensitive Plasma HIV<br />
RNA and Quantitative Antibody Levels in HIV-1-infected<br />
Individuals Who Naturally Maintain Viral Loads below the<br />
Limit of Conventional Detection<br />
Hiroyu Hatano* 1 , E Delwart1,2 , P Norris1,2 , R Hoh1 , M Busch1,2 , J Martin1 ,<br />
and S Deeks1 1 2 Univ of California, San Francisco, US and Blood Systems Res Inst, San<br />
Francisco, CA, US<br />
348 Low-level Virema in HIV-1-infected Patients Classified as<br />
Elite Controllers Compared to Patients on Suppressive ART<br />
Sarah Palmer* 1 , A Wiegand1 , T Miura2 , B Block2 , F Pereyra2 ,<br />
F Maldarelli1 , J Mellors3 , B Walker2 , and J Coffin4 1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US; Partners AIDS<br />
Res Ctr, Massachusetts Gen Hosp, Boston, US; 3Univ of Pittsburgh, PA,<br />
US; and 4Tufts Univ, Boston, MA, US<br />
349 Ongoing Low-level Viral Replication and Polyfunctional CD8<br />
T Cell Responses Detected in the HIV Elite Controllers<br />
Florencia Pereyra* 1 , T Miura1 , S Palmer2 , B Block1 , A Rothchild1 ,<br />
B Baker1 , J Coffin2 , and B Walker1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Charlestown and<br />
Harvard Med Sch, Boston, US and 2NCI-Frederick, MD, US<br />
350 Viral Dynamics of Elite Suppressors in HIV-1 Infection<br />
Jason Dinoso* 1 , S Kim1 , J Blankson1 , and R Siliciano1,2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard<br />
Hughes Med Inst, Baltimore, MD, US<br />
351 Is There a Harmless Level of Plasma Viremia in Untreated<br />
HIV Infection? CD4 + T Cells in the Long-term Follow-up of<br />
Elite Controllers and Controls<br />
Hans-Jurgen Stellbrink* 1 , K Schewe1 , C Hoffmann1 , and E Wolf2 1 2 IPM Study Ctr, Hamburg, Germany and MUC Res, Munich, Germany<br />
352 HIV-1 Proviral Load in Elite Suppressors with Low or<br />
Declining CD4 Counts<br />
J Deayton1,2 , Katherine Groves* 1 , D Bibby2 , H Dreja1 , K Aubin1 ,<br />
C DeSouza2 , J Hand2 , D Clark2 , C Orkin2 , and A McKnight1 1 2 Queen Mary Sch of Med and Dentistry, London, UK and Barts and the<br />
London NHS Trust, UK
CROI 2008 Session 65<br />
353 Relationship between HIV-specific Immune Response,<br />
T Cell Activation, and CD4 + T Cell Depletion in HIV-infected<br />
Patients with Undetectable Plasma HIV RNA Levels in the<br />
Absence of Therapy<br />
Peter Hunt* 1 , E Sinclair1 , H Hatano1 , J McCune1 , B Emu1 , Q Tan1 ,<br />
P Norris2 , M Busch2 , J Martin1 , and S Deeks1 1 2 Univ of California, San Francisco, US and Blood Systems Res Inst, San<br />
Francisco, CA, US<br />
354 The Role of APOBEC3G/F-mediated Hypermutation in the<br />
Control of HIV-1 in Elite Suppressors<br />
Shiv Gandhi* 1 , J Siliciano1 , J Bailey1 , R Siliciano1,2 , and J Blankson1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Howard<br />
Hughes Med Inst, Chevy Chase, MD, US<br />
355 Polyfunctional HIV-specific T Cells in Rectal Mucosa of HIV<br />
Controllers<br />
April Ferre* 1 , P Hunt2 , D Young1 , J Garcia1 , H Yee2 , R Pollard1 , S Deeks2 ,<br />
and B Shacklett1 1 2 Univ of California, Davis, US and Univ of California, San Francisco, US<br />
356 Rare Gag Variants Selected in B*57/5801 HIV-1 Elite<br />
Controllers Induce de novo CTL Responses and Reduce Viral<br />
Replication Capacity<br />
Toshiyuki Miura* 1 , M Brockman1 , A Schneidewind1 , A Raothod1 ,<br />
B Block1 , F Pereyra1 , T Allen1 , M Lobritz2 , E Arts2 , and B Walker1 1 2 Massachusetts Gen Hosp, Boston, US and Case Western Reserve Univ,<br />
Cleveland, OH, US<br />
357 The HLA-B*5701 Allele Is Highly Enriched in Brazilian Elite<br />
Controllers<br />
Maria Teresa Maidana Giret* 1 , E Bermudez-Aza1 , H Tomiyama1 ,<br />
M Melillo Sauer1 , D Watkins2 , and E Kallas1,3 1 2 3 Federal Univ of Sao Paulo, Brazil; Univ of Wisconsin, US; and Univ of<br />
Sao Paulo, Brazil<br />
358 Regain of Viremic Control after Superinfection of an Elite<br />
Controller of HIV-1 Infection<br />
Andrea Rachinger* 1 , M Navis1 , P Groeneveld2 , A van’t Wout1 , and<br />
H Schuitemaker1 1Sanquin Res and Academic Med Ctr, Univ of Amsterdam, The<br />
Netherlands and 2Isala Clin, Zwolle, The Netherlands<br />
359 Increased Expression of KIR3DL1 Subtypes and HLA-B57 in<br />
HIV-exposed Uninfected vs HIV-susceptible Individuals<br />
Salix Boulet* 1 , M Kleyman1 , J Kim1 , P Kamya1 , S Sharafi1 ,<br />
C Tsoukas1 , J Bruneau2 , JP Routy1 , and N Bernard1 1 2 Res Inst of the McGill Univ Hlth Ctr, Montreal, Canada and Ctr Hosp<br />
Univ Montreal, Canada<br />
360 Prevalence and Characterization of HIV-specific Adaptive<br />
Immune Responses in Genital Mucosal Secretions from a<br />
Cohort of High Heterosexual Risk, Seronegative Women in<br />
Chicago<br />
Richard Novak* 1 , L Baum2 , P Graham1 , H Chen1 , W Yang1 , and B Parekh3 1 2 3 Univ of Illinois at Chicago, US; Rush Univ, Chicago, IL, US; and CDC,<br />
Atlanta, GA, US<br />
361a Stronger Memory and Lower Effector T Cell Responses to<br />
HIV in Patients with Long-term Undetectable HIV Viral<br />
Loads under Sustained ART Compared to HIV Controllers<br />
Amelie Guihot* 1 , G Breton1 , R Tubiana1 , B Amellal1 , AG Marcelin1 ,<br />
D Costagliola2 , A Samri1 , C Katlama1 , B Autran1 , G Carcelain1 , and ALT-<br />
ANRS CO15 Study Group and DECAMUNE Study Group<br />
1 2 Hosp Pitie-Salpetriere, Paris, France; and INSERM UMR S720, Paris,<br />
France<br />
361b HIV-1 Gag-specific T Cells in Semen but Not in Peripheral<br />
Blood of HIV High-risk Seronegative Men<br />
Yan Ding*, G Diaz, J Czartoski, J Lee, H Zhu, T Zhu, and J McElrath<br />
Fred Hutchinson Cancer Res Ctr, Univ of Washington, Seattle, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 64–Poster Abstracts<br />
Studies of Non-progressive Infection<br />
362 Host Genetics of Long-term Non-progressors<br />
Milena Nasi* 1 , G Rocco1 , A Riva2 , V Borghi3 , C Casoli4 , M Galli2 ,<br />
G Poli5 , F Prati3 , C Mussini3 , A Cossarizza1 , and Italian Concerted Action<br />
on LTNP “ELVIS”, Inst Superiore di Sanita, Rome, Italy<br />
1 2 Univ of Modena and Reggio Emilia, Italy; Hosp Luigi Sacco, Univ of<br />
Milan, Italy; 3Azienda Ospedaliero Univ, Modena, Italy; 4Univ of Parma,<br />
Italy; and 5San Raffaele Hosp, Milan, Italy<br />
363 Long-term Non-progression of HIV-1 Infection Due to a gagdeletion<br />
Mutation<br />
CYW Tong* 1 , T Dong2 , Y Peng2 , S Frazao Pinheiro2 , K Barlow3 , J Parry3 ,<br />
and S Rowland-Jones2 1 2 Guy’s and St Thomas’ Hosp, London, UK; Med Res Council, Univ of<br />
Oxford, UK; and 3Ctr for Infections, Hlth Protection Agency, London, UK<br />
364 Differential Host Gene Expression in HIV + Long-term Nonprogressors<br />
and Progressors<br />
Maria Salgado* 1 , P Lopez-Romero2 , S Callejas2 , M Lopez1 ,<br />
P Labarga1 , A Dopazo2 , V Soriano1 , and B Rodes1 1 2 Hosp Carlos III, Madrid, Spain and CNIC, Madrid, Spain<br />
365 Characterization of Distinct TRIM5-α mRNA<br />
Polymorphisms in SIV and HIV-1 Long-term Nonprogressors<br />
Nele Jensen* 1,2 , I Stahmer1,2 , C Stahl-Hennig3 , I Hauber2 , J Hauber2 , and<br />
J van Lunzen1,2 1 2 Univ Med Ctr, Hamburg-Eppendorf, Germany; Heinrich Pette Inst<br />
for Experimental Virology and Immunology, Hamburg, Germany; and<br />
3German Primate Res Ctr, Gottingen<br />
366 Anticardiolipin Antibodies, Viral Replication, Anti-HIV<br />
Neutralizing Antibodies and Immune Activation in Nonprogressors<br />
HIV-infected Patients<br />
Valerie Martinez* 1 , MC Diemert1 , M Braibant2 , D Costagliola1 ,<br />
JL Charuel1 , F Barin2 , E Caumes1 , JP Clauvel3 , L Musset1 , B Autran1 , and<br />
the ALT Study Group<br />
1 2 Hosp Pitie-Salpetriere, Paris, France; Univ Francois-Rabelais, Tours,<br />
France; and 3Hosp St Louis, Paris, France<br />
367 Important Deletions and Extremely Low Viral Evolution in a<br />
Subset of HIV-1 Long-term Non-progressor Patients<br />
V Sandonis1 , C Casado1 , G Bello1 , S Garcia2 , C Rodriguez2 , J Romero2 ,<br />
and Cecilio Lopez-Galindez* 1<br />
1 2 Inst Carlos III, Madrid, Spain and IMSALUD, Univ Autonoma de<br />
Madrid, Spain<br />
368 Inhibition of HIV-1 Replication by Freshly Isolated CD8 +<br />
T Cells from HIV Controllers Is Associated with CTL<br />
Proliferation<br />
Boris Julg* 1 , H Chen1,2 , F Pereyra1 , T Miura1,2 , A Piechocka-Trocha1,2 , and<br />
B Walker1,2 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US and<br />
2Howard Hughes Med Inst, Chevy Chase, MD, US<br />
369 HIV-specific Perforin Up-regulation by Effector Memory<br />
CD8 T Cells Is Associated with HIV Non-progression<br />
George Makedonas* 1 , N Hutnick1 , A Hersperger1 , M Ostrowski2 ,<br />
R Kaul2 , K Weinhold3 , and M Betts1 1 2 Univ of Pennsylvania, Philadelphia, US; Univ of Toronto, Canada; and<br />
3Human Vaccine Inst, Duke Univ, Durham, NC, US<br />
370 HIV + Long-term Non-progressors in Rakai, Uganda<br />
Oliver Laeyendecker* 1,2 , A Redd1,2 , T Lutalo3 , R Gray4 , M Wawer4 ,<br />
JB Bwanika3 , F Makumbi3 , J Shott5 , N Kiwanuka3 , T Quinn1,2 , and Rakai<br />
Hlth Sci Prgm<br />
1 2 Lab of Immunoregulation, NIAID, NIH, Baltimore, MD, US; Johns<br />
Hopkins Univ Sch of Med, Baltimore, MD, US; 3Rakai Hlth Sci Project,<br />
Uganda; 4Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore,<br />
MD, US; and 5NIAID-Uganda ICER Prgm, Rakai<br />
371 Characterization of a Subset of Cynomolgus Macaques<br />
Spontaneously Controlling SIVmac251 Infection<br />
S Shin1 , I Karlsson2 , P Versmisse1 , B Malleret2 , O Lambotte3 ,<br />
R Le Grand2 , G Pancino1 , B Vaslin2 , and Asier Saez-Cirion* 1<br />
1 2 Pasteur Inst, Paris, France; CEA, Fontenay-aux-Roses, France; and<br />
3Hosp Bicetre, Le Kremlin Bicetre, France<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 65–Poster Abstracts<br />
(see Session 11 on Monday for corresponding Poster Discussion)<br />
Lymphocyte Depletion in the Gut<br />
372 HIV Pathogenesis: Viral Blitzkrieg or 10 Years’ War?<br />
Cristian Apetrei* 1 , R Gautam1 , T Gaufin1 , R Ribeiro2 , M Pattison1 ,<br />
M Barnes1 , C Monjure1 , A Perelson2 , G Silvestri3 , and I Pandrea1 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Los Alamos Natl Lab,<br />
NM, US; and 3Univ of Pennsylvania, Philadelphia, US<br />
373 Collagen Deposition Limits Immune Reconstitution in the Gut<br />
J Estes1 , J Brenchley2 , A Khoruts3 , J Barthold3 , C Reilly3 , G Beilman3 ,<br />
D Douek2 , A Haase3 , and Timothy Schacker* 3<br />
1 2 NCI-Frederick, MD, US; Vaccine Res Ctr, NIAID, NIH, Bethesda, MD,<br />
US; and 3Univ of Minnesota, Minneapolis, US<br />
374 Disruption of Intestinal Epithelial Integrity and Increased<br />
Microbial Translocation and Systemic Dissemination in HIV<br />
and SIV Infections Are Linked to Impaired IL-17-expressing<br />
Mucosal T Cell Responses<br />
Satya Dandekar*, M Rafatellu, M Macal, S Sankaran, D Verhoeven,<br />
M George, R Santos, and A Baumler<br />
Univ of California, Davis, US<br />
375a Differential Mucosal Pathogenesis of SIV Infection in<br />
Progressing and Long-term Nonprogressing Rhesus<br />
Macaques<br />
Binhua Ling*, M Mohan, T Ooms, A Lackner, P Marx, and R Veazey<br />
Tulane Natl Primate Res Ctr, Covington, LA, US<br />
<strong>Program</strong> 31<br />
Poster Listings
Poster Litings<br />
Session 65 CROI 2008<br />
375b Disturbed Gut Microbiota in HAART-naïve HIV +<br />
Adults: Effect of Intervention with a Specific Prebiotic<br />
Oligosaccharide Mixture<br />
Kaouther Ben Amor* 1 , G Rizzardini2 , C Torti3 , T Quirino4 , M Moroni2 ,<br />
J Knol1 , D Bray5 , A Vriesema1 , M Clerici6 , and A Gori7 1 2 Numico Res, Wageningen, The Netherlands; Hosp Luigi Sacco, Milan,<br />
Italy; 3Univ of Brescia, Italy; 4Hosp Busto Arsizio, Italy; 5ImmunoClin, Paris, France; 6Univ of Milan, Italy; and 7Hosp San Gerardo, Univ of<br />
Milan-Bicocca, Monza, Italy<br />
376 Functional Analysis of Intestinal Epithelial Cells Isolated by<br />
Laser Dissection from SIV-infected Rhesus Macaques in vivo<br />
Michael George*, S Sankaran, I Grishina, and S Dandekar<br />
Univ of California, Davis, US<br />
377 Microbial Translocation Is a Determinant of Persisting<br />
T Cell Hyperactivation in HIV-infected Patients Failing to<br />
Recover CD4 following Long-term HAART<br />
Giusi Maria Bellistri* 1 , V Pegorer1 , C Tincati1 , L Meroni2 , A Gori3 ,<br />
A d’Arminio Monforte1 , and G Marchetti1 1 2 San Paolo Hosp, Univ of Milan, Italy; Luigi Sacco Hosp, Univ of Milan,<br />
Italy; and 3San Gerardo Hosp, Monza, Italy<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 66–Poster Abstracts<br />
Monocyte/Macrophage Studies<br />
378 Up-regulation of PD-L1 on Monocytes and Dendritic Cells by<br />
HIV-1-derived ssRNA<br />
Angela Meier* 1 , A Bagchi2 , H Sidhu1 , G Alter1 , T Suscovich1 ,<br />
H Streeck1 , M Brockman1 , S LeGall1 , J Hellman2 , and M Altfeld1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Med Sch,<br />
Charlestown, US and 2Massachusetts Gen Hosp, Harvard Med Sch,<br />
Boston, US<br />
379 Monocyte Heterogeneity Underlying Phenotypic Changes in<br />
Monocytes according to SIV Disease Stage<br />
Woong-Ki Kim* 1 and K Williams2 1 2 Eastern Virginia Med Sch, Norfolk, US and Boston Coll, Chestnut Hill,<br />
MA, US<br />
380 HIV-mediated Dysregulation of Zinc Homeostasis Confers<br />
Resistance to Apoptosis in Circulating Monocytes during<br />
Viremia<br />
A Raymond1 , B Gekonge1 , A Hancock1 , J Chehimi1 , E Papasavvas1 ,<br />
K Mounzer2 , and Luis Montaner* 1<br />
1 2 Wistar Inst, Philadelphia, PA, US and Philadelphia Field Initiating<br />
Group for HIV Trials, PA, US<br />
381 HIV Modulates Host Gene Expression in Macrophages after<br />
IFN-α2 Treatment<br />
Melissa Sirois* 1 , L Robitaille1 , M Shah1 , C Woelk2 , and J Corbeil1 1 2 Infectious Disease Res Ctr, Laval Univ, Canada and Univ of California,<br />
San Diego, US<br />
382 HIV-1 Activates Macrophages Independent of Toll-like<br />
Receptors, a Potential Mechanism for Dysregulation of<br />
Innate Immunity<br />
Joseph Brown* 1 , J Kohler2 , C Coberley1 , J Sleasman3 , and M Goodenow1 1 2 Univ of Florida Coll of Med, Gainesville, US; Emory Univ, Atlanta, GA,<br />
US; and 3Univ of South Florida Coll of Med and All Children’s Hosp, St<br />
Petersburg, US<br />
383 HIV-1 ssRNA Triggers a Vitamin D-dependent Antiviral<br />
Pathway in Human Monocytes<br />
P Hong, K Corcoran, R Modlin, B Lee, and Stephan Krutzik*<br />
Univ of California, Los Angeles, US<br />
b Monday, 1-4 pm; Hall D<br />
Session 67–Poster Abstracts<br />
Therapy and CNS Infection<br />
384 Predictors of Clinical Outcome and Viro-immunological<br />
Response to cART in an Italian Cohort of HIV-infected Naïve<br />
Patients Affected by Neurological Disorders<br />
M Giancola1 , P Lorenzini1 , A Cingolani2 , M Bongiovanni3 , S Bossolasco4 ,<br />
B Vigo5 , M Finazzi6 , S Casari7 , P Cinque4 , Andrea Antinori* 1 , and Italian<br />
Registry Investigative Neuro AIDS (IRINA) Study Group<br />
1Natl Inst for Infectious Diseases “Lazzaro Spallanzani”, IRCCS, Rome,<br />
Italy; 2Univ Cattolica del Sacro Cuore, Rome, Italy; 3Univ of Milan, Italy;<br />
4 5 6 San Raffaele Sci Inst, Milan, Italy; Niguarda Hosp, Milan, Italy; Hosp<br />
Riuniti, Bergamo, Italy; and 7Univ degli Studi, Brescia, Italy<br />
385 Intracerebral Penetrating ART Are More Efficient on<br />
Survival of HIV + Patients with Progressive Multifocal<br />
Leukoencephalopathy (ANRS CO4 - FHDH)<br />
Jacques Gasnault* 1 , E Lanoy2,3 , M Bentata4 , M Guiguet2,3 , and<br />
D Costagliola2,3 1 2 Hosp Bicetre, Le Kremlin Bicetre, France; INSERM U720, Paris,<br />
France; 3Univ Pierre and Marie Curie, Paris, France; and 4Hosp Avicenne, Bobigny, France<br />
32 15th Conference on Retroviruses and Opportunistic Infections<br />
386 Effect of Combined ART on Brain and Lymphoid Tissue<br />
Virus Burden in An Accelerated Model of SIV Encephalitis in<br />
Rhesus Macaques<br />
Lakshmanan Annamalai* 1 , S Westmoreland1 , D Pauley1 , K Williams2 ,<br />
E Ratai3 , M Lentz3 , R Schinazi4 , N Bischofberger5 , G Gonzalez3 , and<br />
S O’Neil1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA,<br />
US; 2Boston Univ, MA, US; 3AA Martinos Ctr for Biomed Imaging,<br />
Massachusetts Gen Hosp, Charlestown, US; 4Emory Univ Sch of Med and<br />
VAMC, Atlanta, GA, US; and 5Gilead Sci, Foster City, CA, US<br />
387 Intermediate (12 Months) and Long-term (6 Years) Cognitive<br />
Response to HAART in 2 Thai Cohorts<br />
V Valcour1,2,3 , P Sithinamsuwan4 , W Pumpradit5 , J Ananworanich1,3 ,<br />
S Nidhinandana4 , W Apateerapong3 , K Robertson6 , R Paul7 , U Siangphoe3 ,<br />
Cecilia Shikuma* 1,3 , and Southeast Asia Res Collaboration with Hawaii<br />
(SEARCH) 001 Protocol Team<br />
1 2 Hawaii AIDS Clinical Res Prgm, Univ of Hawaii, Honolulu, US; Univ of<br />
California, San Francisco, US; 3South East Asia Res Collaboration with<br />
Univ of Hawaii, Bangkok, Thailand; 4Phramongkutklao Hosp, Bangkok,<br />
Thailand; 5HIV Netherlands Australia Thailand Res Collaboration,<br />
Bangkok; 6Univ of North Carolina at Chapel Hill, US; and 7Univ of<br />
Missouri, St Louis, US<br />
388 Baseline Data from ACTG 5199: The International<br />
Neurological Study<br />
Kevin Robertson* 1 , J Kumwenda2 , K Supparatpinyo3 , S Evans4 , J Jiang4 ,<br />
T Campbell5 , R Price6 , and ACTG 5199 Study Team<br />
1 2 Univ of North Carolina at Chapel Hill, US; Queen Elizabeths, Blantyre,<br />
Malawi; 3Chiang Mai Univ, Thailand; 4Harvard Univ, Boston, MA, US;<br />
5 6 Univ of Colorado Hlth Sci Ctr, Denver, US; and Univ of California, San<br />
Francisco, US<br />
389 Adverse Effect of ddI, ddC, and d4T as a Component of<br />
HAART on Cognitive Function during HIV Infection<br />
Ingo Husstedt*, B Hudelmeier, U Oelker-Gruneberg, N Gregor,<br />
K Kloenne, K Biehl, O Summ, and S Evers<br />
Univ Hosp Muenster, Germany<br />
390 CEP-1347 as an Adjunctive Therapy for HIV-associated<br />
Cognitive Impairment<br />
Dawn Eggert* 1 , S Gorantla1 , H Dou1 , L Poluektova1 ,<br />
D Bozyczko-Coyne2 , L Aimone2 , S Dewhurst3 , S Maggirwar3 ,<br />
H Gelbard3 , and H Gendelman1 1 2 Univ of Nebraska Med Ctr, Omaha, US; Cephalon, Inc, West Chester,<br />
PA, US; and 3Univ of Rochester Med Ctr, NY, US<br />
b Monday, 1-4 pm; Hall D<br />
Session 68–Poster Abstracts<br />
(see Session 26 on Tuesday for corresponding Poster Discussion)<br />
Clinical Developments in Neuropathogenesis<br />
391 Changes in Cognition during HAART: Comparison of 2<br />
Different Scoring Systems to Measure Antiretroviral Drug<br />
Efficacy on HIV Dementia<br />
Valerio Tozzi*, P Balestra, M Salvatori, C Vlassi, G Liuzzi,<br />
S Menichetti, M Zaccarelli, S Cerilli, A Antinori, and P Narciso<br />
Natl Inst for Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy<br />
392 CSF Neural Marker Profile Distinguishes AIDS Dementia<br />
Complex from Alzheimer’s Disease<br />
Magnus Gisslen* 1 , K Blennow1 , B Brew2 , P Cinque3 , L Hagberg1 ,<br />
R Price4 , and H Zetterberg1 1 2 Sahlgrenska Univ Hosp, Gothenburg, Sweden; St Vincent’s Hosp, Univ<br />
of New South Wales, Sydney, Australia; 3San Raffaele Hosp, Milan, Italy;<br />
and 4Univ of California, San Francisco, US<br />
393 HIV Protease Inhibitors and Risk of Peripheral Neuropathy<br />
Ronald Ellis* 1 , J Marquie-Beck1 , P Delaney1 , T Alexander1 , D Clifford2 ,<br />
J McArthur3 , D Simpson4 , C Ake1 , A Collier5 , B Gelman6 , and the<br />
CHARTER Group<br />
1 2 Univ of California, San Diego, US; Washington Univ, St Louis, MO, US;<br />
3 4 Johns Hopkins Univ, Baltimore, MD, US; Mt Sinai Sch of Med, New<br />
York, NY, US; 5Univ of Washington, Seattle, US; and 6Univ of Texas Med<br />
Branch, Galveston, US<br />
394 ART Resistance Influences CSF HIV RNA Levels and<br />
Neuropsychological Performance in HIV-infected Individuals<br />
George Hightower* 1 , S Letendre1 , M Cherner1 , S Gibson1 , R Ellis1,2 ,<br />
C Ignacio1 , R Heaton1 , I Grant1,2 , D Richman1,2 , D Smith1,2 , and San Diego<br />
HIV Neurobehavioral Res Ctr (HNRC) Group<br />
1 2 Univ of California, San Diego, US and San Diego VA Hlthcare Systems,<br />
CA, US<br />
395 CSF t-τ, p-τ and Amyloid-β 1-42 in HIV Infection<br />
Bruce Brew* 1 , M Gisslen2 , L Pemberton1 , P Cinque3 , L Hagberg2 ,<br />
R Price4 , K Blennow2 , H Zetterberg2 , and S Spudich4 1 2 3 St Vincent’s Hosp, Sydney Australia; Gothenburg Univ, Sweden; San<br />
Raffaele Hosp, Milan, Italy; and 4Univ of California, San Francisco, US<br />
396a Comparative Analysis of HIV-specific CD8 + T Cells in<br />
Cerebrospinal Fluid and Peripheral Blood among Treatmentnaïve<br />
HIV-immune Controllers<br />
Shanmugalakshmi Sadagopal*, S Lorey, L Barnett, R Basham,<br />
L Lebo, H Erdem, K Haman, M Avison, D Haas, and S Kalams<br />
Vanderbilt Univ, Nashville, TN, US
CROI 2008 Session 71<br />
396b Abnormal CSF Amyloid β42 Levels Link HIV-associated<br />
Cognitive Disease and Alzheimer’s Disease<br />
David Clifford*, J Kauwe, M Teshome, A Shah, M Spinner, J Morris,<br />
D Holtzman, and A Fagan<br />
Washington Univ, St Louis, MO, US<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 69–Poster Abstracts<br />
Virologic Parameters in NeuroAIDS<br />
397 Tissue-specific Adaptive Changes in R5X4 HIV-1 Env<br />
Variants Compartmentalized in Brain and Lymphoid Tissues<br />
of Individuals with AIDS<br />
Lachlan Gray* 1,2 , M Churchill1 , D Cowley1,3 , J Sterjovski1,3 , A Ellett1 ,<br />
N Saksena4 , P Poumbourios1 , S Wesselingh1,2,3 , D Gabuzda5,6 , and P Gorry1,2,3 1 2 Burnet Inst, Melbourne, Australia; Univ of Melbourne, Australia;<br />
3 4 Monash Univ, Melbourne, Australia; Westmead Millenium Inst,<br />
Australia; 5Dana-Farber Cancer Inst, Boston, MA, US; and 6Harvard Med Sch, Boston, MA, US<br />
398 Low CD4 Dependence and High Avidity for CD4 Determine<br />
Macrophage Tropism, Increased Fusogenicity and Reduced<br />
Sensitivity to Fusion and Other Entry Inhibitors of HIV-1<br />
Envelope Glycoproteins from Brain Tissue and Brainderived<br />
Isolates<br />
F Rossi, B Querido, D Nimmagadda, S Navas-Martin, and<br />
Julio Martin-Garcia*<br />
Drexel Univ Coll of Med, Philadelphia, PA, US<br />
399 Bioinformatic Predictors of Co-receptor Usage Underestimate<br />
the Frequency of R5X4 HIV-1 in Brain and Other Tissues<br />
Megan Mefford* 1,2 , P Gorry3 , K Kunstman4 , S Wolinsky4 , and D Gabuzda1,2 1 2 Dana-Farber Cancer Inst, Boston, MA, US; Harvard Med Sch, Boston,<br />
MA, US; 3Macfarlane Burnet Inst for Med Res and Publ Hlth, Melbourne,<br />
Australia; and 4Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US<br />
400 Compartmentalization and Evolutionary Dynamics of HIV-1<br />
NEF Sequences in the Brain of 5 Individuals<br />
Tulio de Oliveira* 1 , S Lamers2 , M Salemi3 , and M McGrath4 1South African Natl BioInformatics Inst, Univ of Western Cape;<br />
2 3 4 BioinfoExperts, FL, US; Univ of Florida Gainsville, US; and Univ of<br />
California, San Francisco, US<br />
401 Validation of a V3-based Genetic Biomarker of HIV-1<br />
Neurovirulence<br />
Satish Pillai* 1,2 , W Pasutti1 , A McCutchan3 , C Marra4 , D Clifford5 ,<br />
B Gelman6 , D Simpson7 , J McArthur8 , I Grant3 , and J Wong1,2 1 2 VAMC, San Francisco, CA, US; Univ of California, San Francisco,<br />
US; 3Univ of California, San Diego, US; 4Univ of Washington, Seattle,<br />
US; 5Washington Univ, St Louis, MO, US; 6Univ of Texas Med Branch,<br />
Galveston, US; 7Mt Sinai Sch of Med, New York, NY, US; and 8Johns Hopkins Univ, Baltimore, MD, US<br />
402 Differential Induction of IDO and the Kynurenine Pathway<br />
by Neurotropic and Non-Neurotropic Viruses<br />
Apsara Kandanearatchi* 1 , J Wilkinson1 , J Zaunder1 , L Pemberton1 ,<br />
S Maddocks2 , A Cunningham2 , and B Brew1 1Ctr for Immunology, St Vincent’s Hosp, Univ of New South Wales,<br />
Sydney, Australia and 2Millenium Inst, Univ of Sydney, Westmead,<br />
Australia<br />
403 The Neurotrophins NGF, BDNF, and proNGF Induce<br />
Enhancement of HIV-1 Replication in Primary Human<br />
Macrophages<br />
Thiago Souza* 1,2 , D Rodrigues1 , E Araujo3 , C Fontes2 , and D Bou-Habib1 1 2 Oswaldo Cruz Fndn, Rio de Janeiro, Brazil; Federal Univ of Rio de<br />
Janeiro, Brazil; and 3Fluminense Federal Univ, Niteroi, Brazil<br />
404a The Spectrum of HIV-1-associated Neurocognitive Diagnoses<br />
Represents a Continuum of Circulating HIV DNA Levels<br />
Bruce Shiramizu* 1 , A Williams2 , C Shikuma1 , and V Valcour1 1Hawaii AIDS Clinical Res Prgm, John A Burns Sch of Med, Univ<br />
of Hawaii, Honolulu, US and 2Kaiser Fndn Hosp, Ctr for Hlth Res,<br />
Honolulu, Hawaii, US<br />
404b HIV Subtype D Is Associated with a Higher Risk for Dementia<br />
than Subtype A in Sub-Saharan Africa<br />
Ned Sacktor* 1 , N Nakasujja2 , M Rezapour1 , R Skolasky1 , S Musisi2 ,<br />
E Katabira2 , K Robertson3 , D Clifford4 , O Laeyendecker1 , and T Quinn1 1 2 Johns Hopkins Univ, Baltimore, MD, US; Makerere Univ, Kampala,<br />
Uganda; 3Univ of North Carolina at Chapel Hill, US; and 4Washington Univ, St Louis, MO, US<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 70–Poster Abstracts<br />
Studies into Mechanisms of HIV<br />
Neuropathogenesis<br />
405 Pro-inflammatory Cytokine IL-1β Induction by HIV-1 gp120<br />
in Primary Human Macrophages Requires Activation of<br />
Multiple Chemokine Receptor-mediated Protein Kinase<br />
Signaling Pathways<br />
Rick Cheung*, V Ravyn, A Ptasznik, and R Collman<br />
Univ of Pennsylvania, Philadelphia, US<br />
406 Links between Monocyte Chemoattractant Protein-1<br />
Voltage-gated Potassium Channels and Monocyte Mobility in<br />
the Neuropathogenesis of HIV Infection<br />
S Ding, S Ramirez, J Liu, N Gong, Huangui Xiong*, Y Persidsky, and<br />
H Gendelman<br />
Univ of Nebraska Med Ctr, Omaha, US<br />
407 CSF B Cells and CXCL13 in Individuals Who Are HIVinfected<br />
and Have Syphilis or Neurosyphilis<br />
Christina Marra*, L Tantalo, C Maxwell, K Dougherty, B Wood, and<br />
S Lukehart<br />
Univ of Washington, Seattle, US<br />
408 Non-SIV-infected MAC387 + Macrophages Are Major<br />
Components of CNS Lesions in Rhesus Macaques Infected by<br />
SIV<br />
Caroline Soulas* 1 , WK Kim1 , X Alvarez2 , M Lentz3 , EM Ratai3 ,<br />
L Annamalai4 , S Westmoreland4 , G Gonzalez3 , and K Williams1 1Beth Israel Deaconess Med Ctr, Harvard Med Sch, Boston, MA, US;<br />
2 3 Tulane Natl Primate Res Ctr, Covington, LA, US; Massachusetts Gen<br />
Hosp, Harvard Med Sch, Boston, US; and 4New England Primate Res<br />
Ctr, Harvard Med Sch, Southborough, MA, US<br />
409 Increased Autophagy in HIV-1 Infection of Central Nervous<br />
System<br />
Dejiang Zhou*, E Masliah, and S Spector<br />
Univ of California, San Diego, US<br />
410 Evidence of Decreased Glutamate in the Frontal Lobe of HIV<br />
Patients<br />
Napapon Sailasuta* 1 , K Shriner2 , and B Ross1 1 2 Huntington Med Res Inst, Pasadena, CA, US and The Phil Simon Clin,<br />
Pasadena, CA, US<br />
411 Activation of Cerebrospinal Fluid and Blood CD8 + T<br />
Lymphocytes during Primary HIV-1 Infection<br />
Serena Spudich*, R Ronquillo, E Ho, E Lee, R Price, and E Sinclair<br />
Univ of California, San Francisco, US<br />
412a Current CD4 and Reconstituted CD4, Not Nadir CD4,<br />
Predict Current Cerebral White Matter Volume<br />
David Tate* 1,2,3 , J Conley1 , C Guttmann1 , R Paul4 , J Matesan5 , R Cohen3 ,<br />
B Navia6 , and the HIV Neuroimaging Consortium<br />
1 2 Brigham and Women’s Hosp, Boston, MA, US; Boston Univ Sch of Med,<br />
MA, US; 3Warren Alpert Med Sch of Brown Univ, Providence, RI, US;<br />
4 5 Univ of Missouri, St Louis, US; Indiana Univ Sch of Med, Indianapolis,<br />
US; and 6Tufts Univ, Boston, MA, US<br />
412b Cerebrospinal Fluid Soluble Urokinase Plasminogen<br />
Activator Receptor Is Elevated in AIDS Dementia Complex<br />
and Correlates with Virological, Immune Activation and<br />
Neuronal CSF Markers<br />
Paola Cinque* 1 , N Sidenius1 , A Bestetti1 , S Sala1 , A Lazzarin1 , B Brew2 ,<br />
L Hagberg3 , M Gisslen3 , and R Price4 1 2 San Raffaele Sci Inst, Milan, Italy; Univ of New South Wales, Sydney,<br />
Australia; 3Sahlgrenska Univ Hosp, Goteborg, Sweden; and 4Univ of<br />
California, San Francisco, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 71–Poster Abstracts<br />
Co-infection with HCV<br />
413 HIV and HCV Are Associated with Worse<br />
Neuropsychological Performance in Anhui, China<br />
Scott Letendre* 1 , L Cysique1 , C Shi2 , X Yu2 , K Hong3 , Z Wu3 , C Ake1 ,<br />
H Jin1 , I Grant1 , R Heaton1 , and the HNRC Group<br />
1 2 Univ of California, San Diego, US; Inst of Mental Hlth, Peking Univ,<br />
Beijing, China; and 3Natl Ctr for AIDS/STD Control and Prevention,<br />
China CDC, Beijing<br />
414 Molecular and Bioinformatics Evidence of Hepatitis C Virus<br />
Evolution in Brain in HCV and HCV/HIV Patients<br />
Sarah Fishman*, J Murray, F Eng, J Walewski, S Morgello, and<br />
A Branch<br />
Mt Sinai Med Ctr, New York, NY, US<br />
<strong>Program</strong> 33<br />
Poster Listings
Poster Litings<br />
Session 71 CROI 2008<br />
415 Hepatitis C Virus Co-infection Does Not Significantly<br />
Worsen Neuroimaging Measures of Diffusivity in HIVinfected<br />
Patients<br />
David Tate* 1,2,3 , J Conley 1 , R Paul 4 , K Coop 2 , K Bolden 1 , D Laidlaw 5 ,<br />
S Zhang 6 , L Taylor 2 , T Flanigan 2 , and K Tashima 2<br />
1 Brigham and Women’s Hosp, Harvard Med Sch, Boston, MA, US;<br />
2 Warren Alpert Med Sch of Brown Univ, Providence, RI, US; 3 Boston<br />
Univ Sch of Med, MA, US; 4 Univ of Missouri, St Louis, US; 5 Brown Univ,<br />
Providence, RI, US; and 6 Mississippi St Univ, Starkville, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 72–Poster Abstracts<br />
PML and JC Virus<br />
416 New Pathogenic Role of Human Polyomavirus JC in Neurons<br />
Xin Dang* and I Koralnik<br />
Beth Israel Deaconess Med Ctr, Boston, MA, US<br />
417 Role of Immune Reconstitution Inflammatory Syndrome in<br />
“Unmasked” Progressive Multifocal Leukoencephalopathy<br />
N Sidhu and Allen McCutchan*<br />
Univ of California, San Diego, US<br />
418 Frequent Infection of Granule Cell Neurons by JC Virus in<br />
HIV + Progressive Multifocal Leukoencephalopathy Patients<br />
C Wuethrich1 , J Cheng1 , J Joseph1 , S Kesari2 , C Beckwith3 , E Stopa4 ,<br />
J Bell5 , and Igor Koralnik* 1<br />
1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Brigham and<br />
Women’s Hosp and Children Hosp, Boston, MA, US; 3Miriam Hosp,<br />
Providence, RI, US; 4Rhode Island Hosp, Providence, US; and 5Western Gen Hosp, Edinburgh, UK<br />
419 JC Virus in Bone Marrow of HIV + and HIV – Patients<br />
Sabrina Tan*, B Dezube, P Bhargava, C Wuethrich, P Autissier, and<br />
I Koralnik<br />
Beth Israel Deaconess Med Ctr, Boston, MA, US<br />
420 Productive SV40 Infection of Neurons in a Monkey Model of<br />
Progressive Multifocal Leukoencephalopathy<br />
Xin Dang* 1 , C Wuethrich1 , M Axthelm2 , and I Koralnik1 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US and Oregon Natl<br />
Primate Res Ctr, Beaverton, US<br />
b Monday, 1-4 pm; Hall D<br />
Session 73–Poster Abstracts<br />
Studies on T Cell Responses in Viral Infection<br />
421 Evaluation of Antiviral Activity of HIV-1-specific CTL and<br />
Epitope Expression Kinetics<br />
Balamurugan Arumugam*, D Chen, H Ng, A Ali, and O Yang<br />
Univ of California, Los Angeles, US<br />
422 Early Robust SIV-specific CD8 T Cell Response Detected in<br />
situ in Genital and Lymph Tissues from Macaques Infected<br />
with Attenuated SHIV and Subsequently Infected with<br />
Pathogenic SIV<br />
J Hong1 , T Mattila1 , A Hage1 , C White1 , H Kim1 , C Miller2 , A Haase3 , and<br />
Pamela Skinner* 1<br />
1 2 Univ of Minnesota, St Paul, US; Univ of California, Davis, US; and<br />
3Univ of Minnesota, Minneapolis, US<br />
423 Telomerase Up-regulation and Telomere Length Stabilization<br />
in HIV-1-specific CD8 + T Cells from HIV Controllers<br />
Maintain Proliferative and Cytotoxic Activities and Is<br />
Regulated by the PD-1/PDL-1 Pathway<br />
M Lichterfeld1 , D Mou1 , C Pan1 , K Williams1 , M Waring1 , F Pereyra1 ,<br />
G Freeman2 , E Rosenberg1 , B Walker3 , and Xu Yu* 1<br />
1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Harvard Univ Ctr for<br />
AIDS Res, Boston, US; 2Dana-Farber Cancer Inst, Boston, MA, US; and<br />
3Howard Hughes Med Inst, Chevy Chase, MD, US<br />
424 PBMC Subsets Targeted by HIV Present Differential Antigen<br />
Processing Activities Affecting the Production of Epitopes<br />
Estibaliz Lazaro*, S Godfrey, P Stamegna, J Ho, B Walker, and S Le Gall<br />
Massachusetts Gen Hosp, Harvard Med Sch, Boston, US<br />
425 Lack of CD57 Expression on Terminally Differentiated<br />
HIV-specific Clonotypes Provides a Mechanism for in vivo<br />
Persistence<br />
Dirk Meyer-Olson* 1,2,3 , B Simons4 , J Conrad4 , R Smith2 , L Barnett2 ,<br />
S Lorey2 , R Ramalingam2 , S Sadagopal2 , R Schmidt1,3 , and S Kalams2,4 1 2 Medizinische Hochschule Hannover, Germany; Vanderbilt Univ,<br />
Nashville, TN, US; 3Kompetenznetz HIV/BMBF, Germany; and<br />
4Vanderbilt Univ Med Ctr, Nashville, TN, US<br />
426 Antiviral Immunity in HIV-infected vs HIV-naïve Kidney<br />
Transplant Recipients: A Prospective Cohort Study<br />
Olivier Gasser* 1 , F Bihl1 , S Sanghavi2 , C Rinaldo2 , D Rowe2 , S Schaub3 ,<br />
M Roland4 , P Stock4 , C Hess3 , and C Brander1 1 2 Massachusetts Gen Hosp, Harvard Univ, Boston, US; Univ of<br />
Pittsburgh, PA, US; 3Univ Hosp Basel, Switzerland; and 4Univ of<br />
California, San Francisco, US<br />
34 15th Conference on Retroviruses and Opportunistic Infections<br />
427 HIV-Nef but Not HIV Gag-specific CD8 T Cells Increase<br />
Breadth and Magnitude during Intermittent ART Compared<br />
to Continuous Treatment in Patients with Chronic HIV<br />
Infection: The WINDOW-ANRS 106 Trial<br />
Assia Samri* 1 , E Nemes1,2 , I Charreau3 , P Tangre3 , B Puissant4 ,<br />
B Marchou5 , JP Aboulker3 , JM Molina6 , B Autran1 , G Carcelain1 , and the<br />
ANRS 106 Study Team<br />
1 2 Hosp Pitie-Salpetriere, Paris, France; Univ of Modena and Reggio<br />
Emilia, Italy; 3INSERM SC10, Villejuif, France; 4Rangueil Hosp,<br />
Toulouse, France; 5Purpan Hosp, Toulouse, France; and 6Hosp St Louis,<br />
Paris, France<br />
428 Detection of Cytotoxic Leukocyte Antiviral Activity by<br />
Fitness Impact of Nef-mediated HLA Down-regulation<br />
A Ali, H Ng, and Otto Yang*<br />
Univ of California, Los Angeles, US<br />
429 Dynamics of Viral Evolution and Cytotoxic Leukocyte<br />
Responses in HIV-1 Infection<br />
Yi Liu* 1 , J McNevin2 , H Zhao1 , J McElrath2 , and J Mullins1 1 2 Univ of Washington, Seattle, US and Fred Hutchinson Cancer Res Ctr,<br />
Seattle, WA, US<br />
430 Increases of Viral Replication after Interruption of ART<br />
Does Not Affect the Functional Profile of HIV-specific CD8 +<br />
T Cells<br />
M Lopez, N Rallon, V Soriano, I Perez, J Gonzalez-Lahoz, and Jose Benito*<br />
Hosp Carlos III, Madrid, Spain<br />
431 Lack of Evidence for CD8 + T Cell-mediated Selection<br />
Pressure on Proviral Gag p17 and p24 in Chronically<br />
Infected HIV-1 + Individuals<br />
Samantha Westrop* 1 , D Constantinou1 , M Nelson2 , M Jones1 ,<br />
F Gotch1 , and N Imami1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London,<br />
UK<br />
432 ELISpot Responses against the HLA-A2 Restricted Epitope<br />
RT181-189 Are Frequent in ART-naïve Patients but Rare in<br />
Patients with 3TC-resistant Virus<br />
Y Pacheco1 , C Allavena2 , J Arias2 , E Garnier-Andre2 , V Ferre1 ,<br />
E Billaud2 , F Raffi2 , and Dorian McIlroy* 1<br />
1 2 Univ Nantes, France and Ctr Hosp Univ Hotel Dieu, Nantes, France<br />
433 IL-7 and HIV Tat Act Synergistically to Down-regulate<br />
the IL-7 Receptor Alpha-chain on CD8 T Cells through a<br />
Pathway Involving JAK Kinase<br />
Elliott Faller* 1,2 , J Kakal1,2 , and P MacPherson1,2,3 1 2 3 Ottawa Hlth Res Inst, Canada; Univ of Ottawa, Canada; and Ottawa<br />
Hosp, Canada<br />
434 SDF-1a Is a Potent Inducer of HIV-1-specific CD8 + T Cell<br />
Chemotaxis, but Migration of CD8 + T Cells Is Impaired at<br />
High Viral Loads<br />
Amie Meditz*, R Schlichtemeier, J Folkvord, M Givens, K Lesh, G Ray,<br />
M McCarter, and E Connick<br />
Univ of Colorado Hlth Sci Ctr, Denver, US<br />
435 Identification of an N-linked Glycosylation in the C4 Region<br />
of HIV-1 Envelope gp120 that Is Critical for Recognition of<br />
Neighboring CD4 T Cell Epitopes<br />
Hualin Li*, P Chien, M Tuen, M Visciano, S Cohen, S Blais, C Xu,<br />
H Zhang, and C Hioe<br />
New York Univ Sch of Med, New York, US<br />
436 Long-term Effects of Early HAART Treatment on HIVspecific<br />
Immune Responses<br />
Jie Yu* 1 , M Fraham1 , K Owzar1 , H Maecker2 , C Hicks1 , C Gay3 ,<br />
J Eron3 , S Fiscus3 , K Weinhold1 , and G Ferrari1 1 2 Duke Univ Sch of Med, Durham, NC, US; BD Biosci, Immunocytometry<br />
Systems, San Jose, CA, US; and 3Univ of North Carolina at Chapel Hill,<br />
US<br />
437 HLA-DR Expression on CD8 + T Cells Is Due to Their Direct<br />
Interaction with Monocytes<br />
Natalie Hutnick*, G Makedonas, and M Betts<br />
Univ of Pennsylvania, Philadelphia, US<br />
438 Optimizing the Degree of HIV Sequence Diversity Coverage<br />
for the Detection of T Cell Responses<br />
Nicole Frahm* 1 , K Yusim1 , W Fischer1 , M Muldoon2 , B Walker3 ,<br />
B Korber1 , and C Brander3 1 2 Los Alamos Natl Lab, NM, US; Univ of Manchester, Sch of<br />
Mathematics, UK; and 3Partners AIDS Res Ctr, Massachusetts Gen Hosp,<br />
Harvard Med Sch, Boston, US
CROI 2008 Session 76<br />
b Monday, 1-4 pm; Hall D<br />
Session 74–Poster Abstracts<br />
Studies on Cytokines and HIV Infection<br />
439 HIV Infection Results in Impaired IL-7 Signaling in Primary<br />
Human Thymocytes in vitro<br />
Charlene Young* 1,2 and J Angrel1,2,3 1 2 3 Ottawa Hlth Res Inst, Canada; Univ of Ottawa, Canada; and Ottawa<br />
Hosp, Canada<br />
440 A Pivotal Role for Mucosa-associated Epithelial Chemokine<br />
in the Modulation of Mucosal Immunity in HIV Infection<br />
Eleonora Castelletti* 1 , S Lo Caputo2 , L Kuhn3 , M Borelli1 , G Aldrovandi4 ,<br />
M Nebuloni1 , F Veas5 , F Mazzotta2 , and M Clerici1 1 2 3 Univ of Milan, Italy; SS Annunziata Hosp, Florence, Italy; Columbia<br />
Univ, New York, NY, US; 4Univ of Southern California, Los Angeles, US;<br />
and 5Inst for Res and Devt, UR178, Montpellier, France<br />
441 Differences in the Activation of Tumor Necrosis Factor<br />
Superfamily Pathways May Contribute to Age-associated<br />
Differences in Naïve CD4 + Cell Recovery and to Functional<br />
Immune Responses to HAART<br />
Robert Kalayjian* 1 , J Spritzler2 , R Matining2 , P Tebas3 , R Pollard4 ,<br />
A Landay5 , M Lederman6 , and AIDS Clinical Trials Protocol 5015 Team<br />
1 2 MetroHlth Med Ctr, Cleveland, OH, US; Harvard Sch of Publ Hlth,<br />
Boston, MA, US; 3Univ of Pennsylvania, Philadelphia, US; 4Univ of<br />
California, Davis, US; 5Rush Med Coll, Chicago, IL, US; and 6Case Western Reserve Univ, Cleveland, OH, US<br />
442 Expression and Functional Significance of Soluble IL-7Rα<br />
(CD127) In HIV Infection<br />
Angela Crawley* 1,2 , S Faucher3 , and J Angel1,2,4 1 2 3 Ottawa Hlth Res Inst, Canada; Univ of Ottawa, Canada; Ctr for<br />
Infectious Disease, Prevention and Control Hlth Canada, Ottawa; and<br />
4Ottawa Hosp, Canada<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 75–Poster Abstracts<br />
Immune Activation and Lymphocyte Function<br />
443 A Threshold of Partial CD4 + T Cell Restoration in GALT Is<br />
Sufficient for Developing Multi-functional Anti-HIV CD8 +<br />
T Cell Responses and Control of Mucosal Immune Activation<br />
and Viral Suppression in HIV-infected Patients Receiving<br />
HAART<br />
Monica Macal* 1 , S Sankaran1 , TW Chun2 , E Reay1 , J Flamm3 ,<br />
T Prindiville1 , and S Dandekar1 1 2 Univ of California, Davis, US; Lab of Immunoregulation, NIAID, NIH,<br />
Bethesda, MD, US; and 3Kaiser Permanente Med Group, Sacramento,<br />
CA, US<br />
444 HIV Infection Leads to Increased Immune Activation by 2<br />
Distinct Pathways that Differentially Affect CD4 and CD8<br />
T Cells<br />
Marta Catalfamo* 1 , M Di Mascio2 , Z Hu2 , S Srinivasula3 , V Thaker1 ,<br />
J Adelsberger3 , A Rupert3 , M Baseler3 , G Roby1 , and C Lane1 1 2 Lab of Immunoregulation, NIAID, NIH, Bethesda, MD, US; NIAID, NIH,<br />
Bethesda, MD, US; and 3SAIC-Frederick, MD, US<br />
445 Abnormal T Cell Phenotypes Persist Despite Effective HAART<br />
Brinda Emu*, S Deeks, W Moretto, R Hoh, J Martin, D Nixon, and<br />
J McCune<br />
Univ of California, San Francisco, US<br />
446 Enfuvirtide Therapy Increases Naïve and Central Memory<br />
CD4 T Cells, Decreases the Level of Immune Activation and<br />
Apoptosis<br />
H Carsenti Dellamonica1 , J Durant1 , M Ticchioni1 , F Guillouet de Salvador1 ,<br />
J Dufayard Cottalorda1 , R Garraffo2 , Pierre Dellamonica* 1 , and M Gougeon3 1 2 Hosp Archet, Nice, France; Ctr Hosp Univ Necker, Paris, France; and<br />
3Pasteur Inst, Paris, France<br />
447 Dual Function of the Inhibitory Co-receptor PD-1 as a<br />
Marker for Activated and Functionally Impaired T Cells in<br />
SIV-infected Rhesus Macaques<br />
Nadine Salisch* 1,2 , A Awad1 , D Evans1 , and P Johnson1,3 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA,<br />
US; 2Univ Erlangen-Nuremberg, Erlangen, Germany; and 3Massachusetts Gen Hosp, Boston, US<br />
448 CXCR4 Receptor Expression Is More Common on Activated<br />
CD4 + T Cells than CCR5 Expression in HIV-1 Infection<br />
Frederick Hecht*, E Sinclair, A Carrico, P Moran, P Hunt,<br />
M Killian, P Bacchetti, T Ho, S Folkman, and S Deeks<br />
Univ of California, San Francisco, US<br />
449 Phenotypic and Functional Characterization of the Thymus<br />
in HIV-infected Patients<br />
Alessandra Bandera* 1 , G Ferrario2 , M Saresella3 , I Marventano3 ,<br />
G Marchetti4 , D Trabattoni5 , L Gazzola4 , M Clerici5 , and A Gori1 1 2 San Gerardo Hosp, Univ of Milan-Bicocca, Monza, Italy; Luigi Sacco<br />
Hosp, Univ of Milan, Italy; 3Don Carlo Gnocchi Fndn, Milan, Italy; 4San Paolo Hosp, Univ of Milan Med Sch, Italy; and 5Univ of Milan Med Sch,<br />
Italy<br />
450 Common Markers of T Cell Activation Do Not Indicate<br />
Markedly Higher Levels of HIV Infection of CD4 + T Cells in<br />
the Peripheral Circulation<br />
Joe Casazza*, S Adzaku, D Ambrozak, D Douek, M Roederer, and<br />
R Koup<br />
Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US<br />
451 Persistent PD-1 Expression Is Correlated with Poor Immune<br />
Recovery in HAART-treated HIV-1-infected Patients<br />
Katharina Pfistershammer* and N Kohrgruber<br />
Med Univ Vienna, Austria<br />
452 HIV-1-infected Patients with Full Suppression of Viral<br />
Replication but Impaired Recovery of CD4 Cells Display<br />
Immune Activation with Decreased CD28 Expression and<br />
IL-10 Production<br />
Christian Erikstrup* 1,2 , N Lohse2,3 , S Ostrowski1,4 , J Gerstoft1 ,<br />
G Kronborg3 , and H Ullum1 1 2 Rigshospitalet, Copenhagen, Denmark; Aarhus Univ Hosp, Denmark;<br />
3 4 Copenhagen Univ Hosp, Hvidovre, Denmark; and Faculty of Hlth Sci,<br />
Univ of Copenhagen, Denmark<br />
453 Marginal Zone B Cell Memory Populations Are Irreversibly<br />
Depleted in Pediatric HIV<br />
Marianne Jacobsen* 1 , R Thiebaut2 , C Fisher3 , D Sefe1 , M Clapson3 ,<br />
N Klein1 , and H Baxendale1 1 2 3 Inst of Child Hlth, London, UK; INSERM, Bordeaux, France; and Great<br />
Ormond St Hosp for Children, London, UK<br />
454 Abnormal Activation of the JAK/STAT Pathway in CD4 +<br />
T Cells of HIV-infected Patients (ANRS EP33 Study)<br />
Olivier Juffroy* 1 , F Bugault1 , O Lambotte2 , JP Viard3 , L Niel4 ,<br />
A Danckaert1 , JF Delfraissy2 , J Theze1 , and L Chakrabarti1 1 2 3 Pasteur Inst, Paris, France; Ctr Hosp Univ Bicetre, France; Hosp<br />
Necker, Paris, France; and 4Hosp Percy, Clamart, France<br />
455 Potential Pre-treatment Interruption Immunological<br />
Predictors for CD4 Count Change Off Therapy in<br />
Chronically HIV-infected Subjects Having Various Pre-<br />
Treatment Interruption Viral Loads<br />
Kenneth Huang* 1 , S Boulet1 , C Tsoukas1 , M Loutfy2 , and N Bernard1 1 2 Res Inst of the McGill Univ Hlth Care Ctr, Montreal, Canada and Univ<br />
of Toronto, Canada<br />
456 Effects of Timing of Processing and Lymphocyte Isolation on<br />
Detection of CD31 Expression on Naïve CD4 T Cells in HIVinfected<br />
Patients<br />
Jeanette Higgins* 1 , M Proschan2 , J Metcalf2 , R Stevens1 , M Baseler1 ,<br />
C Lane2 , and I Sereti2 1 2 SAIC-Frederick, MD, US and NIH, Bethesda, MD, US<br />
457a High-level Persistence of HIV Antigen-specific CD4 + T Cells<br />
in Untreated Chronic Infection, Detected by a Novel Flow<br />
Cytometric Assay<br />
John Zaunders* 1 , S Pett2 , M Bailey2 , N Seddiki2 , M Munier2 , S Ip2 ,<br />
M Kim3 , A Cunningham3 , D Cooper1,2 , and A Kelleher1,2 1 2 Ctr for Immunology, St Vincent’s Hosp, Darlinghurst, Australia; Natl<br />
Ctr in HIV Epi and Clin Res, Univ of New South Wales, Australia; and<br />
3Westmead Millenium Inst, Sydney, Australia<br />
457b Combined Effects of Interleukin-10 and PD-1 on Virus-specific<br />
CD4 T Cell Proliferation during Chronic HIV-1 Infection<br />
Mark Brockman*, D Kwon, D Tighe, S Le Gall, F Pereyra, B Walker,<br />
and D Kaufmann<br />
Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 76–Poster Abstracts<br />
Studies on Regulatory T Cells<br />
458 Immune Activation Occurs Concomitantly with Immune<br />
Exhaustion and Decrease in Regulatory T Cells in Treatment<br />
Naïve Chronically HIV-infected Patients<br />
Meenakshi Sachdeva*, R Pahwa, M Fischl, K Arheart, and S Pahwa<br />
Univ of Miami Miller Sch of Med, FL, US<br />
459 Functional and Phenotypic Profiling of Suppressive<br />
Regulatory T Cells in a Cohort of HIV-1-infected Individuals<br />
Catherine Burton* 1 , I Eccles-James1 , M Bower1,2 , M Nelson1,2 ,<br />
F Gotch1 , and N Imami1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London,<br />
UK<br />
460 CD4 + T Cell Nadir and Reconstitution of T Regulatory Cells<br />
in HIV-1-infected Patients Receiving HAART<br />
Pascale Ondoa*, H De Puydt, C Vereecken, A De roo, J Clerinx,<br />
T Vermoesen, K Fransen, and L Kestens<br />
Inst of Tropical Med, Antwerp, Belgium<br />
461 Treg-mediated Inhibition of CD8 T Cell Proliferation in HIV +<br />
Subjects Is Reverted through CD39 Function<br />
M Nikolova1,2 , J Lelievre2 , A Bensussan2 , and Yves Levy* 2<br />
1 2 Natl Ctr of Infectious and Parasitic Diseases, Sofia, Bulgaria and Hosp<br />
Henri Mondor, INSERM U84, Creteil, France<br />
<strong>Program</strong> 35<br />
Poster Listings
Poster Litings<br />
Session 76 CROI 2008<br />
462 Regulatory T Cell Frequency Is Associated with Low Cellular<br />
Activation Early after HIV Infection<br />
Karina Carvalho* 1 , L Ndhlovu 2 , M Sauer 1 , H Tomiyama 1 , F Bruno 1 ,<br />
D Nixon 2 , and E Kallas 1<br />
1 Federal Univ of Sao Paulo, Brazil and 2 Univ of California, San<br />
Francisco, US<br />
b Tuesday, 1-4 pm; Hall D<br />
Session 77–Poster Abstracts<br />
Immune Responses and Control of Viremia<br />
463 Effect of B Cell Depletion on Course of SIV Infection in<br />
Rhesus Monkeys<br />
Maurus de la Rosa* 1 , P Chugh1 , V Evans1 , S Finstad1 , S O’Neil2 ,<br />
A Carville2 , M Piatak3 , J Lifson3 , D Montefiori4 , and J Schmitz1 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; New England Primate<br />
Res Ctr, Southborough, MA, US; 3NCI-Frederick, MD, US; and 4Duke Univ Med Ctr, Durham, NC, US<br />
464a Little Evidence for Contribution of Adaptive Immune<br />
Responses to Viral Containment of SIVagm Infection in Vervet<br />
and Sabaeus African Green Monkeys<br />
Roland Zahn* 1 , M Rett1 , C Brown2 , S Goldstein2 , A Carville3 , R White4 ,<br />
R Byrum5 , J Allan4 , V Hirsch2 , and J Schmitz1 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; NIAID, NIH,<br />
Bethesda, MD, US; 3New England Primate Res Ctr, Southborough, MA,<br />
US; 4Southwest Fndn for Biomed Res and Southwest Natl Primate Res<br />
Ctr, San Antonio, TX, US; and 5Bioqual Inc, Rockville, MD, US<br />
464b Subtype C HIV Uses Multiple Pathways to Escape from<br />
Autologous Neutralization<br />
R Rong1 , B Li1 , J Mulenga2 , S Allen1 , J Blackwell1 , and Cynthia Derdeyn* 1<br />
1 2 Emory Univ, Atlanta, GA, US and Zambia Blood Transfusion Svc, Lusaka<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 78–Poster Abstracts<br />
B Cell and Immunoglobulin Studies<br />
465a Functional Evaluation of Monoclonal Antibodies in Protecting<br />
from Mucosal HIV-1 Infection<br />
Lucia Fischetti*, V Buffa, K Klein, and R Shattock<br />
St George`s Univ of London, UK<br />
465b Modeling HIV-1 Escape from Neutralizing Antibodies: Effect<br />
of Original Antigenic Sin and Viral Fitness<br />
Michael Golinski*, D Richman, and S Frost<br />
Univ of California, San Diego, US<br />
466 Crystal Structures of Broadly Neutralizing Human Anti-<br />
HIV-1 Antibodies 3074 and 447-52D in Complex with V3<br />
Peptides<br />
Valicia Burke* 1 , SS Kim1 , H Li1 , M Gorny2 , C Williams2 ,<br />
S Zolla-Pazner1,2 , and XP Kong1 1 2 New York Univ Sch of Med, New York, US and New York VAMC, NY, US<br />
467 Glycosylation of gp41 Shields Epitopes That Are Targets of<br />
Neutralizing Antibodies<br />
Eloisa Yuste*, J Bixby, W Lauer, H Sanford, S Sato, W Johnson, and<br />
R Desrosiers<br />
Harvard Med Sch, Southborough, MA, US<br />
468 HIV-1 Envelope Determinants in Immune Tissue that Confer<br />
Natural Resistance to the CD4 Binding Site Monoclonal<br />
Antibody, b12<br />
Maria Duenas-Decamp* 1 , P Peters1 , D Burton2 , and P Clapham1 1 2 Univ of Massachusetts Med Sch, Worcester, US and Scripps Res Inst, La<br />
Jolla, CA, US<br />
469 Decreased Variable Region Immunoglobulin Gene, Somatic<br />
Hypermutation, and Dysregulated Activation-induced<br />
Deaminase Expression during HIV Infection<br />
Elisabeth Bowers* 1 , K Keays1 , L Beniguel2 , A Asrani3 , S MaWhinney1 ,<br />
B Palmer1 , A Bajar3 , J Thurn3 , R Scamurra3 , and E Janoff1 1 2 Ctr for AIDS Res, Univ of Colorado, Denver, US; Pasteur Inst, Paris,<br />
France; and 3Univ of Minnesota, VAMC, Minneapolis, US<br />
470 Broad Cross-neutralization Mediated by Combination of<br />
Anti-V3 and CD4 Binding Site Antibodies in an HIV-1infected<br />
Patient with Long-term Non-progressive Disease<br />
Shuzo Matsushita*, Y Nishida, J Shibata, A Honda, and K Yoshimura<br />
Ctr for AIDS Res, Kumamoto Univ, Japan<br />
471 The C3-V4 Region Is a Major Target of Autologous<br />
Neutralizing Antibodies in HIV-1 Subtype C Infection<br />
Penny Moore* 1 , E Gray1 , I Choge1 , N Ranchobe1 , K Mlisana2 ,<br />
S Abdool Karim2 , C Williamson3 , L Morris1 , and CAPRISA 002 Study<br />
and the Ctr for HIV/AIDS Vaccine Immunology Consortium<br />
1Natl Inst for Communicable Diseases, Johannesburg, South Africa;<br />
2Ctr for the AIDS Prgm of Res in South Africa, Univ of KwaZulu Natal,<br />
Durban; and 3Inst of Infectious Disease and Molecular Med, Univ of<br />
Cape Town, South Africa<br />
36 15th Conference on Retroviruses and Opportunistic Infections<br />
472 The Structural Basis of the Cross Neutralization of Human<br />
HIV-1 Monoclonal Antibody 3791<br />
Xunqing Jiang* 1 , C Williams2 , M Gorny2 , S Zolla-Pazner2 , and XP Kong1 1 2 New York Univ Sch of Med, NY, US and New York VAMC, US<br />
473 Neutrophil-mediated Destruction of HIV Directed by Broadly<br />
Reactive Anti-HIV and Anti-CD89 Bi-specific Antibody<br />
M Duval1 , M Posner1,2,3 , and Lisa Cavacini* 1,3<br />
1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Dana-Farber Cancer<br />
Inst, Boston, MA, US; and 3Harvard Med Sch, Boston, MA, US<br />
474 Epitope Tagging across the Surface of the HIV-1 Envelope<br />
Spike Reveals an Intrinsic Ability of Virus to Restrict<br />
Antibody Recognition<br />
Ralph Pantophlet*, M Wang, R Aguilar-Sino, and D Burton<br />
Scripps Res Inst, La Jolla, CA, US<br />
475 Reduced Repertoire Complexity of the Heavy Chain<br />
Complementarity Determining Region 3 in HIV Patients<br />
Sabrina Deroo* 1 , S Delhalle1 , M Counson1 , N Beaupain1 , JM Plesseria1 ,<br />
and JC Schmit2 1 2 Publ Res Ctr of Hlth, Luxembourg and Natl Svc of Infectious Diseases,<br />
Hosp Luxembourg<br />
476 Effect of HIV on Impaired Immunoglobulin Class Switch<br />
Recombination and B Cell Signaling in Individuals with<br />
Concomitant Common Variable Immune Deficiency<br />
Chris Tsoukas*, T Lewis, G Vriniotis, and L Sun<br />
McGill Univ Hlth Ctr, Montreal, Canada<br />
477 Effect of HAART on Markers of B Cell Activation in Men<br />
from the Multicenter AIDS Cohort Study<br />
Deborah Regidor*, E Breen, R Detels, and O Martinez-Maza<br />
Univ of California, Los Angeles, US<br />
478 Impaired Naïve and Memory B Cell Expansion in Response<br />
to CpG ODN in HIV Infection<br />
Wei Jiang*, M Lederman, R Mohner, B Rodriguez, C Harding, and<br />
S Sieg<br />
Case Western Reserve Univ, Cleveland, OH, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 79–Poster Abstracts<br />
Studies on NK and Plasmacytoid Dendritic Cells<br />
479 Activated Plasmacytoid and Myeloid Dendritic Cells<br />
Accumulate in Lymphoid Tissue during Asymptomatic,<br />
Chronic HIV-1 Infection<br />
Stephanie Dillon*, K Robertson, S Pan, S MaWhinney, A Meditz,<br />
J Folkvord, E Connick, M McCarter, and C Wilson<br />
Univ of Colorado Hlth Sci Ctr, Denver, US<br />
480 Effect of Chloroquine on TLR Activation in Plasmacytoid<br />
Dendritic Cells<br />
Jeffrey Martinson* 1 , C Montoja2 , Y Chen3 , R Ronquillo1 , L Baum1 , and<br />
A Landay1 1 2 Rush Univ, Chicago, IL, US; Univ of Antioquia, Medellin, Columbia;<br />
and 3Northwestern Univ, Chicago, IL, US<br />
481 HIV-1 Vpr Inhibition of Plasmacytoid Dendritic Cell Derived<br />
Type I Interferon and Impairment of PDC-NK Cell Crosstalk<br />
in vitro<br />
Henoch Hong* 1 , N Bhatnagar1 , U Schubert2 , M Ballmaier1 ,<br />
T Volgmann3 , R Schmidt1,4 , H Heiken1 , and D Meyer-Olson1,4,5 1 2 Hannover Med Sch, Germany; Univ Erlangen, Germany;<br />
3 4 Blutspendedienst, Springe, Germany; KompNet HIV/AIDS, Germany;<br />
and 5Vanderbilt Univ, Nashville, TN, US<br />
482 Differential Regulation of TRAIL and IFN-α by Circulating<br />
PDC during Chronic and Acute Viremia in HIV-infected<br />
Subjects<br />
Bethsebah Gekonge* 1 , E Papasavvas1 , A Hancock1 , C Tomescu1 ,<br />
A Raymond1 , K Vinekar1 , G Reynolds1 , K Mounzer2 , J Chehimi1 , and<br />
L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US and Philadelphia Field Initiating<br />
Group for HIV Trials, PA, US<br />
483 Impaired NK-mediated Antibody-dependent Cellular<br />
Cytotoxicity May Contribute to Poor Antibody-mediated<br />
Inhibition of HIV-1 Replication<br />
Q Liu1 , PN Tsoukas1 , S Rihn1 , A Meier1 , H Streeck1 , M Altfeld1 ,<br />
Yongtao Sun* 2 , and G Alter1 1Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US and<br />
24th Military Med Sch, Xi’an, China<br />
484 Lipopolysaccharide-induced Activation of Natural Killer<br />
Cells from HIV-1-infected Individuals<br />
Martin Goodier* 1 , J Gregson1 , D Constantinou1 , A Steel1 , M Bower2 ,<br />
B Gazzard2 , and F Gotch1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London,<br />
UK
CROI 2008 Session 83<br />
485 Altered Cross-talk between Natural Killer Cells and<br />
Dendritic Cells Due to Peptide HIV p24 aa14-22 Peptidemediated<br />
HLA-E Expression<br />
Daniela Schulte*, C Koerner, B Kraemer, H Nischalke, T Sauerbruch,<br />
U Spengler, J Rockstroh, J Nattermann, and Kompetenznetz HIV/AIDS<br />
Univ of Bonn, Germany<br />
486 Activated NK Cells Inhibit Apoptosis of HIV-1-infected<br />
Dendritic Cells while Inducing Their Maturation by an<br />
HMGB1-dependent Mechanism: Implication for the<br />
Establishment of HIV-1 Reservoirs<br />
Hela Saidi*, MT Melki, and ML Gougeon<br />
Pasteur Inst, Paris, France<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 80–Poster Abstracts<br />
HIV Vaccines: Induction of Neutralizing Antibodies<br />
and Responses<br />
487 Anti-HIV Neutralizing Response Elicited in Rabbits by Anti-<br />
Idiotype Monoclonal Antibodies Mimicking the gp120 CD4binding<br />
Site<br />
Nicasio Mancini* 1 , N Clementi1 , D De Marco1 , S Winfrey2 , P Bagnarelli3 ,<br />
F Vitone4 , M Re4 , J Mascola2 , R Burioni1 , and M Clementi1 1 2 Univ Vita-Salute San Raffaele, Milan, Italy; Vaccine Res Ctr, NIAID,<br />
NIH, Bethesda, MD, US; 3Univ Politecnica delle Marche, Ancona, Italy;<br />
and 4Univ di Bologna, Italy<br />
488 Differential Effect of Broadly Neutralizing Anti-HIV-1<br />
Antibodies on the Formation of Virological Synapses<br />
Marta Massanella*, I Puigdomenech, M Fernandez, M Bofill,<br />
B Clotet, and J Blanco<br />
Hosp Univ Germans Trias i Pujol, Badalona, Spain<br />
489 Alteration in vivo of Humoral Responses to HIV-1 Envelope<br />
gp120 by Antibodies to the CD4 Binding Site of gp120<br />
Maria Luisa Visciano*, M Tuen, M Gorny, and C Hioe<br />
New York Univ Sch of Med and VA New York Harbor Hlthcare System,<br />
New York, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 81–Poster Abstracts<br />
HIV Vaccines: Induction of Cellular Immune<br />
Responses<br />
490 A New Concept for HIV Vaccine: HIV gp41 Peptide<br />
Immunization Prevents NKp44L Expression and CD4 T Cell<br />
Depletion in SHIV-infected Macaques<br />
V Vieillard1 , R Le Grand2 , and Patrice Debre* 1<br />
1 2 INSERM U543, Hosp Pitie-Salpetriere, Paris, France and CEA,<br />
Fontenay-aux-Roses, France<br />
491 SIV-specific CD8 + T Cells Mediated Protection from<br />
Uncontrolled Viral Replication after Vaginal SIV Challenge<br />
in Live-attenuated Immunized Rhesus Macaques<br />
Meritxell Genesca* 1,2 , M Stone1 , D Lu1,2 , J Li1,2 , K Bost1,2 , T Rourke1,2 ,<br />
M McChesney1 , and C Miller1,2 1 2 California Natl Primate Res Ctr, Univ of California, Davis, US and Ctr<br />
for Comparative Med, Univ of California, Davis, US<br />
492 2 Different Immunization Regimens with Single-cycle<br />
SIV Afford Partial Control of Virus Replication after an<br />
Intravenous Challenge with SIVmac239 B Jia1 , Q DeGottardi1 , S Lew1 , A Carville1 , K Mansfield1 , B Richardson2 ,<br />
M Piatak3 , J Lifson3 , and David Evans* 1<br />
1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA,<br />
US; 2Univ of Washington, Seattle, US; and 3SAIC-Frederick and NCI-<br />
Frederick, MD, US<br />
493 Vaccine-induced, SIV-specific CD8 + T Cells Control Viremia<br />
but Do Not Protect from CD4 + T Cell Depletion or AIDS in<br />
SIVmac239-challenged Macaques<br />
J Engram1 , R Dunham1 , B Sumpter2 , G Makedonas1 , M Betts1 ,<br />
S Staprans3 , J Altman2 , D Garber2 , M Feinberg3 , and Guido Silvestri* 1<br />
1 2 Univ of Pennsylvania, Philadelphia, US; Emory Vaccine Ctr and Yerkes<br />
Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US; and 3Merck Res<br />
Labs, West Point, PA, US<br />
494 Immunization by Mucosal Exposure to SIV or HIV-2 during<br />
Chemoprophylaxis with Tenofovir<br />
Lisa Frenkel* 1,2 , L Kuller2 , J Capalungan2 , I Beck1 , CC Tsai2 , SL Hu2 ,<br />
M Agy2 , Y Stevens2 , S Holte2,3 , and D Anderson2 1 2 Seattle Children’s Hosp Res Inst, WA, US; Univ of Washington, Seattle,<br />
US; and 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, US<br />
495 Updated Results from Ongoing Work on the GAIA HIV<br />
Vaccine: Recognition of Class I- and II-restricted Epitopes in<br />
Bamako, Mali, and Providence, US<br />
Karim Coulibaly* 1 , O Koita1 , D Rivera2 , J McMurry2 , L Moise2 ,<br />
W Martin2 , and A De Groot2,3 1 2 3 Univ of Bamako, Mali; EpiVax, Inc, Providence, RI, US; and GAIA<br />
Vaccine Fndn, Providence, RI, US<br />
496 The Depth of CTL Epitope Coverage Correlates with<br />
Strength of Selection in Gag p17 for Subtype B but Not<br />
Subtype C<br />
Mary Pacold* 1 , S Frost1 , A Poon1 , D Smith1,2 , D Richman1,2 , and<br />
S Kosakovsky Pond1 1 2 Univ of California, San Diego, US and San Diego VA Hlthcare Systems,<br />
CA, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 82–Poster Abstracts<br />
HIV Vaccines: Novel Viral Vectors<br />
497a Electroporation of Optimized DNA Vaccines Leads to<br />
Greatly Enhanced Responses in Blood and Mucosal Surfaces<br />
Margherita Rosati* 1 , V Patel1 , C Bergamaschi1 , A Valentin1 , V Kulkarni1 ,<br />
R Jalah1 , C Ohlen1,2 , R Draghia-Akli3 , B Felber1 , and G Pavlakis1 1 2 3 NCI-Frederick, MD, US; SAIC-Frederick, MD, US; and VGX Pharma,<br />
The Woodlands, TX, US<br />
497b Immunogenicity and Protective Efficacy of Replicationdefective<br />
Herpes Simplex Virus Vector-based AIDS Vaccines<br />
Kenneth Chan* 1 , S Pryputniewicz1 , M Kasheta1 , M Rosati2 , J Lifson2,3 ,<br />
G Pavlakis2 , B Felber2 , R Desrosiers1 , D Knipe4 , and A Kaur1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA,<br />
US; 2NCI-Frederick, MD, US; 3SAIC-Frederick, MD, US; and 4Harvard Med Sch, Boston, MA, US<br />
498 Recombinant Varicella Vaccines Induce Immune Responses<br />
to Simian Immunodeficiency Virus Antigens and Reduced<br />
Viral Loads in Immunized Rhesus Macaques<br />
Vicki Traina-Dorge* 1 , R Lorino1 , P Marx1 , Y Ou2 , and W Gray2 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US and Univ of Arkansas<br />
for Med Sci, Little Rock, US<br />
499 Recombinant Foamy Virus Vectors Persistently Express<br />
High Levels of HIV-1 gag: Potential for Vaccine<br />
David Hardy* 1,2 , C Liu1 , T Folks3 , and I Chen2 1 2 Cedars-Sinai Med Ctr, Los Angeles, CA, US; David Geffen Sch of Med,<br />
Univ of California, Los Angeles, US; and 3CDC, Atlanta, GA, US<br />
b Wednesday, 1-4 pm; Hall D<br />
Session 83–Poster Abstracts<br />
HIV Vaccines: Clinical Trials<br />
500 AIDSVAX Immunization Induces HIV-specific CD8 + T Cell<br />
Responses in High-risk HIV–Volunteers Who Subsequently<br />
Acquire HIV Infection<br />
Norman Jones* 1 , P Gilbert2 , A DeCamp2 , M Peterson3 , M Gurwith3 , and<br />
H Cao1 1 2 California Dept of Hlth Svcs, Richmond, US; Fred Hutchinson Cancer Res<br />
Ctr, Seattle, WA, US; and 3Vaxgen, Inc, South San Francisco, CA, US<br />
501 Safety and Immunogenicity of ALVAC-HIV vCP1521 in<br />
Infants Born to HIV-1-infected Women in Uganda (HPTN 027)<br />
Norman Jones* 1 , D Sebikari2 , I Ssewanyana3 , L Baglyos4 , S Zwerski5 ,<br />
M Swenson6 , J Moye7 , F Mmiro2 , L Guay8 , H Cao1 , and HPTN 027<br />
Protocol Team<br />
1 2 California Dept of Publ Hlth, Richmond, US; Makerere Univ–Johns<br />
Hopkins Univ Res Collaboration, Kampala, Uganda; 3Joint Clinical<br />
Res Ctr, Kampala, Uganda; 4Sanofi Pasteur, Swiftwater, PA, US;<br />
5 6 NIAID, NIH, Bethesda, MD, US; Statistical Ctr for HIV/AIDS Res and<br />
Prevention, Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 7Natl Inst of Child Hlth and Human Devt, NIH, Bethesda, MD, US; and 8Johns Hopkins Univ, Baltimore, MD, US<br />
502 Double-blind, Randomized Comparison of a Subunit- and a<br />
Virosomal Influenza Vaccine in Adult HIV + Patients<br />
J Evison, K Muehlemann, and Hansjakob Furrer*<br />
Univ Hosp Berne, Switzerland<br />
503 Nucleic Acid Detection in Patients Whose HIV RNA Levels<br />
Are Near the Lower Limit of Detection: Implications for<br />
Endpoint Determination in HIV Vaccine Trials<br />
Michelle Lally* 1 , R O’Connell2 , S Peel2 , Y Liu3 , C Bautista3 , N Michael2 ,<br />
and L Jagodzinski2 1 2 Warren Alpert Med Sch of Brown Univ, Providence, RI, US; Walter<br />
Reed Army Inst of Res, Rockville, MD, US; and 3Henry M Jackson Fndn,<br />
Rockville, MD, US<br />
504 Male Circumcision as a Component of the Standard for HIV<br />
Prevention: Experience from a Phase IIb Vaccine Trial in<br />
Soweto<br />
Guy de Bruyn* 1 , N Martinson1 , B Nkala1 , T Khosa1 , B Mkhize1 ,<br />
J Kublin2 , L Corey2 , and G Gray1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Fred<br />
Hutchinson Cancer Res Ctr, Seattle, WA, US<br />
<strong>Program</strong> 37<br />
Poster Listings
Poster Litings<br />
Session 84 CROI 2008<br />
b Monday, 1-4 pm; Hall A<br />
Session 84–Poster Abstracts<br />
(see Session 41 on Wednesday for corresponding Poster Discussion)<br />
Molecular Epidemiology: The Americas<br />
505 HIV-1 Transmission Dynamics in Quebec in the HAART Era<br />
Bluma Brenner* 1 , M Roger2 , D Moisi1 , J Cox3 , JP Routy1 , M Wainberg1 ,<br />
and Quebec PHI Study Group<br />
1 2 McGill AIDS Ctr, Jewish Gen Hosp, Montreal, Canada; Ctr Hosp Univ<br />
Montreal, Canada; and 3Quebec Agency of Publ Hlth and Social Svcs,<br />
Canada<br />
506 Tracking Molecular Epidemiology of HIV-1 in Mexico:<br />
Emergence of BG Intersubtype Recombinant<br />
Eduardo Vazquez-Valls* 1 , M Escoto-Delgadillo1 , R Carabez-Hernandez2 ,<br />
and B Torres-Mendoza2 1UMAE Specialties Hosp, Mexican Inst of Social Security, Guadalajara<br />
and 2Univ Hlth Sci Ctr, Univ of Guadalajara, Mexico<br />
507 Evolutionary Dynamics of HIV-1 BF and CB Recombinants<br />
in South America<br />
E Leal1 , L Martins2 , M Janini1 , and Ricardo Diaz* 1<br />
1 2 Federal Univ of Sao Paulo, Brazil and Grad Sch of Agriculture and Life<br />
Sci, Univ of Tokyo, Japan<br />
508 A Foothold for Subtype C in the Americas: Risk Factors<br />
Associated with Subtype C and Non-Subtype C HIV Infection<br />
among HIV Testing Clients in South Brazil<br />
Oliver Bacon* 1 , R da Silva de Souza2 , K Page Shafer1 , R Diaz3 ,<br />
V Debastiani4 , G Preussler5 , M Leticia Ikeda6 , N Barcellos7 , W Steward1 ,<br />
and C Pilcher1 1 2 Univ of California, San Francisco, US; Univ de Caxias do Sul, Rio<br />
Grande, Brazil; 3Paulista Sch of Med, Federal Univ of Sao Paulo, Brazil;<br />
4Ambulatorio de DST/AIDS, Caxias do Sul, Rio Grande do Sul, Brazil;<br />
5Svc de Assistencia Especializado, Ctr de Saude Vila dos Comercarios,<br />
Rio Grande do Sul, Brazil; 6Svc Especializado de DST/AIDS Herbert de<br />
Souza, Rio Grande do Sul, Brazil; and 7Hosp Sanatorio Partenon, Rio<br />
Grande do Sul, Brazil<br />
509 Timing the Introduction of HIV-1 Subtype C in Brazil<br />
Gonzalo Bello*, R Lorete, M Guimaraes, C Bittencourt Passaes, and<br />
M Morgado<br />
Oswaldo Cruz Inst, Fiocruz, Rio de Janeiro, Brazil<br />
b Monday, 1-4 pm; Hall A<br />
Session 85–Poster Abstracts<br />
Molecular Epidemiology: Europe<br />
510 Phylogenetic Surveillance of Viral Genetic Diversity and the<br />
Evolving Molecular Epidemiology of HIV-1<br />
Robert Gifford* 1 , T de Oliveira2 , A Rambaut3 , O Pybus4 , D Dunn5 ,<br />
AM Vandamme6 , P Kellam7 , D Pillay7 , and UK Collaborative Group on<br />
HIV Drug Resistance<br />
1 2 Stanford Univ, Palo Alto, CA, US; Univ of the Western Cape, Bellville,<br />
South Africa; 3Univ of Edinburgh, Scotland; 4Univ of Oxford, UK; 5Med Res Council Clinical Trials Unit, London, UK; 6Katholieke Univ Leuven,<br />
Belgium; and 7Univ Coll London, UK<br />
511 Significant Increase in Prevalence of HIV-1 Recombinant<br />
Forms in a UK Non-B Subtype Clinical Cohort over 10 Years<br />
E MacRae and Clive Loveday* on behalf of the ICVC Clinical<br />
Collaborative Res Group<br />
ICVC Charitable Trust, Buckinghamshire, UK<br />
512 The Contribution of Individuals with Recent Infection to the<br />
Spread of HIV-1 in Switzerland: A 10-year Survey<br />
Sabine Yerly* 1 , V von Wyl2 , T Junier3 , B Ledergerber2 , J Boni2 ,<br />
P Burgisser4 , T Klimkait5 , E Zdobnov3 , L Kaiser1 , H Gunthard2 , and the<br />
HIV Swiss Cohort Study<br />
1 2 Lab of Virology, Geneva, Switzerland; Div of Infectious Diseases,<br />
Zurich, Switzerland; 3Univ of Geneva, Switzerland; 4Ctr Hosp Univ<br />
Vaudois Lausanne, Switzerland; and 5Inst of Med Microbio, Univ Basel,<br />
Switzerland<br />
513 Characteristics of Patients Infected with HIV-1 Subtype D<br />
and CRF01_AE among New HIV Diagnoses in France, 2003<br />
to 2005<br />
D Brand1 , F Cazein2 , F Lot2 , J Pillonel2 , S Brunet1 , D Thierry1 ,<br />
JC Desenclos2 , C Semaille2 , and Francis Barin* 1<br />
1 2 Univ F Rabelais, Tours, France and Inst de Veilles Sanitaire, St<br />
Maurice, France<br />
514 Disease Progression, Virus Evolution, and Co-receptor<br />
Tropism in Individuals with Wild Type and Deficient CCR5<br />
Alleles after Infection with a Closely Related HIV-1 Strain<br />
Chris Verhofstede* 1 , L Stuyver2 , F Van Wanzeele1 , J Pelgrom1 ,<br />
B Van der Gucht1 , E Demecheleer1 , V Van Eygen2 , J Plum1 ,<br />
D Vogelaers1 , and L Vandekerckhove1 1 2 Univ Hosp Gent, Belgium and Virco BVBA, Mechelen, Belgium<br />
515 The Surveillance of HIV-1 Subtype Distribution in the Year<br />
2005 to 2006 in Saint Petersburg, Russia<br />
Elena Dukhovlinova* 1 , A Masharsky1 , T Solovjeva1 , S Verevochkin1 ,<br />
O Toussova1 , N Klimov1 , L Alexander2 , R Heimer2 , and A Kozlov1 1 2 Biomed Ctr, St Petersburg, Russia and Yale Univ, New Haven, CT, US<br />
38 15th Conference on Retroviruses and Opportunistic Infections<br />
b Monday, 1-4 pm; Hall A<br />
Session 86–Poster Abstracts<br />
Molecular Epidemiology: Africa and Asia<br />
516 The Association of Sexual Risk Behavior and Infection with<br />
Multiple or Recombinant Strains of HIV in Rakai, Uganda<br />
Oliver Laeyendecker* 1,2 , M Chen3 , T Ngo1 , T Quinn1,2 , M Arroyo4 ,<br />
F McCutchan4 , N Kiwanuka5 , P Opendi5 , M Wawer3 , R Gray3 , and Rakai<br />
Hlth Sci Prgm<br />
1 2 Lab of Immunoregulation, NIAID, NIH, Baltimore, MD, US; Johns<br />
Hopkins Univ Sch of Med, Baltimore, MD, US; 3Johns Hopkins Univ<br />
Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 4US Military HIV Res<br />
Prgm, Henry M Jackson Fndn, Rockville MD, US; and 5Rakai Hlth Sci<br />
Project, Uganda<br />
517 Identification and Prevalence of Dual Subtype/CRF<br />
Infections at HIV Diagnosis in Cameroon Using a Real Time<br />
PCR-based Hybridization Assay<br />
N Vidal1 , H Diop2 , C Montavon1 , C Butel1 , C Toure-Kane2 , S MBoup2 ,<br />
E Mpoudi Ngole3 , Eric Delaporte* 1 , M Peeters1 , and ANRS 1297<br />
1 2 Inst for Res and Devt, Paris and Univ of Montpellier 1, France; Hosp<br />
Le Dantec, Dakar, Senegal; and 3PRESICA, Military Hosp, Yaounde,<br />
Cameroon<br />
518 20 Years of Prospective Molecular Epidemiology in Senegal:<br />
Changes in HIV Diversity<br />
Donald Hamel* 1 , JL Sankale1 , G Eisen1 , S Thakore-Meloni1 , C Mullins1 ,<br />
A Gueye-NDiaye2 , S MBoup2 , and P Kanki1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US and Cheikh Anta Diop Univ<br />
and Inst of Social Hygiene, Dakar, Senegal<br />
519 Different Patterns of Evolution of HIV-1 Subtypes and CRF<br />
in Southern Countries of Africa and Asia<br />
Herve Fleury<br />
Univ of Bordeaux, France<br />
520 Identification of a Novel CRF and CRF25_cpx in Saudi<br />
Arabia, Based on Full Genome Sequence Analysis of 6 HIV-1<br />
Isolates<br />
J Yamaguchi1 , S Badreddine2 , P Swanson1 , P Bodelle1 , S Devare1 , and<br />
Catherine Brennan* 1<br />
1 2 Abbott Diagnostics, Abbott Park, IL, US and King Faisal Specialist<br />
Hosp and Res Ctr, Jeddah, Saudi Arabia<br />
521 HIV-1 Epidemic in Intravenous Drug User Communities in<br />
Iran Is Driven by Subtype A Viruses<br />
Luigi Buonaguro* 1 , M Tagliamonte1 , H Naderi2 , M Tornesello1 , R Farid3 ,<br />
and F Buonaguro1 1 2 Natl Cancer Inst “Fndn Pascale”, Naples, Italy; Inst of Infectious<br />
Diseases, Univ of Mashhad, Iran; and 3Univ of Mashhad, Iran<br />
522 A Novel Pattern of Evolution of HIV-1 Subtypes and CRF in<br />
Iran<br />
S Samiee1 , Z Soheila Soheili2 , and Herve Fleury* 3<br />
1 2 Iranian Blood Transfusion Org, Tehran; Natl Res Inst of Genetic<br />
Engineering and Biotech, Tehran, Iran; and 3Univ of Bordeaux, France<br />
523 HIV among Injection Drugs Users in Chennai: A Different<br />
Epidemic from Northeastern India?<br />
Sunil Solomon* 1,2 , S Iqbal2 , P Balakrishnan2 , K Murugavel2 ,<br />
S Mehta1 , S Solomon2 , and D Celentano1 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US<br />
and 2YRGCARE, Chennai, India<br />
524 Chronology of the HIV-1 CRF07_BC Expansion in East Asia<br />
Kok Keng Tee* 1,2 , O Pybus3 , H Liao1 , R Uenishi1 , S Hase1 ,<br />
A Kamarulzaman2 , XJ Li1,4 , and Y Takebe1 1 2 Natl Inst of Infectious Diseases, Tokyo, Japan; Univ of Malaya, Kuala<br />
Lumpur, Malaysia; 3Univ of Oxford, UK; and 4Shanghai Jiao Tong Univ,<br />
Shanghai, China<br />
b Monday, 1-4 pm; Hall A<br />
Session 87–Poster Abstracts<br />
Epidemiology and Transmission in Adult<br />
Populations<br />
525 HIV/AIDS in Europe: Epidemiology in 2006 and a New<br />
Framework for Surveillance<br />
Magid Herida* 1 , J Alix2 , I Devaux2 , G Likatavicius2 , S Matic3 , and<br />
A Nardone2 1European Cttr for Disease Prevention and Control, Stockholm, Sweden;<br />
2 3 EuroHIV, Inst de Veille Sanitaire, France; and WHO, Regional Office<br />
for Europe, Copenhagen, Denmark and Stockholm, Sweden<br />
526 Comparison of Global HIV Incidence: Longitudinal and<br />
Cross-sectional Estimates<br />
Melissa Riedesel* 1 , O Laeyendecker1,2 , and T Quinn1,2 1 2 Lab of Immunoregulation, NIAID, NIH, Baltimore, MD, US and Johns<br />
Hopkins Univ Sch of Med, Baltimore, MD, US
CROI 2008 Session 89<br />
527 Delayed and Reduced Heterosexual HIV-1 Transmission in<br />
Zambians with HLA-B*57<br />
J Tang1 , W Shao1 , Y Yoo1 , I Brill1 , J Mulenga2 , D Chanda2 , S Allen3 ,<br />
E Hunter3 , Richard Kaslow* 1 , and Zambia-Emory HIV-1 Res Project<br />
1 2 Univ of Alabama at Birmingham, US; Rwanda-Zambia HIV-1 Res<br />
Group, Lusaka; and 3Emory Univ, Atlanta, GA, US<br />
528 Slower Clinical Progression in Antiretroviral-naïve African<br />
Immigrants Compared to Haitian and Canadian Patients in a<br />
Universal Health Care System<br />
Marina Keller*, Y Lu, R Lalonde, and M Klein<br />
McGill Univ Hlth Ctr, Canada<br />
529 Low Prevalence of HIV-1 and HIV-2 Co-infection<br />
in Pregnant Women in Bissau: Are the 2 Epidemics<br />
Independent?<br />
Erika Gianelli* 1 , F Rankin Bravo2 , A Nanadje2 , D Da Silva Te2 ,<br />
O Bosisio2 , F Adorni1 , B Massetto1 , S Rusconi1 , M Galli1 , and A Riva1 1 2 Univ of Milan, Italy and Assn Céu e Terras, Guinea Bissau, West Africa<br />
530 Higher Adjusted Mortality Rates among Publicly Insured<br />
Patients and Blacks in the HIV Outpatient Study<br />
Frank Palella* 1 , R Baker2 , J Chmiel1 , E Tedaldi3 , R Novak4 , K Buchacz5 ,<br />
and J Brooks5 1 2 Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; Cerner Corp,<br />
Vienna, VA, US; 3Temple Univ Sch of Med, Philadelphia, PA, US; 4Univ of<br />
Illinois at Chicago, Coll of Med, US; and 5CDC, Atlanta, GA, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 88–Poster Abstracts<br />
(see Session 12 on Monday for corresponding Poster Discussion)<br />
New Approaches to HIV Testing<br />
531 Partner Counseling and Referral Outcomes after Acute HIV<br />
Identification in North Carolina<br />
Sandra McCoy* 1 , J Kuruc1 , C Gay1 , C Hurt1 , J Anderson1 , C Pilcher2 ,<br />
J Barnhart3 , J Eron1 , P Leone1,3 , and the North Carolina STAT Team<br />
1 2 Univ of North Carolina at Chapel Hill, US; Univ of California, San<br />
Francisco, US; and 3North Carolina Dept of Hlth and Human Svcs,<br />
Raleigh, US<br />
532 Acceptance of Routine HIV Testing in Medical Inpatients in<br />
Nigeria: Implications for a New HIV Testing Approach in<br />
Sub-Saharan Africa<br />
Olusegun Busari* 1 , M Nakayima2 , O Busari1 , G Oligbu1 , A Adeyemi3 ,<br />
L Onigbogi4 , and HIV Study Group<br />
1 2 Federal Med Ctr, Ido-Ekiti, Nigeria; AIDS Support Org, Masaka,<br />
Uganda; 3Hlthmatch Intl, Lagos, Nigeria; and 4Univ Coll Hosp, Ibadan,<br />
Nigeria<br />
533 Interim Findings from a Multi-site Evaluation of HIV Testing<br />
in Emergency Departments<br />
James Heffelfinger* 1 , R Rothman2 , H Pollack3 , J Brown4 , M Lyons5 ,<br />
G Almond6 , P Sullivan1 , S Barera7 , and G Williams Torres7 1 2 3 CDC, Atlanta, GA, US; Johns Hopkins Univ, Baltimore, MD, US; Univ<br />
of Chicago, IL, US; 4George Washington Univ, Washington, DC, US;<br />
5 6 Univ of Cincinnati Coll of Med, OH, US; Metropolitan Hosp Ctr, New<br />
York, NY, US; and 7Hlth Res and Ed Trust, Chicago, IL, US<br />
534 Revisiting Expectations from Rapid HIV Test and<br />
Confirmation in the Emergency Department<br />
Rochelle Walensky* 1,2,3 , C Arbelaez2 , W Reichmann2 , R Walls2 , J Katz2,4 ,<br />
and E Losina1,2,5 1 2 Massachusetts Gen Hosp, Boston, US; Brigham and Women’s Hosp,<br />
Boston, MA, US; 3Harvard Med Sch, Boston, MA, US; 4Harvard Sch of<br />
Publ Hlth, Boston, MA, US; and 5Boston Univ Sch of Publ Hlth, MA, US<br />
535a Patient Perspectives and Testing Uptake with Abbreviated<br />
versus Standard Pre-test HIV Counseling in the Prenatal<br />
Setting: A Randomized-Controlled, Non-inferiority Trial<br />
Deborah Cohan* 1,2 , E Gomez1,2 , and E Charlebois1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp,<br />
CA, US<br />
535b Using Multiple Rapid HIV Tests at the Point of Care:<br />
Implications for Clinicians Receiving Referrals<br />
Kevin Delaney* 1 , T Knoble2 , J Rurangirwa3 , A Scribner4 , E Hopkins5 ,<br />
B Boyett1 , D White4 , J Haukoos5 , T Dowling2 , and J King3 1 2 CDC, Atlanta, GA, US; HIV Prevention Prgm, City and County of San<br />
Francisco, CA, US; 3Los Angeles County Dept of Hlth, CA, US; 4Highland Hosp, Alameda County Hlth Ctr, Oakland, CA, US; and 5Denver Hlth<br />
Med Ctr, CO, US<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 89–Poster Abstracts<br />
Expanding HIV Testing<br />
536 Ascertainment of HIV, Other Infectious Disease, and<br />
Metabolic Disorders among Psychiatric Inpatients: A Missed<br />
Opportunity<br />
Michael Blank*, A Rothbard, D Young, J Staab, and D Metzger<br />
Univ of Pennsylvania, Philadelphia, US<br />
537 Dramatic Increase of HIV-testing after Implementing<br />
Routine Antenatal HIV-testing in Eastern Uganda<br />
Robert Byamugisha* 1 , M Kagawa1 , J Tumwine2 , C Karamagi2 ,<br />
S Onyango3 , and T Tylleskar4 1 2 Mbale Regional Referral Hosp, Uganda; Makerere Univ, Kampala,<br />
Uganda; 3Ministry of Hlth, Kampala, Uganda; and 4Univ of Bergen,<br />
Norway<br />
538 Routine Offer of a Rapid HIV Test in New York City, Single<br />
Adult Homeless Assessment Shelters<br />
Maureen Malave* 1 , V Woog1 , B Tsoi1 , A Gutkovich2 , D Marder2 ,<br />
M Sweeney1 , and B Cutler1 1 2 New York City Dept of Hlth and Mental Hygiene, NY, US and New York<br />
City Dept of Homeless Svcs, NY, US<br />
539 Undiagnosed HIV Infection among New York City Jail<br />
Entrants, 2006: Results of a Blinded Serosurvey<br />
Y Bennani, F Parvez, L Forgione, J Herrera, Lucia Torian*, M Gbur, and<br />
E Begier<br />
New York City Dept of Hlth and Mental Hygiene, NY, US<br />
540 HIV Prevalence Trends by HIV Testing History, Injection<br />
Drug Use, and Sexual Risk Behaviors among Inmates<br />
Entering New York State Correctional Facilities from 1988 to<br />
2005<br />
L Wang1 , Lou Smith* 1 , L Wright2 , G Birkhead1 , J Wethers1 , M Young1 ,<br />
B Zhu1 , and P Smith1 1 2 New York State Dept of Hlth, Albany, US and New York State Dept of<br />
Correctional Svcs, Albany, US<br />
541 Routine HIV Screening: Testing Patterns in a Highprevalence<br />
City—Washington, DC, 2006 to 2007<br />
A Castel1 , T West2 , T Jolaosho2 , C Wu1 , D Hitchcock2 , L Rennie2 ,<br />
M Magnus1 , M Sansone2 , and Alan Greenberg* 1<br />
1George Washington Univ Sch of Publ Hlth and Hlth Svcs, Washington,<br />
DC, US and 2District of Columbia Dept of Hlth, HIV/AIDS Admin,<br />
Washington, US<br />
542 Gender Differences in Sexual and HIV Testing Behaviors<br />
among Heterosexuals at High Risk for HIV in Washington,<br />
DC<br />
Manya Magnus* 1 , I Kuo1 , A Rawls1 , K Shelley1 , J Peterson1 , F Hamilton2 ,<br />
T West3 , M Sansone3 , and A Greenberg1 1George Washington Univ Sch of Publ Hlth and Hlth Svcs, Washington,<br />
DC, US; 2Family and Med Counseling Svcs, Inc, Washington, DC, US;<br />
and 3District of Columbia Dept of Hlth, HIV/AIDS Admin, Washington,<br />
US<br />
543 Late to Test: Concurrent HIV/AIDS Diagnoses in a City with<br />
High AIDS Prevalence: Washington, DC, 2007<br />
A Castel1 , T Jolaosho2 , M Woolfork2 , I Kuo1 , Tiffany West* 2 , and<br />
A Greenberg1 1George Washington Univ Sch of Publ Hlth and Hlth Svcs, Washington,<br />
DC, US and 2District of Columbia Dept of Hlth, HIV/AIDS Admin,<br />
Washington, US<br />
544a 4 Years of Surveillance of Recent HIV Infections in France,<br />
2003 to 2006<br />
Caroline Semaille* 1 , F Barin2 , J Pillonel1 , F Lot1 , F Cazein1 , R Pinget1 ,<br />
S Brunet2 , D Thierry2 , and JC Desenclos1 1 2 Inst Veille Sanitaire, Saint Maurice, France and Univ Francois-Rabelais,<br />
Natl AIDS Reference Ctr, Ctr Hosp Univ Bretonneau, Tours, France<br />
544b Opt-out Rapid HIV Screening in the Emergency Department:<br />
Preliminary Results from a Prospective Clinical Trial<br />
Jason Haukoos* 1,2 , E Hopkins1 , R Byyny1,2 , B Bongiovanni3 , B Boyett4 ,<br />
B Dillon3 , J Forsyth4 , J Heffelfinger4 , S Johnson2,5 , M Thrun2,6 , and the<br />
Denver Emergency Dept HIV Testing Study Group<br />
1 2 Denver Hlth Med Ctr, CO, US; Univ of Colorado Sch of Med, Denver,<br />
US; 3Colorado Dept of Publ Hlth and Environment, Denver, US; 4CDC, Atlanta, GA, US; 5Univ of Colorado HIV/AIDS Prgm, Denver, US; and<br />
6Denver Publ Hlth, CO, US<br />
<strong>Program</strong> 39<br />
Poster Listings
Poster Litings<br />
Session 90 CROI 2008<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 90–Poster Abstracts<br />
Behavioral Risk in HIV Infection<br />
545 Comparison of Sexual Risk Behaviors in Non-Hispanic Black<br />
and White Men Who Have Sex with Men Recruited in Online<br />
Surveys<br />
M Chiasson1 , Barbara Taylor* 2 , R Scheinmann1 , S Hirshfield1 ,<br />
M Humberstone1 , R Remien3 , R Wolitski4 , and T Wong5 1 2 Med and Hlth Res Assn of New York City, Inc, NY, US; Columbia Univ<br />
Med Ctr, New York, NY, US; 3New York State Psychiatric Inst, Columbia<br />
Univ, New York, US; 4CDC, Atlanta, GA, US; and 5Publ Hlth Agency of<br />
Canada, Ottawa<br />
546 HIV Serosorting Practices among HIV-uninfected Gay<br />
and Bisexual Men in California: San Francisco Bay Area<br />
Residents vs Circuit Party Attendees<br />
Albert Liu* 1,2 , P Kittredge1 , H Raymond1 , and S Buchbinder1,2 1 2 San Francisco Dept of Publ Hlth, CA, US and Univ of California, San<br />
Francisco, US<br />
547 Mood and Sexual Behavior Profiles of Men Who Have Sex<br />
with Men in the Context of Methamphetamine and HIV<br />
Chad Bousman*, M Cherner, B Mausbach, H Atkinson, I Everall,<br />
S Letendre, T Patterson, I Grant, and the HNRC Group<br />
Univ of California, San Diego, US<br />
548 Condom Failure Does Not Explain Increased Risk of HIV<br />
Seroconversion Seen in Uncircumcised Men Who Have Sex<br />
with Men Practicing Insertive Anal Sex<br />
Jonathan Fuchs* 1,2 , E Vittinghoff2 , P Kittredge1 , and S Buchbinder1,2 1 2 San Francisco Dept of Publ Hlth, CA, US and Univ of California, San<br />
Francisco, US<br />
549 The Clinical Presentation of Syphilis in HIV-infected Men<br />
Who Have Sex with Men in an Urban Clinic<br />
Lawrence Siegel*, L Drusin, R Gulick, and T Wilkin<br />
Weill Med Coll of Cornell Univ, New York, NY, US<br />
550 Characteristics and Behaviors Associated with HIV Infection<br />
in a Large Southern Prison System<br />
David Rosen* 1,2 , D Wohl1,2 , B White2 , and V Schoenbach1 1 2 Univ of North Carolina at Chapel Hill Sch of Publ Hlth, US and Univ of<br />
North Carolina at Chapel Hill Sch of Med, US<br />
551 Causal Analysis of the Effect of Migration on HIV High-risk<br />
Behaviors among Mexican Migrants<br />
Melissa Sanchez* 1 , M Hernandez1 , A Vera2 , L Ayala3 , and G Lemp1 1 2 Univ of California, Oakland, US; Univ of California, San Diego, US;<br />
and 3United Hlth Ctrs of the San Joaquin Valley Inc, Parlier, CA, US<br />
552 Correlates of HIV and Other Sexually Transmitted Infections<br />
in Central American Men Who Have Sex with Men: Defining<br />
Priorities for an Underserved Population<br />
A Ghee1 , R Mayorga2 , J Lama3 , C Nunez4 , K Tapia1 , K Holmes1 , and<br />
Jorge Sanchez* 3<br />
1 2 Ctr for AIDS and STD, Univ of Washington, Seattle, US; Org for the<br />
Support of a Comprehensive Sexuality in Response to AIDS, Guatemala<br />
City, Guatemala; 3Investigaciones Medicas en Salud, Lima, Peru; and<br />
4Constella-Futures, Guatemala City, Guatemala<br />
553 Low HIV Incidence and Declining Risk Behaviors in a<br />
Cohort of Injection Drug Users in Chennai, India<br />
Sunil Solomon* 1,2 , D Celentano1 , A Srikrishnan2 , C Vasudevan2 ,<br />
K Murugavel2 , E Thamburaj2 , S Anand2 , M Kumar2 , S Solomon2 , and<br />
S Mehta1 1Johns Hopkins Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US<br />
and 2YRGCARE, Chennai, India<br />
554 Low Rates of HIV Incidence in Core Populations at High<br />
Risk of HIV Infection and Bridge Populations in 6 High HIV<br />
Prevalence States in India<br />
Ramesh Paranjape* 1 , S Kulkarni1 , B Ramesh2 , G Brahmam3 , J Mahanta4 ,<br />
J Dale1 , B Kishore Kumar1 , A Risbud1 , R Gangakhedkar1 , and M Gupte5 1 2 Natl AIDS Res Inst, Pune, India; Karnataka Hlth Promotion Trust,<br />
Bangalore, India; 3Natl Inst of Nutrition, Hyderabad, India; 4Regional Med Res Ctr, Dibrugurh, India; and 5Natl Inst of Epi, Chennai, India<br />
555 Evidence of Declining HIV Infection Rates in Uganda:<br />
Implications for Community-based HIV Vaccine Efficacy<br />
Trials<br />
David Guwatudde* 1,2 , M Eller2 , L Eller2 , M Millard2 , H Kibuuka2 ,<br />
F Wabwire-Mangen1,2 , N Sewankambo3 , D Serwadda1 , N Michael4 ,<br />
M Robb5 , and the Kayunga District Cohort Devt Res Team<br />
1Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala,<br />
Uganda; 2Makerere Univ–Walter Reed Project, Kampala, Uganda;<br />
3 4 Makerere Univ Sch of Med, Kampala, Uganda; Walter Reed Army Inst of<br />
Res, Rockville, MD, US; and 5Henry M Jackson Fndn, Rockville, MD, US<br />
40 15th Conference on Retroviruses and Opportunistic Infections<br />
b Monday, 1-4 pm; Hall A<br />
Session 91–Poster Abstracts<br />
(see Session 28 on Tuesday for corresponding Poster Discussion)<br />
Novel PrEP Agents and Evaluation Strategies<br />
556 An Engineered Bi-functional HIV-1 Neutralizing Protein as a<br />
Potential Microbicide<br />
Vadim Villarroel* 1 , L Lagenaur1,2 , and E Berger1 1 2 NIAID, NIH, Bethesda, MD, US and Osel, Inc, Santa Clara, CA, US<br />
557 Better Protection against HIV-1 Infection in vitro with<br />
Candidate Microbicide Compounds in Combination<br />
Susan Schader* 1,2 , B Scarth2 , S Colby-Germinario1 , J Schachter1 ,<br />
J Nuttall3 , M Gotte2 , and M Wainberg1,2 1 2 Lady Davis Inst, Montreal, Canada; McGill Univ, Montreal, Canada;<br />
and 3Intl Partnership for Microbicides, Silver Spring, MD, US<br />
558 Antiretroviral Pre-exposure Prophylaxis Prevents Vaginal<br />
Transmission of HIV-1 in Humanized BLT Mice<br />
Paul Denton* 1 , J Estes2 , Z Sun1 , F Othieno1 , D Powell1 , A Haase2 , and<br />
V Garcia1 1 2 Univ of Texas Southwestern Med Ctr, Dallas, US and Univ of<br />
Minnesota, Minneapolis, US<br />
559a Size-fitting of Intravaginal Rings for Macaques and in vitro<br />
Release Kinetics of Zinc Finger Inhibitors<br />
James Smith* 1 , K Malcolm2 , E Appella3 , C McConville2 , M Schito3 ,<br />
D Woolfson2 , R Hayashi3 , N Lanier1 , R Otten1 , and S Butera1 1 2 CDC, Atlanta, GA, US; Queen’s Univ of Belfast, Sch of Pharmacy,<br />
Northern Ireland; and 3NCI, NIH, Bethesda, MD, US<br />
559b Safety and Pharmacokinetic Assessment of 28-Day Anti-HIV<br />
Dapivirine Intravaginal Microbicide Rings<br />
Annalene Nel* 1 , S Smythe1 , K Young1 , K Malcolm2 , Z Rosenberg1 , and<br />
J Romano1 1 2 Intl Partnership for Microbicides, Silver Spring, MD, US and Queen’s<br />
Univ, Belfast, Northern Ireland<br />
560 Topical Application of Fully Recombinant RANTES Analogs<br />
Protect Macaques from Vaginal SHIV Transmission<br />
Ronald Veazey* 1 , M Lederman2 , B Ling1 , L Green1 , E Ribka1 , D Mosier3 ,<br />
R Offord4,5 , and O Hartley4 1 2 Tulane Natl Primate Res Ctr, Covington, LA, US; Case Western<br />
Reserve Univ, Cleveland, OH, US; 3Scripps Res Inst, La Jolla, CA, US;<br />
4 5 Univ of Geneva, Switzerland; and Mintaka Fndn for Med Res, Geneva,<br />
Switzerland<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 92–Poster Abstracts<br />
HIV-1 Prevention for Positives<br />
561 Implementation and Evaluation of a Clinic-based Behavioral<br />
Intervention: Positive STEPS for HIV Patients<br />
Lytt Gardner* 1 , G Marks1 , C O’Daniels2 , T Wilson3 , E Quinlivan4 ,<br />
J Wright5 , L Bradley-Springer6 , M Thompson7 , S Raffanti8 , and M Thrun9 1 2 CDC, Atlanta, GA, US; McKing Consulting Corp, Atlanta, GA, US;<br />
3 4 State Univ of New York at Brooklyn, US; Univ of North Carolina at<br />
Chapel Hill, US; 5Univ of Missouri, Kansas City, US; 6Univ of Colorado<br />
Hlth Sci Ctr, Denver, US; 7AIDS Res Consortium of Atlanta, GA, US;<br />
8 9 Vanderbilt Univ, Nashville, TN, US; and Denver Publ Hlth, CO, US<br />
562 Translating Research into Practice: Successful Replication of<br />
a Clinic-based Positive Prevention Intervention<br />
Lisa Hirschhorn* 1 , M Stylos Allan1 , F Marshman1 , D Cornman2 ,<br />
L Kunches1 , Y Hamby1 , S Christie2 , and K McElroy3 1 2 JSI Res and Training, Boston, MA, US; Univ of Connecticut, Storrs,<br />
US; and 3HIV/AIDS Bureau, Hlth Resources and Svcs Admin, Rockville,<br />
MD, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 93–Poster Abstracts<br />
Modeling the Cost-effectiveness and Impact of<br />
PrEP on Resistance<br />
563 Effect of Pre-exposure HIV Prophylaxis on Lifetime Infection<br />
Risk, Survival, and Cost<br />
David Paltiel* 1 , K Freedberg2,3 , C Scott3 , B Schackman4 , E Losina5 ,<br />
B Wang3 , G Seage6 , C Sloan3 , P Sax2,5 , and R Walensky2,3 1 2 Yale Univ Sch of Med, New Haven, CT, US; Harvard Med Sch, Boston,<br />
MA, US; 3Massachusetts Gen Hosp, Boston, US; 4Weill Med Coll of<br />
Cornell Univ, New York, NY, US; 5Brigham and Women’s Hosp, Boston,<br />
MA, US; and 6Harvard Sch of Publ Hlth, Boston, MA, US<br />
564 Modeling the Emergence and Spread of HIV Drug Resistance<br />
from Antiretroviral Pre-exposure Chemoprophylaxis<br />
Ume Abbas* 1 , R Anderson2 , and J Mellors1 1 2 Univ of Pittsburgh, PA, US and Imperial Coll, London, UK
CROI 2008 Session 96<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 94–Poster Abstracts<br />
Preclinical and Clinical Studies of Topical and Oral<br />
PrEP<br />
565 Inhibitory Effect of PRO 2000, a Candidate Microbicide, on<br />
Dendritic Cell-mediated HIV Transmission<br />
Natalia Teleshova* 1 , T Chang1 , A Profy2 , and M Klotman1 1 2 Mt Sinai Sch of Med, New York, NY, US and Indevus Pharma Inc,<br />
Lexington, MA, US<br />
566 Evaluation of the Safety of Carraguard for Vaginal Use by<br />
HIV-infected Women: Results from a Phase I, Randomized,<br />
Placebo-controlled, 3-Treatment Cross-over Study<br />
Catherine McLean* 1 , H Jones2 , J McNicholl3 , J van de Wijgert4 ,<br />
T Medtanavyn5 , W Uthaiworavit6 , S Whitehead3 , J Karon7 , P Kilmarx1 ,<br />
and L Markowitz1 1 2 CDC, Atlanta, GA, US; Population Council, New York, NY, US;<br />
3Thailand Ministry of Publ Hlth-US CDC Collaboration, Nonthaburi;<br />
4 5 Academic Med Ctr, Univ of Amsterdam, The Netherlands; Chiang Rai<br />
Provincial Hlth Office, Thailand; 6Chiang Rai Hosp, Thailand; and<br />
7Emergint Corp, Louisville, KY, US<br />
567 HIV Seroconversion Patterns Observed in the Microbicides<br />
Development <strong>Program</strong>me 301 Trial<br />
Ute Jentsch* 1 , W Stevens1 , P Lunga2 , S McCormack2 , A Nunn2 , C Lacey3 ,<br />
and J Weber4 1Univ of the Witwatersrand, Sch of Pathology, Johannesburg, South<br />
Africa; 2Med Res Council, London, UK; 3Univ of York, Heslington, UK;<br />
and 4Imperial Coll Sch of Med, London, UK<br />
568 Enrollment, Risk Behavior, and Adherence of Injecting Drug<br />
Users in an HIV Prevention Trial in Bangkok<br />
K Choopanya1 , Michael Martin* 2,3 , S Vanichseni1 , U Sangkum1 ,<br />
R Chuachoowong2 , M Leethochawalit4 , S Chiamwongpaet4 ,<br />
S Kittimunkong5 , J McNicholl2,3 , P Suntharasamai1 , and the Bangkok<br />
Tenofovir Study Group<br />
1 2 Bangkok Tenofovir Study Group, Thailand; Thailand Ministry of Publ<br />
Hlth-US CDC Collaboration, Nonthaburi; 3CDC, Atlanta, GA, US;<br />
4 5 Bangkok Metropolitan Admin, Thailand; and Thailand Ministry of Publ<br />
Hlth<br />
569 iPrEx: A Timely Intervention Unfolds in a Population of<br />
Eminent Risk of HIV infection<br />
Jeff McConnell* 1 , R Grant1,2 , P Goicochea3 , J Guanira4 , M Casapia5 ,<br />
O Guerra4 , L Vargas3 , V McMahan1 , and J Lama3,4 1Gladstone Inst of Virology and Immunology, San Francisco, CA, US;<br />
2 3 Univ of California, San Francisco, US; Investigaciones Medicas en<br />
Salud, Lima, Peru; 4Civil Impacta Salud y Educacion, Lima, Peru; and<br />
5Assn Civil Selva Amazonica, Iquitos, Peru<br />
570 No Evidence of Drug-resistance Mutations in a<br />
Seroconverter Exposed to Tenofovir Disoproxil Fumarate<br />
Chemoprophylaxis in Africa<br />
R Atchison1 , L Peterson2 , T Leigler3 , W Cates2 , and R Grant* 1,3<br />
1Gladstone Inst of Virology and Immunology, San Francisco, CA,<br />
US; 2Family Hlth Intl, Durham, NC, US; and 3Univ of California, San<br />
Francisco, US<br />
b Monday, 1-4 pm; Hall A<br />
Session 95–Poster Abstracts<br />
Pharmacokinetics and Children<br />
571 Nelfinavir Pharmacokinetics with an Increased Dose during<br />
the First 2 Weeks of Life<br />
Mark Mirochnick* 1 , K Nielsen-Saines2 , J Pilotto3 , J Pinto4 , V Veloso5 ,<br />
D Holland6 , H Watts7 , J Moye7 , L Mofenson7 , Y Bryson2 , and NICHD/<br />
HPTN 040/PACTG 1043 Protocol Team<br />
1 2 Boston Univ Sch of Med, MA, US; David Geffen Sch of Med, Univ<br />
of California, Los Angeles, US; 3Hosp Geral de Nova Iguaçu, Brazil;<br />
4 5 Federal Univ of Minas Gerais, Belo Horizonte, Brazil; Fiocruz Inst, Rio<br />
de Janeiro, Brazil; 6Univ of California, San Diego, US; and 7Natl Inst of<br />
Child Hlth and Human Devt, NIH, Bethesda, MD, US<br />
572 CYP2C19 Genetic Variants Affect Nelfinavir and M8<br />
Pharmacokinetics and Virologic Response in HIV-1 infected<br />
Children Receiving HAART<br />
Akihiko Saitoh* 1 , E Sarles1 , E Capparelli1 , F Aweeka2 , A Kovacs3 ,<br />
S Buchett4 , A Wiznia5 , S Nachman6 , T Fenton7 , and S Spector1 1 2 Univ of California, San Diego, US; Univ of California, San Francisco,<br />
US; 3Univ of Southern California, Los Angeles, US; 4Harvard Med Sch,<br />
Boston, MA, US; 5Jacobi Med Ctr, Bronx, NY, US; 6State Univ of New York<br />
at Stony Brook, US; and 7Harvard Sch of Publ Hlth, Boston, MA, US<br />
573 Lopinavir Pharmacokinetic Maturational Changes and<br />
Variability in HIV-infected Infants Beginning Kaletra<br />
Therapy at
Poster Litings<br />
Session 96 CROI 2008<br />
583 Early Effectiveness of a NVP-based HAART Regimen among<br />
HIV-infected Children with and without Prior Single-dose<br />
NVP Exposure<br />
Linda Barlow-Mosha*, P Ajunua, M Mubiru, D Bagenda,<br />
M Luttajumwa, B Musoke, M Owor, and P Musoke<br />
Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala, Uganda<br />
584 Initial Growth, CD4, and Viral Load Responses to HAART in<br />
Ugandan Compared to UK/Irish HIV-infected Children<br />
Addy Kekitiinwa* 1 , K Lee2 , A Walker2 , A Maganda1 , K Doerholt2 ,<br />
H Lyall3 , K Butler4 , A Asiimwe1 , M Kline1 , and D Gibb2 1Baylor Coll of Med Children’s Fndn, Pediatric Infectious Disease Clin,<br />
Mulago Hosp, Uganda; 2Med Res Council Clinical Trials Unit, London,<br />
UK; 3St Mary’s Hosp, London, UK; and 4Our Lady’s Hosp for Sick<br />
Children, Dublin, Ireland<br />
585 Examination of HIV-1 Subtype and Response to ART in<br />
Ugandan Children<br />
Addy Kekitiinwa* 1 , P Kasirye1 , D Friedman2 , E Coakley3 , Y Lie3 , and<br />
F Graziano2 1 2 Mulago Hosp, Kampala Uganda; Univ of Wisconsin Hosp and Clin,<br />
Madison, US; and 3Monogram Biosci, South San Francisco, CA, US<br />
586 Efficacy and Safety of Double-boosted SQV/LPV/r<br />
Combination at 96 Weeks in Thai Children Who Have Failed<br />
NRTI/NNRTI-based Regimens<br />
Torsak Bunupuradah* 1 , P Kosalaraksa2 , C Engchanil2 , P Boonrak1 ,<br />
T Hirunyanulux1 , S Ubolyam1 , P Lumbiganon2 , K Ruxrungtham1,3 ,<br />
E Labriola-Tompkins4 , J Ananworanich1,5 , and HIV-NAT 017 Study Team<br />
1 2 HIV Netherlands Australia Thailand Res Collaboration, Bangkok; Khon<br />
Kaen Univ, Thailand; 3Chulalongkorn Univ, Bangkok, Thailand; 4Roche, Nutley, NJ, US; and 5South East Asia Res Collaboration with Univ of<br />
Hawaii, Bangkok, Thailand<br />
b Monday, 1-4 pm; Hall A<br />
Session 97–Poster Abstracts<br />
Resistance after First-line Failure in Children<br />
587 Prospective Analysis of HIV-1 Drug Resistance after<br />
Virologic Failure on ART: Initial Results from a Pediatric<br />
Cohort Study from KwaZulu Natal, South Africa<br />
Henry Sunpath* 1 , H France1 , T Michelle2 , V Marconi3 , R Murphy4 ,<br />
C Kanegai4 , Z Lu5,6 , E Losina5,6 , B Walker6 , and D Kuritzkes4 1 2 McCord Hosp, Durban, South Africa; Inkosi Albert Hosp, Durban,<br />
South Africa; 3TriService AIDS Clinical Consortium, Wilford Hall USAF<br />
Med Ctr, Lackland AFB, TX, US; 4Brigham and Women’s Hosp, Boston,<br />
MA, US; 5Massachusetts Gen Hosp, Boston, US; and 6Harvard Med Sch,<br />
Boston, MA, US<br />
588 HIV-1 Drug Resistance Mutations in Children Failing an<br />
Initial NRTI-based Regimen and Options for a Second-line<br />
Antiretroviral Regimen<br />
Somnuek Sungkanuparph*, N Apiwattanakul, A Thititanyanont,<br />
W Chantratita, and S Sirinavin<br />
Ramathibodi Hosp, Mahidol Univ, Bangkok, Thailand<br />
589 Surveillance of Drug-resistant Mutations in HIV-1 Subtype C<br />
Children Failing ART<br />
Carole Wallis* 1 , L Erasmus1,2 , S Varughese1 , D Ndiweni1 , and<br />
W Stevens1,2 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Natl Hlth<br />
Lab Svc, Johannesburg, South Africa<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 98–Poster Abstracts<br />
Complications, Neurodevelopments and ARTrelated<br />
Toxicities in Children<br />
590 High Risk of Neutropenia in HIV-infected Children<br />
following Treatment with Artesunate + Amodiaquine for<br />
Uncomplicated Malaria in Uganda<br />
Moses Kamya* 1 , A Gasasira1 , J Achan1 , T Ruel2 , E Charlebois2 ,<br />
S Staedke3 , A Kekitiinwa4 , P Rosenthal2 , G Dorsey2 , and D Havlir2 1 2 Makerere Univ Med Sch, Kampala, Uganda; Univ of California, San<br />
Francisco, US; 3London Sch of Hygiene and Tropical Med, UK; and<br />
4Mulago Hosp, Kampala, Uganda<br />
591 Impaired Glucose Tolerance and Other Metabolic<br />
Abnormalities in Adolescents and Young Adults with HIV<br />
Infection Acquired Perinatally or in Childhood<br />
C Hadigan1 , J Purdy2 , C Worrell3 , H Gebrehiwet2 , and Rohan Hazra* 2,3<br />
1 2 3 NIAID, NIH, Bethesda, MD, US; NCI, Bethesda, MD, US; and Natl Inst<br />
of Child Hlth and Human Devt, NIH, Bethesda, MD, US<br />
592 Time Course and Predictors of Glucose Homeostasis in<br />
HAART-treated HIV-infected Children and Adolescents: 4<br />
Years of Follow-up<br />
Alessandra Vigano* 1 , P Brambilla2 , G Pattarino1 , S Stucchi1 , S Fasan1 ,<br />
C Raimondi1 , V Giacomet1 , and G Bedogni3 1 2 Hosp Luigi Sacco, Univ of Milan, Italy; Azienda Sanitaria Locale,<br />
Milan, Italy; and 3Liver Res Ctr, Trieste, Italy<br />
42 15th Conference on Retroviruses and Opportunistic Infections<br />
593 Vitamin Deficiency in Children with Perinatally Acquired<br />
HIV Infection<br />
Richard Rutstein* 1 , A Downes2 , B Zemel1 , J Schall1 , B Hollis3 , and<br />
V Stallings1 1 2 Children’s Hosp of Philadelphia, PA, US; Univ of Pennsylvania Sch of<br />
Med, Philadelphia, US; and 3Med Univ of South Carolina, Charleston, US<br />
594 Neurocognitive Disturbances in HIV-infected Children with<br />
Viremia<br />
Samuel Foster* 1 , L Harris1 , D Armstrong2 , C Kozinetz1 , P Brouwers1 ,<br />
T Miller2 , J Reuben3 , D Glaze1 , S Lipshultz2 , W Shearer1 , and the HIV<br />
Sleep Study Group<br />
1 2 Baylor Coll of Med, Houston, TX, US; Univ of Miami, Leonard M Miller<br />
Sch of Med, FL, US; and 3MD Anderson Cancer Ctr, Univ of Texas,<br />
Houston, US<br />
595 Leg Fat Is Decreased but Arm Fat Is Increased in HIVinfected<br />
Children and Adolescents Receiving Antiretroviral<br />
Medications<br />
Stephen Arpadi* 1 , J Bethel2 , M Horlick1 , M Sarr2 , M Bamji3 , E Abrams4 ,<br />
M Puswani5 , and E Engelson1 1 2 St Luke’s Roosevelt Hosp Ctr, Columbia Univ, New York, NY, US; Westat,<br />
Bethesda, MD, US; 3Metropolitan Hosp Ctr, New York, NY, US; 4Harlem Hosp Ctr, New York, NY, US; and 5Bronx-Lebanon Hosp Ctr, NY, US<br />
596 Applicability of Quantitative Ultrasonography of the Radius<br />
and Tibia in HIV-infected Children and Adolescents<br />
Alessandra Vigano* 1 , L Cafarelli1 , G Pattarino1 , V Giacomet1 , C Cerini1 ,<br />
V Fabiano1 , C Gabiano2 , G Zuccotti1 , and S Mora3 1 2 Hosp Luigi Sacco, Univ of Milan, Italy; Regina Margherita Hosp, Univ<br />
of Turin, Italy; and 3San Raffaele Sci Inst, Milan, Italy<br />
597 Partial Restoration of Mitochondrial DNA Content in<br />
Perinatally HIV-infected Pediatric Patients after Planned<br />
Interruption of HAART<br />
Antoni Noguera* 1 , C Moren1 , E Corrales1 , E Sanchez2 , G Garrabou1 ,<br />
V Rodriguez1 , O Miro1 , and C Fortuny1 1 2 Hosp St Joan de Deu, Univ of Barcelona, Spain and Catalan Agency for<br />
Hlth Tech Assessment and Res, Barcelona, Spain<br />
598 Possible Mitochondrial Dysfunction in a Large US Cohort of<br />
HIV-infected Children<br />
Marilyn Crain* 1 , M Chernoff2 , J Oleske3 , S Brogly2 , K Malee4 , P Borum5 ,<br />
W Mitchell6 , H Fort-Chatterton7 , R Van Dyke8 , and G Seage2 1 2 Univ of Alabama at Birmingham, US; Harvard Sch of Publ Hlth, Boston,<br />
MA, US; 3Univ of Med and Dentistry of New Jersey, New Jersey Med<br />
Sch, Newark, US; 4Children’s Mem Hosp, Chicago, IL, US; 5Univ of<br />
Florida, Gainesville, US; 6Children’s Hosp Los Angeles and Keck Sch of<br />
Med, Univ of Southern California, US; 7Frontier Sci and Tech Res Fndn,<br />
Amherst, NY, US; and 8Tulane Univ, New Orleans, LA, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 99–Poster Abstracts<br />
Mycobacterial Disease in Children<br />
599 Prevalence and Clinical Features of MAC Infection in HIV +<br />
South African Children Attending Harriet Shezi Clinic, Chris<br />
Hani Baragwanath Hospital: A Retrospective Analysis<br />
Lee Kleynhans* 1 , M Palmer1 , A Goga1 , M Yotebien2 , and T Meyers1 1Harriet Shezi Clin, Chris Hani Baragwaneth Hosp, Johannesburg, South<br />
Africa and 2Columbia Univ, New York, NY, US<br />
600 Complications of BCG Vaccination in HIV-infected and<br />
-uninfected Children: CHER Study<br />
Helena Rabie* 1 , A Violari2 , S Madhi2 , D Gibb3 , J Steyn2 , R van Niekerk2 ,<br />
D Josipovic2 , S Innes1 , and M Cotton1 1 2 Faculty of Hlth Sci, Stellenbosch Univ, South Africa; Univ of the<br />
Witwatersrand, Johannesburg, South Africa; and 3Med Res Council<br />
Clinical Trials Unit, London, UK<br />
601 School Attendance as a Risk Factor for Incident TB among<br />
HIV-infected Children in Western Kenya<br />
P Braitstein* 1,2,3 , C Yiannoutsos1 , A Mwangi3,4 , R Vreeman1 ,<br />
Kara Wools-Kaloustian* 1 , J Sidle1,2,3 , B Musick1 , S Ayaya2,3 , J Carter4 , and<br />
W Nyandiko2,3 1 2 3 Indiana Univ, Indianapolis, US; Moi Univ, Eldoret, Kenya; Moi<br />
Teaching and Referral Hosp, Eldoret, Kenya; and 4Brown Univ,<br />
Providence, RI, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 100–Poster Abstracts<br />
Prevention, Identification and Treatment of at-Risk<br />
and HIV-infected Adolescents<br />
602 Comparison of the Current Health Status and Selected<br />
Baseline Characteristics of Perinatally and Behaviorally<br />
HIV-infected Children and Adolescents, through 24 Years<br />
of Age in the US: The CDC LEGACY Cohort Study, 2006 to<br />
2007<br />
Kenneth Dominguez* 1 , B Bohannon 1 , J Milum 2 , and the CDC LEGACY<br />
Consortium<br />
1 CDC, Atlanta, GA, US and 2 Ginn Group Inc, Atlanta, GA, US
CROI 2008 Session 104<br />
603 Discordance in HAART Utilization Rates in HIV-1-infected<br />
Adolescents in a Multi-site US Cohort<br />
Allison Agwu* 1 , J Ellen1 , R Rutstein2 , A Gaur3 , S Spector4 , R Warford5 ,<br />
G Siberry1 , and K Gebo1 for the HIV Res Network<br />
1 2 Johns Hopkins Univ, Baltimore, MD, US; Children’s Hosp of<br />
Philadelphia, PA, US; 3St Jude Children’s Res Hosp, Memphis, TN, US;<br />
4 5 Univ of California, San Diego, US; and St Luke’s Roosevelt Hosp, New<br />
York, NY, US<br />
604 Directly Observed Therapy for Non-adherent HIV-infected<br />
Adolescents—Lessons Learned, Challenges Ahead<br />
Aditya Gaur* 1 , M Belzer2 , P Britto3 , P Garvie1 , C Hu3 , B Graham4 ,<br />
K Klingman5 , M Neely6 , G McSherry7 , and P Flynn1 1 2 St Jude Children’s Res Hosp, Memphis, TN, US; Children’s Hosp Los<br />
Angeles, CA, US; 3Harvard Sch of Publ Hlth, Boston, MA, US; 4Frontier Sci and Tech Res Fndn, Amherst, NY, US; 5Div of AIDS, NIAID, NIH,<br />
Bethesda, MD, US; 6Univ of Southern California, Los Angeles, US; and<br />
7Univ of Med and Dentistry of New Jersey, Newark, US<br />
605 Poor Virologic Control in Pregnant Adolescents with<br />
Perinatally Acquired HIV Infection as Compared to<br />
Horizontally Infected Pregnant Women<br />
Usha Phillips* 1 , J Sansary2 , M Rosenberg2 , J Dobroszycki2 , M Katz2 ,<br />
A Wiznia2 , and J Abadi2 1Montefiore Med Ctr, Albert Einstein Coll of Med, Bronx, NY, US and<br />
2Jacobi Med Ctr, Albert Einstein Coll of Med, Bronx, NY, US<br />
606 Risk Factors for HIV Infection among Sexually Active<br />
Adolescents and Youth Seeking Voluntary Counseling and<br />
Testing in Haiti<br />
Tsogzolmaa Dorjgochoo* 1 , F Noel2,3 , M Deschamps2,3 ,<br />
H Theodore2,3 , W Dupont1 , P Wright1,3 , D Fitzgerald2,3 , S Vermund1 , and<br />
J Pape2,3 1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US; Weill Med Coll of<br />
Cornell Univ, New York, NY, US; and 3GHESKIO, Port-au-Prince, Haiti<br />
607 Preparing for Adolescent HIV Vaccine Trials: Will<br />
Adolescent Participants Experience Social Harms?<br />
Daniella Mark* 1 , H Jaspan1,2 , E Burrell1 , P Mthimunye1 ,<br />
K Middelkoop1 , N Soka1 , R Wood1 , and LG Bekker1 1Desmond Tutu HIV Ctr, Inst of Infectious Disease and Molecular Med,<br />
Univ of Cape Town, South Africa and 2Tygerberg Hosp, Cape Town, South<br />
Africa<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 101–Poster Abstracts<br />
Special Considerations in Laboratory Studies for<br />
Children<br />
608 Evaluation of Relationship between CD4 and Total<br />
Lymphocyte Count in Children with HIV<br />
Jason Brophy*, E Atenafu, S Read, D Stephens, J Beyene, and A Bitnun<br />
Hosp for Sick Children, Toronto, Canada<br />
609 Utility of Total Lymphocyte Count as a Surrogate Marker for<br />
CD4 Cell Count in HIV-infected Children<br />
Leah Githinji* 1 , D Mbori-Ngacha2 , and E Obimbo1 1 2 Univ of Nairobi, Kenya and CDC, Atlanta, GA, US<br />
610 Discordance between Absolute CD4 + T Lymphocyte Count<br />
and CD4 + T Lymphocyte Percentage among HIV + Children<br />
in Botswana<br />
Elizabeth Lowenthal* 1,2 , H Jibril1,3,4 , H Draper2 , M Marape1,2 , M McGrann1,2 ,<br />
M Sechele1 , O Rankopo1 , B Kgathi1 , R Sello1 , and G Anabwani1,2 1Botswana Baylor Children’s Clinical Ctr of Excellence, Gaborone;<br />
2 3 Baylor Intl Pediatric AIDS Initiative, Houston, TX, US; Botswana<br />
Ministry of Hlth; and 4Princess Marina Hosp, Gaborone, Botswana<br />
611 Normal Laboratory Reference Values for Ugandan and<br />
Malawian Infants: A Comparison with the DAIDS Toxicity<br />
Tables<br />
Irene Lubega* 1 , M Fowler1 , A Elbireer1 , D Bagenda1 , G Kafulafula2 ,<br />
J Ko3 , L Mipando4 , M Mubiru1 , N Kumwenda3 , and T Taha3 1Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala,<br />
Uganda; 2Coll of Med, Univ of Malawi; 3Johns Hopkins Univ Bloomberg<br />
Sch of Publ Hlth, Baltimore, MD, US; and 4Johns Hopkins-Malawi Coll<br />
of Med Res Project<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 102–Poster Abstracts<br />
Transmission and Diagnosis of HIV Infection in<br />
Infants and Children<br />
612 Benefits of Routine HIV Screening in Sick Children in<br />
Nigeria<br />
L Lu 1 , Omotayo Bolu* 1 , C Omeogu 2 , A Abutu 3 , C Nwude 3 , R Akpan 3 ,<br />
K Bond 3 , E Ngige 4 , CY Ou 1 , and J Vertefeuille 2<br />
1 CDC, Atlanta, GA, US; 2 USAID, Abuja, Nigeria; 3 Global AIDS Prgm,<br />
CDC Nigeria, Abuja; and 4 Federal Ministry of Hlth, Abuja, Nigeria<br />
613a Validity and Acceptability of Rapid HIV-1 Tests in 9-monthold<br />
Infants in Kenya<br />
Jessica Opoku-Anane* 1 , J Kinuthia2,3 , F Njiri John3 , M Chung4 ,<br />
D Mbori-Ngacha2,3 , G John-Stewart4 , C Farquhar4 , and J Kiari2,3 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Kenyatta Natl<br />
Hosp, Nairobi, Kenya; 3Univ of Nairobi, Kenya; and 4Univ of Washington,<br />
Seattle, US<br />
613b Practice of Offering a Child Pre-masticated Food: An<br />
Unrecognized Possible Risk Factor for HIV Transmission<br />
Aditya Gaur* 1 , K Dominguez2 , M Kalish2 , D Rivera-Hernandez3 ,<br />
M Donohoe1 , and C Mitchell3 1 2 St Jude Children’s Res Hosp, Memphis, TN, US; CDC, Atlanta, GA, US;<br />
and 3Univ of Miami, Leonard M Miller Sch of Med, FL, US<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 103–Poster Abstracts<br />
Immune Response in Children<br />
614 Profile of T Cell Immune Responses in HIV-infected<br />
Children from Uganda<br />
Isaac Ssewanyana* 1 , M Elrefaei2 , G Dorsey3 , T Ruel3 , E Charlebois3 ,<br />
A Gasasira4 , M Kamya4 , J Achan4 , D Havlir3 , and H Cao2 1 2 Joint Clin Res Ctr, Kampala, Uganda; California Dept of Publ Hlth,<br />
Richmond, US; 3Univ of California, San Francisco, US; and 4Makerere Univ, Kampala, Uganda<br />
615 Dynamics of T Cell Activation Accompanying CD4 Recovery<br />
in Antiretroviral-treated HIV-infected Ugandan Children<br />
Theodore Ruel* 1 , I Ssewanyana2 , J Achan3 , A Gasasira4 , M Kamya3 ,<br />
A Kekitiinwa5 , J Wong1 , H Cao6 , D Havlir1 , and E Charlebois1 1 2 Univ of California, San Francisco, US; Joint Clin Res Ctr, Kampala,<br />
Uganda; 3Faculty of Med, Makerere Univ, Kampala, Uganda; 4Univ of<br />
California, Berkeley, US; 5Baylor Coll of Med, Mulago Hosp, Kampala,<br />
Uganda; and 6California Dept of Hlth Svcs, Richmond, US<br />
616 Protease Inhibitor-based Therapy and Enhanced CD8 +<br />
T Cell Apoptosis in HIV-infected Adolescents<br />
Jun Zuo* 1 , J Church2 , M Belzer2 , C Kitchen1 , B Ank1 , I Schmidt1 , and<br />
P Krogstad1 1David Geffen Sch of Med, Univ of California, Los Angeles, US and<br />
2Children’s Hosp Los Angeles and Keck Sch of Med at Univ of Southern<br />
California, US<br />
617 High Apoptosis Levels and Decreased B Memory Cell<br />
Percentages Leads to Long-term Serologic Memory Damage<br />
in HIV-infected Children<br />
Maristela Miyamoto*, S Pessoa, E Ono, R Succi, R Salomao, and<br />
I de Moraes-Pinto<br />
Federal Univ of Sao Paulo, Brazil<br />
618 Long-term Serologic Immune Response to Hepatitis B<br />
Vaccination and CD38 + Expression on CD8 + T Lymphocytes<br />
in HIV-infected Adolescents on HAART<br />
Silvana Pessoa*, M Miyamoto, E Ono, A Gouvea, R Salomao, L Weckx,<br />
I de Moraes-Pinto, and R Succi<br />
Federal Univ of Sao Paulo, Brazil<br />
619a Safety and Immunogenicity of a Quadrivalent Vaccine to<br />
Prevent Human Papilloma Virus Infection in HIV-infected<br />
Children: IMPAACT P1047<br />
Adriana Weinberg* 1 , LY Song2 , E Handelsman3 , A Moscicki4 ,<br />
J Patterson1 , A Saah5 , D Radley5 , J Read6 , M Levin1 , and IMPAACT<br />
P1047 Team<br />
1 2 Univ of Colorado Sch of Med, Denver, US; Statistical and Data Analysis<br />
Ctr, Harvard Sch of Publ Hlth, Boston, MA, US; 3Div of AIDS, NIAID,<br />
NIH, Bethesda, MD, US; 4Univ of California, San Francisco, US; 5Merck & Co, West Point, PA, US; and 6Natl Inst of Child Hlth and Human Devt,<br />
NIH, Bethesda, MD, US<br />
619b Antigen-specific CD4 + Immune Responses against HIV<br />
Measured by ELISpot in Vertically HIV-infected HAARTtreated<br />
Children after Planned Treatment Interruption<br />
L Alsina1 , Antoni Noguera* 1 , R Bellido2 , L Ruiz2 , E Sanchez3 , and<br />
C Fortuny1 1 2 Hosp St Joan de Deu, Univ of Barcelona, Spain; irsiCaixa Fndn,<br />
Hosp Germans Trias i Pujol, Univ Autonoma de Barcelona, Spain; and<br />
3Catalan Agency for Hlth Tech Assessment and Res, Barcelona, Spain<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 104–Poster Abstracts<br />
Viral and Host Factors Associated with Pediatric<br />
Disease Progression<br />
620 Association of HIV-1 Infectivity on CCR5-bearing Cells with<br />
Survival in Vertically-infected Ugandan Infants<br />
Jessica Church* 1 , W Huang 2 , A Mwatha 3 , J Toma 2 , D Donnell 3 ,<br />
L Guay 1 , F Mmiro 4 , P Musoke 5 , B Jackson 1 , and S Eshleman 1<br />
1 Johns Hopkins Univ, Baltimore, MD, US; 2 Monogram Biosci, South San<br />
Francisco, CA, US; 3 Statistical Ctr for HIV/AIDS Res and Prevention,<br />
Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; 4 Makerere<br />
Univ–Johns Hopkins Univ Res Collaboration, Kampala, Uganda; and<br />
5 Makerere Univ, Kampala, Uganda<br />
<strong>Program</strong> 43<br />
Poster Listings
Poster Litings<br />
Session 104 CROI 2008<br />
621 Genetic Variants of Toll-like Receptors-2, -4, and -9 Are Not<br />
Associated with HIV-1 Disease in Children<br />
Kumud Singh* 1 , P Ruan2 , T Fenton2 , and S Spector1 1 2 Univ of California, San Diego, US and Harvard Sch of Publ Hlth,<br />
Boston, MA, US<br />
622 RANTES-403-G/A Variants Are Associated with HIV-1<br />
Disease Progression and CNS Impairment in Children
CROI 2008 Session 110<br />
637 Risk Factors for Mother-to-Child Transmission of HIV-1<br />
from Breastfeeding in a Randomized Clinical Trial in<br />
Botswana: The Mashi Study<br />
Roger Shapiro* 1 , L Smeaton2 , S Lockman3 , I Thior4 , R Rossenkhan4 ,<br />
C Wester4 , L Stevens4 , J Leidner2 , J Makhema4 , and M Essex2 1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Harvard Sch of Publ<br />
Hlth, Boston, MA, US; 3Brigham and Women’s Hosp, Boston, MA, US;<br />
and 4Botswana Harvard Sch of Publ Hlth AIDS Initiative Partnership for<br />
HIV Res and Ed, Gaborone<br />
638 HIV-free Survival at 12 Months among Children Born to<br />
HIV-infected Women Receiving Antiretrovirals from 34 to 36<br />
Weeks of Pregnancy<br />
Isabelle de Vincenzi and the Kesho Bora Study Group<br />
WHO, Geneva, Switzerland<br />
639 Decrease in HIV-1 Mother-to-Child Transmission in Women<br />
Receiving Postnatal HAART: 12-Month Follow-up Data<br />
M Marazzi1 , L Palombi2 , G Liotta2 , P Germano3 , N Abdul Majid4 ,<br />
I Zimba4 , A Doro Altan2 , G Bortolot3 , and Karin Nielsen-Saines* 5<br />
1 2 3 LUMSA Univ, Rome, Italy; Univ of Tor Vergata, Rome, Italy; DREAM<br />
Prgm, Community of St Egidio, Italy; 4Benfica Hlth Ctr, Maputo,<br />
Mozambique; and 5David Geffen Sch of Med, Univ of California, Los<br />
Angeles, US<br />
640 Comparison of Adverse Fetal Outcomes in HIV-1-infected<br />
Antiretroviral-naïve Pregnant Women Who Have Received<br />
Combivir and Either Nevirapine or Nelfinavir for Prevention<br />
of Mother-to-Child Transmission Antenatally<br />
Rose Masaba* 1 , R Ndivo1 , I Nyangau1 , K Achola1 , C Zeh2 ,<br />
M Thigpen3 , P Weidle3 , and T Thomas2 1 2 3 Kenya Med Res Inst, Kisumu; CDC Kenya, Kisumu; and CDC, Atlanta,<br />
GA, US<br />
641 Low Birth Weight with Nevirapine-based ART in Abidjan,<br />
Côte d’Ivoire: The ANRS Ditrame Plus Cohort and MTCT-<br />
Plus Initiative, 2001 to 2007<br />
Didier Ekouevi* 1,2 , B Tonwe-Gold1,3 , R Becquet1 , P Coffie1,2 , P Toure3 ,<br />
V Leroy1 , I Viho2 , S Blanche4 , F Dabis1 , and E Abrams5 1INSERM U593, Inst for Publ Hlth, Epi and Devt, Bordeaux, France;<br />
2Natl Agency for AIDS Res Ditrame Plus Project, Abidjan, Côte d’Ivoire;<br />
3 4 ACONDA, NGO, Abidjan, Côte d’Ivoire; Hosp Necker, Paris France;<br />
and 5MTCT-Plus Initiative, New York, NY, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 108–Poster Abstracts<br />
Infant Feeding, PMTCT and Infant Outcome<br />
642 Predictors of Early and Late MTCT of HIV in a<br />
Breastfeeding Population: HIVNET 012 Experience,<br />
Kampala, Uganda<br />
Jim Aizire* 1 , F Mmiro1 , A Mwatha2 , S Eshleman3 , D Donell2 ,<br />
M Fowler3 , M Allen4 , P Musoke1 , B Jackson3 , and L Guay3 1Makerere Univ–Johns Hopkins Univ Res Collaboration, Kampala,<br />
Uganda; 2Statistical Ctr for HIV/AIDS Res and Prevention, Fred<br />
Hutchinson Cancer Res Ctr, Seattle, WA, US; 3Johns Hopkins Univ Sch of<br />
Med, Baltimore, MD, US; and 4Family Hlth Intl, Durham, NC, US<br />
643 Risk Factors for and Timing of Infant Mortality among HIVexposed<br />
Children: A Randomized Clinical Trial in Botswana<br />
Shahin Lockman* 1,2,3 , L Smeaton3 , R Shapiro2,3,4 , I Thior2 , C Wester2 ,<br />
J Makhema2 , A Ogwu2 , A Asmelash2 , E van Widenfelt2 , and M Essex2,3 1 2 Brigham and Women’s Hosp, Boston, MA, US; Botswana Harvard Sch<br />
of Publ Hlth AIDS Initiative Partnership for HIV Res and Ed, Gaborone;<br />
3 4 Harvard Sch of Publ Hlth, Boston, MA, US; and Beth Israel Deaconess<br />
Med Ctr, Boston, MA, US<br />
644 Infectious Morbidity and Mortality in Formula-fed Infants<br />
Born to Women Infected by HIV<br />
Karin Nielsen-Saines* 1 , H Watts2 , J Pilotto3 , E Joao4 , G Gray5 ,<br />
J McIntyre6 , J Bethel7 , L Mofenson2 , M Camarca7 , J Moye2 , and the<br />
NICHD HPTN 040 Study Team<br />
1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US; Natl Inst<br />
of Child Hlth and Human Devt, NIH, Bethesda, MD, US; 3Hosp Geral de<br />
Nova Iguacu, Rio de Janeiro, Brazil; 4Hosp dos Servidores do Estado,<br />
Rio de Janeiro, Brazil; 5Soweto Clinical Trials Unit, Johannesburg, South<br />
Africa; 6Univ of the Witwatersrand, Johannesburg, South Africa; and<br />
7Westat, Rockville, MD, US<br />
645 Assessment of Exclusive Breastfeeding among HIV + Mothers:<br />
PMTCT Study Kisumu, Kenya<br />
John Okanda* 1 , R Ndivo1 , P Ongwena1 , V Sewe1 , M Thigpen2 ,<br />
C Borkowf2 , and T Thomas3 1 2 3 Kenya Med Res Inst, Kisumu; CDC, Atlanta, GA, US; and CDC Kenya,<br />
Kisumu<br />
646 Influence of a Safe Water System Intervention on Diarrhea<br />
Rates among Exclusively Breastfed Infants Who Were<br />
Weaned Rapidly at 6 Months in the Kisumu Breastfeeding<br />
Study, Kisumu, Kenya<br />
Timothy Thomas* 1 , J Harris2 , S Greene2 , R Masaba3 , J Okanda3 ,<br />
R Ndivo3 , I Nyangau3 , M Fowler4 , M Thigpen2 , and R Quick2 1 2 3 CDC Kenya, Kisumu; CDC, Atlanta, GA, US; Kenya Med Res Inst,<br />
Kisumu; and 4Makerere Univ–Johns Hopkins Univ Res Collaboration,<br />
Kampala, Uganda<br />
647 Discontinuation or Modification of Study Drug Regimen<br />
among Women in a Trial of HAART for PMTCT in Kisumu,<br />
Kenya<br />
Prisca Odhiambo* 1 , R Masaba1 , L Ochieng1 , R Ndivo1 , F Motende1 ,<br />
and T Thomas2 1 2 Kenya Med Res Inst, Kisumu and CDC Kenya, Kisumu<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 109–Poster Abstracts<br />
Properties of Breast Milk<br />
648 Antiretroviral Drug Concentrations in Breast Milk and<br />
Breastfeeding Infants<br />
Amanda Corbett* 1 , A Kashuba1 , N Rezk1 , D Jamieson2 , C Chasela3 ,<br />
L Hyde3 , G Tegha3 , G Joaki3 , D Kamwendo3 , C van der Horst1 , and BAN<br />
Study Team<br />
1 2 Univ of North Carolina at Chapel Hill, US; CDC, Atlanta, GA, US; and<br />
3Univ of North Carolina Project, Lilongwe, Malawi<br />
649 HIV-1 Persists in Breast Milk Cells Despite ART to Prevent<br />
MTCT<br />
Dara Lehman* 1,2 , M Chung2 , G John-Stewart2 , B Richardson1,2 ,<br />
J Kiarie3 , and J Overbaugh1 1 2 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US; Univ of Washington,<br />
Seattle, US; and 3Univ of Nairobi, Kenya<br />
650 Changes in Breast Milk Viral Load Due to Mastitis in 38<br />
Zambian HIV-infected, Breastfeeding Women<br />
Katherine Semrau* 1 , L Kuhn2 , D Decker3 , M Sinkala4 , D Brooks1 ,<br />
H Cabral1 , C Kankasa5 , D Thea1 , and G Aldrovandi3,6 1 2 3 Boston Univ, MA, US; Columbia Univ, New York, NY, US; Children’s<br />
Hosp Los Angeles, CA, US; 4Catholic Med Mission Bd, Lusaka, Zambia<br />
and Univ of Alabama at Birmingham, US; 5Univ Teaching Hosp, Lusaka,<br />
Zambia; and 6Univ of Southern California, Los Angeles, US<br />
651 Comparison of HIV-1 Sequences from Plasma, and Cell-free<br />
and Cell-associated Breast Milk in Treated and Untreated<br />
Women in Mozambique<br />
Mauro Andreotti* 1 , C Galluzzo1 , G Guidotti1 , P Germano2 , S Mancinelli2 ,<br />
R Amici1 , M Marazzi3 , S Vella1 , L Palombi4 , and M Giuliano1 1 2 Inst Superiore di Sanita, Rome, Italy; DREAM Prgm, Community of<br />
St Egidio, Italy; 3DREAM Prgm, Libera Univ Maria SS Assunta, Rome,<br />
Italy; and 4DREAM Prgm, Univ of Tor Vergata, Rome, Italy<br />
652 Potent SIV-specific Cellular Immune Responses in Breast<br />
Milk of SIV-infected, Lactating Rhesus Monkeys<br />
Sallie Permar* 1,2 , H Kang1 , A Carville3 , N Letvin1 , and Ctr for<br />
HIV/AIDS Vaccine Immunology<br />
1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Children’s Hosp<br />
Boston, MA, US; and 3New England Primate Res Ctr, Harvard Med Sch,<br />
Southborough, MA, US<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 110–Poster Abstracts<br />
Risk, Timing and Viral Genetics of MTCT<br />
653 Very Low Risk of MCTC in Women on HAART Who<br />
Achieve Viral Suppression: The UK and Ireland, 2000 to<br />
2006<br />
Claire Townsend* 1 , M Cortina-Borja1 , C Peckham1 , A de Ruiter2 ,<br />
H Lyall3 , and P Tookey1 1 2 Univ Coll London Inst of Child Hlth, UK; St Thomas’ Hosp, London,<br />
UK; and 3St Mary’s Hosp, London, UK<br />
654 Amniocentesis and MTCT: The French ANRS EPF Cohort<br />
CO1/11<br />
Laurent Mandelbrot* 1,2,3 , C Jasseron4 , D Ekoukou5 , A Batallan6 ,<br />
A Bongain7 , E Pannier8 , S Blanche9,10 , R Tubiana11 , C Rouzioux9,10 ,<br />
J Warszawski3,4,12 , and the ANRS French Perinatal Cohort EPF<br />
1 2 Hosp Louis Mourier, Colombes, France; Univ Paris 7 Diderot, Paris,<br />
France; 3INSERM U822, Le Kremlin Bicetre, France; 4Hosp Bicetre, Le<br />
Kremlin-Bicetre, France; 5Hosp Delafontaine, St Denis, France; 6Hosp Bichat, Paris, France; 7Hosp L’Archet 2, Nice, France; 8Hosp Cochin,<br />
Paris, France; 9Hosp Necker, Paris, France; 10Univ Paris 5, France;<br />
11 12 Hosp Pitie-Salpetriere, Paris, France; and Univ Paris Sud, Le Kremlin-<br />
Bicetre, France<br />
<strong>Program</strong> 45<br />
Poster Listings
Poster Litings<br />
Session 110 CROI 2008<br />
655 Interpretation of Serum α-Fetoprotein, Human Chorionic<br />
Gonadotrophin, and the Risk of Down’s Syndrome in<br />
Pregnant Women Infected with HIV<br />
James Franklin* 1 , M Douglas2 , A Clarke3 , G Nartey4 , P Tookey5 ,<br />
M Cortina-Borja5 , J Smith2 , and G Taylor1 1 2 Faculty of Med, Imperial Coll, London, UK; St Mary’s Hosp, London,<br />
UK; 3St Thomas’ Hosp, London, UK; 4Ealing Hosp, Southall, UK; and<br />
5Med Res Council Ctr of Epi for Child Hlth, Inst of Child Hlth, Univ Coll<br />
London, UK<br />
656 Early Viral Load Reduction in Pregnant Women Differs<br />
according to Antiretroviral Regimen<br />
C Bell1 , M Douglas2 , Y Gilleece1 , N Desmond3 , and Graham Taylor* 2<br />
1 2 Royal Sussex County Hosp, Brighton, UK; Imperial Coll Hlth Care,<br />
NHS Trust, London, UK; and 3Garden Clin, Slough, UK<br />
657 Factors Associated with MTCT in South African Women<br />
with Advanced Immunosuppression Initiated on HAART<br />
during Pregnancy<br />
V Black1 , Risa Hoffman* 2 , C Sugar2 , P Menon1 , F Venter1 , J Currier2 , and<br />
H Rees1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Univ of<br />
California, Los Angeles Ctr for Clinical AIDS Res and Ed, US<br />
658 Maternal/Fetal DNA Admixture Is Associated with HIV-1<br />
MTCT<br />
Jesse Kwiek* 1 , L Arney2 , V Harawa3 , B Pedersen2 , V Mwapasa3 ,<br />
S Rogerson4 , and S Meshnick2 1 2 Ohio State Univ, Columbus, US; Univ of North Carolina at Chapel Hill,<br />
US; 3Coll of Med, Blantyre, Malawi; and 4Univ of Melbourne, Australia<br />
659 Role of β-Defensin-1 in MTCT HIV-1 Transmission<br />
E Ricci1 , S Malacrida1 , M Zanchetta1,2 , M Montagna2 , C Giaquinto1 , and<br />
Anita De Rossi* 1,2<br />
1 2 Univ of Padova, Italy and IOV-IRCCS, Padova, Italy<br />
660 Characterization of Vertically Transmitted Subtype C HIV<br />
during Acute Infection<br />
Laura Heath* 1 , S Conway2,3 , K Nakamura2,4 , K Semrau5 , D Thea5 ,<br />
L Kuhn6 , J Mullins1 , and G Aldrovandi2,3 1 2 Univ of Washington, Seattle, US; Children’s Hosp Los Angeles, CA, US;<br />
3 4 Univ of Southern California, Los Angeles, US; Keck Sch of Med, Univ<br />
of Southern California, Los Angeles, US; 5Boston Univ Sch of Publ Hlth,<br />
MA, US; and 6Columbia Univ, New York, NY, US<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 111–Poster Abstracts<br />
Co-infections during Pregnancy<br />
661 Hepatitis B or Hepatitis C Co-infection in HIV-infected<br />
Pregnant Women in Europe<br />
Claire Thorne* 1 , M Landes2 , ML Newell1 , and European Collaborative<br />
Study Coinfection Sub-Study Group<br />
1 2 Univ Coll London, UK and Univ of Toronto, Canada<br />
662 Vertical Transmission of Hepatitis C Virus and Clinicoepidemiological<br />
Characteristics in a Cohort of HIV/HCV-coinfected<br />
Mothers<br />
Olga Nieto* 1 , E Munoz1 , M Gonzalez-Tome1 , T Ramos2 ,<br />
M Fernandez-Ibieta2 , C Rojo1 , I Solis2 , and L Prieto1 for the Spanish<br />
Mother-Infants Pairs Cohort<br />
1 2 Hosp 12 de Octubre, Madrid, Spain and Hosp Univ Getafe, Madrid,<br />
Spain<br />
663 Transmission of Congenital and Postnatal Cytomegalovirus<br />
among HIV-exposed Infants: The Effect of Prenatal Maternal<br />
HAART<br />
Toni Frederick*, A Kovacs, J Homans, L Spencer, A Stek, W Mack,<br />
E Operskalski, and F Kramer<br />
Keck Sch of Med, Univ of Southern California, Los Angeles, US<br />
664 Congenital Cytomegalovirus Infection in Infants Born to<br />
HIV-infected Mothers, Prevalence and Risk Factors: ANRS<br />
French Perinatal EPF Cohort CO1/10/11<br />
G Guibert1 , J Warszawski1,2 , J Le Chenadec1 , Y Benmebarek3 , JP Teglas1 ,<br />
S Blanche4 , L Mandelbrot5,6 , R Tubiana7 , Christine Rouzioux* 4,8 ,<br />
M Leruez-Ville4,8 , and the ANRS French Perinatal Cohort EPF<br />
1 2 INSERM U822, Le Kremlin Bicetre, France; Univ Paris Sud, Le<br />
Kremlin-Bicetre, France; 3Hosp Bicetre, Le Kremlin-Bicetre, France;<br />
4 5 Hosp Necker, Paris, France; Hosp Louis Mourier, Colombes, France;<br />
6 7 Univ Paris 7 Diderot, Paris, France; Hosp Pitie-Salpetriere, Paris,<br />
France; and 8Univ Paris 5, France<br />
665 MTCT of HIV-2: The French ANRS Perinatal Cohort EPF-<br />
CO1/11<br />
C Jasseron1 , M Burgard2,3 , JP Teglas4 , S Matheron5 , F Damond5 ,<br />
K Hamrene1 , S Blanche2,3 , C Rouzioux2,3 , J Warszawski4,6 ,<br />
Laurent Mandelbrot* 7,8 , and the ANRS French Perinatal Cohort EPF<br />
1 2 Hosp Bicetre, Le Kremlin-Bicetre, France; Hosp Necker, Paris, France;<br />
3 4 Univ Paris 5, France; INSERM U822, Le Kremlin Bicetre, France;<br />
5 6 Hosp Bichat, Paris, France; Univ Paris Sud, Le Kremlin-Bicetre,<br />
France; 7Univ Paris 7 Diderot, Paris, France; and 8Hosp Louis Mourier,<br />
Colombes, France<br />
46 15th Conference on Retroviruses and Opportunistic Infections<br />
b Monday, 1-4 pm; Hall A<br />
Session 112–Poster Abstracts<br />
Health Outcomes in Women<br />
666 Causes of Death in HIV-infected Women and Their Evolution<br />
Since 2000: The Mortalité 2000 and 2005 Surveys, ANRS EN19<br />
Mojgan Hessamfar-Bonarek* 1,2 , G Chene1,2,3 , P Cacoub4,5 , D Salmon6 ,<br />
T May7 , E Rosenthal8 , C Lewden1,3 , D Costagliola9 , P Morlat1,2,3 , and<br />
Mortalité 2000 and 2005 Study Group<br />
1 2 INSERM U593, Bordeaux, France; Ctr Hosp Univ Bordeaux, France;<br />
3 4 5 Univ Bordeaux 2, France; Hosp Pitie-Salpetriere, Paris, France; Univ<br />
Pierre and Marie Curie, Paris, France; 6Ctr Hosp Univ Cochin-Tarnier,<br />
Paris, France; 7Ctr Hosp Nancy, France; 8Ctr Hosp Univ Nice, France;<br />
and 9INSERM U720, Paris, France<br />
667 Association of Pre-treatment Nutritional Status with CD4<br />
and Viral Load Response to ART in Rwandan Women<br />
Kathryn Anastos* 1 , Q Shi2 , D Lu3 , J Rusine4 , M Cohen5 , J Mugabo6 ,<br />
F Ndamage6 , A Binagwaho7 , D Kotler8 , and Rwanda Women’s<br />
Interassociation Study and Assessment (RWISA)<br />
1 2 Montefiore Med Ctr, Bronx, NY, US; New York Med Coll, Valhalla, US;<br />
3 4 Data Solutions LLC, Bronx, NY, US; Natl Reference Lab, Ministry of<br />
Hlth, Kigali, Rwanda; 5CORE Ctr and Storger Hosp, Chicago, IL, US;<br />
6 7 Treatment and Res on AIDS Ctr, Ministry of Hlth, Kigali, Rwanda; Natl<br />
Commission to Fight AIDS, Kigali, Rwanda; and 8St Luke’s Hosp Ctr,<br />
New York, NY, US<br />
668 Treatment Interruption after HAART Prophylaxis in<br />
HIV-infected Pregnant Women in Mozambique: The Drug<br />
Resource Enhancement and Malnutrition <strong>Program</strong><br />
L Palombi1 , M Marazzi2 , P Germano3 , G Guidotti4 , M Magnano San Lio3 ,<br />
N Abdul Magid5 , M Andreotti4 , S Vella4 , and Marina Giuliano* 4<br />
1 2 DREAM Prgm, Univ of Tor Vergata, Rome, Italy; Libera Univ Maria<br />
SS Assunta, Rome, Italy; 3DREAM Prgm, Rome, Italy; 4Inst Superiore di<br />
Sanita, Rome, Italy; and 5Machava Gen Hosp, Maputo, Mozambique<br />
b Monday, 1-4 pm; Hall A<br />
Session 113–Poster Abstracts<br />
Infertility in HIV-infected Women<br />
669 Premature Ovarian Deficiency in HIV-infected Women<br />
Marialuisa Partisani* 1 , J Ohl2 , C Demangeat1 , F Binder-Foucard1 ,<br />
I Nisand2 , and JM Lang1 1 2 Hosp Univ of Strasbourg, France and Ctr d’AMP, CMCO-SIHCUS,<br />
Schiltigheim, France<br />
670 Infertility Treatment by in vitro Fertilization or Intracytoplasmic<br />
Sperm Injections in Chronic HIV-1 Serodifferent<br />
Couples: Do Women, HIV Infection, or Infertility<br />
Influence Results?<br />
Roland Tubiana*, N Prisant, F Marguet, S Dominguez, M Naouri,<br />
O Rosemblum, G Lefebvre, D Vauthier, A Marcelin, C Poirot, and Pitie<br />
Salpetriere AMP a Risque Viral Study Group<br />
Hosp Pitie-Salpetriere, Paris, France<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 114–Poster Abstracts<br />
Influence of Gender on HIV Replication and<br />
Viremia<br />
671 Estradiol and Progesterone Regulate HIV-1 Replication in<br />
Peripheral Blood Mononuclear Cells<br />
Susana Asin* 1,2 , A Heimberg2 , S Eszterhas1,2 , C Rollenhagen2 , and<br />
A Howell1,2 1 2 VAMC, White River Junction, VT, US and Dartmouth Med Sch,<br />
Lebanon, NH, US<br />
672 Gender-associated Differences in Pre-ART Plasma HIV-1<br />
RNA in Diverse Areas of the World Vary by CD4 + Cell Count<br />
Beatriz Grinsztejn* 1 , L Smeaton2 , V De Gruttola2 , R Barnett3 , J Currier4 ,<br />
E Swann3 , J Hakim5 , T Flanigan6 , N Kumarasamy7 , T Campbell8 , and the<br />
PEARLS Study Team of the ACTG<br />
1Evandro Chagas Clinical Res Inst, Oswaldo Cruz Fndn, Manguinhos,<br />
Brazil; 2Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth,<br />
Boston, MA, US; 3NIH, Bethesda, MD, US; 4Univ of California, Los<br />
Angeles, US; 5Univ of Zimbabwe Coll of Hlth Sci, Harare; 6Warren Alpert<br />
Med Sch of Brown Univ, Providence, RI, US; 7YRGCARE, Chennai,<br />
India; and 8Univ of Colorado Hlth Sci Ctr, Denver, US
CROI 2008 Session 118<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 115–Poster Abstracts<br />
HIV Replication, Immune Activation, HSV-2<br />
Co-infection, and Genital Shedding in Women<br />
673 Effects of Viral Replication on Immune Activation and Fat<br />
Metabolism in a Cohort of Treatment-naïve HIV-1-infected<br />
African Women<br />
Livio Azzoni* 1 , N Crowther2 , C Firnhaber2 , A Foulkes3 , D Glencross2 ,<br />
M Kaplan4 , W Stevens2 , I Sanne2 , T van der Merwe5 , and L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US; Univ of the Witwatersrand,<br />
Johannesburg, South Africa; 3Univ of Massachusetts, Amherst, US;<br />
4 5 Rosebank Clin, Johannesburg, South Africa; and Univ of Pretoria and<br />
Network Hlthcare Holdings, South Africa<br />
674 Association between Immune Activation and HIV RNA-1<br />
Genital Tract Shedding<br />
L Spencer1 , R Karim1 , A Landay2 , W Mack1 , T Stiller1 , L Al-Harthi2 , and<br />
Andrea Kovacs* 1<br />
1Keck Sch of Med, Univ of Southern California, Los Angeles, US and<br />
2Rush Med Ctr, Chicago, IL, US<br />
675 Association between Genital Tract HIV-1 RNA Shedding and<br />
Mucosal Inflammation among Women on Effective ART with<br />
Undetectable Plasma Viral Load<br />
Chia-Ching Wang* 1 , T Liu2 , B Anderson2,3 , A DeLong2 , S Chapman1 ,<br />
J Kurpewski1 , J Ingersoll4 , A Caliendo4 , and S Cu-Uvin1,2 1 2 Miriam Hosp, Providence, RI, US; Brown Univ, Providence, RI, US;<br />
3 4 Womens and Infants Hosp, Providence, RI, US; and Emory Univ Sch of<br />
Med, Atlanta, GA, US<br />
676 Herpes Simplex Virus Suppressive Treatment Decreases<br />
Plasma and Genital HIV-1 Viral Loads in HSV-2/HIV-1<br />
Co-infected Women: A Randomized, Placebo-controlled,<br />
Cross-over Trial<br />
Jared Baeten* 1 , L Strick1 , A Lucchetti2 , W Whittington1 , J Sanchez2 ,<br />
R Coombs1 , A Magaret1 , A Wald1,3 , L Corey1,3 , and C Celum1 1 2 Univ of Washington, Seattle, US; Assn Civil Impacta Salud y Ed, Lima,<br />
Peru; and 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, US<br />
677 Diversity of pol Sequence and Envelope Tropism of Plasma<br />
and Cervical Viruses among HIV + Pregnant Women in<br />
Zimbabwe<br />
J Lint1 , Seble Kassaye* 1 , S Dalai1 , E Johnston1 , J Manasa2 ,<br />
L Zijenah2 , and D Katzenstein1 1 2 Stanford Univ, Palo Alto, CA, US and Univ of Zimbabwe, Harare<br />
678 Distribution and Analysis of HIV-1 Variants in the Uterine<br />
Cervix and as Related to HIV-1 in the Peripheral Blood<br />
M Bull1,2 , G Learn1 , S McElhone2 , J Hitti1 , D Lockhart1 , S Holte1,3 ,<br />
J Dragavon1 , R Coombs1 , J Mullins1 , and Lisa Frenkel* 1,2<br />
1 2 Univ of Washington, Seattle, US; Seattle Children’s Hosp Res Inst, WA,<br />
US; and 3Fred Hutchinson Cancer Res Ctr, Seattle, WA, US<br />
b Monday, 1-4 pm; Hall A<br />
Session 116–Poster Abstracts<br />
Acute HIV/SIV Infection: Characterization of<br />
Transmitted Viruses<br />
679 Analysis of HIV-1 Envelope Diversity during Acute and<br />
Chronic Infection<br />
Jeffrey Anderson* 1 , L Ping1 , B Keele2 , Y Tang1 , J Salazar-Gonzalez2 ,<br />
K Dang1 , S Galvin1 , C Mapanje3 , M Cohen1 , R Swanstrom1 , and the Ctr<br />
for HIV/AIDS Vaccine Immunology Consortium<br />
1 2 Univ of North Carolina at Chapel Hill, US; Univ of Alabama at<br />
Birmingham, US; and 3Lilongwe Central Hosp, Malawi<br />
680 Identification and Characterization of the Transmitted<br />
HIV-1 Envelope<br />
Brandon Keele* 1 , E Giorgi2 , J Salazar-Gonzalez1 , J Decker1 ,<br />
B Gaschen2 , B Haynes3 , A Perelson2 , B Korber2 , B Hahn1 , G Shaw1 , and<br />
the Ctr for HIV/AIDS Vaccine Immunology Consortium<br />
1 2 Univ of Alabama at Birmingham, US; Los Alamos Natl Lab, NM, US;<br />
and 3Duke Univ, Durham, NC, US<br />
681 Viral env Diversity and Transmission Clusters in Primary<br />
HIV Infection: The Zurich Primary HIV Infection Study<br />
Philip Rieder* 1 , B Joos1 , V von Wyl1 , H Kuster1 , C Leemann1 ,<br />
U von Both1 , J Boni2 , S Yerly3 , M Fischer1 , H Gunthard1 , and Swiss HIV<br />
Cohort Study<br />
1 2 Univ Hosp Zurich, Switzerland; NZR Univ, Zurich, Switzerland; and<br />
3Univ Hosp Geneva, Switzerland<br />
682 Heterosexually Transmitted Viruses in Uganda Possess<br />
Signature Envelope Genotypes<br />
Manish Sagar* 1 , O Laeyendecker2,3 , J Gamiel3 , M Wawer4 , R Gray4 ,<br />
D Serwadda5 , N Sewankambo5 , J Toma6 , W Huang6 , T Quinn2,3 , and Rakai<br />
Hlth Sci Prgm<br />
1 2 Brigham and Women’s Hosp, Cambridge, MA, US; Lab of<br />
Immunoregulation, NIAID, NIH, Baltimore, MD, US; 3Johns Hopkins<br />
Univ Sch of Med, Baltimore, MD, US; 4Johns Hopkins Univ Bloomberg<br />
Sch of Publ Hlth, Baltimore, MD, US; 5Makerere Univ, Kampala,<br />
Uganda; and 6Monogram Biosci, South San Francisco, CA, US<br />
683 Accessing the Fitness Impact of the Full Array of gp120 and<br />
p24 CTL Escape Mutations following an Acute Infection<br />
Eric Arts* 1 , R Troyer1 , J McNevin2 , Y Liu3 , R Krizan1 , A Abraha1 ,<br />
D Tebit1 , H Zhao3 , J McElrath2 , and J Mullins3 1 2 Case Western Reserve Univ, Cleveland, OH, US; Fred Hutchinson<br />
Cancer Res Ctr, Seattle, WA, US; and 3Univ of Washington, Seattle, US<br />
684 Identification of Early CTL Escape Mutations in Transmitted<br />
HIV-1 Genomes<br />
Jesus Salazar-Gonzalez* 1 , M Salazar1 , M Liu2 , P Borrow3 ,<br />
N Goonetilleke2 , A McMichael2 , M Cohen4 , B Korber5 , B Hahn1 , G Shaw1 ,<br />
and the Ctr for HIV/AIDS Vaccine Immunology Consortium<br />
1 2 Univ of Alabama at Birmingham, US; Weatherall Inst of Molecular<br />
Med, Oxford, UK; 3Jenner Inst, Newbury, UK; 4Univ of North Carolina at<br />
Chapel Hill, US; and 5Los Alamos Natl Lab, NM, US<br />
685 Oral Transmission of Single-cycle SIV in Neonatal Macaques<br />
Bin Jia* 1 , C Mische1 , M Piatak2 , A Carville1 , S O’Neil1 , J Lifson2 , and<br />
D Evans1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA,<br />
US and 2SAIC-Frederick and NCI-Frederick, MD, US<br />
b Monday, 1-4 pm; Hall A<br />
Session 117–Poster Abstracts<br />
Acute HIV/SIV Infection: Immune Responses<br />
686 HIV-specific Gag T Cell Responses during Acute Infection<br />
Early Disease Are Associated with the Control of Viremia<br />
Michel Ndongala* 1 , Y Peretz1 , S Boulet1 , P Kamya1 , J Routy1 ,<br />
C Tremblay2 , D Rouleau2 , R LeBlanc2 , C Tsoukas1 , N Bernard1 , and<br />
Quebec PI Cohort, Montreal Canada<br />
1 2 McGill Univ, Monteal, Canada and Univ of Montreal, Canada<br />
687 HIV-specific, Activated, and Regulatory T Lymphocytes<br />
during Acute HIV Infection<br />
E Nemes1 , E Lugli1 , L Bertoncelli1 , F Prati2 , M Nasi1 , S Manzini1 ,<br />
M Pinti1 , R Esposito2 , Andrea Cossarizza* 1 , and C Mussini2 1 2 Univ of Modena and Reggio Emilia, Italy and Hosp Univ Azienda,<br />
Modena, Italy<br />
688 Early Disregulation of the Expression of Activating and<br />
Inhibitory Receptors on both CD56dim and CD56bright NK<br />
subsets in HIV-1-infected Individuals<br />
Paola Mantegani*, G Tambussi, L Galli, C Tassandin, A Galli,<br />
G Travi, A Lazzarin, and C Fortis<br />
San Raffaele Sci Inst, Milan, Italy<br />
689 Ligand-dependent Expansion of NK Cell Populations during<br />
Acute HIV-1 Infection<br />
Galit Alter* 1 , K Walter1 , S Rihn1 , H Streeck1 , A Meier1 , E Rosenberg1 ,<br />
M Martin2 , M Carrington2 , and M Altfeld1 1 2 Partners AIDS Res Ctr, Massachusetts Gen Hosp, Boston, US and SAIC-<br />
Frederick, Lab of Genomic Diversity, MD, US<br />
690 Comparative Analysis of Immune Events during Acute<br />
Simian Immunodeficiency Virus Infection in Sooty<br />
Mangabeys and Rhesus Macaques<br />
Mareike Meythaler* 1,2 , Z Wang1 , S Pryputniewicz1 , A Martinot1 ,<br />
M Kasheta1 , B Ling3 , P Marx3 , S O’Neil1 , and A Kaur1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA,<br />
US; 2Inst of Clinical and Molecular Virology, Univ Hosp Erlangen,<br />
Germany; and 3Tulane Natl Primate Res Ctr, Covington, LA, US<br />
691 Comparison in early CD4 T Cell Count Evolution in HIV-1<br />
Seroconverters in Côte d’Ivoire and France: The ANRS<br />
PRIMO-CI and SEROCO Cohorts<br />
Charlotte Lewden* 1,2 , R Thiebaut2,3 , F Boufassa4 , C Grondin1,2 ,<br />
A Coulibaly5 , R Seng4 , T Toni5 , C Rouzioux6 , A Minga5 , L Meyer4 , and<br />
ANRS 1220 PRIMO-CI and CO2 SEROCO Study Groups<br />
1 2 3 INSERM U593, Bordeaux, France; Univ Bordeaux 2, France; INSERM<br />
U875, Bordeaux, France; 4INSERM U822, Univ Paris Sud XI, Le Kremlin<br />
Bicetre, France; 5Prgm PACCI, Abidjan Côte d’Ivoire; and 6Ctr Hosp<br />
Univ Necker, Paris, France<br />
692 Acute SIV Infection Results in Selective Depletion of<br />
Proliferating CD4 + T Cells in Neonatal Rhesus Macaques<br />
Xiaolei Wang*, H Xu, B Pahar, T Rasmussen, A Lackner, and<br />
R Veazey<br />
Tulane Natl Primate Res Ctr, Covington, LA, US<br />
b Monday, 1-4 pm; Hall A<br />
Session 118–Poster Abstracts<br />
Acute HIV Infection: Treatment<br />
693 Interrupted ART of Acute Compared with Recent HIV<br />
Infection: Final Results of ACTG 371<br />
Paul Volberding* 1 , E Connick 2 , R Bosch 3 , E Aga 3 , C Pettinelli 4 , M Hirsch 3 ,<br />
M Vogler 5 , S Little 6 , L Demeter 7 , and AIDS Clinical Trials Group<br />
1 Univ of California, San Francisco, US; 2 Univ of Colorado, Denver, US;<br />
3 Harvard Univ, Boston, MA, US; 4 NIAID, NIH, Bethesda, MD, US; 5 New<br />
York Univ, New York, US; 6 Univ of California, San Diego, US; and 7 Univ<br />
of Rochester, NY, US<br />
<strong>Program</strong> 47<br />
Poster Listings
Poster Litings<br />
Session 118 CROI 2008<br />
694 Early Short-course HAART Initiated at the Time of Primary<br />
HIV Infection Provides No Sustained Benefit in Terms of<br />
Time to CD4 Decline below 350/mm3 : Results of a Propensity<br />
Analysis within the ANRS PRIMO Cohort<br />
L Desquilbet1 , Bruno Hoen* 2 , C Goujard3 , C Deveau1 , J Warszawski1 ,<br />
L Meyer1 , and the ANRS PRIMO Cohort Study Group<br />
1 2 INSERM U822, Le Kremlin Bicetre, France; Univ Hosp Besancon,<br />
France; and 3Hosp Bicetre, Le Kremlin Bicetre, France<br />
695 Can HAART Initiation at Early Acute HIV Infection<br />
Benefit the Immune-virology Outcome Despite Subsequent<br />
Treatment Cessation? The ANRS Reservoirs’ Study Group<br />
Thierry Prazuck* 1 , A Lafeuillade2 , L Hocqueloux1 , JP Viard3 ,<br />
V Avettand Fenoel3 , and C Rouzioux3 1 2 Ctr Hosp Regional Orleans La Source, France; Hosp Chalucet, Toulon,<br />
France; and 3Ctr Hosp Univ Necker, Paris, France<br />
696 Early Initiation of HAART during Primary HIV Infection<br />
Enhances CD127 Expression and Proliferative Capacities of<br />
HIV-specific CD8 + T Cells<br />
Camille Lecuroux* 1 , I Girault1 , O Lambotte1 , A Urrutia1 , F Boutboul2 ,<br />
B Autran2 , M Sinet1 , A Venet1 , and the ANRS CO6-PRIMO Cohort and<br />
the ANRS EP36-HIC Study Group<br />
1INSERM U802, Paris XI, Hosp Bicetre, Le Kremlin Bicetre, France and<br />
2INSERM U543, Hosp Pitie-Salpetriere, Paris, France<br />
697 The Effect of ART of Different Durations in Primary HIV<br />
Infection<br />
N Pantazis1 , Giota Touloumi* 1 , P Vanhems2 , J Gill3 , K Porter4 , and<br />
CASCADE Collaboration<br />
1 2 Athens Univ Med Sch, Greece; CNRS UMR 5558, Univ Lyon 1, France;<br />
3 4 Southern Alberta HIV Clin, Calgary, Canada; and Med Res Council<br />
Clinical Trials Unit, London, UK<br />
698a A Multi-state Markov Model for the Natural History of<br />
Recent, Drug-naïve HIV-1 Infection and the Initiation of ART<br />
Lorne Walker*, S Frost, and S Little<br />
Univ of California, San Diego, US<br />
698b Temporary ART during Primary HIV-1 Infection Lowers the<br />
Viral Set-point: The Prospective, Randomized Primo-SHM<br />
Study<br />
Radjin Steingrover* 1,2,3 , I Schellens4 , A Verbon5 , K Brinkman6 ,<br />
A Zwinderman4 , S Jurriaans2 , F Miedema4 , J Lange4 , D van Baarle4 , and<br />
J Prins1,2 1 2 Ctr for Infection and Immunity Amsterdam, The Netherlands; Academic<br />
Med Ctr, Amsterdam, The Netherlands; 3Intl Antiviral Therapy Evaluation<br />
Ctr, Amsterdam, The Netherlands; 4Univ Med Ctr, Utrecht, The<br />
Netherlands; 5Academic Hosp Maastricht, The Netherlands; and 6Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands<br />
698c An Open-label Randomized Trial to Determine the Virologic<br />
and Immunologic Effects of 4-Weeks of Cyclosporine A Given<br />
in Combination with ART during Acute and Early Infection<br />
Martin Markowitz* 1 , F Vaida2 , S Little2 , C Hare3 , H Balfour4 , E Ferguson5 ,<br />
K Schafer2 , D Richman2 , and the AIN 501 and ACTG 5216 Study Team<br />
1Aaron Diamond AIDS Res Ctr, The Rockefeller Univ, New York, NY, US;<br />
2 3 Univ of California, San Diego, US; Univ of California, San Francisco,<br />
US; 4Univ of Minnesota, Minneapolis, US; and 5Div of AIDS, NIAID,<br />
NIH, Bethesda, MD, US<br />
b Monday, 1-4 pm; Hall A<br />
Session 119–Poster Abstracts<br />
Acute HIV Infection: Recognition and Correlates of<br />
Transmission<br />
699 Diagnosing Acute HIV Infection in North Carolina:<br />
Challenges and Opportunities<br />
Kara McGee* 1 , S Kim1 , A Johnson2 , J Kuruc2 , S McCoy2 , L McNeil1 ,<br />
C Gay2 , D Margolis2 , J Eron2 , and C Hicks1 1 2 Duke Univ Med Ctr, Durham, NC, US and Univ of North Carolina at<br />
Chapel Hill, US<br />
700 Acute HIV-1 Infection Is Highly Prevalent in Ugandan<br />
Outpatients Suspected of Malaria<br />
Lisa Bebell* 1 , C Pilcher2 , G Dorsey2 , D Havlir2 , M Kamya3 , M Busch4 ,<br />
P Rosenthal2 , T Nugent5 , C Bentsen6 , and E Charlebois2 1Columbia Univ Coll of Physicians and Surgeons, New York, NY, US;<br />
2 3 Univ of California, San Francisco, US; Makerere Univ Med Sch,<br />
Kampala, Uganda; 4Blood Systems Res Inst, San Francisco, CA, US;<br />
5 6 Gen-Probe, San Diego, CA, US; and Bio-Rad, Redmond, WA, US<br />
701 Correlates of HIV Transmission among MSM<br />
David Butler* 1 , D Smith1,2 , E Cachay1 , G Hightower1 , T Nugent3 ,<br />
D Richman1,2 , and S Little1 1 2 Univ of California, San Diego, US; VA Hlthcare System, San Diego, CA,<br />
US; and 3Gen-Probe, San Diego, CA, US<br />
48 15th Conference on Retroviruses and Opportunistic Infections<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 120–Poster Abstracts<br />
Immune-Based Therapies: Cytokines<br />
702 Predictors of Slow Disease Progression in ART-naïve HIV-1infected<br />
Patients Treated with IL-2: 3 Year Extended Followup<br />
of the Interstart ANRS 119 Trial<br />
Jean-Michel Molina* 1 , Y Levy2 , I Fournier3 , T Boulet3 , M Bentata4 ,<br />
G Beck-Wirth5 , D Sereni1 , F Jeanblanc6 , F Simon1 , JP Aboulker3 , and the<br />
ANRS 119-Interstart Study Team<br />
1 2 Hosp St Louis, Paris, France; Hosp Henri Mondor, Creteil, France;<br />
3 4 INSERM SC10, Villejuif, France; Hosp Avicenne, Bobigny, France;<br />
5 6 Hosp Emile Muller, Mulhouse, France; and Hosp Edouard Herriot,<br />
Lyon, France<br />
703 Immunological Success Is Predicted by Enfuvirtide but Not<br />
Interleukin-2 in Immunocompromised Patients, Final Results<br />
of the ANRS 123 ETOILE Randomized Trial<br />
Jean-Paul Viard* 1 , C Fagard2 , C Rouzioux1 , E Pereira2 , M Bentata3,4,5 ,<br />
N Colin de Verdiere4 , G Pahlavan5 , L Weiss6 , Y LEvy7 , G Chene2 , and the<br />
ANRS 123 Study Group<br />
1 2 Ctr Hosp Univ Necker, Paris, France; INSERM U593, Bordeaux,<br />
France; 3Ctr Hosp Univ Avicenne, Bobigny, France; 4Ctr Hosp Univ St<br />
Louis, Paris, France; 5Ctr Hosp Univ Bichat, Paris, France; 6Ctr Hosp<br />
Univ Georges Pompidou, Paris, France; and 7Ctr Hosp Univ Henri-<br />
Mondor, Creteil, France<br />
704 CD4 T Cell Survival following Intermittent IL-2 Therapy Is<br />
Predictive of CD4 T Cell Increases in HIV-infected Patients<br />
Sarah Read* 1 , R Lempicki2 , M Di Mascio1 , S Srinivasula1,2 , I Sereti1 ,<br />
R Davey1 , J Tavel1 , CY Huang1 , C Lane1 , and J Kovacs3 1 2 NIAID, NIH, Bethesda, MD, US; SAIC-Frederick, MD, US; and<br />
3Warren G Magnuson Clinical Ctr, NIH, Bethesda, MD, US<br />
705 Response to IL-2 in Patients with Immunodiscordant<br />
Response to HAART Is Associated with Long-term Clinical<br />
Benefit<br />
Matilde Sanchez-Conde*, J Lopez, C Rodriguez, M Ramirez, I Gutierrez,<br />
J Cosin, J Berenguer, and P Miralles<br />
Hosp Gregorio Maranon, Madrid, Spain<br />
706 During HAART Interruption Interleukin-2 Was Ineffective<br />
in Maintaining Baseline CD4 T Cell Counts in IL-2experienced<br />
Recipients: Results of a Randomized, Controlled<br />
Trial<br />
Brian Porter* 1 , K Anthony2 , J Shen1 , B Hahn1 , B Blackwelder1 ,<br />
C Lane1 , J Kovacs1 , R Davey1 , and I Sereti1 1 2 NIH, Bethesda, MD, US and Univ of Pennsylvania Hlth System,<br />
Philadelphia, US<br />
707 IL-7 Immunotherapy and T Cell Homeostasis in SIV + ARTtreated<br />
Macaques<br />
Amanda Leone* 1 , M Rohankedkhar2 , A Okoye2 , B Assouline3 ,<br />
M Morre3 , F Villinger4 , L Picker2 , and D Sodora1 1 2 Seattle Biomed Res Inst, WA, US; Vaccine and Gene Therapy Inst and<br />
Oregon Natl Primate Res Ctr, Oregon Hlth and Sci Univ, Beaverton, US;<br />
3 4 Cytheris SA, Issy les Moulineaux, France; and Emory Univ, Atlanta,<br />
GA, US<br />
708 Sustained Immunological Efficacy of Repeated r-hIL-7 Doses<br />
in HIV-1-infected Patients: Long-term Follow-up of a Phase<br />
I/II Multicenter Study<br />
Yves Levy* 1,2 , L Weiss2,3,4 , C Goujard5 , JP Viard6 , JM Molina7 , F Boue8 ,<br />
C Lacabaratz2 , C Rouzioux6 , M Morre9 , and JF Delfraissy6 1 2 3 Henri Mondor Hosp, Creteil, France; INSERM, Creteil, France; Hosp<br />
Georges Pompidou, Paris, France; 4Univ Rene Descartes, Paris, France;<br />
5 6 Hosp Bicetre, Le Kremlin Bicetre, France; Ctr Hosp Univ Necker, Paris,<br />
France; 7St Louis Hosp, Paris, France; 8Hosp Antoine Beclere, Clamart,<br />
France; and 9Cytheris, France<br />
709 Early T Cell Homing following Recombinant Simian<br />
Glycosylated IL-7 Injection in Rhesus Macaques<br />
S Beq1 , S Rozlan2 , D Gautier1 , B Assouline2 , P Lavedan1 ,<br />
Michel Morre* 2 , and R Cheynier1 1 2 Pasteur Inst, Paris, France and Cytheris SA, Issy les Moulineaux,<br />
France<br />
710 Morpholino Antisense Oligomers Targeting Human IL-10<br />
Pre-mRNA Splice Sites Modulate IL-10 Secretion by Human<br />
Dendritic Cells<br />
Richard Bestwick* 1 , D Mourich1 , N Marshall1 , M Lubkin1 , S Oda1 ,<br />
S Thompson2 , K Warfield3 , S Bavari3 , and P Iversen1 1 2 AVI BioPharma Inc, Corvallis, OR, US; Oregon Hlth Sci Univ,<br />
Portland, US; and 3USAMRIID, Fort Detrick, Frederick, MD, US<br />
711 Interleukin-27, a Novel Anti-HIV Cytokine, Inhibits HIV-1<br />
Replication in Macrophages with the Activation of Multiple<br />
Interferon-inducible Genes<br />
Terrence Brann* 1 , J Yang1 , DW Huang1 , B Fullmer1 , J Adelsberger1 ,<br />
R Lempicki1 , M Baseler1 , C Lane2 , and T Imamichi1 1 2 SAIC-Frederick, MD, US and NIAID, NIH, Bethesda, MD, US
CROI 2008 Session 123<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 121–Poster Abstracts<br />
Immune-Based Therapies: Therapeutic Vaccines<br />
712 Safety and Analyses of Very Low-level Viremia during<br />
Therapeutic HIV-1 Immunizations in Young Adults on<br />
HAART: Long-term Persistence of Dominant Plasma Clones<br />
Derived from Residual Replication-competent Virus in CD4 +<br />
T Cells<br />
Carlum Shiu* 1 , C Cunningham2 , C Ziemniak1 , P Muresan3 , L Fox4 ,<br />
E Sheeran5 , A Gaur6 , I Febo7 , K Luzuriaga8 , D Persaud1 , and Pediatric<br />
ACTG P1059 Team<br />
1 2 Johns Hopkins Univ, Baltimore, MD, US; Duke Univ Med Ctr, Durham,<br />
NC, US; 3Statistical and Data Analysis Ctr, Boston, MA, US; 4NIAID, NIH, Bethesda, MD, US; 5Social & Sci Systems, Silver Spring, MD, US;<br />
6 7 St Jude Children’s Res Hosp, Memphis, TN, US; Univ of Puerto Rico,<br />
San Juan; and 8Univ of Massachusetts, Worcester, US<br />
713 Augmentation of HIV-1-specific Cell-mediated Immune<br />
Responses following Vaccination with Recombinant Modified<br />
Vaccinia Ankara-Fowlpox Vaccines in HIV-1-infected Young<br />
Adults on Suppressive ART<br />
Thomas Greenough* 1 , C Cunningham2 , M McManus1 , L Fox3 ,<br />
P Muresan4 , D Persaud5 , D Panicali6 , J Sullivan1 , and K Luzuriaga1 1 2 Univ of Massachusetts Med Sch, Worcester, US; Duke Univ, Durham,<br />
NC, US; 3Div of AIDS, NIAID, NIH, Bethesda, MD, US; 4Harvard Univ,<br />
Boston, MA, US; 5Johns Hopkins Univ Sch of Med, Baltimore, MD, US;<br />
and 6Therion Biologics Corp, Cambridge, MA, US<br />
714 Therapeutic HIV Vaccination with ALVAC ± Remune<br />
Delays Virologic Rebound with No Effect on Virologic Setpoint<br />
following Interruption of ART<br />
Jonathan Angel* 1 , JP Routy2 , C Tremblay3 , R Woods4 , J Singer4 ,<br />
N Bernard2 , C Kovacs5 , F Smaill6 , S Gurunathan7 , and R Sekaly3 1 2 3 Univ of Ottawa, Canada; McGill Univ, Montreal, Canada; Univ of<br />
Montreal, Canada; 4Canadian HIV Trial Network, Vancouver; 5Canadian Immunodeficiency Res Collaborative, Toronto; 6McMaster Univ,<br />
Hamilton, Canada; and 7Sanofi Pasteur, Swiftwater, PA, US<br />
715 Single DermaVir Patch Treatment of HIV + Individuals<br />
Induces Long-lasting, High-magnitude, and Broad HIVspecific<br />
T Cell Responses<br />
Julianna Lisziewicz* 1 , S Calarota2 , D Banhegyi3 , Z Lisziewicz1 ,<br />
E Ujhelyi3 , and F Lori2 1 2 Genetic Immunity, Budapest, Hungary, and McLean, VA, US; Res Inst<br />
for Genetic and Human Therapy, Pavia, Italy and Cambridge, MA, US;<br />
and 3United St Istvan and St Laszlo Hosp, Budapest, Hungary<br />
716 Immunogenicity and Efficacy of an MVA-nef Vaccine in a<br />
Randomized Controlled Phase-II-Study in HIV-1-infected<br />
Patients with CD4 Counts >250/µL followed by Structured<br />
Treatment Interruption<br />
Thomas Harrer* 1,2 , H Jaeger2,3 , M Helm4 , D Gorriahn5 , L Schneider6 , and<br />
E Harrer1,2 1 2 Univ Hosp Erlangen, Germany; German Competence Network on<br />
HIV/AIDS; 3Practice Dr Jaeger, Munich, Germany; 4Practice Dr Helm,<br />
Nurnberg, Germany; 5Practice Dr Gorriahn, Munich, Germany; and<br />
6Practice Dr Schneider, Furth, Germany<br />
717 DNA Therapeutic Vaccination of Chronically Infected<br />
Macaques Provides a Persistent Virological Benefit<br />
G Pavlakis1 , A von Gegerfelt1 , A Valentin1 , Margherita Rosati* 1 ,<br />
C Bergamaschi1 , V Patel1 , C Alicea1 , A Khan2 , R Draghia-Akli2 , and<br />
B Felber1 1 2 NCI-Frederick, MD, US and VGX Pharma, The Woodlands, TX, US<br />
718 HIV Protease Inhibitors Suppress Antigen Expression by<br />
Live Poxvirus-based Vaccines: A Potentially Negative Effect<br />
of ART on Efficacy of Live-vectored Vaccines<br />
N Hu1 , C Shikuma1 , B Shiramizu1 , J Yewdell2 , B Moss2 , and Qigui Yu* 1<br />
1 2 Univ of Hawaii at Manoa, Honolulu, US and NIH, Bethesda, MD, US<br />
b Wednesday, 1-4 pm; Hall A<br />
Session 122–Poster Abstracts<br />
Immune-Based Therapies: Novel Approaches<br />
719 Treatment of HIV-1 Infection by Allogeneic CCR5-δ32/δ32<br />
Stem Cell Transplantation: A Promising Approach<br />
Gero Hutter*, D Nowak, M Mossner, S Ganepola, K Allers, T Schneider,<br />
J Hofmann, I Blau, WK Hofmann, and E Thiel<br />
Med Univ of Berlin, Germany<br />
720 Reprogramming Cellular and Humoral Immunocomponents<br />
to Kill and Neutralize HIV-1: A Novel Investigatory and<br />
Therapeutic System<br />
Aviva Joseph* 1 , J Zheng1 , A Follenzi1 , D Katinger2 , R Kunert2 ,<br />
B Walker3 , and H Goldstein1 1 2 Albert Einstein Coll of Med, Bronx, NY, US; Inst of Applied Microbio,<br />
Vienna, Austria; and 3Partners AIDS Res Ctr, Massachusetts Gen Hosp,<br />
Harvard Med Sch, Boston, US<br />
721 Effects of Recombinant Growth Hormone on T Cell<br />
Phenotype and Function in vitro and in vivo during Treated<br />
HIV-1 Infection<br />
Alison Cranage* 1 , G Moyle2 , M Bower2 , B Gazzard2 , F Gotch1 , and<br />
N Imami1 1 2 Imperial Coll, London, UK and Chelsea and Westminster Hosp, London,<br />
UK<br />
722 A Study of Leflunomide to Target Immune Activation in<br />
HIV: Results of a Pilot Study<br />
Sarah Read*, M De Grezia, E Ciccone, R DerSimonian, W Gao,<br />
C Rehm, A Pau, R Davey, C Lane, and I Sereti<br />
NIAID, NIH, Bethesda, MD, US<br />
723 A Specific Mixture of Prebiotic Oligosaccharides Reduces<br />
Hyper-immune Activation and Improves NK Cell Cytolytic<br />
Activity in HAART-naïve HIV + Adults<br />
Belinda van’t Land* 1,2 , K Benlhassan-Chahour3 , G Rizzardini4 ,<br />
A Vriesema2 , J Garssen1,2 , D Trabattoni5 , D Bray3 , A Gori6 , M Clerici5 , and<br />
COPA Study Team<br />
1 2 Utrecht Inst for Pharma Sci, The Netherlands; Numico Res,<br />
Wageningen, The Netherlands; 3ImmunoClin, Paris, France; 4Hosp Luigi<br />
Sacco, Milan, Italy; 5Univ of Milan, Italy; and 6Hosp San Gerardo, Univ<br />
of Milan-Bicocca, Monza, Italy<br />
724 Evaluation of Natural Killer Cells and Expression of KIR<br />
and Lectin-like Receptors in HIV-1-infected Patients after<br />
2 Years of Different Strategies of Structured Therapy<br />
Interruption<br />
G Mestre1 , F Garcia1 , E Martinez1 , A Milinkovic1 , A Leon1 , A Lopez1 ,<br />
J Lozano2 , J Pena2 , J Gatell1 , and Montserrat Plana* 1<br />
1 2 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain and Hosp Reina Sofia,<br />
Cordoba, Spain<br />
725 Influence of Repeated Cycles of Structured Therapy<br />
Interruption on the Rate of Recovery of CD4 + T Cells after<br />
HAART Resumption<br />
A Leon, E Martinez, A Milinkovic, B Mora, R Argelich, A Lopez,<br />
T Gallart, Montserrat Plana*, J Gatell, and F Garcia<br />
Hosp Clin-IDIBAPS, Univ of Barcelona, Spain<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 123–Poster Abstracts<br />
ART: Novel Approaches I<br />
726a Biochemical Mechanism of HIV-1 Reverse Transcriptase<br />
Inhibition and Resistance to Translocation-deficient Reverse<br />
Transcriptase Inhibitors<br />
Bruno Marchand* 1 , L Michailidis1 , A Fopoussi1 , E Kodama2 ,<br />
M Matsuoka2 , N Ashida3 , E Nagy4 , M Parniak4 , H Mitsuya5,6 , and<br />
S Sarafianos1 1 2 3 Univ of Missouri, Columbia, US; Kyoto Univ, Japan; Yamasa Corp,<br />
Chiba, Japan; 4Univ of Pittsburgh, PA, US; 5Kumamoto Univ, Japan; and<br />
6NIH, Bethesda, MD, US<br />
726b Drug Susceptibility Profile of OBP-601, a Novel NRTI, Using a<br />
Comprehensive Panel of NRTI- or NNRTI-resistant Viruses<br />
Jan Weber* 1 , J Weberova1 , A Vazquez1 , Y Urata2 , T Matsuda2 , R Shafer3 ,<br />
E Arts4 , and M Quinones-Mateu1 1 2 Diagnostic Hybrids Inc, Cleveland, OH, US; Oncolys BioPharma,<br />
Tokyo, Japan; 3Stanford Univ, Palo Alto, CA, US; and 4Case Western<br />
Reserve Univ, Cleveland, OH, US<br />
727 Antiviral and Pharmacokinetic Properties of 3’-Azido-2’,3’-<br />
Dideoxypurines that Exhibit Potent Activity against Drugresistant<br />
HIV-1<br />
Nicolas Sluis-Cremer* 1 , D Koontz1 , B Hernandez-Santiago2 , K Rapp2 ,<br />
F Amblard2 , L Bondada2 , S Coats3 , R Schinazi2 , and J Mellors1 1 2 Univ of Pittsburgh Sch of Med, PA, US; Emory Univ and VAMC,<br />
Decatur, GA, US; and 3RFS Pharma, LLC, Tucker, GA, US<br />
728 Characterization of a NNRTI, UK-453,061 in vitro<br />
Julie Mori* 1 , R Corbau1 , D Lewis2 , S Ellery2 , H Mayer2 , M Perros1 , and<br />
M Westby1 1 2 Pfizer Global R&D, Sandwich Labs, Kent, UK and Pfizer Global R&D,<br />
New London, CT, US<br />
729 Genotypic Resistance and Phenotypic Cross-resistance<br />
Profile in vitro for a Novel NNRTI: IDX899<br />
Douglas Richman* 1 , J Jakubik2 , C Chapron2 , L Hubbard2 , L Gray2 ,<br />
M Seifer2 , and D Standring2 1Univ of California, San Diego and VA San Diego Hlthcare System, US<br />
and 2Idenix Pharma, Inc, Cambridge, MA, US<br />
730 RDEA427 and RDEA640 Are Novel NNRTI with Potent<br />
Anti-HIV Activity against NNRTI-resistant Viruses<br />
Anneke Raney*, R Hamatake, W Xu, JM Vernier, JL Girardet,<br />
P Weingarten, and B Quart<br />
Ardea Biosci, Inc, San Diego, CA, US<br />
731 An IQ Assessment of RDEA806, a Potent NNRTI with an<br />
Excellent Activity Profile in the Presence of Human Serum<br />
Proteins<br />
Robert Hamatake*, W Xu, A Raney, JL Girardet, M Nguyen, LT Yeh,<br />
and B Quart<br />
Ardea Biosci, Inc, San Diego, CA, US<br />
<strong>Program</strong> 49<br />
Poster Listings
Poster Litings<br />
Session 123 CROI 2008<br />
732 GS-8374, a Novel HIV Protease Inhibitor, Does Not Alter<br />
Peripheral Glucose Disposal in a Healthy Rodent Model<br />
System<br />
Christian Callebaut* 1 , Q Yan2 , J Koster2 , L Tsai1 , T Cihlar1 , and P Hruz2 1 2 Gilead Sci, Foster City, CA, US and Washington Univ Sch of Med, St<br />
Louis, MO, US<br />
733 Non-peptidyl Small Molecule Protease Dimerization<br />
Inhibitors: Molecular and Structural Analysis of Their<br />
HIV-1 Inhibition and Interactions with Protease Monomer<br />
Subunit<br />
Yasuhiro Koh* 1 , D Das2 , M Amano1 , D Davis2 , J Li3 , S Leschenko3 ,<br />
A Baldridge3 , R Yarchoan2 , A Ghosh3 , and H Mitsuya1,2 1 2 Kumamoto Univ Sch of Med, Japan; NCI, NIH, Bethesda, MD, US; and<br />
3Purdue Univ, West Lafayette, IN, US<br />
734 INH-I001, an HIV Integrase Inhibitor with Potent in vitro<br />
Anti-HIV Activity: Microsome and Cytosol Stability Studies,<br />
Cytochrome P450 Data and Pharmacokinetics<br />
Vasu Nair* 1 , X Ma1 , C White1 , S Blue1 , G Chi1 , and J Patti2 1 2 Univ of Georgia, Athens, US and Inhibitex, Inc, Alpharetta, GA, US<br />
735 Novel Treatment Strategies in HIV-1 Drug Discovery:<br />
Targeting the HIV-1 Integrase-LEDGF/p75 Interaction<br />
Frauke Christ* 1 , H Langedijk2 , K Bartholomeeussen1 , and Z Debyser1 1 2 Katholieke Univ Leuven, Belgium and Pepscan Systems, Lelystad, The<br />
Netherlands<br />
736 Induction in vitro of HIV-1 Variants Resistant to a Lowmolecular<br />
CD4 Mimic Compound, N-(4-Chlorophenyl)-N’-<br />
(2,2,6,6-tetramethylpiperidin-4-yl)-oxalamide<br />
Kazuhisa Yoshimura* 1 , J Shibata1 , A Honda1 , Y Yamada2 , H Masuno2 ,<br />
H Tamamura2 , and S Matsushita1 1 2 Ctr for AIDS Res, Kumamoto Univ, Japan and Inst of Biomaterials and<br />
Bioengineering, Tokyo Med and Dental Univ, Japan<br />
737 PF-232798, a Second Generation Oral CCR5 Antagonist<br />
Patrick Dorr*, M Westby, L McFadyen, J Davis, P Stupple,<br />
D Middleton, F Perruccio, R Jones, J Mori, and M Perros<br />
Pfizer, Sandwich, UK<br />
738 ESN-196, a Novel, Small-molecule CCR5 Antagonist Inhibits<br />
R5 HIV Infection<br />
T Ferain1 , D Schols2 , J Bernard1 , R Sleigh1 , F Ooms1 , J Huck1 , V Dupriez1 ,<br />
and Graeme Fraser* 1<br />
1 2 Euroscreen SA, Brussels and Gosselies, Belgium and Rega Inst for Med<br />
Res, Katholieke Univ Leuven, Belgium<br />
739 Potent CCR5 Inhibition by Fully Recombinant RANTES<br />
Analogs Requires Neither Internalization Nor Signaling<br />
Donald Mosier* 1 , R Nedellec1 , J Salkowitz-Bokal1 , M Coetzer1 ,<br />
M Lederman2 , R Offord3 , and O Hartley3 1 2 Scripps Res Inst, La Jolla, CA, US; Case Western Reserve Univ,<br />
Cleveland, OH, US; and 3Univ of Geneva, Switzerland<br />
741 Peptide “Stapling” Dramatically Enhances the Biophysical<br />
Properties of HIV Fusion Inhibitors<br />
Gregory Bird* 1,2 , N Madani1,2 , A Hubicki1,2 , J Sodroski1,2 , and<br />
L Walensky1,2 1 2 Dana-Farber Cancer Inst, Boston, MA, US and Harvard Med Sch,<br />
Boston, MA, US<br />
742 Type I Interferons Vary in Their Ability to Inhibit HIV<br />
Replication in Primary Macrophages<br />
SH Wie1 , S Rought2 , P Du2 , D Richman2 , and Christopher Woelk* 2<br />
1 2 Catholic Univ of Korea, Seoul, South Korea and Univ of California, San<br />
Diego, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 124–Poster Abstracts<br />
ART: Novel Approaches II<br />
743 Ritonavir-, Lopinavir-, and Efavirenz-containing<br />
Nanoparticles: in vitro Release of ART<br />
Chris Destache*, T Belgum, G Elsasser, K Christensen, and A Shibata<br />
Creighton Univ, Omaha, NE, US<br />
744 HIV-1 Inhibition with Multi-valent Gold Nanoparticles<br />
Mary Catherine Bowman* 1 , E Ballard2 , C Akerson2 , J D’Antonio2 ,<br />
D Feldheim3 , C Melander2 , and D Margolis1 1 2 Univ of North Carolina at Chapel Hill, US; North Carolina State Univ,<br />
Raleigh, US; and 3Univ of Colorado, Boulder, US<br />
745 Anti-retroviral Nanoformulations for HIV-1-associated<br />
Cognitive Impairments<br />
Huanyu Dou* 1 , C Grotepas1 , M Boska1 , C Destache2 , B Rabinow3 , and<br />
H Gendelman1 1 2 Univ of Nebraska Med Ctr, Omaha, US; Creighton Univ Sch of<br />
Pharmacy and Hlth Professions, Omaha, NE, US; and 3Baxter Hlthcare<br />
Corp, Round Lake, IL, US<br />
50 15th Conference on Retroviruses and Opportunistic Infections<br />
746 The Non-peptidic Carbohydrate-binding Pradimycin<br />
Antibiotics Inhibit HIV infection, Viral Capture by<br />
DC-SIGN, and Viral Transmission and thus May Qualify as<br />
Potential Microbicide Candidate Drugs<br />
J Balzarini1 , K Francois1 , D Huskens1 , J Auwerx1 , K Van Laethem1 ,<br />
Y Igarashi2 , T Oki3 , and Dominique Schols* 1<br />
1 2 Rega Inst for Med Res, Katholieke Univ Leuven, Belgium; Toyama<br />
Prefectural Univ, Japan; and 3Keck Sch of Med, Univ of Southern<br />
California, Los Angeles, US<br />
747 Carbohydrate-binding Agents Inhibit HIV-1 Infection<br />
of Human Primary Monocyte-derived Macrophages and<br />
Prevent MDM-directed Viral Capture and Subsequent<br />
Transmission to CD4 + T Lymphocytes<br />
Michela Pollicita* 1 , D Schols2 , S Aquaro3 , W Peumans4 ,<br />
E Van Damme4 , C Perno1 , and J Balzarini2 1 2 Univ of Tor Vergata, Rome, Italy; Rega Inst for Med Res, Katholieke<br />
Univ Leuven, Belgium; 3Univ of Calabria, Rende, Italy; and 4Ghent Univ,<br />
Belgium<br />
748 CD7-specific Single Chain Antibody-mediated Delivery of<br />
siRNA to T Cells Inhibits HIV Replication in a Humanized<br />
Mouse Model<br />
Priti Kumar* 1 , H Ban2 , S Kim1 , M Peipp3 , G Fey3 , L Schultz4 , N Manjunath1 ,<br />
S Lee2 , and P Shankar1 1 2 Immune Disease Inst, Boston, MA, US; Hanyang Univ, Seoul, Korea;<br />
3 4 Univ of Erlangen, Germany; and Jackson Lab, Bar Harbor, ME, US<br />
749 Protein Phosphatase-1 as a New Target for Anti-HIV-1<br />
Therapeutics<br />
T Ammosova1 , D Kovalskyy2 , V Yedavalli3 , V Gordeuk1 , KT Jeang3 , and<br />
Sergei Nekhai* 1<br />
1 2 Howard Univ, Washington, DC, US; Natl Taras Shevchenko Univ, Kiev,<br />
Ukraine; and 3NIAID, NIH, Bethesda, MD, US<br />
750 Anti-HIV Activity of Aprepitant and Synergistic Interactions<br />
with Other Antiretrovirals<br />
Mark Manak* 1 , D Moshkoff1 , L Nguyen1 , S Dryga1 , J Lathey2 , and<br />
S Douglas3 1 2 SeraCare Life Sci, Inc, Gaithersburg, MA, US; Sanofi Pasteur,<br />
Swiftwater, PA, US; and 3Children’s Hosp Philadelphia, PA, US<br />
751 A Novel Inhibitor of the HIV-1 Vpu Protein Can Inhibit the<br />
Replication of SHIV in a CD4 + T Cell Line<br />
Sarah Hill* 1 , C Luscombe2 , J Wilkinson2 , G Ewart2 , and E Stephens1 1 2 Univ of Kansas Med Ctr, Kansas City, US and Biotron Ltd<br />
752 Evaluation of the Lymphocyte Trafficking Drug FTY720 in<br />
SHIV-infected Rhesus Macaques<br />
Ellen Kersh* 1 , M Premenko-Lanier2 , W Luo1 , D Adams1 , J Mitchell1 ,<br />
G Garcia-Lerma1 , S Butera1 , T Folks1 , R Otten1 , and J Altman2 1 2 CDC, Atlanta, GA, US and Emory Vaccine Ctr, Atlanta, GA, US<br />
753a Lentiviral Delivered VRX496 Long Antisense Sequences<br />
Exerts Molecular Pressure on HIV-1 in Human Subjects<br />
Vladimir Lukashov* 1 , M Quinones-Mateu2 , G McGarrity3 , T Rebello3 , and<br />
L Humeau3 1 2 Academic Med Ctr, Amsterdam, The Netherlands; Diagnostic Hybrids<br />
Inc, Athens, OH, US; and 3VIRxSYS Corp, Gaithersburg, MD, US<br />
753b Dose Response Curve Slope Sets Class-specific Limits on<br />
Inhibitory Potential of Anti-HIV Drugs<br />
Lin Shen* 1 , S Peterson1 , A Sedaghat1 , M McMahon1 , M Callender1 ,<br />
H Zhang1 , Y Zhou1 , K Anderson2 , E Acosta3 , and R Siliciano1,4 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Yale Univ Sch of<br />
Med, New Haven, CT, US; 3Univ of Alabama at Birmingham Sch of Med,<br />
US; and 4Howard Hughes Med Inst, Baltimore, MD, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 125–Poster Abstracts<br />
Clinical Pharmacology of Reverse Transcriptase<br />
Inhibitors<br />
754 Compartmental Kinetics of Intracellular Tenofovir<br />
Courtney Fletcher* 1 , T King1 , L Bushman1 , J Kiser1 , P Anderson1 ,<br />
J Brenchley2 , D Douek2 , and T Schacker3 1 2 Univ of Colorado Hlth Sci Ctr, Denver, US; NIAID, NIH, Bethesda, MD,<br />
US; and 3Univ of Minnesota, Minneapolis, US<br />
755 Intracellular Accumulation of Tenofovir and Emtricitabine<br />
in vitro Highlight the Inhibitor Role of Efavirenz for<br />
Multidrug Resistance-associated Protein 1, MRP1<br />
Laurence Bousquet* 1 , A Pruvost1 , N Didier1 , R Farinotti2 , and<br />
A Mabondzo1 1 2 CEA, iBiTecS, Gif sur Yvette, France and Univ Paris Sud XI, Chatenay-<br />
Malabry, France<br />
756 Positron Emission Tomography Agent for Non-invasive<br />
Imaging of Antiretroviral Drug Penetration and Kinetics in<br />
vivo<br />
Michele Di Mascio* 1 , S Srinivasula2 , M Collins3 , E Lim4 , L Cheng1 , and<br />
D Kiesewetter5 1 2 3 NIAID, NIH, Bethesda, MD, US; SAIC-Frederick, MD, US; Bioqual Inc,<br />
Rockville, MD, US; 4Univ of Pennsylvania, Philadelphia, US; and 5Natl Inst<br />
of Biomed Imaging and BioEngineering, NIH, Bethesda, MD,US
CROI 2008 Session 127<br />
757 Comparison of Package-insert Recommendations for Renal<br />
Dosing and Prescribed Dosing of Products Containing<br />
Tenofovir: The VA Experience<br />
Barbara Phillips*, P Belperio, L Mole, and V Katseva<br />
Veterans Hlth Admin, Palo Alto, CA, US<br />
758 Pharmacological Mechanisms Leading to Early Virologic<br />
Failure of 2 Antiretroviral Regimens: Didanosine,<br />
Lamivudine, and Tenofovir, and Abacavir, Lamivudine, and<br />
Tenofovir<br />
Lucun Bi* 1 , J Russell1 , N Mordwinkin1 , J Lam2 , and S Louie1 1Univ of Southern California Sch of Pharmacy, Los Angeles, US and<br />
2Loma Linda Univ Sch of Pharmacy, CA, US<br />
759 Pharmacogenetics of Plasma Drug Exposure and Treatment<br />
Outcomes with Efavirenz-containing Regimens: An ACTG<br />
Study<br />
David Haas* 1 , H Ribaudo2 , A Motsinger3 , B Schackman4 , R Gulick4 ,<br />
E Acosta5 , M Schwab6 , E Schaeffeler6 , G Morse7 , G Robbins8 , and the<br />
ACTG<br />
1 2 Vanderbilt Univ, Nashville, TN, US; Statistical and Data Analysis Ctr,<br />
Harvard Sch of Publ Hlth, Boston, MA, US; 3North Carolina State Univ,<br />
Raleigh, US; 4Weill Med Coll of Cornell Univ, New York, NY, US; 5Univ of Alabama at Birmingham, US; 6Margarete Fischer-Bosch Inst for<br />
Clinical Pharma, Stuttgart, Germany; 7State Univ of New York at Buffalo,<br />
US; and 8Harvard Univ, Boston, MA, US<br />
760 Pharmacokinetics of Nevirapine and Rifampicin in TB/HIV<br />
Co-infected Patients in Burkina Faso<br />
Alberto Matteelli* 1 , N Saleri1,3 , M Regazzi2 , P Villani2 , V Bonkoungou3 ,<br />
J Simpore3 , A Carvalho1 , M Cusato2 , G Carosi1 , and M Dembele3 1 2 Inst of Infectious and Tropical Diseases, Univ of Brescia, Italy; Inst of<br />
Pharmacology, IRCCS, San Matteo, Pavia, Italy; and 3Natl TB Prgm,<br />
Ministry of Hlth, Burkina Faso<br />
761 Efavirenz Induces CYP450 2B6 Activity as Measured by<br />
Bupropion Hydroxylation in Healthy Subjects<br />
Sarah Robertson* 1 , F Maldarelli2 , V Natarajan3 , E Formentini4 , R Alfaro5 ,<br />
and S Penzak5 1 2 US Food and Drug Admin, Silver Spring, MD, US; NCI, Bethesda, MD,<br />
US; 3SAIC-Frederick, MD, US; 4NIH, Bethesda, MD, US; and 5Clinical Res Ctr, NIH, Bethesda, MD, US<br />
762 Pharmacokinetics and Pharmacodynamics of the NNRTI<br />
TMC125 in Treatment-experienced HIV-1-infected Patients:<br />
Pooled 24-week Results of DUET-1 and DUET-2<br />
Thomas Kakuda* 1 , J Wade2 , E Snoeck2 , M Peeters3 , C Corbett3 ,<br />
G De Smedt3 , L Leopold1 , J Vingerhoets3 , B Woodfall3 , and R Hoetelmans3 1 2 Tibotec, Inc, Yardley, PA, US; Exprimo NV, Mechelen, Belgium; and<br />
3Tibotec BVBA, Mechelen, Belgium<br />
763 Pharmacokinetic Interaction of the Next Generation NNRTI<br />
UK-453,061 with Other Antiretrovirals and Assessment of<br />
Safety and Tolerability in Healthy Male Subjects<br />
G Langdon1 , J Davis1 , G Layton1 , H Choo2 , MN Ndongo3 , A Milton4 , and<br />
Manoli Vourvahis* 4<br />
1 2 Pfizer Global R&D, Sandwich, UK; Pfizer Res Clin, Singapore Gen<br />
Hosp; 3Pfizer Res Clin, Erasme, Brussels, Belgium; and 4Pfizer Global<br />
R&D, New London, CT, US<br />
764 Dose-escalation Safety, Tolerability, and Pharmacokinetics of<br />
a Novel HIV-1 NNRTI [IDX899] in Healthy Subjects<br />
Douglas Mayers*, M Hard, D Damphousse, B Fielman,<br />
J Sullivan-Bolyai, B Belanger, and XJ Zhou<br />
Idenix Pharma, Inc, Cambridge, MA, US<br />
b Tuesday, 1-4 pm; Hall A<br />
Session 126–Poster Abstracts<br />
Clinical Pharmacology of Protease Inhibitors<br />
765 Lopinavir/Ritonavir 500/125 mg Twice-daily + Efavirenz<br />
Approximate the Pharmacokinetic Exposure of LPV/r<br />
400/100 mg Twice-daily Administered Alone in Healthy<br />
Adult Subjects<br />
Juki Ng*, C Klein, J Xiong, YL Chiu, T Doan, C Rolle, C Holas,<br />
R Stryker, and B Bernstein<br />
Abbott Labs, Abbott Park, IL, US<br />
766a Increased Lopinavir Concentrations on Once-daily Tablets as<br />
Compared with Capsules and Liquid Formulations<br />
Brookie Best* 1 , G Rieg2 , S Sun1 , S Jain1 , C Kemper3 , C Diamond4 ,<br />
A Hermes5 , R Haubrich1 , E Daar2 , and California Collaborative Treatment<br />
Group (CCTG) 585 Team<br />
1 2 Univ of California, San Diego, US; Los Angeles Biomed Res Inst at<br />
Harbor-UCLA Med Ctr and Univ of California, Los Angeles, US; 3Santa Clara Valley Med Ctr, San Jose, CA, US; 4Univ of California, Irvine, US;<br />
and 5Abbott Labs, Abbott Park, IL, US<br />
766b Hepatic Transaminase Elevations and Gastrointestinal<br />
Intolerance when HIV-negative Healthy Volunteers on<br />
Rifampin add Twice-daily Atazanavir ( 300 mg)/Ritonavir<br />
(100 mg): ACTG Protocol A5213<br />
David Haas* 1 , S Koletar2 , L Laughlin2 , M Kendall3 , C Suckow3 ,<br />
J Gerber4 , A Zolopa5 , R Bertz6 , M Child6 , E Acosta7 , and the A5213 Study<br />
Team<br />
1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US; Ohio State Univ,<br />
Columbus, US; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ<br />
Hlth, Boston, MA, US; 4Univ of Colorado Hlth Sci Ctr, Denver, US;<br />
5 6 Stanford Univ, Palo Alto, CA, US; Bristol-Myers Squibb, Princeton, NJ,<br />
US; and 7Univ of Alabama at Birmingham, US<br />
767 Pharmacokinetic Interaction between Tipranavir/Ritonavir<br />
and Rosuvastatin<br />
Paul Pham* 1 , L Lee1 , E Fuchs1 , P Barditch-Crovo1 , K Carson1 ,<br />
C Radebaugh1 , S Everts1 , P Piliero2 , and C Flexner1 1 2 Johns Hopkins Univ, Baltimore, MD, US and Boehringer Ingelheim<br />
Pharma, Inc, Ridgefield, CT, US<br />
768 Inhibitory Quotient as a Predictor of Virological Response to<br />
Darunavir-based Salvage Regimens<br />
Jose Molto* 1 , J Santos1 , N Perez-Alvarez1,2 , S Cerdeno3 , C Miranda1 ,<br />
S Khoo4 , L Else4 , J Llibre1 , M Valle5 , and B Clotet1,3 1Hosp Univ Germans Trias i Pujol and Fndn Lluita contra la SIDA,<br />
Badalona, Spain; 2Univ Politecnica de Barcelona, Spain; 3Hosp Univ<br />
Germans Trias i Pujol and Fndn irsiCaixa, Badalona, Spain; 4Univ of<br />
Liverpool, UK; and 5Hosp de la Santa Creu i Sant Pau, Barcelona, Spain<br />
769 Pharmacokinetic/Pharmacodynamic Analyses of Once-daily<br />
Darunavir in the ARTEMIS Study<br />
Vanitha Sekar* 1 , C Vanden Abeele2 , B Van Baelen2 , P Vis3 , L Lavreys2 ,<br />
M De Pauw2 , S Dincq2 , T Vangeneugden2 , S Spinosa-Guzman2 , and<br />
R Hoetelmans2 1 2 Tibotec Inc, Yardley, PA, US; Tibotec, Inc, Mechelen, Belgium; and<br />
3Exprimo NV, Mechelen, Belgium<br />
770 Switch from Ritonavir-boosted to Unboosted Atazanavir<br />
Guided by Monitoring Atazanavir Concentrations in a<br />
Clinical Setting<br />
Sonia Rodriguez-Novoa*, J Morello, P Barreiro, I Maida,<br />
P Garcia-Gasco, G Gonzalez-Pardo, A Parra, I Jimenez-Nacher, and<br />
V Soriano<br />
Hosp Carlos III, Madrid, Spain<br />
771 Influence of the Orosomucoid Polymorphism on Amprenavir<br />
Pharmacokinetics in HIV-infected Patients: ANRS104 Trial<br />
A Barrail-Tran1 , C Cosson1 , G Raguin2 , G Chene3 , PM Girard4 , and<br />
Anne-Marie Taburet* 1<br />
1 2 Hosp Bicetre, Le Kremlin Bicetre, France; Croix St Simon Hosp, Paris,<br />
France; 3INSERM U593, Bordeaux, France; and 4Hosp St Antoine, Paris,<br />
France<br />
772 Association between Blips and Subtherapeutic Antiretroviral<br />
Plasma Levels<br />
S Fiorante, Sonia Rodriguez Novoa*, P Garcia Gasco, J Morello,<br />
F Blanco, G Gonzalez Pardo, A Parra, I Jimenez Nacher,<br />
J Gonzalez Lahoz, and V Soriano<br />
Hosp Carlos III, Madrid, Spain<br />
773 Integrating Pharmacokinetics and Antiretroviral Resistance<br />
Testing in Clinical HIV-1 Management<br />
Jennifer King* 1 , I Ofotokun2 , M Rivas2 , V Johnson1,3 , and E Acosta1 1 2 Univ of Alabama at Birmingham, US; Emory Univ Sch of Med, Atlanta,<br />
GA, US; and 3Birmingham VAMC, AL, US<br />
b Monday, 1-4 pm; Hall B<br />
Session 127–Poster Abstracts<br />
ART: Treatment-naïve Patients<br />
774 Efficacy and Safety of Abacavir/Lamivudine Compared to<br />
Tenofovir/Emtricitabine in Combination with Once-daily<br />
Lopinavir/Ritonavir through 48 Weeks in the HEAT Study<br />
Kimberly Smith* 1 , D Fine2 , P Patel3 , N Bellos4 , L Sloan5 , P Lackey6 ,<br />
D Sutherland-Phillips3 , C Vavro3 , Q Liao3 , and M Shaefer3 1 2 Rush Univ Med Ctr, Chicago, IL, US; Johns Hopkins Univ Sch of<br />
Med, Baltimore, MD, US; 3GlaxoSmithKline, Research Triangle Park,<br />
NC, US; 4Southwest Infectious Disease Assoc, Dallas, TX, US; 5North Texas Infectious Disease Consultants, Dallas, US; and 6ID Consultants,<br />
Charlotte, NC, US<br />
775 Study M05-730 Primary Efficacy Results at Week 48: Phase<br />
3, Randomized, Open-label Study of Lopinavir/ritonavir<br />
Tablets Once Daily vs Twice Daily, Co-administered with<br />
Tenofovir DF + Emtricitabine in ARV-naïve HIV-1-infected<br />
Subjects<br />
J Gathe1 , Barbara da Silva* 2 , M Loutfy3 , D Podzamczer4 , R Rubio5 ,<br />
S Gibbs2 , T Marsh2 , C Naylor2 , L Fredrick2 , and B Bernstein2 1 2 Therapeutic Concepts, Houston, TX, US; Abbott Labs, Abbott Park, IL,<br />
US; 3Maple Leaf Med Clin, Toronto, Canada; 4Hosp Univ de Bellvitge,<br />
Barcelona, Spain; and 5Hosp 12 de Octubre, Madrid, Spain<br />
<strong>Program</strong> 51<br />
Poster Listings
Poster Litings<br />
Session 127 CROI 2008<br />
776 Effect of Baseline Characteristics on Treatment Outcomes<br />
in ACTG 5142: A Prospective, Randomized, Phase III Trial<br />
of NRTI-, PI-, and NNRTI-sparing Regimens for Initial<br />
Treatment of HIV-1 Infection<br />
Sharon Riddler* 1 , R Haubrich2 , G DiRienzo3 , L Peeples3 , W Powderly4 ,<br />
K Garren5 , D Butcher6 , J Rooney7 , D Havlir8 , J Mellors1 , and ACTG 5142<br />
Study Team<br />
1 2 Univ of Pittsburgh, PA, US; Univ of California, San Diego, US;<br />
3 4 Harvard Sch of Publ Hlth, Boston, MA, US; Univ Coll Dublin, Ireland;<br />
5 6 Abbott Labs, Abbott Park, IL, US; Bristol-Myers Squibb, Plainsboro,<br />
NJ, US; 7Gilead Sci, Foster City, CA, US; and 8Univ of California, San<br />
Francisco, US<br />
777 Analysis of the Relationship between Antiretroviral<br />
Medication Adherence and Class-specific Resistance in a<br />
Large Prospective Randomized Clinical Trial<br />
Edward Gardner* 1 , G Peng2 , E Telzak3 , S Sharma2 , K Huppler Hullsiek2 ,<br />
W Burman1 , M Chesney4 , G Friedland5 , R MacArthur6 , S Mannheimer7 ,<br />
and the Intl Network for Strategic Initiatives in Global HIV Trials<br />
(INSIGHT)<br />
1 2 Denver Publ Hlth, CO, US; Univ of Minnesota, Minneapolis, US;<br />
3 4 Bronx-Lebanon Hosp Ctr, NY, US; Natl Ctr for Complementary and<br />
Alternative Med, NIH, Bethesda, MD, US; 5Yale Univ Sch of Med, New<br />
Haven, CT, US; 6Wayne State Univ, Detroit, MI, US; and 7Columbia Univ<br />
Coll of Physicians and Surgeons, New York, NY, US<br />
778 A 2-Months-off/4-Months-on HAART Is Clinically Not<br />
Inferior to Continuous Therapy but Leads to Unacceptable<br />
Resistance Rates in African Adults with >350 CD4/mm3 at<br />
First Interruption: Final Results of the Trivacan Trial<br />
Christine Danel* 1 , R Moh1 , ML Chaix2 , D Gabillard3 , B Kouadio1 , T Toni4 ,<br />
C Rouzioux2 , R Salamon3 , E Bissagnene5 , X Anglaret3 , and ANRS 1269<br />
Study Group<br />
1 2 Prgm PACCI, Abidjan, Côte d’Ivoire; Ctr Hosp Univ Necker, Paris,<br />
France; 3INSERM U593, Bordeaux, France; 4CeDReS, Abidjan, Côte<br />
d’Ivoire; and 5Infectious and Tropical Diseases Svc, Abidjan, Côte<br />
d’Ivoire<br />
779 Efficacy and Safety of Dual-PI Regimens for the Treatment<br />
of ART-naïve HIV-1 Subjects: 2IP ANRS 127, a Randomized<br />
Pilot Study<br />
Roland Landman* 1 , C Chazallon2 , D Descamps1 , C Capitant2 ,<br />
G Peytavin1 , C Katlama3 , G Pialoux4 , M Bentata5 , JP Aboulker2 , P Yeni1 ,<br />
and ANRS 127 Study Group<br />
1 2 Hosp Bichat-Claude Bernard, Paris, France; INSERM SC10, Villejuif,<br />
France; 3Hosp Pitie-Salpetriere, Paris, France; 4Hosp Tenon, Paris,<br />
France; and 5Hosp Avicenne, Bobigny, France<br />
780 Double Protease Inhibitor, RTI-sparing Therapy Regimen in<br />
Naïve HIV-1-infected Patients: 24-Week Virologic Response<br />
Analysis of the LORAN Trial<br />
K Ulbricht* 1 , M Stoll1 , G Behrens1 , B Salzberger2 , H Jessen3 , A Jessen3 ,<br />
B Kuhlmann4 , A Trein5 , H Heiken1 , and R Schmidt1 1 2 3 Hannover Med Sch, Germany; Univ of Regensburg, Germany; Private<br />
Practice Motzstr, Berlin, Germany; 4Praxis Georgstr, Hannover; and<br />
5Private Practice Schwabstr, Stuttgart, Germany<br />
781 Effect of a 48-week Lopinavir/r Monotherapy on HIV1-DNA<br />
in Blood Cells in the MONARK Trial<br />
Veronique Avettand-Fenoel* 1 , P Flandre2 , ML Chaix1 , J Ghosn3 ,<br />
C Delaugerre1 , F Raffi4 , P NgoVan5 , I Cohen-Codar5 , JF Delfraissy3 , and<br />
C Rouzioux1 1 2 Ctr Hosp Univ Necker, Univ Paris-Descartes, France; INSERM U720,<br />
Paris, France; 3Ctr Hosp Univ Bicetre, Le Kremlin-Bicetre, France; 4Ctr Hosp Univ Nantes, France; and 5Abbott France<br />
782 Reasons for Treatment Success with Initial ART: An<br />
Analysis of 22,635 Participants in 64 Randomized, Controlled<br />
Trials and 14 Prospective Cohorts<br />
Andrew Carr* 1 and J Amin2 1 2 St Vincent’s Hosp, Sydney, Australia and Natl Ctr in HIV Epi and Clin<br />
Res, Univ of New South Wales, Sydney, Australia<br />
783 Outcomes of Abacavir- and Efavirenz-based HAART:<br />
Comparison of ACTG 5095 Trial Results with Observational<br />
Cohort Studies<br />
Michael Mugavero* 1 , M May2 , H Ribaudo3 , J Sterne2 , S Napravnik4 ,<br />
M Egger5 , M Saag1 , R Gulick6 , and ACTG and ART-CC<br />
1 2 3 Univ of Alabama at Birmingham, US; Univ of Bristol, UK; Harvard Sch<br />
of Publ Hlth, Boston, MA, US; 4Univ of North Carolina at Chapel Hill,<br />
US; 5Univ of Berne, Switzerland; and 6Weill Med Coll of Cornell Univ,<br />
New York, NY, US<br />
784 Similar Responses Observed in ARV-naïve Patients Treated<br />
through Clinical Trials vs Clinical Practice<br />
Justin Routman* 1 , J Willig1 , A Westfall1 , S Abroms2 , M Varshney1 ,<br />
S Adusumilli1 , J Allison1 , K Savage1 , M Saag1 , M Mugavero1 , and<br />
UAB 1917 HIV/AIDS Clinic Cohort<br />
1 2 Univ of Alabama at Birmingham, US and Univ of Pennsylvania,<br />
Philadelphia, US<br />
785 Prediction of AIDS-defining Illnesses or Death after the<br />
Initiation of HAART<br />
Bryan Lau* 1,2 , S Gange2 , G Chander1 , J Keruly1 , and R Moore1,2 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US and Johns Hopkins<br />
Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US<br />
52 15th Conference on Retroviruses and Opportunistic Infections<br />
786 Nevirapine Administered Once Daily Is as Efficient as a<br />
Twice-daily Dosing: A Collaborative Cohort Study<br />
Alexandra Calmy* 1 , A Nguyen1 , J Lange2 , M Battegay3 , F de Wolf4 ,<br />
P Reiss2 , B Hirschel1 , and F Wit2 for the Swiss HIV Cohort Study and The<br />
Netherlands ATHENA Observational Cohort<br />
1 2 Univ Hosp Geneva, Switzerland; Ctr for Poverty-Related Communicable<br />
Diseases, Academic Med Ctr, Amsterdam, The Netherlands; 3Univ Hosp Basel, Switzerland; and 4HIV Monitoring Fndn, Amsterdam, The<br />
Netherlands<br />
787 Single Antiretroviral Switches for Pregnant Women<br />
Compared to Non-pregnant Women and Men Who Initiated<br />
HAART in the MTCT-Plus Initiative<br />
Patricia Toro*, M Katyal, D Nash, and R Carter<br />
Columbia Univ, New York, NY, US<br />
b Monday, 1-4 pm; Hall B<br />
Session 128–Poster Abstracts<br />
ART: Treatment-experienced Patients<br />
788 48-Week Results from BENCHMRK-1, a Phase III Study<br />
of Raltegravir in Patients Failing ART with Triple-class<br />
Resistant HIV-1<br />
David Cooper* 1 , J Gatell2 , J Rockstroh3 , C Katlama4 , P Yeni5 ,<br />
A Lazzarin6 , X Xu7 , R Isaacs7 , H Teppler7 , BY Nguyen7 , and the<br />
BENCHMRK-1 Study Group<br />
1 2 Univ of New South Wales, Sydney, Australia; Univ of Barcelona, Spain;<br />
3 4 5 Univ of Bonn, Germany; Hosp Pitie-Salpetriere, Paris, France; Hosp<br />
Bichat-Claude Bernard, Paris, France; 6San Raffaele Sci Inst, Milan,<br />
Italy; and 7Merck Res Labs, West Point, PA, US<br />
789 48-Week Results from BENCHMRK-2, a Phase III Study<br />
of Raltegravir in Patients Failing ART with Triple-class<br />
Resistant HIV<br />
Roy Steigbigel* 1 , P Kumar2 , J Eron3 , M Schechter4 , M Markowitz5 ,<br />
M Loutfy6 , J Zhao7 , R Isaacs6 , BY Nguyen7 , H Teppler7 , and the<br />
BENCHMRK-2 Study Group<br />
1 2 State Univ of New York at Stony Brook, US; Georgetown Univ Med<br />
Ctr, Washington, DC, US; 3Univ North Carolina at Chapel Hill, US;<br />
4 5 Federal Univ of Rio de Janeiro, Brazil; Aaron Diamond AIDS Res Ctr,<br />
The Rockefeller Univ, New York, NY, US; 6Univ of Toronto, Canada; and<br />
7Merck Res Labs, West Point, PA, US<br />
790 DUET-1: Week-48 Results of a Phase III Randomized<br />
Double-blind Trial to Evaluate the Efficacy and Safety of<br />
TMC125 vs Placebo in 612 Treatment-experienced HIV-1infected<br />
Patients<br />
Richard Haubrich* 1 , P Cahn2 , B Grinsztejn3 , J Lalezari4 , J Madruga5 ,<br />
A Mills6 , M Peeters7 , J Vingerhoets7 , K Iveson8 , and G De Smedt7 on<br />
behalf of the DUET-I Study Group<br />
1 2 Univ of California, San Diego, US; Hosp “Juan A Fernandez” and Fndn<br />
Huesped, Buenos Aires, Argentina; 3Inst de Pesquisa Clinica Evandro<br />
Chagas, FIOCRUZ, Brazil; 4Quest Clinical Res, San Francisco, CA, US;<br />
5 6 Ctr de Referencia e Treinamento DST/AIDS, Sao Paulo, Brazil; Private<br />
Practice, Los Angeles, CA, US; 7Tibotec BVBA, Mechelen, Belgium; and<br />
8Tibotec, Inc, Yardley, PA, US<br />
791 DUET-2: Week-48 Results of a Phase III Randomized<br />
Double-blind Trial to Evaluate the Efficacy and Safety of<br />
TMC125 vs Placebo in 591 Treatment-experienced HIV-1infected<br />
Patients<br />
Margaret Johnson* 1 , T Campbell2 , B Clotet3 , C Katlama4 , A Lazzarin5 ,<br />
W Towner6 , M Peeters7 , J Vingerhoets7 , S Bollen7 , and G De Smedt7 on<br />
behalf of the DUET-2 Study Group<br />
1 2 Royal Free Hosp, London, UK; Univ of Colorado Hlth Sci Ctr, Denver,<br />
US; 3Hosp Univ Germans Trias i Pujol and irsiCaixa Fndn, Barcelona,<br />
Spain; 4Hosp Pitie-Salpetriere, Paris, France; 5San Raffaele Univ, Milan,<br />
Italy; 6Kaiser Permanente, Los Angeles, CA, US; and 7Tibotec BVBA,<br />
Mechelen, Belgium<br />
792 Efficacy and Safety of Maraviroc plus Optimized<br />
Background Therapy in Treatment-experienced Patients<br />
Infected with CCR5-Tropic HIV-1: 48-Week Combined<br />
Analysis of the MOTIVATE Studies<br />
David Hardy* 1 , J Reynes2 , I Konourina3 , D Wheeler4 , S Moreno5 ,<br />
E van der Ryst3 , W Towner6 , A Horban7 , H Mayer8 , and J Goodrich8 1 2 David Geffen Sch of Med, Univ of California, Los Angeles, US; Univ<br />
Hosp of Montpellier, France; 3Pfizer Global R&D, Sandwich, UK;<br />
4 5 Infectious Diseases Physicians, Inc, Annandale, VA, US; Hosp Ramon y<br />
Cajal, Madrid, Spain; 6Kaiser Permanente, Los Angeles, CA, US; 7Szpital Zakazny Centrum Diagnostyki i Terapii AIDS, Warsaw, Poland; and<br />
8Pfizer Global R&D, New London, CT, US<br />
793 24-Week Data from Study AVX-201: A Prospective,<br />
Randomized, Double-blind, Dose-ranging Phase IIb Study of<br />
Apricitabine in Treatment-experienced Patients with M184V<br />
and NRTI Resistance<br />
Pedro Cahn* 1 , J Altclas2 , M Martins3 , M Losso4 , I Cassetti5 , S Cox6 ,<br />
D Cooper7 , and the AVX-201 Study Group<br />
1 2 Fndn Huesped, Buenos Aires, Argentina; Sanatorio de la Trinidad<br />
Mitre, Buenos Aires, Argentina; 3Inst Oulton, Cordoba, Argentina; 4Hosp JM Ramos Mejia, Buenos Aires, Argentina; 5Helios Salud, Buenos Aires,<br />
Argentina; 6Avexa Ltd, Melbourne, Australia; and 7Natl Ctr for HIV<br />
Epidemiology and Clin Res, Univ of New South Wales, Australia
CROI 2008 Session 131<br />
794 Pharmacokinetics and Potent Anti-HIV-1 Activity of<br />
Amdoxovir plus Zidovudine in a Randomized Double-blind<br />
Placebo-controlled Study<br />
Robert Murphy* 1 , C Zala2 , C Ochoa3 , P Tharnish4 , J Mathew4 ,<br />
E Fromentin5 , G Asif5 , S Hurwitz5 , N Kivel4 , and R Schinazi5 1 2 Univ Pierre and Marie Curie, Paris, France; Hosp Privado Modelo,<br />
Buenos Aires, Argentina; 3ACLIRES-Argentina, Buenos Aires; 4RFS Pharma, LLC, Tucker, GA, US; and 5Emory Univ Sch of Med and VAMC,<br />
Atlanta, GA, US<br />
795 Vicriviroc in Combination Therapy with an Optimized ART<br />
Regimen for Treatment-experienced Subjects: VICTOR-E1<br />
Barry Zingman* 1 , J Suleiman2 , E DeJesus3 , J Slim4 , C Mak5 ,<br />
M McCarthy5 , N Case5 , and L Dunkle5 1 2 Montefiore Med Ctr, Bronx, NY, US; Brazilmed Assistencia Medica e<br />
Pesquisa, Sao Paolo; 3Orlando Immunology Ctr, FL, US; 4St Michael’s<br />
Med Ctr, Newark, NJ, US; and 5Schering-Plough Res Inst, Kenilworth,<br />
NJ, US<br />
796 More Pronounced Effect of Integrase Inhibitor Raltegravir<br />
on Proviral DNA Reduction that other Antiretroviral Drugs<br />
in Patients Achieving Undetectable Viremia<br />
Sari Arponen*, J Benito, S Lozano, F Blanco, C Garrido,<br />
C de Mendoza, J Gonzalez-Lahoz, and V Soriano<br />
Hosp Carlos III, Madrid, Spain<br />
797 The Use and Response to Second Combination ART<br />
Regimens in EuroSIDA<br />
Alessandro Cozzi-Lepri* 1 , M Cunnington2 , A Lazzarin3 , B Clotet4 ,<br />
B Knysz5 , P Gargalianos6 , C Katlama7 , A Karlsson8 , A Phillips1 ,<br />
J Lundgren9 , and EuroSIDA Study Group<br />
1 2 Royal Free and Univ Coll London Med Sch, UK; GlaxoSmithKline<br />
R&D, UK; 3San Raffaele Vita-Salute Univ, Milan, Italy; 4Fndns irsiCaixa<br />
and Lluita contra la SIDA, Badalona, Spain; 5Wrocaw Med Univ, Poland;<br />
6 7 1st IKA Hosp, Athens, Greece; Hosp Pitie-Salpetriere, Paris, France;<br />
8 9 Karolinska Univ Hosp, Stockholm, Sweden; and Copenhagen HIV Prgm,<br />
Hvidovre, Denmark<br />
798 Long-term Consequences of the Delay between Virologic<br />
Failure of HAART and Regimen Modification: A Prospective<br />
Cohort Study<br />
Maya Petersen* 1 , M van der Laan2 , S Napravnik3 , J Eron3 , R Moore4 ,<br />
and S Deeks1 1 2 Univ of California, San Francisco, US; Univ of California, Berkeley,<br />
US; 3Univ of North Carolina at Chapel Hill, US; and 4Johns Hopkins<br />
Univ, Baltimore, MD, US<br />
799 Outcomes of Patients Switched from Enfuvirtide to<br />
Raltegravir within a Virologically Suppressive Regimen<br />
Marianne Harris* 1 , G Larsen1 , and J Montaner2 1 2 St Paul’s Hosp, Vancouver, Canada and BC Ctr for Excellence in<br />
HIV/AIDS, Vancouver, Canada<br />
800 The Relationship of CCR5 Inhibitors to CD4 Cell Count<br />
Changes: A Meta-analysis of Recent Clinical Trials in<br />
Treatment-experienced Subjects<br />
Timothy Wilkin* 1 , H Ribaudo2 , and R Gulick1 1 2 Weill Med Coll of Cornell Univ, New York, NY, US and Harvard Sch of<br />
Publ Hlth, Boston, MA, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 129–Poster Abstracts<br />
ART: Adherence<br />
801 No Decline in High Levels of Electronic Pill Cap,<br />
Unannounced Home Pill Count, and Patient-reported<br />
Adherence to Free ART over 12 Months in Rural Uganda<br />
David Bangsberg* 1 , N Emenyonu1 , I Andia2 , M Bwana2 , L Pepper2 ,<br />
K Ragland1 , S Weiser1 , J Hahn1 , S Deeks1 , and J Martin1 1 2 Univ of California, San Francisco, US and Mbarara Univ Sci Tech,<br />
Kampala, Uganda<br />
803 Rates of Ritonavir Non-adherence and Dose Staggering in<br />
HIV + Patients Receiving Ritonavir-boosted Atazanavir or<br />
Fosamprenavir<br />
Jonathan Shuter* 1,2 , R Rode3 , J Sarlo1 , and B Zingman1,2 1 2 Montefiore Med Ctr, Bronx, NY, US; Albert Einstein Coll of Med, Bronx,<br />
NY, US; and 3Abbott Labs, Abbott Park, IL, US<br />
804 Adherence to Protease Inhibitors: Analysis of 776 Patients’<br />
Electronically Compiled Dosing Histories<br />
B Vrijens1 , AC Lange1 , and Pietro Vernazza* 2<br />
1 2 Aardex Inc, Baar, Switzerland and Hosp Cantonal, St Gallen,<br />
Switzerland<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 130–Poster Abstracts<br />
HIV Care in Different Settings<br />
805 Person-years Lost by Late Presentation for HIV Care in<br />
Maryland<br />
Richard Moore*, J Keruly, and J Bartlett<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
806 Delayed Diagnosis of HIV Infection and Late Initiation of<br />
ART in the Swiss HIV Cohort Study<br />
M Wolbers1 , H Bucher1,2 , H Furrer3 , M Rickenbach4 , M Cavassini4 ,<br />
R Weber5 , P Schmid6 , E Bernasconi7 , B Hirschel8 , Manuel Battegay* 2 , and<br />
the Swiss HIV Cohort Study<br />
1 2 Basel Inst for Clin Epidemiology, Switzerland; Univ Hosp Basel,<br />
Switzerland; 3Univ Hosp Berne, Switzerland; 4Univ Hosp Lausanne,<br />
Switzerland; 5Univ Hosp Zurich, Switzerland; 6Cantonal Hosp, St Gall,<br />
Switzerland; 7Regional Hosp Lugano, Switzerland; and 8Univ Hosp<br />
Geneva, Switzerland<br />
807 Food Insecurity Is Associated with Incomplete HIV RNA<br />
Suppression among Homeless and Marginally Housed HIVinfected<br />
Individuals in San Francisco<br />
Sheri Weiser* 1 , E Frongillo2 , K Ragland1 , E Riley1 , and D Bangsberg1 1 2 Univ of California, San Francisco, US and Arnold Sch of Publ Hlth,<br />
Univ of South Carolina, Columbia, US<br />
808 What Frequency of Monitoring Is Needed for Healthcare in<br />
an HIV-infected Person?<br />
Joanne Reekie* 1 , B Gazzard2 , H Sambatakou3 , L Machala4 , A Chiesi5 ,<br />
J van Lunzen6 , N Clumeck7 , O Kirk8 , A Mocroft1 , J Lundgren8 , and<br />
EuroSIDA Study Group<br />
1 2 Royal Free and Univ Coll Med Sch, London, UK; Chelsea and<br />
Westminster Hosp, London, UK; 3Ippokration Gen Hosp, Athens, Greece;<br />
4 5 Faculty Hosp Bulovka, Pargue, Czech Republic; Inst Superiore di<br />
Sanita, Rome, Italy; 6Univ Med Ctr Hamburg-Eppendorf, Germany;<br />
7 8 Hosp St Pierre, Brussels, Belgium; and Copenhagen HIV Prgm, Univ of<br />
Copenhagen, Denmark<br />
809 Disparate Virologic Response to HAART between Ethnicities<br />
Amy Weintrob* 1 , G Grandits2 , B Agan3 , A Ganesan4 , N Crum-Cianflone5 ,<br />
S Fraser6 , S Patel7 , G Wortmann1 , S Wegner8 , and V Marconi3 1 2 Walter Reed Army Med Ctr, Washington, DC, US; Univ of Minnesota,<br />
Minneapolis, US; 3San Antonio Military Med Ctr, TX, US; 4Natl Naval<br />
Med Ctr, Bethesda, MD, US; 5Naval Med Ctr San Diego, CA, US; 6Tripler Army Med Ctr, Honolulu, HI, US; 7Naval Med Ctr Portsmouth, VA, US;<br />
and 8Uniformed Svcs Univ, Bethesda, MD, US<br />
810 Race and Sex Differences in HAART Use and Mortality<br />
among HIV-infected Persons in Care<br />
Diana Lemly* 1 , B Shepherd2 , T Hulga2 , P Rebeiro2 , S Stinnette2 ,<br />
R Blackwell3 , S Bebawy2 , A Kheshti3 , T Sterling2 , and S Raffanti2,3 1 2 Vanderbilt Univ Sch of Med, Nashville, TN, US; Vanderbilt Univ,<br />
Nashville, TN, US; and 3Comprehensive Care Ctr, Nashville, TN, US<br />
811 Indicators of the Use of Healthcare Interventions across<br />
Europe<br />
Daria Podlekareva* 1 , J Reekie2 , A Rakhmanova3 , A Horban4 ,<br />
A Mocroft2 , I Karpov5 , P Domingo6 , F Antunes7 , O Kirk1 , J Lundgren1 , and<br />
EuroSIDA Study Group<br />
1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free<br />
and Univ Coll London Med Sch, UK; 3Botkin Hosp of Infectious Diseases,<br />
St Petersburg, Russia; 4Wojewodzki Szpital Zakazny, Warsaw, Poland;<br />
5 6 Belarus State Med Univ, Minsk; Hosp de la Santa Creu i Sant Pau,<br />
Barcelona, Spain; and 7Hosp Santa Maria, Lisbon, Portugal<br />
b Monday, 1-4 pm; Hall B<br />
Session 131–Poster Abstracts<br />
Treatment Outcomes in Scale-up <strong>Program</strong>s<br />
812 When to Start ART in Resource-limited Settings<br />
Rochelle Walensky* 1,2,3 , L Wolf1 , R Wood4 , K Freedberg1,2,5,6 , N Martinson7,8 ,<br />
D Paltiel9 , X Anglaret10,11 , M Fofana1 , H Ribaudo5 , and E Losina1,3,6 1 2 Massachusetts Gen Hosp, Boston, US; Harvard Med Sch, Boston, MA,<br />
US; 3Brigham and Women’s Hosp, Boston, MA, US; 4Univ of Cape Town,<br />
South Africa; 5Harvard Sch of Publ Hlth, Boston, MA, US; 6Boston Univ<br />
Sch of Publ Hlth, MA, US; 7Perinatal HIV Res Unit, Johannesburg, South<br />
Africa; 8Johns Hopkins Univ Sch of Med, Baltimore, MD, US; 9Yale Univ<br />
Sch of Publ Hlth, New Haven, CT, US; 10Prgm PACCI, Abidjan Côte<br />
d’Ivoire; and 11Univ Victor Segalen, Bordeaux, France<br />
813 Evaluation of the Adult 2006 World Health Organization<br />
HIV/AIDS Clinical Staging in Predicting Initiation of ART in<br />
Uganda<br />
Steven Baveewo* 1 , F Ssali2 , C Karamagi1 , and E Katabira1 1 2 Makerere Univ Med Sch, Kampala, Uganda and Joint Clinical Res Ctr,<br />
Kampala, Uganda<br />
<strong>Program</strong> 53<br />
Poster Listings
Poster Litings<br />
Session 131 CROI 2008<br />
814 Normalization of CD4 Count in Thai Patients Started<br />
NNRTI-based Regimens at Low Nadir CD4 Count<br />
Tanakorn Apornpong* 1 , N Phanuphak 1 , S Limpongsanurak 2 ,<br />
W Luesomboon 3 , A Tangsathapornpong 4 , N Singhakovinta 5 , C Viravasiri 6 ,<br />
P Toro 7 , E Abrams 7 , and P Phanuphak 1<br />
1 Thai Red Cross AIDS Res Ctr, Bangkok; 2 King Chulalongkorn Memorial<br />
Hosp, Bangkok, Thailand; 3 Queen Sawangwattana Memorial Hosp,<br />
Chonburi, Thailand; 4 Thammasat Univ Hosp, Bangkok, Thailand; 5 Queen<br />
Sirikit Hosp, Chonburi, Thailand; 6 Police Gen Hosp, Bangkok, Thailand;<br />
and 7 Columbia Univ, New York, NY, US<br />
815 Evaluation of Outcomes in a Large HIV Comprehensive<br />
Scale-up <strong>Program</strong>: The Harvard PEPFAR Nigeria<br />
Ernest Ekong* 1 , S Meloni 2 , D Onwujekwe 3 , C Okany 4 , I Adewole 5 ,<br />
R Nkado 6 , W Gashau 7 , J Idoko 8 , R Murphy 9 , and P Kanki 2<br />
1 APIN Plus/Harvard PEPFAR Nigeria, Lagos; 2 Harvard-PEPFAR Prgm,<br />
Nigeria and Harvard Sch of Publ Hlth, Boston, MA, US; 3 Nigerian Inst of<br />
Med Res, Lagos; 4 Lagos Univ Teaching Hosp, Nigeria; 5 Univ Coll Hosp,<br />
Ibadan, Nigeria; 6 68 Military Hosp, Lagos, Nigeria; 7 Univ Maiduguri<br />
Teaching Hosp, Nigeria; 8 Jos Univ Teaching Hosp, Nigeria; and<br />
9 Northwestern Univ, Chicago, IL, US<br />
816 Initial Treatment Outcomes from a Rural-based ART Scaleup<br />
<strong>Program</strong> in East Africa: The UARTO Cohort<br />
Jeffrey Martin* 1 , N Emenyonu 1 , M Bwana 2 , I Andia 2 , J Bennett 1 , H Cao 3 ,<br />
P Hunt 1 , R Harrigan 4 , S Deeks 1 , D Bangsberg 1 , and East Africa IeDEA<br />
Consortium<br />
1 Univ of California, San Francisco, US; 2 Mbarara Univ of Sci and Tech,<br />
Uganda; 3 California Dept of Hlth Svcs, Richmond, US; and 4 BC Ctr for<br />
Excellence in HIV/AIDS, Vancouver, Canada<br />
817 Maximum Capacity of Restoration of CD4 Counts Is Lower<br />
in HIV-1-infected Patients from Sub-Saharan Africa during<br />
the First Months of cART: ATHENA Cohort<br />
A Kesselring1 , Luuk Gras* 1 , F Wit2,3 , P Reiss2,3 , and F de Wolf1 1 2 HIV Monitoring Fndn, Amsterdam, The Netherlands; Academic Med<br />
Ctr, Univ of Amsterdam, The Netherlands; and 3Ctr for Poverty-Related<br />
Communicable Diseases, Amsterdam, The Netherlands<br />
818 Learning Curve: Increasing Benefit of HAART according to<br />
Year of Initiation in a Middle-income Country<br />
Carlos Beltran*, D Gallardo, M Wolff, J Arancibia, C Gallo, M Ayala,<br />
I Becerra, S Karelovic, and Chilean AIDS Cohort<br />
Chilean AIDS Cohort<br />
819 Mortality of HIV-1-infected Patients Starting ART in Sub-<br />
Saharan Africa: The IeDEA Prognostic Model<br />
Margaret May* 1 , A Boulle2 , E Messou3 , H Tweya4 , L Myer2 , R Wood2 ,<br />
J Sterne1 , M Schechter5 , M Egger6 , and ART-LINC and Intl Epidemiological<br />
Databases to Evaluate AIDS (IeDEA) Southern and Western Africa<br />
1 2 3 Univ of Bristol, UK; Univ of Cape Town, South Africa; CeDReS,<br />
ACONDA, Abidjan, Côte d’Ivoire; 4Lighthouse Clin, Lilongwe, Malawi;<br />
5 6 Federal Univ of Rio de Janeiro, Brazil; and Univ of Berne, Switzerland<br />
820 Time Trends in Demographic and Clinical Characteristics<br />
of Patients Starting ART in Lower-income Countries: The<br />
ART-LINC Collaboration of IeDEA<br />
O Keiser1 , K Anastos2 , E Balestre3 , A Boulle4 , P Braitstein5 , M Brinkhof1 ,<br />
E Sprinz6 , L Myer4 , N Kumarasamy7 , Francois Dabis* 3 , and the ART-<br />
LINC Collaboration of IeDEA<br />
1 2 3 Univ of Bern, Switzerland; Lincoln Hosp, New York, NY, US; Univ<br />
Victor Segalen, Bordeaux, France; 4Univ of Cape Town, South Africa;<br />
5 6 Moi Univ, Eldoret, Kenya; Hosp de Clinicas de Porto Alegre, Brazil;<br />
and 7YRGCARE, Chennai, India<br />
821 Virologic Outcomes and ART Adherence in Adolescents<br />
Compared with Adults in Southern Africa<br />
Jean Nachega* 1 , M Hislop2 , D Dowdy1 , M Cotton3 , L Regensberg2 ,<br />
R Chaisson1 , and G Maartens4 1 2 Johns Hopkins Univ, Baltimore, MD, US; Aid for AIDS Disease Mgmt<br />
Prgm, Cape Town, South Africa; 3Univ of Stellenbosch, Tygerberg, South<br />
Africa; and 4Univ of Cape Town, South Africa<br />
822 2-Year Virologic Outcomes of an Alternative AIDS Care<br />
Model: Evaluation of a Peer Health Worker and Nursestaffed<br />
Community-based <strong>Program</strong> in Uganda<br />
S Alamo1 , Larry Chang* 2 , S Guma1 , J Christopher1 , T Suntoke3 ,<br />
R Omastete1 , J Montis1 , T Quinn2,3 , M Juncker1 , and S Reynolds2,3 1 2 Reach Out Mbuya Parish HIV/AIDS Initiative, Kampala, Uganda; Johns<br />
Hopkins Med Inst, Baltimore, MD, US; and 3NIAID, NIH, Bethesda, MD,<br />
US<br />
823 Immunologic Benefits of Complete vs Partial Virologic<br />
Suppression in Patients Initiating ART in Gugulethu, South<br />
Africa<br />
Elena Losina* 1,2,3 , Y Chang2 , R Kaplan4 , E Campbell4 , R Walensky1,2,5,6 ,<br />
K Freedberg2,3,5,6 , and R Wood4 1 2 Brigham and Women’s Hosp, Boston, MA, US; Massachusetts Gen<br />
Hosp, Boston, US; 3Boston Univ Sch of Publ Hlth, MA, US; 4Univ of Cape<br />
Town, South Africa; 5Harvard Med Sch, Boston, MA, US; and 6Harvard Sch of Publ Hlth, Boston, MA, US<br />
54 15th Conference on Retroviruses and Opportunistic Infections<br />
824 Predictors of Clinical and Immunological Outcomes among<br />
HIV-infected Subjects on ART in Tanzania<br />
Guerino Chalamilla* 1 , M Mwanyika-Sando2 , C Hawkins1 , S Unni1 ,<br />
S Kaaya2 , A Kibao3 , D Mtasiwa3 , and W Fawzi1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US; Muhimbili Univ of Hlth and<br />
Allied Sci, Dar es Salaam, Tanzania; and 3Dar es Salaam City Council,<br />
Tanzania<br />
825 Risk Factors for Discordant Responses to HAART at<br />
Themba Lethu Clinic, Johannesburg, South Africa<br />
Daniel Westreich* 1 , B Malope2 , P MacPhail2 , S Nagar2 , A Van Rie1 ,<br />
and I Sanne2 1 2 Univ of North Carolina at Chapel Hill, Sch of Publ Hlth, US and Univ<br />
of the Witwatersrand, Johannesburg, South Africa<br />
826 Effect of Early Immunovirologic Discordant Responses<br />
on Mortality in Naïve HIV-1-infected Adults Initiating<br />
Treatment in Resource-constrained Countries<br />
Suely Tuboi* 1 , A Pacheco2 , P Braitstein3 , M May4 , R Stone1 , E Sprinz5 ,<br />
D Nash6 , R Wood7 , L Harrison1 , M Schechter8 , and ART-LINC of IeDEA<br />
1 2 Univ of Pittsburgh, PA, US; Oswaldo Cruz Fndn, Rio de Janeiro, Brazil;<br />
3Indiana Univ Sch of Med, Indianapolis, US and Moi Univ Sch of Med,<br />
Eldoret, Kenya; 4Univ of Bristol, UK; 5Federal Univ of Rio Grande do<br />
Sul, Porte Alegre, Brazil; 6Columbia Univ, New York, NY, US; 7Univ of<br />
Cape Town, South Africa; and 8Federal Univ of Rio de Janeiro, Brazil<br />
827 Determinants of Knowledge of Access to ART in Rural<br />
KwaZulu Natal, South Africa<br />
Till Barnighausen* 1,2 , F Tanser1 , G Cooke1,3 , and ML Newell1,4 1Africa Ctr for Hlth and Population Studies, Univ of KwaZulu Natal,<br />
Somkhele, South Africa; 2Harvard Sch of Publ Hlth, Boston, MA, US;<br />
3 4 Imperial Coll, London, UK; and Inst of Child Hlth, London, UK<br />
828 Novel Modular Education of Inpatients with AIDS in a<br />
Resource-poor National AIDS Treatment Center: Impact<br />
of Learning Outcomes on Adherence to HAART and<br />
Cotrimoxazole Prophylaxis, Development of Opportunistic<br />
Infections, and Mortality<br />
Olusegun Busari*, G Oligbu, O Busari, and HIV Study Group<br />
Federal Med Ctr, Ido-Ekiti, Nigeria<br />
829 Changes in Depression and Daily Functioning with Initiation<br />
of ART in HIV-infected Adults in Rural Uganda<br />
Naomi Bock* 1 , CW Lee1 , S Bechange2 , J Moore1 , K Khana2 , W Were2 ,<br />
R King2 , J Mermin2 , F Kaharuza2 , and R Bunnell2 1 2 CDC, Atlanta, GA, US and CDC Uganda, Entebbe<br />
830 Rapid Implementation of More Efficacious ART Regimens<br />
for the Prevention of Mother-to-Child Transmission of HIV<br />
in Rwanda<br />
Landry Tsague* 1 , G Tene1 , C Adje-Toure1 , S Koblavi1 , V Mugisha1 ,<br />
J Rubin1 , G Vandebriel1 , R Sahabo1 , F Tsiouris2 , and E Abrams2 1Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, Kigali,<br />
Rwanda and 2Columbia Univ Mailman Sch of Publ Hlth, New York, NY,<br />
US<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 132–Poster Abstracts<br />
Switching Therapy/Treatment Failure in Scale-up<br />
<strong>Program</strong>s<br />
831 Lopinavir/Ritonavir (LPV/r) + 2 Nucleoside Analogues as<br />
Second-line ART in Protease Inhibitor-naïve Adults in South<br />
Africa: Outcomes and Adverse Effects<br />
Richard Murphy* 1 , H Sunpath2 , A Nijhawan3 , M McLellan1 , and<br />
D Kuritzkes1 1 2 Brigham and Women’s Hosp, Boston, MA, US; McCord Hosp, Durban,<br />
South Africa; and 3Brown Univ Med Sch and Miriam Hosp, Providence,<br />
RI, US<br />
832 Immunological Response to Boosted PI-containing Secondline<br />
ART after Switching for Clinical/Immunological Criteria<br />
Is Comparable to Response to First-line in Patients with Low<br />
CD4 Counts in Africa<br />
Cleophas Chimbetete* 1 , C Kityo2 , P Munderi3 , A Walker4 , A Reid1 ,<br />
F Ssali2 , H Grosskurth3 , J Darbyshire4 , C Gilks5 , and Dart Trial<br />
1 2 3 Univ of Zimbabwe, Harare; Joint Clin Res Ctr, Kampala, Uganda; Med<br />
Res Council/Uganda Virus Res Inst Prgm on AIDS, Entebbe, Uganda;<br />
4 5 Med Res Council Clinical Trials Unit, London, UK; and Imperial Coll<br />
London, UK<br />
833 Clinical and Immunologic Correlates of Mortality and<br />
Virologic Failure among HIV-infected Individuals Receiving<br />
ART >90 Days in Rural Uganda<br />
David Moore* 1,2,3 , S Malamba1 , J Tappero1 , W Were1 , R Degerman1 ,<br />
R Downing1 , and J Mermin1 1 2 Global AIDS Prgm, CDC Uganda, Entebbe; BC Ctr for Excellence<br />
in HIV/AIDS, Vancouver, Canada; and 3Univ of British Columbia,<br />
Vancouver, Canada
CROI 2008 Session 135<br />
834 Immunological Monitoring as an Indicator of Virological<br />
Failure May Lead to Premature Switch to Second-line ART<br />
Regimens<br />
Rami Kantor* 1 , L Diero2 , A DeLong1 , W Emonyi2 , S Kimaiyo2 ,<br />
P Chan1 , J Carter1 , and N Buziba2 1 2 Brown Univ, Providence, RI, US and Moi Univ, Eldoret, Kenya<br />
835 Probability and Predictors of Survival, Drop-out, or Switch<br />
to a WHO Standard Second-line ART Regimen in Resourcelimited<br />
Settings with Viral Load Monitoring Availability:<br />
The DREAM <strong>Program</strong><br />
M Marazzi1 , L Palombi2 , G Guidotti3 , P Germano4 , G Tintisona4 ,<br />
M Magnano San Lio4 , and Andrea De Luca* 5<br />
1 2 Libera Univ Maria SS Assunta, Rome, Italy; Univ of Tor Vergata, Rome,<br />
Italy; 3Inst Superiore di Sanita, Rome, Italy; 4DREAM Prgm, Community<br />
of St Egidio, Italy; and 5Catholic Univ, Rome, Italy<br />
836 Botswana’s ART Failure Management: A 5-Year Review<br />
of the Infectious Disease Care Clinic at Princess Marina<br />
Hospital<br />
Ava Avalos* 1 , T Gaolathe2 , S Cloutier1 , N Ndwapi1 , F Doualla-Bell3 ,<br />
M Mosepele4 , M Zwanila1 , H Moffat4 , K Seipone4 , and M Wainberg3 1 2 Botswana Ministry of Hlth; Botswana Harvard Sch of Publ Hlth AIDS<br />
Initiative Partnership for HIV Res and Ed, Gaborone; 3McGill Univ AIDS<br />
Ctr, Montreal, Canada; and 4Princess Marina Hosp, Gaborone, Botswana<br />
837 Effectiveness and Safety of Generic Second-line PI-based<br />
ART in Western India<br />
Sanjay Pujari* 1,2 , A Dravid3 , N Gupte4 , A Dhananjay3 , M Lynette2 , and<br />
J Sinnott2 1 2 3 Inst of Infectious Diseases, Pune, India; Univ of Tampa, FL, US; Inst of<br />
Infectious Diseases, Pune, India; and 4Consultant Biostatistician<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 133–Poster Abstracts<br />
(see Session 27 on Tuesday for corresponding Poster Discussion)<br />
Risk Factors for Lost-to-Follow-up in Resourcelimited<br />
Settings<br />
838 Characteristics of Facilities and <strong>Program</strong>s Delivering HIV<br />
Care and Treatment Services Are Associated with Loss to<br />
Follow-up Rates in <strong>Program</strong>s from 7 Sub-Saharan African<br />
Countries<br />
Denis Nash* 1 , C Korves1 , S Saito1 , S Sherman1 , B Elul1 , D Hoos1 ,<br />
V Mugisha2 , M Sheriff3 , W El Sadr1 , and Intl Ctr for AIDS Care and<br />
Treatment Prgms (ICAP)<br />
1 2 Columbia Univ Mailman Sch of Publ Hlth, New York, NY, US; Columbia<br />
Univ, Intl Ctr for AIDS Care and Treatment Prgms, Kigali, Rwanda; and<br />
3Columbia Univ, Intl Ctr for AIDS Care and Treatment Prgms, Nairobi,<br />
Kenya<br />
839 Loss to Care and Death before ART: Patients Eligible for<br />
Treatment Who Do Not Make It in Durban, South Africa<br />
Ingrid Bassett* 1,2,3 , B Wang1 , S Chetty4 , J Giddy4 , Z Lu1 , E Losina2,3,5 ,<br />
R Walensky1,2,3,6 , and K Freedberg1,3,5,6 1 2 Massachusetts Gen Hosp, Boston, US; Brigham and Women’s Hosp,<br />
Boston, MA, US; 3Harvard Med Sch, Boston, MA, US; 4McCord Hosp,<br />
Durban, South Africa; 5Boston Univ Sch of Publ Hlth, MA, US; and<br />
6Harvard Sch of Publ Hlth, Boston, MA, US<br />
840 Losses to Follow-up in a Large ART <strong>Program</strong> in Uganda<br />
A Muwanga, Philippa Easterbrook*, P Schaefer, M Wandera, D Okello,<br />
B Castelnuovo, M Kamya, and A Kambugu<br />
Infectious Disease Inst, Kampala, Uganda<br />
841 Loss to Follow-up in Community Clinics in South Africa:<br />
Role of CD4 Count, Gender, and Pregnancy<br />
Bingxia Wang* 1,2 , E Losina1,3,4 , R Stark5 , A Munro5 , R Walensky1,2,3 ,<br />
M Wilke5 , D Martin5 , Z Lu1 , K Freedberg1,2,4,6 , and R Wood7 1 2 Massachusetts Gen Hosp, Boston, US; Harvard Med Sch, Boston, MA,<br />
US; 3Brigham and Women’s Hosp, Boston, MA, US; 4Boston Univ Sch of<br />
Publ Hlth, MA, US; 5South Africa Catholic Relief Svcs; 6Harvard Sch of<br />
Publ Hlth, Boston, MA, US; and 7Univ of Cape Town, South Africa<br />
842 What Becomes of the Defaulters? A Sampling-based<br />
Approach to Determine Outcomes of Patients Who Become<br />
Lost to Follow-up in ART Scale-up <strong>Program</strong>s in Africa<br />
Elvin Geng* 1 , D Bangsberg1 , N Musinguzi2 , N Emenyonu1 , M Bwana2 ,<br />
D Glidden1 , C Yiannoutsos3 , S Deeks1 , J Martin1 , and East Africa IeDEA<br />
Consortium<br />
1 2 Univ of California, San Francisco, US; Mbarara Univ of Sci and Tech,<br />
Uganda; and 3Indiana Univ, Indianapolis, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 134–Poster Abstracts<br />
Complications in Resource-limited Settings<br />
843 Clinical Features Associated with Lactic Acidosis in Malawi<br />
Cecelia Kanyama* 1 , D Gomes2 , E Katengeza1 , N Saukila1 , H Tweya3 ,<br />
G Joaki1 , R Weigel3 , M Hosseinipour1,2 , and Lighthouse Group<br />
1 2 Univ of North Carolina Project, Lilongwe, Malawi; Univ of North<br />
Carolina at Chapel Hill, US; and 3Lighthouse Clin, Lilongwe, Malawi<br />
844 Low-dose Erythropoietin in the Management of HIV-related<br />
Anemia in Uganda<br />
F Ssali1 , J Kayiwa1 , T Otim1 , M Ssemmanda1 , and Eugene Kinyanda* 2<br />
1 2 Joint Clin Res Ctr, Kampala, Uganda and Med Res Council, Entebbe,<br />
Uganda<br />
845 Cause-specific Mortality and Contribution of Immune<br />
Reconstitution Inflammatory Syndrome during the First 2<br />
Years of ART in Uganda<br />
Barbara Castelnuovo* 1 , A Kambugu1 , A Kiragga1 , K Kigonya1 ,<br />
M Kamya2 , and P Easterbrook1 1 2 Infectious Diseases Inst, Kampala, Uganda and Makerere Univ,<br />
Kampala, Uganda<br />
846a Evaluation of Expert Opinion vs 2 Case Definitions of<br />
Immune Reconstitution Inflammatory Syndrome in a South<br />
African Cohort<br />
L Haddow1,2 , Yunus Moosa* 1 , N Khanyile1 , Q Zulu1 , N Sithole1 ,<br />
F Ibrahim2 , and P Easterbrook2 1 2 Univ of KwaZulu Natal, Durban, South Africa and King’s Coll London,<br />
UK<br />
846b Does Cotrimoxazole Prophylaxis Improve Outcomes after<br />
ART Initiation in HIV-infected African Adults: A Causal<br />
Analysis Using Marginal Structural Models<br />
Ann Sarah Walker* 1 , D Ford1 , F Ssali2 , P Munderi3 , A Reid4 ,<br />
A Kambugu5 , C Gilks6 , A Babiker1 , and the DART Trial Team<br />
1 2 Med Res Council Clinical Trials Unit, London, UK; Joint Clin Res<br />
Ctr, Kampala, Uganda; 3Med Res Council/Uganda Virus Res Inst Prgm<br />
on AIDS, Entebbe, Uganda; 4Univ of Zimbabwe, Harare; 5Infectious Diseases Inst, Mulago, Uganda; and 6Imperial Coll, London, UK<br />
b Monday, 1-4 pm; Hall B<br />
Session 135–Poster Abstracts<br />
New Mechanisms of HIV-1 Drug Resistance<br />
847 I132M in HIV-1 Reverse Transcriptase Confers NNRTI<br />
Resistance but NRTI Hypersusceptibility<br />
Zandrea Ambrose* 1 , CW Sheen1 , D Nissley2 , and N Sluis-Cremer1 1 2 Univ of Pittsburgh Sch of Med, PA, US and SAIC-Frederick, MD, US<br />
848 High Phenotypic Resistance to AZT Correlates with an<br />
Increased Availability of Pre-translocated Complexes<br />
throughout the Viral Genome<br />
Brian Scarth* and M Gotte<br />
McGill Univ, Montreal, Canada<br />
849 Introduction of the 64/65 Nucleotide Polymorphisms of<br />
Subtype C HIV-1 into Subtype B HIV-1 Selects for the K65R<br />
Mutational Pathway in Cell Culture<br />
Cedric Invernizzi*, D Coutsinos, D Moisi, M Oliveira, B Spira,<br />
B Brenner, and M Wainberg<br />
McGill Univ AIDS Ctr, Montreal, Canada<br />
850 Effect of Different Enfuvirtide-resistance Mutations on<br />
Variability of the Rev Responsive Element and the rev Gene<br />
in Patients on Enfuvirtide Treatment<br />
Eva Poveda*, M Gonzalez, V Briz, J Gonzalez-Lahoz, and V Soriano<br />
Hosp Carlos III, Madrid, Spain<br />
851 The Pressure Imposed by T-20 Selects Mutations also in the<br />
Regulatory Protein Rev<br />
Valentina Svicher* 1 , R D’Arrigo2 , C Alteri1 , M Trignetti1 , S Dimonte1 ,<br />
A Callegaro3 , S Lo Caputo4 , S Aquaro5 , P Narciso2 , and CF Perno2 1 2 Univ of Tor Vergata, Rome, Italy; Natl Inst of Infectious Diseases,<br />
L Spallanzani, Rome, Italy; 3Hosp Riuniti, Bergamo, Italy; 4Hosp Santa<br />
Maria Annunziata, Florence, Italy; and 5Univ of Calabria, Rende, Italy<br />
852 Impaired Replication Conferred by the N43D Gp41 Mutation<br />
Could Be Restored by Changes in the Gp120 Protein<br />
Cecilia Cabrera* 1 , S Marfil1 , E Garcia1 , L Ruiz1 , M Bofill2 , B Clotet1 , and<br />
J Blanco1 1 2 Fndn irsiCaixa, Badalona, Spain and ICREA, Barcelona, Spain<br />
853 Discordant Effects of Gag Cleavage Site Mutations on the<br />
IC50 of Protease Inhibitors and on HIV Replicative Capacity<br />
Romina Quercia* 1 , E Dam1,2 , D Descamps3 , X Duval3 , A Hance1 , and<br />
F Clavel1 1 2 INSERM U552, Paris, France; Eurofins-Viralliance, Paris, France; and<br />
3Hosp Bichat-Claude Bernard, Paris, France<br />
<strong>Program</strong> 55<br />
Poster Listings
Poster Litings<br />
Session 135 CROI 2008<br />
854 Prevalence, Mutational Patterns, and Phenotypic Correlates<br />
of the L76V Protease Mutation in Relation to LPV-associated<br />
Mutations<br />
Michael Norton* 1 , T Young1 , N Parkin2 , D Tokimoto1 , L Lu1 ,<br />
T Pilot-Matias1 , E Stawiski2 , K Stewart1 , D Kempf1 , and R Sibtain1 1 2 Abbott Labs, Abbott Park, IL, US and Monogram Biosci, South San<br />
Francisco, CA, US<br />
855 A General Method for Identifying Treatment-selected<br />
Resistance Directly from Clinical Records Predicts New<br />
Cross-class HIV Reverse Transcriptase Mutations Arising<br />
from Inhibitor Combinations<br />
Richard Belew* 1 , M Chang1 , J Fessel2 , D Looney3 , C Mathews4 ,<br />
SY Rhee5 , R Shafer5 , and J Wong6 1 2 Univ of California, San Diego, US; Kaiser Permanente, Oakland,<br />
CA, US; 3VA Hlthcare System, San Diego, CA, US; 4Owen Clin, Univ<br />
of California, San Diego, US; 5Stanford Univ, Palo Alto, CA, US; and<br />
6VAMC and Univ of California, San Francisco, US<br />
856 Tracing Pathways of Resistance to Reverse Transcriptase<br />
Inhibitors from Sequencing Mixtures in HIV-1<br />
Art Poon* 1 , D Richman1,2 , and S Frost1 1 2 Univ of California, San Diego, US and VA Hlthcare System, San Diego,<br />
CA, US<br />
857 HIV-1 Vif Mutants with Suboptimal Anti-APOBEC Activity<br />
Facilitate Emergence of Drug Resistance<br />
L Mulder, A Harari, and Viviana Simon*<br />
Mt Sinai Sch of Med, New York, NY, US<br />
858 APOBEC-mediated Sequence Editing and Epidemiological<br />
Surveillance of Transmitted HIV-1 Drug Resistance<br />
Robert Gifford*, SY Rhee, N Eriksson, T Liu, M Kiuchi, A Das, and<br />
R Shafer<br />
Stanford Univ, Palo Alto, CA, US<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 136–Poster Abstracts<br />
Resistance to New Antiretrovirals<br />
859 Viral Resistance to the HIV-1 Maturation Inhibitor<br />
Bevirimat in the Context of a Protease that Confers<br />
Resistance to Protease Inhibitors<br />
Catherine Adamson* 1 , K Waki1 , S Ablan1 , K Salzwedel2 , and E Freed1 1 2 NCI-Frederick, MD, US and Panacos Pharma, Inc, Gaithersburg, MD,<br />
US<br />
860 Characterization of Resistance Properties of a New Integrase<br />
Inhibitor S/GSK364735<br />
Tomokazu Yoshinaga* 1 , K Nakahara1 , M Kobayashi1 , S Miki1 , A Sato1 ,<br />
E Garvey2 , S Foster2 , M Underwood2 , B Johns2 , and T Fujiwara1 1 2 Shionagi, Settsu, Japan and GlaxoSmithKline<br />
861 Effect of M184V, P119S, and T165A HIV-1 RT Mutations on<br />
Enzyme Behaviors and Viral Growth<br />
Guangwei Yang* 1 , E Paintsil1 , G Dutschman1 , CJ Wang1 , H Tanaka2 ,<br />
M Baba3 , and YC Cheng1 1 2 Yale Univ, New Haven, CT, US; Showa Univ, Tokyo, Japan; and<br />
3Kagoshima Univ, Japan<br />
862 Co-receptor Tropism, ENV Genotype, and in vitro<br />
Susceptibility to CCR5 Antagonists during a 14-Day<br />
Monotherapy Study with INCB9471<br />
Susan Erickson-Viitanen* 1 , K Abremski1 , K Solomon1 , R Levy1 , E Lam2 ,<br />
J Whitcomb2 , R Lloyd3 , R Mathis3 , J Reeves2 , and D Burns3 1 2 Incyte Corp, Wilmington, DE, US; Monogram Biosci, South San<br />
Francisco, CA, US; and 3Res Think Tank, Buford, GA, US<br />
863 Effect of Virus Concentration on in vitro Measurement of<br />
Phenotypic Resistance to the CCR5 Antagonist Vicriviroc<br />
C Buontempo, R Ogert, L Ba, P Buontempo, L Wojcik, J Howe,<br />
R Ralston, and Julie Strizki*<br />
Schering-Plough Res Inst, Kenilworth, NJ, US<br />
864 Detection of Viral Co-receptor Tropism Changes with a<br />
High-sensitivity Phenotypic Assay among HIV-infected<br />
Patients with Drug-resistant Viremia<br />
Peter Hunt* 1 , S Deeks1 , W Huang2 , E Coakley2 , D Han2 , C Petropoulos2 ,<br />
M Bates2 , R Hoh1 , J Martin1 , and J Reeves2 1 2 Univ of California, San Francisco, US and Monogram Biosci, South San<br />
Francisco, CA, US<br />
865 Evaluating the Role of Etravirine in the Second-line<br />
ART after Failing an Initial NNRTI-based Regimens in a<br />
Resource-limited Setting<br />
Somnuek Sungkanuparph* 1 , W Manosuthi2 , S Kiertiburanakul1 ,<br />
B Piyavong1 , and W Chantratita1 1Ramathibodi Hosp, Mahidol Univ, Bangkok, Thailand and<br />
2Bamrasnaradura Infectious Diseases Inst, Ministry of Publ Hlth,<br />
Nonthaburi, Thailand<br />
56 15th Conference on Retroviruses and Opportunistic Infections<br />
866 Prevalence of TMC125 Resistance-associated Mutations in a<br />
Large Panel of Clinical Isolates<br />
Gaston Picchio* 1 , J Vingerhoets2 , M Staes3 , L Tambuyzer2 , L Bacheler4 ,<br />
T Pattery3 , and MP de Bethune2 1 2 3 Tibotec, Inc, Yardley, PA, US; Tibotec BVBA, Mechelen, Belgium; Virco<br />
BVBA, Mechelen, Belgium; and 4VircoLab Inc, Durham, NC, US<br />
867 Etravirine-resistance Mutations in Patients with Virologic<br />
Failure on Nevirapine or Efavirenz-based HAART<br />
Babafemi Taiwo* 1 , B Chaplin2 , J Stanton1 , S Meloni2 , S Akanmu3 ,<br />
W Gashau4 , J Idoko5 , I Adewole6 , R Murphy1 , and P Kanki2 1 2 Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; Harvard<br />
Sch of Publ Hlth, Boston, MA, US; 3Lagos Univ Teaching Hosp, Nigeria;<br />
4 5 Univ of Maiduguri Teaching Hosp Nigeria; Jos Univ Teaching Hosp,<br />
Nigeria; and 6Univ Coll Hosp, Ibadan, Nigeria<br />
868 Prevalence of Mutations with Effect on Virological Response<br />
to Etravirine in Routine Clinical Samples<br />
Josep Llibre* 1 , J Santos1 , T Puig2 , A Blanco2 , R Paredes1 , B Mothe1 , and<br />
B Clotet1,2 1Hosp Univ Germans Trias i Pujol and Fndn Lluita contra la SIDA,<br />
Barcelona, Spain and 2 Fndn irsiCaixa, Barcelona, Spain<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 137–Poster Abstracts<br />
(see Session 13 on Monday for corresponding Poster Discussion)<br />
Emerging Patterns of Resistance to New<br />
Antiretrovirals<br />
869 An Enhanced Version of the Trofile HIV Co-receptor<br />
Tropism Assay Predicts Emergence of CXCR4 Use in<br />
ACTG5211 Vicriviroc Trial Samples<br />
Jacqueline Reeves* 1 , D Han1 , T Wilkin2 , T Wrin1 , D Kuritzkes3 ,<br />
C Petropoulos1 , J Whitcomb1 , N Parkin1 , R Gulick2 , and E Coakley1 1 2 Monogram Biosci, South San Francisco, CA, US; Weill Med Coll of<br />
Cornell Univ, New York, NY, US; and 3Brigham and Women’s Hosp,<br />
Cambridge, MA, US<br />
870 Emergence in vivo of Vicriviroc Resistance in HIV-1 Subtype<br />
C: Role of V3 Loop and Susceptibility to Other CCR5<br />
Antagonists<br />
Athe Tsibris* 1,2 , M Sagar2,3 , Z Su4 , C Flexner5 , W Greaves6 , P Skolnik7 ,<br />
E Coakley8 , M Subramanian9 , R Gulick10 , and D Kuritzkes2,3 1 2 Massachusetts Gen Hosp, Boston, US; Harvard Med Sch, Boston, MA,<br />
US; 3Brigham and Women’s Hosp, Boston, MA, US; 4Harvard Sch of<br />
Publ Hlth, Boston, MA, US; 5Johns Hopkins Univ, Baltimore, MD, US;<br />
6 7 Schering-Plough Res Inst, Kenilworth, NJ, US; Boston Med Ctr, MA,<br />
US; 8Monogram Biosci, South San Francisco, CA, US; 9Human Genome<br />
Sci, Rockville, MD, US; and 10Weill Med Coll of Cornell Univ, New York,<br />
NY, US<br />
871 Changes in V3 Loop Sequence Associated with Failure<br />
of Maraviroc Treatment in Patients Enrolled in the<br />
MOTIVATE 1 and 2 Trials<br />
Marilyn Lewis* 1 , J Mori1 , P Simpson1 , J Whitcomb2 , X Li3 , D Roberston1 ,<br />
and M Westby1 1 2 Pfizer Global R&D, Sandwich Labs, Kent, UK; Monogram Biosci, South<br />
San Francisco, CA, US; and 3Faculty of Life Sci, Univ of Manchester, UK<br />
872 Naturally Occurring Polymorphisms in HIV-1 Group M, N,<br />
and O Integrase: Implications for Integrase Inhibitors<br />
John Hackett*, B Harris, V Holzmayer, J Yamaguchi, KC Luk,<br />
C Brennan, G Schochetman, S Devare, and P Swanson<br />
Abbott Diagnostics, Abbott Park, IL, US<br />
873 Development of vircoTYPE HIV-1 Resistance Analysis,<br />
Including Clinical Cutoffs for TMC125, a New NNRTI<br />
Bart Winters* 1 , J Villacian1 , E Van Craenenbroeck1 , and L Bacheler2 1 2 Virco BVBA, Mechelen, Belgium and VircoLab Inc, Durham, NC, US<br />
874 Characterization of Virologic Failures on Darunavir/<br />
Ritonavir in the Randomized, Controlled, Phase III TITAN<br />
Trial in Treatment-experienced Patients<br />
Sandra De Meyer* 1 , E Lathouwers1 , I Dierynck1 , E De Paepe1 ,<br />
B Van Baelen1 , T Vangeneugden1 , S Spinosa-Guzman1 , G Picchio2 , and<br />
MP de Bethune1 1 2 Tibotec BVBA, Mechelen, Belgium and Tibotec Inc, Yardley, PA, US<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 138–Poster Abstracts<br />
Minor Drug-resistant Variants: Detection and<br />
Clinical Significance<br />
875 Ultra-deep Pyrosequencing of HBV Quasispecies in<br />
3TC-treated and -untreated HIV-co-infected Patients<br />
Severine Margeridon-Thermet* 1 , N Shulman 1 , C Wang 1 , A Ahmed 1 ,<br />
B Gharizadeh 1 , B Simen 2 , J Simons 2 , M Egholm 2 , and R Shafer 1<br />
1 Stanford Univ, Palo Alto, CA, US and 2 454 Life Sci/Roche, Branford, CT,<br />
US
CROI 2008 Session 143<br />
876 Novel HIV-1 Integrase Mutations, Found as Minority<br />
Quasispecies in Patients Naïve to Integrase Inhibitors,<br />
Are Associated with Decreased Susceptibility to Integrase<br />
Inhibitors in vitro<br />
Francesca Ceccherini-Silberstein* 1 , K Van Baelen2 , D Armenia1 ,<br />
M Trignetti1 , L Fabeni1 , E Rondelez2 , A Antinori3 , M Andreoni1 ,<br />
L Stuyver2 , and C Perno1,3 1 2 Univ of Tor Vergata, Rome, Italy; Virco BVBA, Mechelen, Belgium; and<br />
3Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy<br />
877 Evolution of Minority Drug-resistant Viral Populations<br />
during Treatment Interruption<br />
D Wang, C Hicks, N Goswami, F Cai, and Feng Gao*<br />
Duke Univ Med Ctr, Durham, NC, US<br />
878 Virologic Success of Different Strategies for Initial ART<br />
Regimens Is Predicted by the Type and Detection Level<br />
of Minor Drug-resistant Variant Detected by Ultra Deep<br />
Sequencing: The CPCRA 058 FIRST Study<br />
Katherine Huppler Hullsiek* 1 , G Peng1 , B Simen2 , J Simons2 , M Egholm2 ,<br />
R Novak3 , R MacArthur4 , and M Kozal5 1 2 Univ of Minnesota, Minneapolis, US; 454 Life Sci/Roche, Branford, CT,<br />
US; 3Univ of Illinois at Chicago, US; 4Wayne State Univ, Detroit, MI, US;<br />
and 5Yale Univ, New Haven, CT, US<br />
879 The Prevalence of Drug-resistant Virus as a Minority<br />
Quasispecies before Initiating ART Is Not Associated with<br />
Therapy Failure in Persons Initiating Therapy with Truvada<br />
plus PI/r or NNRTI<br />
Karin Metzner* 1 , H Walter1 , P Rauch1 , P Braun2 , H Knechten2 , R Ehret2 ,<br />
N Sichtig3 , R Kaiser3 , J van Lunzen4 , and B Ranneberg5 1 2 Univ of Erlangen-Nuremberg, Germany; Praxis Zentrum Blondelstrasse,<br />
Aachen, Germany; 3Univ of Cologne, Inst of Virology, Germany; 4Univ Med Ctr, Hamburg-Eppendorf, Germany; and 5Gilead Sci, Martinsried,<br />
Germany<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 139–Poster Abstracts<br />
New Resistance Technologies<br />
880 Measurement of Maturation Inhibitor Susceptibility Using<br />
the PhenoSenseHIV Assay<br />
Sunny Choe* 1 , Y Feng1 , K Limoli1 , K Salzwedel2 , S McCallister2 ,<br />
W Huang1 , and N Parkin1 1 2 Monogram Biosci, South San Francisco, CA, US and Panacos Pharma,<br />
Inc, Gaithersburg, MD, US<br />
881 Performance of Prototype Integrase Genotyping Reagents for<br />
Analysis of Diverse HIV-1 Strains<br />
P Smith1 , V Holzmayer2 , L Fang1 , P Swanson2 , J Hackett2 , and Natalia<br />
Marlowe* 1<br />
1 2 Celera, Alameda, CA, US and Abbott Diagnostics, Abbott Park, IL, US<br />
882 Quantification of Resistance to Protease, Reverse<br />
Transcriptase, and Integrase Inhibitors Based on 3’Gag/<br />
PR/RT/INT-Recombinant Viruses: A Useful Tool in the<br />
Upcoming Era of Integrase Inhibitors<br />
Kenneth Henry* 1 , A Vazquez2 , J Weber2 , R Gibson1 , J Weberova2 ,<br />
E Arts1 , and M Quinones-Mateu2 1 2 Case Western Reserve Univ, Cleveland, OH, US and Diagnostic Hybrids<br />
Inc, Cleveland, OH, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 140–Poster Abstracts<br />
HIV-1 Drug Resistance: Genital Shedding and<br />
Recombination<br />
883 Viral Shedding and Drug Resistance in Plasma and Genital<br />
Compartments among Viremic, Multi-drug-experienced<br />
HIV-infected Men and Women<br />
Rami Kantor* 1 , M Wantman2 , D Katzenstein3 , D Bettendorf2 , R Bosch2 ,<br />
S Fiscus4 , R D’Aquila5 , L Frenkel6 , R Coombs6 , and ACTG A5077 Study<br />
Team<br />
1 2 Brown Univ, Providence, RI, US; Harvard Sch of Publ Hlth, Boston,<br />
MA, US; 3Stanford Univ, Palo Alto, CA, US; 4Univ of North Carolina<br />
at Chapel Hill, US; 5Vanderbilt Univ, Nashville, TN, US; and 6Univ of<br />
Washington, Seattle, US<br />
884 Multidrug-resistant HIV-1 and Recombination between<br />
Variants from the Genital Tract and Plasma: A Longitudinal<br />
Analysis<br />
Kimdar Kemal* 1 , C Kitchen2 , H Burger1,3 , B Foley4 , T Klimkait5 ,<br />
F Hamy5 , K Anastos6 , M Suchard2 , V Minin2 , and B Weiser1,3 1 2 Wadsworth Ctr, New York State Dept of Hlth, Albany, US; Univ of<br />
California, Los Angeles, US; 3Albany Med Coll, NY, US; 4Los Alamos<br />
Natl Lab, NM,US; 5Inst of Med Microbio, Univ of Basel and In Pheno<br />
AG, Switzerland; and 6Montefiore Hosp, Bronx, NY, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 141–Poster Abstracts<br />
HIV-2 Drug Resistance<br />
885 Selection of K65R Mutation in HIV-2 Patients Exposed to<br />
Abacavir<br />
Berta Rodes* 1 , C Toro1 , R Colombatti2 , A Simon1 , F Ricardi2 , C Vieira2 ,<br />
A Coin2 , and V Soriano1 1 2 Hosp Carlos III, Madrid, Spain and Hosp Comunita St’Egidio, Bissau,<br />
Guinea Bissau<br />
886 Phenotypic Susceptibility in vitro to Raltegravir and<br />
Elvitegravir and Polymorphism of the Integrase Gene of<br />
HIV-2 Clinical Isolates<br />
Benedicte Roquebert* 1 , F Damond1 , G Collin1 , G Peytavin1 , A Benard2 ,<br />
S Matheron1 , G Chene2 , F Brun-Vezinet1 , D Descamps1 , and French<br />
ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)<br />
1 2 Hosp Bichat-Claude Bernard, Paris, France and INSERM U593,<br />
Bordeaux, France<br />
887 The Role of Innate Polymorphisms in Drug-selected Reverse<br />
Transcriptase Mutations in HIV-1 and HIV-2 Subtypes<br />
Michel Ntemgwa*, B Brenner, T Toni, M Oliveira, D Moisi, B Spira,<br />
E Asahchop, J Schachter, J Martinez-Cajas, and M Wainberg<br />
McGill Univ AIDS Ctr, Jewish Gen Hosp, Montreal, Canada<br />
b Monday, 1-4 pm; Hall B<br />
Session 142–Poster Abstracts<br />
Viral Rebound and Emergence of Drug Resistance<br />
888 RT-SHIV Subpopulation Dynamics before and during the<br />
Course of Antiviral Therapy<br />
Wei Shao* 1 , M Kearney2 , F Maldarelli2 , J Mellors3 , R Stephens1 ,<br />
J Lifson4 , V KewalRamani2 , Z Ambrose2 , J Coffin5 , and S Palmer2 1 2 Advanced Biomed Computing Ctr, SAIC-Frederick, MD, US; HIV Drug<br />
Resistance Prgm, NCI-Frederick, MD, US; 3Univ of Pittsburgh, PA, US;<br />
4 5 SIAC-Frederick, MD, US; and Tufts Univ, Boston, MA, US<br />
889 Differences in the Dynamics of Viral Rebound and Evolution<br />
of Resistance between CBV/NVP and CBV/ABC Uncovered<br />
in the Absence of Viral Load Monitoring in Real Time:<br />
NORA Substudy of the DART Trial<br />
Nicaise Ndembi* 1 , D Pillay2 , R Goodall3 , A McCormick2 , A Burke3 ,<br />
F Lyagoba1 , P Munderi1 , P Katundu4 , S Tugume4 , and P Kaleebu1 on<br />
behalf of the DART Virology<br />
1 2 Med Res Council/Uganda Virus Res Inst, Entebbe; Ctr for Virolgy, Univ<br />
Coll London, UK; 3Med Res Council Clinical Trials Unit, London, UK;<br />
and 4Joint Clin Res Ctr, Kampala, Uganda<br />
890 Absence of Protease Resistance with Virologic Rebound<br />
by Single Genome Sequencing on Atazanavir/Ritonavir as<br />
Simplified Maintenance Therapy: ACTG 5201<br />
John McKinnon* 1 , T Wilkin2 , S Swindells3 , G DiRienzo4 , C Fletcher5 ,<br />
D Margolis6 , G Thal7 , B Bastow8 , K Droll4 , J Mellors1 , and the ACTG<br />
A5201 Study Group<br />
1 2 Univ of Pittsburgh, PA, US; Weill Med Coll of Cornell Univ, New York,<br />
NY, US; 3Univ of Nebraska Med Ctr, Omaha, US; 4Harvard Sch of Publ<br />
Hlth, Boston, MA, US; 5Univ of Colorado Hlth Sci Ctr, Denver, US; 6Univ of North Carolina at Chapel Hill, US; 7Bristol-Myers Squibb, Plainsboro,<br />
NJ, US; and 8ACTG Operations Ctr, Silver Spring, MD, US<br />
b Monday, 1-4 pm; Hall B<br />
Session 143–Poster Abstracts<br />
HIV-1 Drug Resistance after First-line Therapy<br />
891 Drug Resistance after Virological Failure of First-line<br />
HAART in Resource-rich and Resource-poor Settings, a<br />
Meta-Analysis<br />
Ravindra Gupta* 1 , A Hill2 , and D Pillay1,3 1 2 3 Univ Coll London, UK; Univ of Liverpool, UK; and Hlth Protection<br />
Agency, UK<br />
892 Low Risk of Initial ART Failure in Patients with Wild Type<br />
HIV-1 by Standard Genotypic Resistance Testing<br />
Jeffrey Fessel* 1 , SY Rhee2 , D Klein1 , L Hurley1 , T Liu2 , S Follansbee1 ,<br />
S Slome1 , J Flamm1 , M Horberg1 , and R Shafer2 1 2 Kaiser Permanente Med Care Prgm, CA, US and Stanford Univ, Palo<br />
Alto, CA, US<br />
893 The High Frequency of Clinically Significant Mutations<br />
following First-line Generic HAART Failure: Implications<br />
for Second-line Options in Resource-limited Settings<br />
N Kumarasamy* 1 , V Madhavan1 , K Venkatesh2 , S Saravanan1 , R Kantor2 ,<br />
P Balakrishnan1 , B Devaleenol1 , S Solomon1 , K Mayer2 , and R Schooley3 1 2 YRGCARE, Voluntary Hlth Svcs, Chennai, India; Warren Alpert Med<br />
Sch of Brown Univ, Providence, RI, US; and 3Univ of California, San<br />
Diego, US<br />
<strong>Program</strong> 57<br />
Poster Listings
Poster Litings<br />
Session 143 CROI 2008<br />
894 Long-term Probability of Detecting HIV Drug Resistance in<br />
Drug-naïve Patients Starting Currently Recommended Firstline<br />
Combination ART<br />
Alessandro Cozzi-Lepri* 1 , D Dunn 2 , D Pillay 3 , C Sabin 1 , E Fearnhill 2 ,<br />
A Phillips 1 , and UK HIV Drug Resistance Database and UK CHIC Study<br />
Groups<br />
1 Royal Free and Univ Coll London Med Sch, UK; 2 Med Res Council<br />
Clinical Trials Unit, London, UK; and 3 Univ Coll London, UK<br />
b Monday, 1-4 pm; Hall B<br />
Session 144–Poster Abstracts<br />
Changing Prevalence of HIV-1 Drug Resistance<br />
895 Drastically Declining Incidence of HIV Drug Resistance:<br />
The End of the Beginning?<br />
V Lima, E Hudson, B Wynhoven, B Yip, R Hogg, J Montaner, and<br />
Richard Harrigan*<br />
BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada<br />
896 The Proportion of Individuals without Further Treatment<br />
Options Has Stabilized at Low Levels in the Swiss HIV<br />
Cohort Study<br />
Viktor von Wyl* 1 , S Yerly2 , J Boni3 , P Burgisser4 , T Klimkait5 ,<br />
S Bonhoeffer6 , B Ledergerber1 , H Gunthard1 , and the Swiss HIV Cohort<br />
Study (SHCS)<br />
1 2 3 Univ Hosp Zurich, Switzerland; Geneva Univ Hosp, Switzerland; Univ<br />
of Zurich, Switzerland; 4Lausanne Univ Hosp, Switzerland; 5Univ of<br />
Basel, Switzerland; and 6Swiss Federal Inst of Tech, Zurich<br />
897 Causes of Death and Accumulation of Class Drug-resistance<br />
among Survivors and Non-survivors in a Large Cohort of<br />
ARV-naïve Individuals<br />
Vikram Gill* 1,2 , K Fernandes1 , B Wynhoven1 , A Low1,2 , V Lima1 ,<br />
R Hogg1 , and R Harrigan1,2 1 2 BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada and Univ of<br />
British Columbia, Vancouver, Canada<br />
898 Methamphetamine Use Is Not Associated with Increased<br />
Accumulation of HIV-1 Drug-resistant Mutations<br />
Hong-Ha Truong* 1,2 , T Kellogg3 , E Vittinghoff1 , J Martin1 , S Deeks1 ,<br />
R Grant1,2 , G Colfax3 , and P Lum1 1 2 Univ of California, San Francisco, US; Gladstone Inst of Virology and<br />
Immunology, San Francisco, CA, US; and 3San Francisco Dept of Publ<br />
Hlth, CA, US<br />
899 Survey of HIV-1 Drug-resistance Mutations in Recently<br />
Infected, Antiretroviral-naïve Patients from Sub-Saharan<br />
Africa and Southeast Asia<br />
Ahidjo Ayouba* 1 , E Nerrienet2 , L Truong Xuan3 , L Vergne1 , E Mpoudi<br />
Ngole4 , D Valea5 , N Ngo-Giang-Huong6 , D Costagliola7 , M Peeters1 ,<br />
ML Chaix8 , and ANRS 12134 Study Group<br />
1 2 Inst for Res and Devt, UMR145, Montpellier, France; Inst Pasteur,<br />
Phnom Penh, Cambodge; 3Inst Pasteur, Ho Chi Minh City, Vietnam;<br />
4 5 CRESAR/IRD/IMPM, Yaounde, Cameroon; Ctr Muraz, Bobo Dioulasso,<br />
Burkina Faso; 6Chiang Mai Univ, Thailand; 7INSERM U720, Paris,<br />
France; and 8Ctr Hosp Univ Necker, Paris, France<br />
b Monday, 1-4 pm; Hall B<br />
Session 145–Poster Abstracts<br />
Impact of Subtype on HIV-1 Drug Resistance<br />
900 The Effect of Sequence Polymorphisms on CRF01_AE<br />
Protease Structure<br />
Rajintha Bandaranayake* 1 , M Prabu-Jeyablab1 , J Kakizawa2 , W Sugiura2 ,<br />
and C Schiffer1 1 2 Univ of Massachusetts Med Sch, Worcester, US and Natl Inst of<br />
Infectious Diseases, Tokyo, Japan<br />
901 Subtype-specific Differences in ART Drug Resistance<br />
Mutations and TAM Pathways from Nigerian Patients<br />
Beth Chaplin* 1 , G Eisen1 , J Idoko2 , E Idigbe3 , D Olaleye4 , JL Sankale1 ,<br />
R Murphy5 , and P Kanki1 1 2 Harvard Sch of Publ Hlth, Boston, MA, US; Jos Univ Teaching Hosp,<br />
Nigeria; 3Natl Inst of Med Res, Lagos, Nigeria; 4Univ Coll Hosp, Ibadan,<br />
Nigeria; and 5Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US<br />
902 Transmission of HIV-1 Drug Resistance and Forward<br />
Transmission Events in the Aquitaine Cohort, 1996 to 2006<br />
P Recordon-Pinson1,2 , S Capdepont1,2 , D Neau1,2,3 , P Morlat1,2 , JL Pellegrin1,2 ,<br />
A Groppi2 , R Thiebaut3 , F Dabis3 , H Fleury1,2 , Bernard Masquelier* 1,2 , and<br />
ANRS CO3 Aquitaine Cohort<br />
1 2 Ctr Hosp Univ Bordeaux, France; Univ Victor Segalen, Bordeaux,<br />
France; and 3INSERM U593 and EO338, Bordeaux, France<br />
58 15th Conference on Retroviruses and Opportunistic Infections<br />
b Monday, 1-4 pm; Hall B<br />
Session 146–Poster Abstracts<br />
Simplified Diagnostics for Resource-limited<br />
Settings<br />
903 An Improved Microfluidic Device for Point-of-care CD4 +<br />
T Cell Counting through Automated Monocyte Depletion<br />
Xuanhong Cheng* 1 , D Irimia1 , R Tompkins1 , M Toner1 , and<br />
W Rodriguez1,2 1 2 Massachusetts Gen Hosp, Boston, US and Brigham and Women’s Hosp,<br />
Boston, MA, US<br />
904 Evaluation of Peripheral Blood CD4 + T Cells in HIV + Persons<br />
with a Portable Analyzer<br />
J Estes1 , B Bhagwandin2 , S Jackinsky2 , E Most2 , and Timothy Schacker* 3<br />
1 2 3 NCI-Frederick, MD, US; LabNow, Inc, Austin, TX, US; and Univ of<br />
Minnesota, Minneapolis, US<br />
905 Implementation of an Affordable Colorimetric HIV Viral<br />
Load Assay in Monitoring HIV-1- and HIV-2-infected<br />
Patients on HAART in a Resource-limited Setting<br />
Abraham Alabi*, M Cotten, and S Rowland-Jones<br />
Med Res Council Labs, Banjul, Gambia<br />
906 The Cavidi Exavir Viral Load and Phenotype Assays in<br />
Comparison to HIV-1 RNA and Genotyping Assays<br />
Susan Fiscus*, A Cachafeiro, and S Napravnik<br />
Univ of North Carolina at Chapel Hill, US<br />
907 Automated Detection of HIV in Infants Using the New COBAS<br />
Ampliprep/COBAS Taqman HIV-1 Qualitative Test<br />
Wendy Stevens*, L Erasmus, J Moloi, and T Taleng<br />
Univ of the Witwatersrand, Johannesburg, South Africa<br />
b Monday, 1-4 pm; Hall B<br />
Session 147–Poster Abstracts<br />
Evaluation of Serodiagnostic Assays<br />
908 False Negative Rapid HIV Tests in Durban, South Africa<br />
Ingrid Bassett* 1 , S Chetty2 , J Giddy2 , S Reddy3 , E Losina1 , K Freedberg1 ,<br />
and R Walensky1 1 2 Massachusetts Gen Hosp, Boston, US; McCord Hosp, Durban, South<br />
Africa; and 3Univ of KwaZulu Natal, Durban, South Africa<br />
909 Relative Performances of 1 Compared to 2 ELISA Tests on<br />
the First Serum Sample to Diagnose HIV-1 Infection<br />
Dominique Costagliola* 1 , F Damond2 , P Palmer3 , C Rouzioux4 , and<br />
F Brun-Vezinet4 1 2 INSERM U720, Univ Pierre and Marie Curie, Paris, France; Hosp<br />
Bichat-Claude Bernard, Paris, France; 3St Louis Hosp, Paris, France;<br />
and 4Ctr Hosp Univ Necker, Paris, France<br />
b Monday, 1-4 pm; Hall B<br />
Session 148–Poster Abstracts<br />
HLA Testing: Refinements and Cost-effectiveness<br />
910 HLA-B*5701: Rapid Testing by Luminex Technology and<br />
UK Prevalence<br />
Mark Gompels*, R Lock, S Johnston, K Hopkins, and J Ward<br />
North Bristol NHS Trust, UK<br />
911 Genetic Testing in HIV Care: Clinical Effect and Costeffectiveness<br />
of HLA-B*5701 Screening to Guide First-line<br />
Abacavir Use<br />
Bruce Schackman* 1 , C Scott2 , R Walensky2,3,4 , E Losina2,3,5 ,<br />
K Freedberg2,4,5,6 , and P Sax3,4 1 2 Weill Med Coll of Cornell Univ, New York, NY, US; Massachusetts<br />
Gen Hosp, Boston, US; 3Brigham and Women’s Hosp, Boston, MA, US;<br />
4 5 Harvard Med Sch, Boston, MA, US; Boston Univ Sch of Publ Hlth, MA,<br />
US; and 6Harvard Sch of Publ Hlth, Boston, MA, US<br />
912 Statistical Refinement of Low- and Intermediate-resolution<br />
HLA Class I Typing<br />
J Listgarten1 , Z Brumme2 , G Xiaojiang3 , B Walker2 , M Carrington3 ,<br />
P Goulder2,4 , and David Heckerman* 1<br />
1 2 Microsoft Res, Redmond WA, US; Partners AIDS Res Ctr, Boston, MA,<br />
US; 3SAIC-Frederick and NCI-Frederick, MD, US; and 4Univ of Oxford,<br />
UK<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 149–Poster Abstracts<br />
Impact of Subtype on HIV Quantification<br />
913 Comparison Test between the Abbott RealTime and the<br />
Cobas TaqMan Assays for the RNA Quantification of CRF02<br />
and other HIV-1 Non-B Subtypes<br />
Marc Wirden*, AG Marcelin, AA Zaina, JC Piot, L Kalkias,<br />
B Amellal, R Tubiana, A Simon, C Katlama, and V Calvez<br />
Hosp Pitie-Salpetriere, Paris, France
CROI 2008 Session 152<br />
914 Assessment of 3 Commercial Assays for HIV-1 RNA<br />
Quantification of Non-B Subtypes in Plasma Samples: The<br />
Kesho Bora Preparatory Study<br />
F Rouet 1 , V Foulongne 2 , K Steegen 3 , P Becquart 4 , D Valea 1 ,<br />
K Mandaliya 5 , S Luchters 6 , R Nduati 7 , E Njagi 7 , Philippe Van de Perre* 2 ,<br />
and the Kesho Bora Study Group<br />
1 Ctr Muraz, Bob-Dioulasso, Burkina Faso; 2 Univ Montpellier 1 and Ctr<br />
Hosp Univ Montpellier, France; 3 Intl Ctr for Reproductive Hlth, Ghent,<br />
Belgium; 4 CIRMF, Franceville, Gabon; 5 Coast Provincial Gen Hosp,<br />
Mombasa, Kenya; 6 Intl Ctr for Reproductive Hlth, Mombasa, Kenya; and<br />
7 Kenyatta Natl Hosp, Nairobi, Kenya<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 150–Poster Abstracts<br />
New Diagnostic and Monitoring Tools<br />
915 Enhanced Europium Nanoparticle-based Immunoassay for<br />
Sensitive and Early Detection of HIV-1 Capsid Antigen<br />
Shixing Tang* 1 , J Zhao1 , H Harma2 , X Wang1 , P Norris3 , S Stramer4 , and<br />
I Hewlett1 1 2 Food and Drug Admin, Bethesda, MD, US; Univ of Turku, Finland;<br />
3 4 Blood Systems Res Inst, San Francisco, CA, US; and American Red<br />
Cross, Gaithersburg, MD, US<br />
916 HIV-1 Single-copy Assay Detects Biological Variation in<br />
Viremia in Patients Suppressed on ART<br />
Nadia Urban* 1 , A Wiegand1 , S Palmer1 , J Mican2 , A O’Shea2 ,<br />
C Rehm2 , S Kottilil2 , J Mellors3 , J Coffin1 , and F Maldarelli1 1 2 HIV Drug Resistance Prgm, NCI-Frederick, MD, US; Lab of<br />
Immunoregulation, NIAID, NIH, Bethesda, MD, US; and 3Univ of<br />
Pittsburgh, PA, US<br />
917 Accurate Representation of in vivo HIV-1 Quasispecies Plays<br />
an Important Role in the Quantification of Viral Tropism:<br />
A Comparison of 3 Different Methods to Generate env-<br />
Recombinant Viruses<br />
J Weber1 , K Henry2 , R Gibson2 , J Weberova1 , A Vazquez1 , E Arts2 , and<br />
Miguel E Quinones-Mateu* 1<br />
1 2 Diagnostic Hybrids Inc, Cleveland, OH, US and Case Western Reserve<br />
Univ, Cleveland, OH, US<br />
918 Usefulness of a Dendogram Plot Technique in Clustering<br />
Homogeneous Subgroups of Multi-treated HIV-1 Patients in<br />
Accordance with their Mutational Pattern<br />
Nuria Perez-Alvarez* 1,2 , J Llibre1 , B Clotet1,3 , and the Conference Call<br />
Spanish Group<br />
1 2 Lluita contra la SIDA Fndn, Barcelona, Spain; Univ Politecnica de<br />
Catalunya, Barcelona, Spain; and 3Fndn irsiCaixa, Barcelona, Spain<br />
919 SensiTrop QT: A Novel Molecular Diagnostic Assay for the<br />
Detection and Quantification of HIV Co-receptor Tropism<br />
Wenhui Li*, E Webb, L Nary, and T Robins<br />
Pathway Diagnostics, Malibu, CA, US<br />
920a Comparison of Results from the SensiTrop vs Trofile Assays on 100 Samples from the Maraviroc Expanded Access<br />
<strong>Program</strong><br />
Randall Tressler* 1 , H Valdez1 , E van der Ryst2 , I James2 , M Lewis2 ,<br />
J Wheeler2 , and S Than1 1 2 Pfizer Inc, New York, NY, US and Pfizer Global R&D, Sandwich, UK<br />
920b High-quality Care Delivery in HIV by the Use of a<br />
Computerized Data System<br />
John Zurlo* 1 , T Crook1 , C Whitener1 , D Greenawalt1 , P Albright1 ,<br />
J Powers1 , and J Quick2 1 2 Penn State Univ, Hershey Med Ctr, Hershey, US and MajCo Svcs,<br />
Hershey, PA, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 151–Poster Abstracts<br />
Diagnosis and Monitoring Using Dried Specimens<br />
921 Validation and Quality Assurance of the Infant Diagnostic<br />
PCR Test Using a Second Spot from the Same Dried Blood<br />
Spot Sample in Nigeria<br />
Chin-Yih Ou* 1 , O Bolu1 , K Bond2 , R Audu1 , A Abimiku3 , K Diallo1 , L Lu1 ,<br />
T Jelpe2 , M Okoye4 , A Abubakar2 , and Federal Ministry of Hlth<br />
1 2 3 CDC, Atlanta, GA, US; CDC Nigeria, Abuja; Inst of Human Virology,<br />
Jos, Nigeria; and 4USAID, Abuja, Nigeria<br />
922 A Low-cost Real-time PCR Assay for HIV-1 Diagnosis and<br />
Quantification Using Dried Blood Spots<br />
Nishaki Mehta* 1 , S Trzmielina1 , M Eliot2 , B Nonyane2 , A Foulkes2 ,<br />
J Sullivan1 , K Luzuriaga1 , and M Somasundaran1 1 2 Univ of Massachusetts Med Sch, Worcester, US and Univ of<br />
Massachusetts Sch of Publ Hlth and Hlth Sci, Amherst, US<br />
923 Qualitative Analysis of Dried Blood Spots for the Diagnosis<br />
of Infants and Detection of Acute Infection from Pooled<br />
Samples<br />
R Kerr, G Player, S Fiscus, and Julie Nelson*<br />
Univ of North Carolina at Chapel Hill, US<br />
924 HIV-1 DNA Yield from Dried Blood Spots Is Diminished<br />
after Storage at 37oC Compared to -20oC Caroline Mitchell and IMPAACT Dried Blood Spot Working Group<br />
Univ of Washington, Seattle, US<br />
925 Validation of the NucliSens EasyQ Assay on Dried Fluid<br />
Spots for Monitoring of HIV-1 Infection in South Africa<br />
Mohammed Abdo* 1 , G Sherman2 , and W Stevens2 1 2 Wits Pediatric HIV Clin, Johannesburg, South Africa and Univ of the<br />
Witwatersrand, Johannesburg, South Africa<br />
926 Correlation between HIV-1 Viral Load Quantification<br />
Measured in Dried Blood Spots and Plasma Using 2<br />
Commercial Assays<br />
Carolina Garrido*, N Zahonero, V Soriano, and C de Mendoza<br />
Hosp Carlos III, Madrid, Spain<br />
927 Efficient HIV-1 Drug Resistance Genotyping from Dried<br />
Blood Spots Stored for 1 Year at 4ºC<br />
A Youngpairoj1 , S Masciotra1 , C Garrido2 , N Zahonero2 , C de Mendoza2 ,<br />
and Gerardo Garcia-Lerma* 1<br />
1 2 CDC, Atlanta, GA, US and Hosp Carlos III, Madrid, Spain<br />
928 Dried Blood Spots and the Ultra-sensitive p24 Antigen Assay<br />
for the Diagnosis of Perinatal HIV Infection<br />
Ada Cachafeiro* 1 , G Sherman2 , A Sohn3 , C Beck-Sague4 , and S Fiscus1 1 2 Univ of North Carolina at Chapel Hill, US; Univ of the Witwatersrand,<br />
Johannesburg, South Africa; 3Univ of California, San Francisco, US; and<br />
4Clinton Fndn HIV AIDS Initiative, Santo Domingo, Dominican Republic<br />
b Monday, 1-4 pm; Hall B<br />
Session 152–Poster Abstracts<br />
Dyslipidemia: Role of ART and Interventions for<br />
Management<br />
929 Fasted Lipid Changes after Administration of Maraviroc or<br />
Efavirenz in Combination with Zidovudine and Lamivudine<br />
for 48 Weeks to Treatment-naïve HIV-infected Patients<br />
E DeJesus* 1 , S Walmsley2 , C Cohen3 , D Cooper4 , B Hirschel5 ,<br />
J Goodrich6 , H Valdez7 , J Heera6 , N Rajicic6 , and H Mayer6 1 2 Orlando Immunology Ctr, FL, US; Univ of Toronto, Canada;<br />
3 4 Community Res Initiative of New England, Boston, MA, US; Univ of<br />
New South Wales, Australia; 5Hosp Univ of Geneva, Switzerland; 6Pfizer Global R&D, New London, CT, US; and 7Pfizer Inc, New York, NY, US<br />
930 Plasma Exposure of 100 mg Once and Twice Daily Decreases<br />
HDL and CD36 Expression but Only Twice-daily Dosing<br />
Increases Triglycerides: Potential Effect of Ritonavir on<br />
Cardiovascular Disease<br />
Marta Boffito* 1 , S Collot-Teixeira2 , F De Lorenzo3 , L Waters1 , C Fletcher1 ,<br />
D Back4 , S Mandalia1 , A Pozniak1 , J McGregor2 , and B Gazzard1 1 2 3 St Stephen’s Ctr, London, UK; King’s Coll London, UK; Chelsea and<br />
Westminster Hosp NHS Fndn Trust, London, UK; and 4Univ of Liverpool,<br />
UK<br />
931 The Effect of Hepatitis C Infection on Metabolic Parameters<br />
following Initial Therapy of HIV-infected Subjects with<br />
Nucleoside ± NNRTI Regimens<br />
Cecilia Shikuma* 1 , H Ribaudo2 , E Zheng2 , M Glesby3 , W Meyer4 ,<br />
K Tashima5 , B Bastow6 , D Kuritzkes7 , R Gulick3 , and ACTG A5095 Study<br />
Team<br />
1 2 Univ of Hawaii, Honolulu, US; Harvard Sch of Publ Hlth, Boston,<br />
MA, US; 3Weill Med Coll of Cornell Univ, New York, NY, US; 4Quest Diagnostics, Baltimore, MD, US; 5Brown Univ, Providence, RI, US;<br />
6 7 Social & Sci Systems, Silver Spring, MD, US; and Brigham and<br />
Women’s Hosp, Boston, MA, US<br />
932 Changes in Markers of Atherogenic Dyslipidemia,<br />
Inflammation, and Platelet Activation with Treatment with<br />
Pravastatin, Fenofibrate, or the Combination: Results from<br />
the ACTG A5087 Team<br />
Carl Fichtenbaum* 1 , TM Yeh2 , S Evans2 , J Aberg3 , and ACTG<br />
1 2 Univ of Cincinnati Coll of Med, OH, US; Harvard Sch of Publ Hlth,<br />
Cambridge, MA, US; and 3New York Univ Sch of Med, NY, US<br />
933 ART Exposure and Insulin Resistance in the Women’s<br />
Interagency HIV Study<br />
Phyllis Tien* 1 , M Schneider2 , S Cole2 , A Levine3 , M Cohen4 , J DeHovitz5 ,<br />
M Young6 , and J Justman7 1 2 VAMC and Univ of California, San Francisco, US; Johns Hopkins Univ<br />
Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3Univ of Southern<br />
California, Los Angeles, US; 4CORE Ctr and Stroger Hosp, Chicago,<br />
IL, US; 5State Univ of New York Downstate Med Ctr, Brooklyn, US;<br />
6 7 Georgetown Univ Med Ctr, Washington, DC, US; and Columbia Univ,<br />
New York, NY, US<br />
934 Differences in Lopinavir Plasma Concentrations Comparing<br />
Kaletra Film Coated Tablets and Soft Gelatin Capsules<br />
Translate into Distinct Lipid Abnormalities<br />
Judit Morello*, S Rodriguez-Novoa, F Blanco, A Rubio,<br />
I Jimenez-Nacher, and V Soriano<br />
Hosp Carlos III, Madrid, Spain<br />
<strong>Program</strong> 59<br />
Poster Listings
Poster Litings<br />
Session 153 CROI 2008<br />
b Monday, 1-4 pm; Hall B<br />
Session 153–Poster Abstracts<br />
Lypoatrophy/Lipohypertrophy: Predictors and<br />
Interventions<br />
935 Clinical Associations of Extremity Fat Loss: ACTG 5142, a<br />
Prospective, Randomized, Phase III Trial of NRTI-, PI-, and<br />
NNRTI-sparing Regimens for ART of Naïve, HIV-1-infected<br />
Subjects<br />
Richard Haubrich* 1 , S Riddler2 , G DiRienzo3 , Y Zheng3 , W Powderly4 , K<br />
Garren5 , D Butcher6 , J Rooney7 , J Mellors2 , D Havlir8 , and the ACTG 5142<br />
Study Team<br />
1 2 Univ of California, San Diego, US; Univ of Pittsburgh, PA, US;<br />
3Harvard Sch of Publ Hlth, Statistical and Data Analysis Ctr, Boston,<br />
MA, US; 4Univ Coll Dublin, Ireland; 5Abbott Labs, Abbott Park, IL, US;<br />
6 7 Bristol-Myers Squibb, Plainsboro, NJ, US; Gilead Sci, Foster City, CA,<br />
US; and 8Univ of California, San Francisco, US<br />
936 Chromium Supplementation Decreases Insulin Resistance<br />
and Trunk Fat<br />
E Aghdassi, Irving Salit*, S Mohammed, B Arendt, and J Allard<br />
Univ Hlth Network, Toronto, Canada<br />
937 ZDV/3TC/LPV/r, but Not NVP/LPV/r, Is Associated with<br />
Limb Fat Loss and Relative Abdominal Fat Accumulation<br />
after 24 Months in ATT-naïve HIV-1-infected Men:<br />
MEDICLAS, a Randomized Clinical Trial<br />
Marit van Vonderen* 1 , M van Agtmael1 , E Hassink2 , A Milinkovic3 ,<br />
K Brinkman4 , S Geerlings5 , M Ristola6 , A van Eeden7 , S Danner1 ,<br />
P Reiss5 , and the MEDICLAS Study Group<br />
1 2 VU Univ Med Ctr, Amsterdam, The Netherlands; Intl Antiviral Therapy<br />
Evaluation Ctr, Amsterdam, The Netherlands; 3Hosp Clin, Barcelona,<br />
Spain; 4Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands;<br />
5 6 Academic Med Ctr, Univ of Amsterdam, The Netherlands; Helsinki<br />
Univ Central Hosp, Finland; and 7Medisch Centrum Jan van Goyen,<br />
Amsterdam, The Netherlands<br />
938 Switching from Combivir to Truvada Preserves Limb Fat:<br />
Results of a DEXA Sub-study of a 48-Week Randomized<br />
Study<br />
Graeme Moyle* 1 , M Fisher2 , and SWEET Study Group<br />
1 2 Chelsea and Westminster Hosp, London, UK and Brighton and Sussex<br />
Univ Hosp, Brighton, UK<br />
939 Influence of NRTI Choice and Efavirenz vs Lopinavir<br />
Treatment Options on Lipoatrophy-associated Adipose<br />
Tissue Toxicity: A Longitudinal Study<br />
E Hammond, B McKinnon, C Pace, D Nolan, and Simon Mallal*<br />
Murdoch Univ and Royal Perth Hosp, Australia<br />
940 Changes in Body Composition Attributable to Lamivudine,<br />
Stavudine, Zidovudine, and Abacavir in HIV-infected<br />
Persons Initiating ART<br />
Judith Shlay* 1 , S Sharma2 , G Bartsch2 , G Peng2 , C Gibert3 , C Grunfeld4 ,<br />
and the CPCRA and INSIGHT<br />
1 2 Denver CPCRA, Denver Publ Hlth, CO, US; Univ of Minnesota,<br />
Minneapolis, US; 3Wide-Reaching AIDS Prgm, VAMC and George<br />
Washington Univ, Washington, DC, US; and 4VAMC and Univ of<br />
California, San Francisco, US<br />
941 How Much Fat Loss Is Needed for Lipoatrophy to Become<br />
Clinically Evident?<br />
Daniel Podzamczer* 1 , E Ferrer1 , E Martinez2 , L del Rio3 , I Ruiz1 ,<br />
J Rosales3 , E Ribera4 , P Barrufet5 , J Llibre6 , M Aranda7 , and the ABCDE<br />
Study Team<br />
1 2 Hosp Univ de Bellvitge, Barcelona, Spain; Hosp Clin, Barcelona, Spain;<br />
3 4 5 CETIR, Barcelona, Spain; Hosp Vall d’Hebron, Barcelona, Spain; Hosp<br />
de Mataro, Barcelona, Spain; 6Hosp Germans Trials i Pujol, Badalona,<br />
Spain; and 7Hosp de Terrassa, Barcelona, Spain<br />
942 Relationship of NRTI-mediated Mitochondrial DNA<br />
Depletion and Respiratory Chain Activity in Primary Human<br />
Subcutaneous Adipocytes<br />
Metodi Stankov*, R Schmidt, G Behrens, and the German Competence<br />
Network HIV/AIDS<br />
Hannover Med Sch, Germany<br />
943 Data on 52-Week Safety and Efficacy of Tesamorelin, a<br />
Growth Hormone-releasing Factor Analogue, in HIVinfected<br />
Patients with Abdominal Fat Accumulation<br />
J Falutz1 , S Allas2 , JC Mamputu2 , D Kotler3 , M Somero4 , D Berger5 ,<br />
S Brown6 , G Richmond7 , J Fessel8 , and Steven Grinspoon* 9<br />
1 2 Montreal Gen Hosp, McGill Univ Hlth Ctr,Canada; Theratechnologies<br />
Inc, Montreal, Canada; 3St Luke’s Roosevelt Hosp Ctr, Columbia Univ<br />
Coll of Physicians and Surgeons, New York, NY, US; 4Palm Springs, CA,<br />
US; 5Northstar Hlth Care, Chicago, IL, US; 6AIDS Res Alliance, West<br />
Hollywood, CA, US; 7Broward Gen Med Ctr, Fort Lauderdale, FL, US;<br />
8 9 Kaiser Fndn Res Inst, CA, US; and Massachusetts Gen Hosp, Harvard<br />
Med Sch, Boston, US<br />
60 15th Conference on Retroviruses and Opportunistic Infections<br />
944 Effects of Diet and Exercise and Rosiglitazone on Body<br />
Composition and Lipids, including Oxidized LDL in HIV +<br />
and HIV – Men and Women<br />
David Mun* 1 , E Engelson1,2 , J Albu1,2 , M Sharma2 , T Pitea2 , and<br />
D Kotler1,2 1Columbia Univ Coll of Physicians and Surgeons, New York, NY, US and<br />
2St Luke’s Roosevelt Hosp Ctr, New York, NY, US<br />
945 Relationship between Polymerase Gamma Polymorphisms<br />
and ART-induced Lipodystrophy in HIV-infected Patients: A<br />
Case Control Study<br />
Franck Chiappini*, E Teicher, D Vittecoq, and A Lemoine<br />
Hosp Paul Brousse, Villejuif, France<br />
946 Lipoatrophy and Lipohypertrophy Are Independently<br />
Associated with Hypertension: The Effect of Lipoatrophy<br />
but not Lipohypertrophy on Hypertension Is Independent of<br />
Obesity<br />
Heidi Crane* 1 , C Grunfeld2 , R Harrington1 , and M Kitahata1 1 2 Univ of Washington, Seattle, US and Univ of California, San Francisco,<br />
US<br />
947 Incidence of Lipodystrophy and Metabolic Syndrome after<br />
the Initiation of Combined ART in Sub-Saharan cART-naïve<br />
Patients<br />
Serge Eholie* 1 , K Lacombe2,3,4 , L Denoeud4 , C Adje1 , F Cao4 ,<br />
O Bouchaud5 , L Slama6 , R Landmann7 , E Bissagnene1 , and PM Girard3,4 1 2 Hosp de Treichville, Abidjan, Côte d’Ivoire; INSERM UMR S707, Paris,<br />
France; 3Univ Pierre and Marie Curie, Paris, France; 4Hosp St Antoine,<br />
Paris, France; 5Hosp Avicenne, Bobigny, France; 6Hosp Tenon, Paris,<br />
France; and 7Hosp Bichat, Paris, France<br />
948 Evaluation of Pregnancy PBMC and Placental MtDNA in<br />
HIV-infected, HAART-treated Women, Compared to HIVuninfected<br />
Women<br />
Helene Cote* 1,2 , E Maan3 , E Papp1 , T Chaworth-Musters3 , I Gadawski1 ,<br />
J van Schalkwyk3 , M Jitratkosol3 , J Forbes3 , D Burdge3 , D Money2,3 , and<br />
the HIV Perinatal Study Group<br />
1 2 Univ of British Columbia, Vancouver, Canada; Women’s Hlth Res<br />
Inst, Vancouver, Canada; and 3Children’s and Women’s Hlth Ctr of BC,<br />
Vancouver, Canada<br />
b Monday, 1-4 pm; Hall B<br />
Session 154–Poster Abstracts<br />
Atherosclerosis, Cardiovascular Risk and HIV<br />
Infection<br />
949 Inflammatory Markers Correlate with Carotid Intima<br />
Media Thickness and Endothelial Activation in HIV-infected<br />
Patients<br />
Allison Ross* 1 , N Rizk1 , M O’Riordan1 , J Adell1 , N Storer1 ,<br />
M Tungsiripat2 , V Dogra3 , D Harrill1 , D Nakamoto1 , and G McComsey1 1Case Western Reserve Univ and Univ Hosp Med Ctr, Cleveland, OH,<br />
US; 2Cleveland Clin Fndn, OH, US; and 3Univ of Rochester Med Ctr,<br />
NY, US<br />
950 Metabolic Risk Factors for Mortality in HIV + Patients<br />
Olamide Jarrett* 1,2 , R Ruthazer1,2 , T Knox1,2 , and C Wanke1,2 1 2 Tufts Univ, Boston, MA, US and Tufts-New England Med Ctr, Boston,<br />
MA, US<br />
951 Role of ART, Viral Replication, and HIV Infection in<br />
Atherosclerosis<br />
Priscilla Hsue* 1 , P Hunt1 , J Martin1 , A Schnell1 , C Kalapus2 , and S Deeks1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp,<br />
CA, US<br />
952 Carotid Intima Media Thickness in HIV-infected Subjects<br />
and Community Controls<br />
Marek Smieja* 1 , E Lonn1 , F Smaill1 , S Buracond1 , S Smith1 , S Anand1 ,<br />
K Gough2 , J Gill3 , S Trottier4 , M Harris5 , and the Canadian HIV Vascular<br />
Study Investigators<br />
1 2 McMaster Univ, Hamilton, Canada; St Michael’s Hosp, Toronto,<br />
Canada; 3Univ of Calgary, Canada; 4Univ Laval, Canada; and 5St Paul’s<br />
Hosp, Vancouver, Canada<br />
953 A Longitudinal Study of Changes in Circulating Markers of<br />
Endothelial Function in HIV Patients Starting Combination<br />
ART<br />
1,2 3 3 3 Ulrik Sloth Kristoffersen* , K Kofoed , G Kronborg , AK Giger ,<br />
A Kjaer1,2 , and AM Lebech3 1 2 Rigshospitalet, Copenhagen, Denmark; Univ of Copenhagen, Denmark;<br />
and 3Hvidovre Univ Hosp, Copenhagen, Denmark<br />
954 Endothelial Activation Markers Are Linked to HIV Status<br />
and Are Independent of ART and Lipoatrophy<br />
Allison Ross*, R Armentrout, M O’Riordan, N Storer, D El Bejjani,<br />
N Rizk, D Harrill, and G McComsey<br />
Case Western Reserve Univ and Univ Hosp Med Ctr, Cleveland, OH, US<br />
955 A Pilot Study of the TNF-α Inhibitor Pentoxifylline to<br />
Improve HIV-related Endothelial Dysfunction<br />
Samir Gupta*, R Johnson, C Saha, K Mather, J Waltz, M Greenwald,<br />
M Clauss, and M Dube<br />
Indiana Univ Sch of Med, Indianapolis, US
CROI 2008 Session 158<br />
956 Risk for Cardiovascular Disease and Regional Adipose Tissue<br />
Depots among HIV-infected Men and Women in the Study of<br />
Fat Redistribution and Metabolic Changes in HIV Infection<br />
David Wohl* 1 , J Currier2 , E Madden3 , R Scherzer3 , P Tien3 , and<br />
C Grunfeld4 1 2 Univ of North Carolina at Chapel Hill, US; Univ of California, Los<br />
Angeles, US; 3VAMC, San Francisco, CA, US; and 4Univ of California,<br />
San Francisco, US<br />
957a Arterial Stiffness in HIV-infected and HIV-uninfected<br />
Rwandan Women<br />
Jason Lazar* 1 , Q Shi2 , A Kagame3 , X Wu4 , M Cohen5 , F Ndamage6 ,<br />
J Mugabo6 , K Anastos7 , and Rwanda Women’s Interassociation Study and<br />
Assessment (RWISA)<br />
1 2 Downstate Med Ctr, Brooklyn, NY, US; New York Med Coll, Valhalla,<br />
US; 3Central Hosp of Kigali, Rwanda; 4Data Solutions LLC, Bronx, NY,<br />
US; 5CORE Ctr and Stroger Hosp, Chicago, IL, US; 6Treatment and Res<br />
on AIDS Ctr, Ministry of Hlth, Kigali, Rwanda; and 7Montefiore Med Ctr,<br />
Bronx, NY, US<br />
957b Effect of ART on Triglyceride and HDL Cholesterol of<br />
Apolipoprotein A5 Genetic Variants in HIV-infected Subjects<br />
Alexandra Mangili* 1,2 , J Gerrior1 , J Ordovas3 , and C Wanke1,2 1 2 Tufts Univ Sch of Med, Boston, MA, US; Tufts-New England Med Ctr,<br />
Boston, MA, US; and 3US Dept of Agriculture, Human Nutrition Res Ctr<br />
on Aging, Boston, MA<br />
957c Do Thymidine Analogues, Abacavir, Didanosine and<br />
Lamivudine Contribute to the Risk of Myocardial Infarction?<br />
The D:A:D Study<br />
C Sabin1 , S Worm2 , R Weber3 , W El-Sadr4 , P Reiss5 , R Thiébaut6 , S DeWit7 ,<br />
M Law8 , A Phillips1 , Jens Lundgren* 2,9 , and the D:A:D Study Group<br />
1 2 Univ Coll London and Royal Free Hosp, UK; Univ of Copenhagen,<br />
Denmark; 3Univ Hosp Zurich, Switzerland; 4Columbia Univ, New York,<br />
NY, US; 5Academic Med Ctr, Amsterdam, The Netherlands; 6Inst for<br />
Publ Hlth, Epi and Devt, Univ Victor Segalen Bordeaux 2, France; 7St Pierre Univ Hosp, Brussels, Belgium; 8Univ of New South Wales, Sydney,<br />
Australia; and 9Rigshospitalet, Copenhagen, Denmark<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 155–Poster Abstracts<br />
Hepatic Complications<br />
958 Evolution of Non-alcoholic Fatty Liver Disease in HIVinfected<br />
Patients: Incidence, Characteristics, and Predictors<br />
Giovanni Guaraldi* 1 , N Squillace1 , C Stentarelli1 , G Orlando1 ,<br />
R D’Amico1 , G Ligabue1 , F Fiocchi1 , S Zona1 , R Esposito1 , and F Palella2 1 2 Univ of Modena and Reggio Emilia, Modena, Italy and Feinberg Sch of<br />
Med, Northwestern Univ, Chicago, IL, US<br />
959 Exposure to Antiretrovirals and Risk for Advanced Liver<br />
Fibrosis: Harmful Effect of Drug-related Metabolic<br />
Abnormalities?<br />
Francisco Blanco*, P Barreiro, P Ryan, J Troya, S Arponen, E Vispo,<br />
L Martin-Carbonero, P Labarga, J Gonzalez-Lahoz, and V Soriano<br />
Hosp Carlos III, Madrid, Spain<br />
960 Low Hepatoxicity in Patients Randomized to Switching to<br />
Nevirapine Once Daily vs Continuing with Nevirapine Twice<br />
Daily<br />
Daniel Podzamczer* 1 , M Olmo1 , J Sanz2 , V Boix3 , B Clotet4 , H Knobel5 ,<br />
G Leibenger1 , P Domingo6 , J Pineda7 , C Vilades8 , and the NODy Study<br />
Group<br />
1 2 Hosp Univ de Bellvitge, Barcelona, Spain; Hosp Ppe de Asturias,<br />
Madrid, Spain; 3Hosp Gral de Alicante, Alicante, Spain; 4Hosp Germans<br />
Trials i Pujol, Badalona, Spain; 5Hosp del Mar, Barcelona, Spain; 6Hosp St Pau, Barcelona, Spain; 7Hosp Valme, Seville, Spain; and 8Hosp Joan<br />
XXIII, Tarragona, Spain<br />
961 Liver Histology and Hepatic Mitochondrial Function in<br />
HIV-1-infected Patients on ART with Chronic Transaminase<br />
Elevation<br />
Marc-Antoine Valantin* 1 , P Ingiliz1 , F Charlotte1 , F Mejda1 ,<br />
S Dominguez1 , R Tubiana1 , C Duvivier2 , A Lombes1 , Y Benhamou1 , and<br />
C Katlama1 1 2 Hosp Pitie-Salpetriere, Paris, France and Ctr Hosp Univ Necker, Paris,<br />
France<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 156–Poster Abstracts<br />
Markers of Inflammation, Immunodeficiency and<br />
Complications<br />
962 The Relationship between Inflammatory Cytokines and Body<br />
Composition in HIV Seropositive and Seronegative Men in a<br />
Substudy of the Multicenter AIDS Cohort Study<br />
Todd Brown* 1 , X Xu 1 , F Palella 2 , L Kingsley 3 , M Witt 4 , J Margolick 1 , and<br />
A Dobs 1<br />
1 Johns Hopkins Univ, Baltimore, MD, US; 2 Northwestern Univ, Chicago,<br />
IL, US; 3 Univ of Pittsburgh, PA, US; and 4 Univ of California, Los<br />
Angeles, US<br />
963 Non-AIDS Co-morbidities by CD4 Level and HAART Use in<br />
Clinical Practice<br />
Richard Moore*, K Gebo, G Lucas, and J Keruly<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
964 Acute Viral Rebound as a Result of Structured Treatment<br />
Interruptions in Chronically HIV-1-infected Subjects: A<br />
Pathway to Cardiovascular Risk?<br />
Emmanouil Papasavvas* 1 , L Azzoni1 , M Pistilli1 , A Hancock1 ,<br />
G Reynolds1 , C Gallo2 , J Kostman2,3 , K Mounzer2 , J Shull2 , and L Montaner1 1 2 Wistar Inst, Philadelphia, PA, US; Philadelphia Field Initiating Group<br />
for HIV Trials, PA, US; and 3Univ of Pennsylvania, Philadelphia, US<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 157–Poster Abstracts<br />
Changes in Bone Mineral Density<br />
965 Short-term Bone Loss in HIV-infected Premenopausal<br />
Women<br />
Michael Yin* 1 , S Cremers1 , D Lu2 , E Shane1 , W Gao2 , D McMahon1 , and<br />
K Anastos2 1 2 Columbia Univ Med Ctr, New York, NY, US and Montefiore Med Ctr,<br />
Bronx, NY, US<br />
966 Bone Mineral Density 96 Weeks after ART Initiation: A<br />
Randomized Trial Comparing Efavirenz-based Therapy<br />
with a Lopinavir/Ritonavir-containing Regimen with<br />
Simplification to LPV/r Monotherapy<br />
Todd Brown* 1 , G McComsey2 , M King3 , R Qaqish3 , B Bernstein3 , and<br />
B da Silva3 1 2 Johns Hopkins Univ, Baltimore, MD, US; Case Western Reserve Univ,<br />
Cleveland, OH, US; and 3Abbott Labs, Abbott Park, IL, US<br />
967 First-line PI-containing Regimens Enhance Decreased Bone<br />
Mineral Density Greater than NNRTI-containing Regimen in<br />
HIV-1-infected Patients: A Substudy of the HIPPOCAMPE–<br />
ANRS 121 Trial<br />
C Duvivier1,2,3 , S Kolta4 , L Assoumou2,3 , J Ghosn1,2,3 , S Rozenberg1 ,<br />
R Murphy1,2 , C Katlama1,2,3 , Dominique Costagliola* 2,3 , and the ANRS 121<br />
Study Group<br />
1 2 Hosp Pitie-Salpetriere, Paris, France; Univ Pierre and Marie Curie,<br />
Paris, France; 3INSERM UMR S720, Paris, France; and 4Hosp Cochin,<br />
Univ Paris-Descartes, Paris, France<br />
968 Tenofovir Use Is Associated with an Increase in Serum<br />
Alkaline Phosphatase in the Swiss HIV Cohort Study<br />
Christoph Fux* 1 , A Rauch1 , M Simcock2,3 , H Bucher2,3 , B Hirschel4 ,<br />
M Opravil5 , P Vernazza6 , M Cavassini7 , E Bernasconi8 , H Furrer1 , and<br />
Swiss HIV Cohort Study (SHCS)<br />
1 2 Univ Hosp Berne, Switzerland; Basel Inst for Clin Epi, Switzerland;<br />
3 4 5 Univ Hosp Basel, Switzerland; Geneva Univ Hosp, Switzerland; Univ<br />
Hosp Zurich, Switzerland; 6Kantonsspital, St Gallen, Switzerland; 7Ctr Hosp Univ Vaudois Lausanne, Switzerland; and 8Hosp Civico, Lugano,<br />
Switzerland<br />
969 Risk Factors for Reduced Bone Mineral Density in HIVinfected<br />
Individuals in the Modern HAART Era<br />
Silvia Guillemi*, F Ng, W Zhang, V Lima, C Rocha, M Harris,<br />
G Bondy, A Belzberg, and J Montaner<br />
BC Ctr for Excellence in HIV/AIDS, Providence Hlth Care and Univ of<br />
British Columbia, Vancouver, Canada<br />
970 Reduced Bone Mineral Density in HCV- or HBV-co-infected<br />
Patients: 2-year Follow-up, ANRS CO3 Aquitaine Cohort,<br />
France<br />
Charles Cazanave* 1,2 , M Dupon1,2 , V Lavignolle-Aurillac3 , N Barthe2 ,<br />
S Lawson-Ayayi1,2,3 , N Mehsen2 , D Lacoste1,2 , JL Pellegrin1,2 , D Neau1,2,3 ,<br />
and F Dabis1,2,3 for the Groupe d’Epidemiologie Clinique du SIDA en<br />
Aquitaine (GECSA)<br />
1 2 COREVIH-Aquitaine, France; Bordeaux Univ Hosp, France; and<br />
3INSERM U593, Inst for Publ Hlth, Epi and Devt, Univ Victor Segalen,<br />
Bordeaux, France<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 158–Poster Abstracts<br />
Renal Disease<br />
971 Deterioration of Renal Function Associated with Current<br />
Level of Immunodeficiency<br />
Ole Kirk* 1 , A Mocroft2 , A d’Arminio Monforte3 , AB Eg Hansen4 ,<br />
J Gatell5 , S Caplinskas6 , G Faetkenheuer7 , P Reiss8 , E Vinogradova9 ,<br />
J Lundgren1 , and the EuroSIDA Study Group<br />
1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free<br />
and Univ Coll London Med Sch, UK; 3Hosp San Paulo, Milan, Italy;<br />
4 5 Rigshospitalet, Copenhagen, Denmark; Hosp Clin of Barcelona, Spain;<br />
6 7 8 Lithuanian AIDS Ctr, Vilnius; Univ Hosp Cologne, Germany; Univ of<br />
Amsterdam, The Netherlands; and 9St Petersburg AIDS Ctr, Russia<br />
972 Chronic Kidney Disease Incidence and Progression to Endstage<br />
Renal Disease in HIV-infected Individuals: A Tale of<br />
2 Races<br />
Gregory Lucas*, B Lau, M Atta, D Fine, J Keruly, and R Moore<br />
Johns Hopkins Univ, Baltimore, MD, US<br />
<strong>Program</strong> 61<br />
Poster Listings
Poster Litings<br />
Session 158 CROI 2008<br />
973 Proteinuria, Glomerular Filtration Rate Reductions, and<br />
Associated Factors among HIV-infected and -uninfected Men<br />
in the Multicenter AIDS Cohort Study<br />
Frank Palella* 1 , X Li2 , L Kingsley3 , S Gupta4 , R Detels5 , J Margolick2 ,<br />
J Phair1 , and L Jacobson2 1 2 Feinberg Sch of Med, Northwestern Univ, Chicago, IL, US; Johns<br />
Hopkins Univ, Baltimore, MD, US; 3Univ of Pittsburgh, PA, US; 4Indiana Univ Sch of Med, Indianapolis, US; and 5Univ of California, Los Angeles,<br />
US<br />
974 The Effects of HIV-1 Viral Suppression and Non-viral Factors<br />
on Clinically Significant Proteinuria in the HAART Era<br />
Samir Gupta* 1 , N Franceschini2 , L Szczech3 , M Smurzynski4 ,<br />
R Kalayjian5 , and ACTG Longitudinal Linked Randomized Trials<br />
(ALLRT) Study Team<br />
1 2 Indiana Univ Sch of Med, Indianapolis, US; Univ of North Carolina at<br />
Chapel Hill, US; 3Duke Univ, Durham, NC, US; 4Harvard Sch of Publ<br />
Hlth, Boston, MA, US; and 5MetroHlth Med Ctr, Cleveland, OH, US<br />
975 Effect of Tenofovir on Renal Function in Patients Using<br />
HAART<br />
Michael Horberg* 1 , B Tang2 , W Towner2 , S Bersoff-Matcha3 , D Klein4 ,<br />
M Silverberg1 , W Chen2 , L Hurley4 , J Chang2 , and J Blank3 1 2 Kaiser Permanente, Oakland, CA, US; Kaiser Permanente Southern<br />
California, Pasadena, US; 3Kaiser Permanente Mid-Atlantic, Washington,<br />
DC, US; and 4Kaiser Permanente Northern California, Oakland, US<br />
976 HIV Care and the Incidence of Acute Renal Failure<br />
J Roe, L Campbell, F Ibrahim, B Hendry, and Frank Post*<br />
King’s Coll London, UK<br />
977a Inefficient Renal Transport of NRTI GS-9148 Indicates Its<br />
Low Potential for Nephrotoxicity<br />
G Laflamme1 , A Ray1 , R Fisher2 , R Mackman1 , and Tomas Cihlar* 1<br />
1 2 Gilead Sci, Foster City, CA, US and Vitron, Tucson, AZ, US<br />
977b A Comparison between Different GFR-estimations<br />
and [125I]-iothalamate, the Gold Standard for GFRmeasurement,<br />
in HIV-infected Patients on HAART<br />
Saskia Vrouenraets* 1,2 , E Fernandez Garcia2 , F Wit1,2 , K Brinkman3 ,<br />
F Hoek1 , R Krediet1 , and P Reiss1,2 for the PREPARE Study Group<br />
1 2 Academic Med Ctr, Amsterdam, The Netherlands; Intl Antiviral Therapy<br />
Evaluation Ctr, Amsterdam, The Netherlands; and 3Onze Lieve Vrouwe<br />
Gasthuis, Amsterdam, The Netherlands<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 159–Poster Abstracts<br />
Impact on Cardiac Function<br />
978 Prevalence and Risk Factors in HIV-infected Persons for<br />
Echocardiographic Abnormalities in the Era of Modern<br />
HAART<br />
K Mondy1 , J Gottdiener2 , Turner Overton* 1 , K Henry3 , L Conley4 ,<br />
T Bush4 , J Hammer5 , C Carpenter6 , M Kojic6 , J Brooks4 , and SUN Study<br />
Investigators<br />
1 2 Washington Univ Sch of Med, St Louis, MO, US; Univ of Maryland,<br />
Baltimore, US; 3HIV Prgm, Hennepin County Med Ctr, Univ of<br />
Minnesota, US; 4CDC, Atlanta, GA, US; 5Univ of Colorado Hlth Sci Ctr,<br />
Denver, US; and 6Miriam Hosp, Providence, RI, US<br />
979 Diastolic Dysfunction is Common in Asymptomatic HIV<br />
Patients<br />
Priscilla Hsue* 1 , H Farah1 , A Bolger1 , S Palav2 , S Ahmed2 , A Schnell1 ,<br />
S Deeks1 , J Martin1 , and D Waters1 1 2 Univ of California, San Francisco, US and San Francisco Gen Hosp,<br />
CA, US<br />
980 Myocarditis Associated with Combined ART in CD8 + Celldepleted<br />
Rhesus Macaques<br />
Lakshmanan Annamalai* 1 , S Westmoreland1 , E Ludlage2 , K Williams3 ,<br />
E Ratai4 , M Lentz4 , R Schinazi5 , N Bischofberger6 , G Gonzalez4 , and<br />
S O’Neil1 1New England Primate Res Ctr, Harvard Med Sch, Southborough, MA,<br />
US; 2Ctr for Comparative Med, Massachusetts Gen Hosp, Charlestown,<br />
US; 3Boston Univ, MA, US; 4AA Martinos Ctr for Biomed Imaging,<br />
Massachusetts Gen Hosp, Charlestown, US; 5Emory Univ Sch of Med and<br />
VAMC, Atlanta, GA, US; and 6Gilead Sci, Foster City, CA, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 160–Poster Abstracts<br />
Hypersensitivity Reactions: Other Drug Toxicities<br />
981 HCP5-Single Nucleotide Polymorphism: A Simple Screening<br />
Tool for Predicting Abacavir Hypersensitivity Reactions<br />
S Colombo 1 , Andri Rauch* 2 , M Rotger 1 , J Fellay 3 , C Fux 2 , C Thurnheer 2 ,<br />
H Furrer 2 , D Goldstein 3 , A Telenti 1 , and Swiss HIV Cohort Study<br />
1 Univ Hosp Lausanne, Switzerland; 2 Univ Hosp Bern, Switzerland; and<br />
3 Duke Univ, Durham, NC, US<br />
62 15th Conference on Retroviruses and Opportunistic Infections<br />
982 Genetic Factors Predicting Abacavir Hypersensitivity and<br />
Tolerance in HLA-B*5701 + Individuals: Combined Analysis<br />
from PREDICT-1, SHAPE, and a Multinational Study<br />
D Nolan1 , D Thorborn2 , M Schaefer3 , R Laird1 , A Rauch4 , J Montaner5 ,<br />
A Hughes3 , I James1 , S Mallal1 , Elizabeth Phillips* 6 , and PREDICT-<br />
1(CNA106030) & SHAPE (ABC107442) Study Teams<br />
1Ctr for Clinical Immunology and Biomed Statistics, Murdoch Univ,<br />
Royal Perth Hosp, Australia; 2GlaxoSmithKline, Brentford, UK;<br />
3 4 GlaxoSmithKline, Research Triangle Park, NC, US; Inselspital Bern,<br />
Switzerland; 5BC Ctr for Excellence in HIV/AIDS, Vancouver, Canada;<br />
and 6Ctr for Clinical Pharma and Infectious Diseases, Murdoch Univ,<br />
Western Australia<br />
983 Risks Associated with Nevirapine Use in Pregnant and Nonpregnant<br />
Women<br />
Erika Aaron* 1 , M Kempf2 , S Criniti1 , E Tedaldi3 , A Warriner2 , R Kumar2 ,<br />
E Gracely1 , and L Bachmann2 1 2 Drexel Univ Coll of Med, Philadelphia, PA, US; Univ of Alabama at<br />
Birmingham, US; and 3Temple Univ Sch of Med, Philadelphia, PA, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 161–Poster Abstracts<br />
in vitro and Animal Studies of Metabolic Toxicity<br />
984 Acute Inhibition of Mitochondrial Function by Efavirenz<br />
Induces Changes in Cellular Lipid Metabolism<br />
A Blas-Garcia, M Rocha, F Baixauli, A Alvarez, V Victor, and<br />
Juan Esplugues*<br />
Univ of Valencia and CIBEREHD, Spain<br />
985 NNRTI, Efavirenz and Nevirapine, Induce Leukocyte–<br />
Endothelial Cell Interactions in the Microvasculature<br />
M Andrade1 , F Baixauli1 , A Blas-Garcia1 , Juan Esplugues* 1,2 , and<br />
A Alvarez1,2 1 2 Univ of Valencia, Spain and CIBEREHD, Valencia, Spain<br />
986 Nef Inhibits Glucose Uptake by Adipocytes and May Induce<br />
Insulin Resistance in HIV + Patients<br />
Laura Cheney*, J Hou, S Morrison, J Pessin, and R Steigbigel<br />
State Univ of New York at Stony Brook, US<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 162–Poster Abstracts<br />
ART Toxicity in Resource-limited Settings<br />
987 Evaluation of ART-related Toxicity Values in Harvard<br />
PEPFAR Nigeria Treatment <strong>Program</strong><br />
Seema Meloni* 1 , E Ekong2 , D Onwujekwe3 , C Okany4 , I Adewole5 ,<br />
R Nkado6 , W Gashau7 , J Idoko8 , R Murphy9 , and P Kanki1 1Harvard-PEPFAR Prgm, Nigeria and Harvard Sch of Publ Hlth, Boston,<br />
MA, US; 2APIN Plus/Harvard PEPFAR, Lagos, Nigeria; 3Nigerian Inst of<br />
Med Res, Lagos; 4Lagos Univ Teaching Hosp, Nigeria; 5Univ Coll Hosp,<br />
Ibadan, Nigeria; 668 Military Hosp, Lagos, Nigeria; 7Univ Maiduguri<br />
Teaching Hosp, Nigeria; 8Jos Univ Teaching Hosp, Nigeria; and<br />
9Northwestern Univ, Chicago, IL, US<br />
988 Outcome of Stavudine-induced Peripheral Neuropathy in<br />
HIV-infected Individuals in Rural Uganda<br />
Gerald Mwima* 1 , D Moore1,2,3 , W Were1 , S Malamba1 , J Mermin1 ,<br />
P Weidle4,5 , F Asiimwe1 , F Forna4,5 , A Barasa1 , and J Tappero1 1 2 Global AIDS Prgm, CDC Uganda, Entebbe; BC Ctr for Excellence<br />
in HIV/AIDS, Vancouver, Canada; 3Faculty of Med, Univ of British<br />
Columbia, Vancouver, Canada; 4Natl Ctr for HIV, STD and TB<br />
Prevention, CDC, Atlanta, GA, US; and 5Global AIDS Prgm, CDC,<br />
Atlanta, GA, US<br />
989 The Cost of Switching from Stavudine to Tenofovir in Firstline<br />
ARV Regimens in South Africa<br />
Ian Sanne* 1 , L Long1 , M Fox2 , and S Rosen2 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Boston<br />
Univ, MA, US<br />
990 Early and Late Toxicities of the First-line Antiretroviral<br />
Regimen in Johannesburg, South Africa<br />
Emily Wong* 1 , D Murdoch2 , J Yarrow3 , J Wing4 , C Feldman4 , and<br />
W Venter3,4 1 2 Univ of California, San Francisco, US; Duke Univ Med Ctr, Durham,<br />
NC, US; 3Reproductive Hlth and HIV Res Unit, Johannesburg, South<br />
Africa; and 4Univ of the Witswatersrand, Johannesburg, South Africa<br />
991 Comparison of Laboratory Based Blood Lactate<br />
Measurements to a Point-of-care Device<br />
Francesca Conradie* 1 , I Sanne1 , P Macphail1 , L Heine1 , P Majuba2 , and<br />
D Rubel2 1Helen Joseph Hosp, Univ of the Witwatersrand, Johannesburg, South<br />
Africa and 2Right to Care, Themba Lethu Clin, Johannesburg, South<br />
Africa
CROI 2008 Session 166<br />
992 Lactate Measurement of Patients with Suspected Lactic<br />
Acidosis with a Hand-held Analyzer in a Large Outpatient<br />
HIV Clinic in Kampala, Uganda<br />
A Kiragga 1 , P Ocama 1 , Steve Reynolds* 2 , H Ojiambo 1 , A Kambugu 1 , and<br />
B Castelnuovo 1<br />
1 Infectious Disease Inst, Kampala, Uganda and 2 Rakai Hlth Svcs Prgm,<br />
Uganda<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 163–Poster Abstracts<br />
TB Screening and Diagnostics<br />
993 TB Screening for Active Disease among HIV-infected Indian<br />
Pregnant Women at Delivery Is Feasible and Has Good<br />
Negative Predictive Value<br />
Amita Gupta* 1 , U Nayak2 , N Gupte3 , L Garde3 , S Patil3 , R Bhosale4 ,<br />
A Kakrani4 , A Bhore4 , J Sastry3 , and R Bollinger1 on behalf of the India<br />
SWEN Study Team<br />
1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Johns Hopkins<br />
Univ Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3BJ Med Coll and<br />
Johns Hopkins Univ, Pune, India; and 4BJ Med Coll, Pune, India<br />
994 Utility of Sputum Smear and Culture in TB Diagnosis in a<br />
Community with High HIV and TB Prevalence<br />
K Middelkoop, Linda-Gail Bekker*, and R Wood<br />
Desmond Tutu HIV Ctr, Inst of Infectious Disease and Molecular Med,<br />
Univ of Cape Town, South Africa<br />
995 Lymphoproliferative Responses to Mycobacterial Antigens<br />
during HIV-associated TB<br />
Timothy Lahey* 1 , M Matee2 , L Mtei2 , and F von Reyn1 1 2 Dartmouth Med Sch, Lebanon, NH, US and Muhimbili Univ Coll of Hlth<br />
Sci, Dar es Salaam, Tanzania<br />
996 2 Whole-blood Immunological Assays and Tuberculin Skin<br />
Test as Diagnostic Tools for Latent TB Infection in HIV +<br />
Patients from a Low-prevalence Country<br />
T Wolf1 , Christoph Stephan* 1 , U Goetsch2 , O Bellinger2 , G Nisius1 ,<br />
G Oremek1 , H Sauer1 , HR Brodt1 , R Gottschalk2 , and S Staszewski1 1 2 Med Ctr at Univ Hosp Frankfurt, Germany and Municipal Publ Hlth<br />
Office, Frankfurt, Germany<br />
997 The Immunoregulation of the Tuberculin Skin Test Is<br />
Related to FoxP3 Expression by Circulating CD4 + T Cells in<br />
Chronic HIV Infection<br />
Heike Sarrazin* 1 , K Wilkinson2 , J Andersson3 , M Rangaka2 , L Radler3 ,<br />
K van Veen2 , C Lange1 , and R Wilkinson2 1 2 Res Ctr Borstel, Germany; Univ of Cape Town, South Africa; and<br />
3Karolinska Inst, Stockholm, Sweden<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 164–Poster Abstracts<br />
HIV/TB Co-infection<br />
998 TB Risk and Smoking in HIV-infected Adults: A Prospective<br />
Cohort<br />
Neil Martinson* 1 , J Golub1 , R Chaisson1 , M Moshabela2 , N Tshabangu2 ,<br />
G de Bruyn2 , S Nayagar2 , G Gray2 , J McIntyre2 , and P Pronyk3 1 2 Johns Hopkins Univ Ctr for TB Res, Baltimore, MD, US; Univ of<br />
the Witwatersrand, Johannesburg, South Africa; and 3Univ of the<br />
Witwatersrand Sch of Publ Hlth, Johannesburg, South Africa<br />
999 Decreased Mortality Associated with Latent TB Treatment<br />
among HIV-infected Persons in Tanzania<br />
Conrad Kabali* 1 , L Mtei2 , F von Reyn3 , K Pallangyo2 , R Waddell3 , and<br />
R Horsburgh1 1 2 Boston Univ Sch of Publ Hlth, MA, US; Muhimbili Univ Coll of Hlth Sci,<br />
Dar es Salaam, Tanzania; and 3Dartmouth Med Sch, Hanover, NH, US<br />
1000 Characteristics and Clinical Outcome of Patients with HIVassociated<br />
TB in Europe and Argentina<br />
Daria Podlekareva* 1 , A Mocroft2 , A Panteleev3 , J Toibaro4 ,<br />
A Rakhmanova5 , V Riekstina6 , H Furrer7 , O Suetnov8 , F Post9 , O Kirk1 ,<br />
and the HIV/TB Study Group<br />
1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free and<br />
Univ Coll London Med Sch, UK; 3St Petersburg City TB Hosp #2, Russia;<br />
4 5 Hosp JM Ramos Mejia, Buenos Aires, Argentina; Botkin Hosp of<br />
Infectious Diseases, St Petersburg, Russia; 6State Agency of TB and Lung<br />
Diseases, Riga, Latvia; 7Univ Hosp Bern, Switzerland; 8Regional Ctr for<br />
AIDS Prophylaxis, Gomel, Belarus; and 9King’s Coll London, UK<br />
1001 TB after HAART Initiation in the US and Canada<br />
Timothy Sterling and North American AIDS Cohort Collaboration on Res<br />
and Design (NA-ACCORD) of the IeDEA<br />
Vanderbilt Univ, Nashville, TN, US<br />
1002 Effect of TB on HIV Viral Load Response in Patients<br />
Accessing ART at Themba Lethu Clinic, South Africa<br />
Sharlaa Faesen* 1 , B Malope1 , D Westreich2 , P MacPhail1 , and I Sanne1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Univ of<br />
North Carolina at Chapel Hill, US<br />
1003 FoxP3-expressing Cells Are Poorly Represented in Lymph<br />
Nodes from HIV/M. tuberculosis Co-infected Patients<br />
Lidia Gazzola* 1 , M Nebuloni2 , F Zanini2 , M Saresella3 , G Marchetti1 ,<br />
M Clerici4 , A d’Arminio Monforte1 , and A Gori5 1 2 San Paolo Hosp, Univ of Milan, Italy; Luigi Sacco Hosp, Univ of Milan,<br />
Italy; 3Don Carlo Gnocchi Fndn, Milan, Italy; 4Univ of Milan, Italy; and<br />
5San Gerardo Hosp, Univ of Milan-Bicocca, Italy<br />
1004 Maturation of Dendritic Cells by M. tuberculosis Dramatically<br />
Inhibits MHC-II Antigen Presentation of HIV-1<br />
David Canaday* and D McDonald<br />
Case Western Reserve Univ Sch of Med, Cleveland, OH, US<br />
1005 A Factorial Study of the Effect of HIV, TB, and<br />
Pharmacogenetics on the Pharmacokinetics and<br />
Pharmacodynamics of Anti-TB Drugs<br />
Geraint Davies* 1,2 , N Cheirakul3 , N Saguenwong4 , A Chaiprasert3 ,<br />
C Chuchuttaworn5 , B Eompokalap4 , S Likanonsakul4 , N White2 , D Back1 ,<br />
and S Khoo1 1 2 Univ of Liverpool, UK; Faculty of Tropical Med, Mahidol Univ,<br />
Bangkok, Thailand; 3Siriraj Hosp, Bangkok, Thailand; 4Bamrasnaradura Infectious Diseases Inst, Nonthaburi, Thailand; and 5Central Chest Hosp,<br />
Nonthaburi, Thailand<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 165–Poster Abstracts<br />
(see Session 29 on Tuesday for corresponding Poster Discussion)<br />
TB-associated Immune Reconstitution<br />
Inflammatory Syndrome<br />
1006 M. tuberculosis-specific T Cell Expansions and the<br />
Pathogenesis of the HIV-TB-associated Immune<br />
Reconstitution Inflammatory Syndrome<br />
G Meintjes1 , K Wilkinson2 , K van Veen1 , K Rebe3 , D Pepper3 ,<br />
K Skolimowska4 , M Rangaka1 , R Seldon1 , G Maartens1 , and<br />
Robert Wilkinson* 1<br />
1 2 3 Univ of Cape Town, South Africa; Natl Inst of Med Res, London, UK; GF<br />
Jooste Hosp, Manenberg, South Africa; and 4Imperial Coll London, UK<br />
1007 Biomarkers of Immune Activation Are Predictors of HIV<br />
Immune Reconstitution Inflammatory Syndrome<br />
David Boulware* 1 , D Meya2 , T Bergemann1 , I Vlasova1 , A Kambugu2 ,<br />
K McAdam2 , E Janoff3 , and P Bohjanen1 1 2 Univ of Minnesota, Minneapolis, US; Infectious Disease Inst, Makerere<br />
Univ, Kampala, Uganda; and 3Univ of Colorado Hlth Sci Ctr, Denver, US<br />
1008 Immunologic Markers as Predictors of TB-associated<br />
Immune Reconstitution Inflammatory Syndrome in HIV and<br />
TB Co-infected Persons in Thailand<br />
Hong Van Tieu* 1 , J Ananworanich2 , A Avihingsanon3,4 ,<br />
W Apateerapong2 , S Sirivichayakul4,5 , S Klongugkara6 ,<br />
B Boonchokchai2 , U Siangphoe2 , S Hammer1 , and W Manosuthi6 1Columbia Univ Coll of Physicians and Surgeons, New York, NY, US;<br />
2South East Asia Res Collaboration with Univ of Hawaii, Bangkok,<br />
Thailand; 3HIV Netherlands Australia Thailand Res Collaboration,<br />
Bangkok; 4Thai Red Cross AIDS Res Ctr, Bangkok; 5Chulalongkorn Univ, Bangkok, Thailand; and 6Bamrasnaradura Infectious Diseases Inst,<br />
Nonthaburi, Thailand<br />
1009 High Rates of Drug-resistant TB among Patients with<br />
Suspected TB Immune Reconstitution Inflammatory<br />
Syndrome in South Africa<br />
Kevin Rebe* 1,2 , G Meintjes1,2 , M Rangaka1 , D Pepper2 , C Morroni1 ,<br />
G Maartens1 , and R Wilkinson1,2,3 1 2 Univ of Cape Town, South Africa; GF Jooste Hosp, Manenberg, South<br />
Africa; and 3Imperial Coll, London, UK<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 166–Poster Abstracts<br />
Cryptococcal and Herpesvirus Infections<br />
1010 The Use of HAART Is Associated with Decreased Risk of<br />
Death during Initial Treatment of Cryptococcal Meningitis in<br />
HIV-infected Adults in Botswana<br />
G Bisson1 , R Nthobatsong1 , R Thakur1 , G Lesetedi1 , K Vinekar2 , P Tebas1 ,<br />
S Gluckman1 , T Gaolathe3 , and Rob Roy MacGregor* 1<br />
1 2 Univ of Pennsylvania Sch of Med, Philadephia, US; Univ of<br />
Pennsylvania, Philadelphia, US; and 3Infectious Diseases Care Clin,<br />
Gaborone, Botswana<br />
1011 The Specificity and Positive Predictive Value of Quantitative<br />
Serum Cryptococcal Antigen Titers in Identifying<br />
Complicated HIV-associated Meningeal Cryptococcosis: Cutpoint<br />
Analysis<br />
Sean Kandel*, E Cachay, and W Mathews<br />
Univ of California, San Diego, US<br />
1012 Cytomegalovirus Viremia in Infants in South Africa: A<br />
Descriptive Study in a High HIV Prevalence Setting<br />
Nei-Yuan Hsiao* 1 , M Zampoli2 , B Morrow2 , H Zar2 , and D Hardie1 1 2 Natl Hlth Lab Svc, Univ of Cape Town, South Africa and Red Cross<br />
Children’s Hosp, Univ of Cape Town, South Africa<br />
<strong>Program</strong> 63<br />
Poster Listings
Poster Litings<br />
Session 166 CROI 2008<br />
1013 Phenotypic and Functional Characterization of<br />
Cytomegalovirus-specific Regulatory T Cells<br />
Adriana Tovar-Salazar*, R Jesser, J Patterson, and A Weinberg<br />
Univ of Colorado Hlth Sci Ctr, Denver, US<br />
1014 Mechanisms of How HIV Infection Affects Herpes Zoster<br />
Occurrence<br />
Chenglong Liu* 1 , A Wilkes2 , R Detels3 , L Jacobson4 , R Kaslow5 ,<br />
J Margolick4 , J Phair6 , and C Rinaldo7 1 2 Georgetown Univ, Washington, DC, US; George Washington Univ,<br />
Washington, DC, US; 3Univ of California, Los Angeles, US; 4Johns Hopkins Univ, Baltimore, MD, US; 5Univ of Alabama at Birmingham, US;<br />
6 7 Northwestern Univ, Chicago, IL, US; and Univ of Pittsburgh, PA, US<br />
1015 Assessment of Varicella Vaccine-specific Immune Responses<br />
among HIV-infected Patients: A Cross-sectional Analysis<br />
Nathalie De Castro*, M Carmagnat, S Kerneis, C Scieux, S Chevret,<br />
C Rabian, and JM Molina<br />
Hosp St Louis, Univ of Paris 7, France<br />
1016 CNS Detection of HIV and Herpes Viruses in HIV-associated<br />
Tuberculous Meningitis—Innocent Bystander or the Enemy<br />
within?<br />
Estee Torok* 1 , N Ngoc2 , T Chau2 , T Hien2 , N Chau2 , J Farrar1 , and<br />
M de Jong1 1 2 Oxford Univ, Ho Chi Minh City, Vietnam and Hosp for Tropical<br />
Diseases, Ho Chi Minh City, Vietnam<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 167–Poster Abstracts<br />
Infectious Complications<br />
1017 AIDS-defining Illnesses Occurring in Treatment-experienced<br />
HIV-1-infected Patients Followed in the ACTG Longitudinal<br />
Linked Randomized Trials Study<br />
Susan Koletar* 1 , M Smurzynski2 , K Wu2 , A Collier3 , R Bosch2 , and<br />
C Benson4 1 2 Ohio State Univ, Columbus, US; Harvard Sch of Publ Hlth, Boston,<br />
MA, US; 3Univ of Washington, Seattle, US; and 4Univ of California, San<br />
Diego, US<br />
1018 Hospitalization for Pneumonia among Individuals with and<br />
without HIV in Denmark 1995 to 2004: A Population-based<br />
Nationwide Cohort Study<br />
Ole Sogaard* 1 , N Lohse2 , J Gerstoft3 , G Kronborg4 , L Ostergaard1 ,<br />
C Pedersen5 , G Pedersen6 , N Obel3 , and the Danish HIV Cohort Study<br />
1 2 Aarhus Univ Hosp, Skejby, Denmark; Aarhus Univ Hosp, Denmark;<br />
3 4 Copenhagen Univ Hosp, Denmark; Copenhagen Univ Hosp, Hvidovre,<br />
Denmark; 5Odense Univ Hosp, Denmark; and 6Aarhus Univ Hosp,<br />
Aalborg, Denmark<br />
1019 The Effect of Chronic Trimethoprim/Sulfamethoxazole Use<br />
on Nasal Carriage of Staphylococcus aureus in HIV-infected<br />
Patients<br />
Shandra Day*, S Koletar, J Mangino, K Stevenson, and M Para<br />
Ohio State Univ, Columbus, US<br />
1020 NKT Cells Regulate Cell Activation in HIV/Leprosy-co-infected<br />
Patients<br />
Karina Carvalho* 1 , J Snnyder-Cappione2 , L Ndhlovua2 , F Bruno1 ,<br />
S Maeda1 , J Yamashita1 , M Xavier3 , P Haslett4 , D Nixon2 , and E Kallas1 1 2 Federal Univ of Sao Paulo, Brazil; Univ of California, San Francisco,<br />
US; 3Federal Univ of Para, Brazil; and 4Univ of Miami, FL, US<br />
1021 Immunogenicity and Safety of Yellow Fever Vaccination in<br />
HIV-infected Patients<br />
O Veit1 , M Niedrig2 , M Cavassini3 , B Hi-Gung2 , C Chappuis3 ,<br />
E Mossdorf4 , P Schmid5 , T Staub6 , Hansjakob Furrer* 1 , and Swiss HIV<br />
Cohort Study<br />
1 2 Univ Hosp Berne, Switzerland; Robert Koch Inst, Berlin, Germany;<br />
3 4 Ctr Hosp Univ Vaudois Lausanne, Switzerland; Univ Hosp Basel,<br />
Switzerland; 5Cantonal Hosp, St Gall, Switzerland; and 6Inst of Infectious<br />
Diseases, Univ Berne, Switzerland<br />
b Wednesday, 1-4 pm; Hall B<br />
Session 168–Poster Abstracts<br />
Malignancies<br />
1022 Incidence and Predictors of Anal Squamous Intraepithelial<br />
Lesions in the SUN Study after 1 Year of Follow-up<br />
Lois Conley* 1 , T Bush1 , T Darragh2 , J Palefsky2 , M Kojic3 , H Martin4 ,<br />
E Unger1 , T Overton5 , S Cu-Uvin3 , and J Brooks1 1 2 3 CDC, Atlanta, GA, US; Univ of California, San Francisco, US; Miriam<br />
Hosp, Providence, RI, US; 4Park-Nicollet Inst, Minneapolis, MN, US; and<br />
5Washington Univ Sch of Med, St Louis, MO, US<br />
1023 Cervical Human Papillomavirus Infection in HIV-1-infected<br />
Pregnant Women in Zimbabwe<br />
David Hill* 1 , D Katzenstein1 , A Shetty2 , C Ley3 , J Palefsky4 , and<br />
Y Maldonado1 1 2 Stanford Univ Sch of Med, Palo Alto, CA, US; Wake Forest Univ Baptist<br />
Med Ctr, Winston-Salem, NC, US; 3Caradon Consulting, San Carlos, CA,<br />
US; and 4Univ of California, San Francisco, US<br />
64 15th Conference on Retroviruses and Opportunistic Infections<br />
1024 Human Papillomavirus Prevalence and Genotype<br />
Correlation with Cervical Cytopathology in Ugandan<br />
Women<br />
Janis Taube* 1 , B Kamira2 , M Motevalli1 , C Nakabiito2 , R Lukande3 ,<br />
D Kelly1 , P Gravitt1 , F Mmiro2 , D Bagenda2 , and B Jackson1 1 2 Johns Hopkins Med Inst, Baltimore, MD, US; Makerere Univ–Johns<br />
Hopkins Univ Res Collaboration, Kampala, Uganda; and 3Makerere Univ, Kampala, Uganda<br />
1025 HTLV-I bZIP Factor Gene Induces T Cell Lymphoma and<br />
Confers Infiltrative Phenotype to T Cells in Transgenic Mice<br />
Y Satou, JI Yasunaga, M Yoshida, and Masao Matsuoka*<br />
Inst for Virus Res, Kyoto Univ, Japan<br />
1026 Treatment of AIDS-related Lymphoma: Rituximab May Be<br />
Beneficial Even in Severely Immunosuppressed Patients<br />
C Wyen1 , Gerd Faetkenheuer* 1 , M Oette2 , A Plettenberg3 , J Rockstroh4 ,<br />
J van Lunzen5 , C Mayr6 , S Esser7 , M Hentrich8 , and C Hoffmann9 1 2 3 Univ of Cologne, Germany; Univ of Dusseldorf, Germany; ifi Inst,<br />
Hamburg, Germany; 4Univ of Bonn, Germany; 5Univ Med Ctr, Hamburg-<br />
Eppendorf, Germany; 6Ärzteforum Seestrasse, Berlin, Germany; 7Univ of<br />
Essen, Germany; 8Hosp Harlaching, Munich, Germany; and 9IPM Study<br />
Ctr, Hamburg, Germany<br />
b Monday, 1-4 pm; Hall B<br />
Session 169–Poster Abstracts<br />
Hepatitis B Co-infection<br />
1028 The Epidemiology of Hepatitis B Virus Infection in HIV-1infected<br />
Individuals over 20 Years: The Effect of HAART<br />
and Vaccination<br />
H Chun1,2 , A Fieberg3,4 , K Huppler Hullsiek3,4 , N Crum-Cianflone2,4 ,<br />
W Bradley4 , A Ganesan4,5 , A Weintrob4,6 , Robert Barthel* 7 , and<br />
M Landrum4,8 1 2 Naval Hlth Res Ctr, San Diego, CA, US; Naval Med Ctr San Diego, CA,<br />
US; 3Univ of Minnesota, Minneapolis, US; 4Infectious Disease Clinical<br />
Res Prgm, Bethesda, MD, US; 5Natl Naval Med Ctr, Bethesda, MD,<br />
US; 6Walter Reed Army Med Ctr, Washington, DC, US; 7Naval Med Ctr<br />
Portsmouth, VA, US; and 8San Antonio Med Ctr, Fort Sam Houston, TX,<br />
US<br />
1029 Death, HIV Suppression, and CD4 Recovery among HIV/<br />
HBV-co-infected Men Receiving ART: MACS<br />
Christopher Hoffmann* 1 , E Seaberg2 , K D’Acunto3 , M Witt4 , J Phair5 ,<br />
and C Thio1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Johns Hopkins Univ<br />
Bloomberg Sch of Publ Hlth, Baltimore, MD, US; 3Univ of Pittsburgh Sch<br />
of Publ Hlth, PA, US; 4David Geffen Sch of Med, Univ of California, Los<br />
Angeles, US; and 5Feinberg Sch of Med, Northwestern Univ, Chicago, IL,<br />
US<br />
1030 Chronic HBV/HIV Co-infection and HIV Suppression, CD4<br />
Recovery, Mortality, and Hepatotoxicity in an African ART<br />
Cohort<br />
Christopher Hoffmann* 1 , S Charalambous2 , D Martin3 , K Fielding4 ,<br />
A Moss3 , G Churchyard2 , R Chaisson1 , A Grant4 , and C Thio1 1 2 Johns Hopkins Univ Sch of Med, Baltimore, MD, US; Aurum Inst for<br />
Hlth Res; 3Toga Labs, Zambia; and 4London Sch of Hygiene and Tropical<br />
Med, UK<br />
1031 Effect of HBV DNA Levels on HIV Infection and Response to<br />
ART in a HIV/HBV-co-infected Nigerian Cohort<br />
J Idoko1 , S Meloni2 , M Muazu1 , C Hawkins3 , B Badung1 , N Ladep1 ,<br />
P Kanki2 , R Murphy3 , E Ekong4 , and Chloe Thio* 5<br />
1 2 Jos Univ Teaching Hosp, Plateau, Nigeria; Harvard Sch of Publ Hlth,<br />
Boston, MA, US; 3Feinberg Sch of Med, Northwestern Univ, Chicago, IL,<br />
US; 4Harvard-PEPFAR Prgm, Lagos, Nigeria; and 5Johns Hopkins Univ,<br />
Baltimore, MD, US<br />
1032 HBV-specific T Cell Responses in HIV-1/HBV-co-infected<br />
Individuals Increase Transiently but Are Not Sustained<br />
following 48 Weeks of HBV-active ART<br />
Judy Chang* 1 , S Sirivichayakul2 , A Avihingsanon2 ,<br />
P Thantiworasit2 , D Cooper3 , G Matthews3 , G Dore3 , K Ruxrungtham2 , and<br />
S Lewin1,4,5 1 2 Univ of Melbourne, Australia; HIV-NAT and Chulalongkorn Univ,<br />
Bangkok, Thailand; 3Natl Ctr in HIV Epi and Clin Res, Univ of New<br />
South Wales, Sydney, Australia; 4Alfred Hosp, Melbourne, Australia; and<br />
5Monash Univ, Melbourne, Australia<br />
1033 Immunopathogenesis of Hepatic Flares after Initiation of<br />
ART in HIV/HBV-co-infected Individuals<br />
Megan Crane* 1 , B Oliver2 , G Matthews3 , A Avihingsanon4 , P Price2,5 ,<br />
K Visvanathan1 , M French2,5 , G Dore3 , K Ruxrungtham4 , and S Lewin1,6 1 2 Monash Univ, Melbourne, Australia; Univ of Western Australia, Perth;<br />
3Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales,<br />
Australia; 4HIV Netherlands Australia Thailand Res Collaboration,<br />
Bangkok; 5Royal Perth Hosp, Australia; and 6Alfred Hosp, Melbourne,<br />
Australia
CROI 2008 Session 171<br />
1034 Selection of Lamivudine Resistance Profile Is Constrained by<br />
HBV Genotypes in Mono- and HIV-co-infected Patients<br />
Valentina Svicher* 1 , C Gori2 , M Trignetti1 , M Visca3 , G Cappiello3 ,<br />
M Angelico4 , G De Sanctis5 , F Ceccherini-Silberstein1 , A Spano3 , and<br />
CF Perno1 1 2 Univ of Tor Vergata, Rome, Italy; Natl Inst of Infectious Diseases,<br />
L Spallanzani, Rome, Italy; 3San Pertini Hosp, Rome, Italy; 4Univ of Tor<br />
Vergata, Rome, Italy; and 5Policlinico “Umberto I”, Rome, Italy<br />
1035 Identification of HBV Pre-surface and Surface Mutations<br />
among HIV + Individuals with Occult HBV Infection<br />
Christina Martin*, N Shire, S Rouster, T Shata, K Sherman, and<br />
J Blackard<br />
Univ of Cincinnati, OH, US<br />
1036 Long-term Serologic Follow-up of HIV-infected Women with<br />
Isolated Hepatitis B Core Antibody: Predictors of Acquisition<br />
of Hepatitis B Surface Antibody<br />
Michael Lin* 1,2 , C Evans3 , E Operskalski4 , M Augenbraun5 ,<br />
A Howard6 , M Young7 , L Benning8 , M Peters9 , A French1,2 , and Women’s<br />
Interagency HIV Study (WIHS)<br />
1 2 Rush Univ Med Ctr, Chicago, IL, US; CORE Ctr and Stroger Hosp,<br />
Chicago, IL, US; 3Univ of Illinois at Chicago, US; 4Univ of Southern<br />
California, Los Angeles, US; 5State Univ of New York Downstate Med<br />
Ctr, Brooklyn, US; 6Montefiore Med Ctr, Bronx, NY, US; 7Georgetown Univ Med Ctr, Washington, DC, US; 8Johns Hopkins Univ Bloomberg Sch<br />
of Publ Hlth, Baltimore, MD, US; and 9Univ of California, San Francisco,<br />
US<br />
1037 Effect of Nationwide Hepatitis B Vaccination <strong>Program</strong> on<br />
Prevalence of HBV Infection and Factors Associated with<br />
Maintaining Protective Anti-HBs Antibody Titers among<br />
HIV-infected Persons<br />
HY Sun1 , WC Ko2 , HC Lee2 , SY Chang1 , and Chien-Chin Hung* 1<br />
1 2 Natl Taiwan Univ Coll of Med, Taipei and Natl Cheng-Kung Univ Hosp,<br />
Taiwan<br />
1038 Occult Hepatitis B Virus Infection in HIV Patients in an<br />
Urban Clinic in Johannesburg, South Africa<br />
Cynthia Firnhaber* 1 , R Viana1 , A Reyneke1 , D Schultz1 , B Malope1 ,<br />
P Macphail1 , I Sanne1 , A Di Bisceglie2 , and M Kew1 1 2 Univ of the Witwatersrand, Johannesburg, South Africa and Univ of St<br />
Louis, MO, US<br />
1039 Longitudinal Evaluation of Hepatitis B, C, or D Viremia in<br />
HIV-HBV-co-infected Patients: Virological Interactions and<br />
Effects of Treatment<br />
Anders Boyd* 1 , K Lacombe1,2,3 , P Miailhes4 , J Gozlan2,3 , P Bonnard5 ,<br />
JM Molina6 , C Lascoux-Combe6 , L Serfaty3 , M Desvarieux1,2,7 , and<br />
PM Girard2,3 1 2 INSERM UMR S707, Paris, France; Univ Pierre and Marie Curie,<br />
Paris, France; 3Hosp St Antoine, Paris, France; 4Hosp Hotel Dieu, Hosp<br />
Civils de Lyon, France; 5Hosp Tenon, Paris, France; 6Hosp St Louis,<br />
Paris, France; and 7Columbia Univ Mailman Sch of Publ Hlth, New York,<br />
NY, US<br />
1040 HBsAg Quantification as Surrogate of Hepatitis Delta Virus<br />
Replication in HIV-co-infected Patients<br />
J Martinez-Alarcon1 , J Sheldon1,2 , Marcelle Bottecchia* 1,2 ,<br />
A Madejon1,2 , C Toro1 , P Rios1,2 , J Garcia-Samaniego1,2 , and V Soriano1 1 2 Hosp Carlos III, Madrid, Spain and Ciber of Liver Diseases, Madrid,<br />
Spain<br />
b Monday, 1-4 pm; Hall B<br />
Session 170–Poster Abstracts<br />
Hepatitis C Co-infection: Cellular Immune<br />
Responses and Pathogenesis<br />
1041 HIV/HCV Co-infection Results in Increased T Cell Activation<br />
and Impaired IL-7-mediated T Lymphocyte Homeostasis:<br />
Possible Exploitation as Predictors of Anti-HCV Therapy<br />
Response<br />
G Marchetti1 , Marco Bongiovanni* 1 , V Pegorer1 , L Gazzola1 ,<br />
G Bellistri1 , T Bini1 , A Gori2 , and A d’Arminio Monforte1 1 2 San Paolo Hosp, Univ of Milan, Italy and San Gerardo Hosp, Monza,<br />
Italy<br />
1042 Immune Activation Is Not Associated with Annual Rate of<br />
CD4 Decline in HIV/HCV-co-infected Women<br />
Roksana Karim* 1 , W Mack1 , G Neuman1 , L Spencer1 , L Al-Harthi2 , and<br />
A Kovacs1 1 2 Univ of Southern California, Los Angeles, US and Rush Univ Med Ctr,<br />
Chicago, IL, US<br />
1043 Influence of HIV, HCV, and HIV/HCV-co-infection on Level,<br />
Phenotype, and Activation Status of FoxP3 + CD4 + Regulatory<br />
T Cells<br />
Norma Rallon*, M Lopez, V Soriano, J Garcia-Samaniego,<br />
M Romero, P Labarga, P Garcia-Gasco, J Gonzalez-Lahoz, and J Benito<br />
Hosp Carlos III, Madrid, Spain<br />
1044 Enhanced Activation of Liver-infiltrating CD8 + T Cells in<br />
HCV-infected Patients with HIV Co-infection<br />
Henry Radziewicz*, C Ibegbu, H Scarborough, M Fernandez, M Osborn,<br />
H Hon, K Workowski, K Obideen, M Wehbi, and A Grakoui<br />
Emory Univ, Atlanta, GA, US<br />
1045 HCV-specific CD4 + T Cell Responses Can Be Primed<br />
in Acute Concomitant HIV/HCV Co-infection and Are<br />
Preserved by Early ART<br />
Julian Schulze zur Wiesch* 1,2 , D Pieper1 , J Mohn1 , T Eiermann2 ,<br />
A Lohse2,3 , J Hauber1 , I Stahmer1 , and J van Lunzen4 1Heinrich Pette Inst for Experimental Virology and Immunology, Hamburg,<br />
Germany; 2Univ of Hamburg, Germany; 3Universitaetsklinikum Hamburg<br />
Eppendorf, Germany; and 4Univ of Hamburg Med Ctr, Germany<br />
1046 HCV Co-infection Is Associated with Increased CD4 + T Cell<br />
Apoptosis in HIV-infected Patients – Disappearance of this<br />
Effect upon Successful HAART<br />
Christian Koerner* 1 , D Schulte1 , B Kramer1 , S Mauss2 , G Schmutz2 ,<br />
P Hegener2 , G Faetkenheuer3 , J Nattermann1 , U Spengler1 , J Rockstroh1 ,<br />
and Kompetenznetz HIV/AIDS<br />
1 2 Univ of Bonn, Germany; Ctr for HIV and Hepatogastroenterology,<br />
Düsseldorf, Germany; and 3Univ of Cologne, Germany<br />
1047 Comparisons between Heroin Injection Drug Use and<br />
Methadone on Antigen-specific Cellular Immune Responses<br />
in HIV/HCV and HCV Infection<br />
Camilla Graham* 1 , M Kress1 , E Edwards2 , T Heeren2 , D Nunes3 ,<br />
P Skolnik3 , S Tumilty3 , R Horsburgh2 , D Cotton2,3 , M Koziel1 , and<br />
members of CHARM<br />
1 2 Beth Israel Deaconess Med Ctr, Boston, MA, US; Boston Univ Sch of<br />
Publ Hlth, MA, US; and 3Boston Med Ctr, MA, US<br />
1048 HIV gp120 Sensitizes Human Hepatocytes to TRAILmediated<br />
Apoptosis via JNKII<br />
Stacey Rizza*, B Shepard, G Bren, and A Badley<br />
Mayo Clin, Rochester, MN, US<br />
1049 Detection of HIV in Liver Biopsies and Intrahepatic<br />
Lymphocytes<br />
G Ma, A Barrett, K Sherman, T Shata, and Jason Blackard*<br />
Univ of Cincinnati Coll of Med, OH, US<br />
b Monday, 1-4 pm; Hall B<br />
Session 171–Poster Abstracts<br />
Hepatitis C Co-infection: Fibrosis<br />
1050 An Emerging Syndrome of Rapid Liver Fibrosis in HIVinfected<br />
Men with Acute HCV Infection<br />
Daniel Fierer*, A Uriel, D Carriero, A Klepper, D Dieterich, M Mullen,<br />
S Thung, I Fiel, and A Branch<br />
Mt Sinai Sch of Med, New York, NY, US<br />
1051 Prospective Validation of Simple Biological Markers in<br />
Assessing Liver Fibrosis in HIV/HCV/co-infected Patients<br />
Jordi Tor*, C Tural, R Muga, I Ojanguren, E Barluenga, A Sanvisens,<br />
E Martinez, C Rey-Joly, and B Clotet<br />
Hosp Univ Germans Trias i Pujol and Univ Autonoma de Barcelona,<br />
Spain<br />
1052 Liver Fibrosis in Chronic Hepatitis C Patients with<br />
Persistently Normal Aminotransferases: Effect of HIV<br />
Infection<br />
Luz Martin-Carbonero* 1 , V de Ledinghen2 , A Moreno2 , I Maida3 ,<br />
P Barreiro1 , E Vispo1 , G Satta3 , M Romero1 , J Garcia-Samaniego1 , and<br />
V Soriano1 1 2 Hosp Carlos III, Madrid, Spain; Haut-Leveque Hosp, Bordeaux, France;<br />
and 3Univ of Sassari, Italy<br />
1053 Improving the Differentiation of Mild from Significant Liver<br />
Fibrosis in HIV/HCV-co-infected Patients Using Transient<br />
Elastometry<br />
Jose del Valle* 1 , J Macias1 , P Barreiro2 , A Rivero3 , A Gutierrez4 ,<br />
M Rios-Villegas5 , D Merino6 , M Gonzalez-Serrano7 , E Vispo2 , and<br />
J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain; Hosp Carlos III, Madrid, Spain;<br />
3 4 Hosp Univ Reina Sofia, Cordoba, Spain; Hosp Univ Virgen del Rocio,<br />
Seville, Spain; 5Hosp Univ Virgen de la Macarena, Seville, Spain; 6Hosp Juan Ramon Jimenez, Huelva, Spain; and 7Hosp Univ Virgen de la<br />
Victoria, Malaga, Spain<br />
1054 Severity of Liver Disease Associated with IL-10 DNA<br />
Polymorphisms in Patients Co-infected with HIV and HCV<br />
Marion Peters* 1 , J Andersen2 , K Sherman3 , R Chung4 , C Graham5 ,<br />
M Koziel5 , and ACTG 5071 Team<br />
1 2 Univ of California, San Francisco, US; Harvard Sch of Publ Hlth,<br />
Boston, MA, US; 3Univ of Cincinnati, OH, US; 4Massachusetts Gen Hosp,<br />
Harvard Med Sch, Boston, US; and 5Beth Israel Deaconess Med Ctr,<br />
Harvard Med Sch, Boston, MA, US<br />
<strong>Program</strong> 65<br />
Poster Listings
Poster Litings<br />
Session 171 CROI 2008<br />
1055 Increased Rates of Fibrosis Progression between Sequential<br />
Liver Biopsies in HIV/HCV-co-infected Patients<br />
Juan Macias* 1 , J Berenguer2 , A Arizcorreta3 , A Rivero4 , A Gutierrez5 ,<br />
M Gonzalez-Serrano6 , E Ortega7 , P Miralles2 , J Mira1 , and J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain; Hosp Univ Gregorio Maranon,<br />
Madrid, Spain; 3Hosp Univ Puerta del Mar, Cadiz, Spain; 4Hosp Univ<br />
Reina Sofia, Cordoba, Spain; 5Hosp Univ Virgen del Rocio, Seville,<br />
Spain; 6Hosp Univ Virgen de la Victoria, Malaga, Spain; and 7Hosp Gen<br />
Univ de Valencia, Spain<br />
1056 Histological Findings, Predictors of Severe Fibrosis, and<br />
Assessment of Factors with Effect on the Fibrosis Progression<br />
Rate in HIV-infected Patients with Chronic Hepatitis C in the<br />
Era of HAART<br />
Ana Moreno*, S Diz, A Moreno, L Moreno, A Muriel, J Zamora,<br />
C Quereda, M Perez-Elias, R Barcena, and S Moreno<br />
Hosp Ramon y Cajal, Madrid, Spain<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 172–Poster Abstracts<br />
Hepatitis C Co-infection: Markers, Outcome and<br />
Effect of ART<br />
1057 Factors Associated with Survival and First Hepatic<br />
Decompensation in a Large Prospective Cohort of HIV/HCVco-infected<br />
Patients with Liver Cirrhosis<br />
M Lopez-Dieguez1 , M Montes2 , C Quereda3 , M Von Wichmann4 ,<br />
J Berenguer5 , J Pascual2 , C Tural6 , F Pulido7 , H Esteban8 , Jose Arribas* 2 ,<br />
and GESIDA 37/03-FIPSE 36465/03 Study Group<br />
1 2 3 Hosp Clin, Barcelona, Spain; Hosp La Paz, Madrid, Spain; Hosp<br />
Ramon y Cajal, Madrid, Spain; 4Hosp Donostia, San Sebastian, Spain;<br />
5 6 Hosp Gregorio Maranon, Madrid, Spain; Hosp Germans Trials i<br />
Pujol, Badalona, Spain; 7Hosp 12 de Octubre, Madrid, Spain; and 8ACE, GESIDA, Madrid, Spain<br />
1058 Effect of Hepatitis C Viremia on HIV-infected Individuals in<br />
Nigeria<br />
Nimzing Ladep Gwamzhi* 1 , C Hawkins2 , S Meloni3 , M Muazu1 ,<br />
B Badung1 , R Chung4 , P Kanki3 , E Ekong5 , J Idoko1 , and C Graham6 1 2 Jos Univ Teaching Hosp, Plateau, Nigeria; Feinberg Sch of Med,<br />
Northwestern Univ, Chicago, IL, US; 3Harvard Sch of Publ Hlth, Boston,<br />
MA, US; 4Massachusetts Gen Hosp, Boston, US; 5Military Reference<br />
Hosp, Lagos, Nigeria; and 6Beth Israel Deaconess Med Ctr, Boston, MA,<br />
US<br />
1059 Natural History of Compensated Hepatitis C Virus-related<br />
Cirrhosis in HIV-infected Patients<br />
Jose Garcia-Garcia* 1 , M Aguilar-Guisado2 , A Rivero3 ,<br />
J Giron-Gonzalez4 , M Gonzalez-Serrano5 , D Merino6 , M Rios-Villegas7 ,<br />
J Macias1 , J Gomez-Mateos1 , and J Pineda1 for the Grupo para el Estudio<br />
de las Hepatitis Víricas de la SAEI<br />
1 2 Hosp Univ de Valme, Seville, Spain; Hosp Univ Virgen del Rocio,<br />
Seville, Spain; 3Hosp Univ Reina Sofia, Cordoba, Spain; 4Hosp Puerta<br />
del Mar, Cadiz, Spain; 5Hosp Univ Virgen de la Victoria, Malaga, Spain;<br />
6 7 Hosp Juan Ramon Jimenez, Huelva, Spain; and Hosp Univ Virgen de la<br />
Macarena, Seville, Spain<br />
1060 Use of Serum Markers to Assess Progression of Liver<br />
Disease in HIV/HCV-co-infected Women<br />
K Bambha1 , A French2 , C Pierce3 , E Seaberg3 , H Strickler4 , A Howard4 ,<br />
G Sharp5 , P Tien1 , Marion Peters* 1 , and WIHS<br />
1 2 Univ of California, San Francisco, US; Stroger Hosp of Cook County,<br />
Chicago, IL, US; 3Johns Hopkins Univ, Baltimore, MD, US; 4Albert Einstein Coll of Med, Bronx, NY, US; and 5NIAID, NIH, Bethesda, MD, US<br />
1061 Association of HIV Infection and HIV/HCV Co-infection<br />
with C-reactive Protein Levels: The FRAM Study<br />
J Reingold1,2 , C Wanke3 , D Kotler4 , C Lewis5 , S Heymsfield6 , P Tien1,2 ,<br />
P Bacchetti1 , R Scherzer2 , Carl Grunfeld* 1,2 , M Shlipak1,2 , and FRAM Study<br />
1 2 Univ of California, San Francisco, US; VAMC, San Francisco, CA,<br />
US; 3Tufts Univ, Boston, MA, US; 4St Luke’s Roosevelt Hosp, New York,<br />
NY, US; 5Univ of Alabama at Birmingham, US; and 6Merck Res Labs,<br />
Rahway, NJ, US<br />
1062 Prognostic Factors of Mortality in HCV/HIV-co-infected<br />
Liver Transplant Recipients: The FIPSE OLT-HIV-05 -<br />
GESIDA 45-05 Cohort Study<br />
Jose Miro* 1 , M Montejo2 , L Castells3 , A Rafecas4 , P Miralles5 ,<br />
J Fortun6 , M Blanes7 , M De La Mata8 , F Torres1 , A Rimola1 , and Spanish<br />
OLT in HIV-infected Patients Working Group<br />
1 2 Hosp Clin-IDIBAPS, Univ of Barcelona, Spain; Hosp Cruces, Bilbao,<br />
Spain; 3Hosp Univ Vall d’Hebron, Barcelona, Spain; 4Hosp Univ de<br />
Bellvitge, Barcelona, Spain; 5Hosp Gregorio Maranon, Madrid, Spain;<br />
6 7 Hosp Ramon y Cajal, Madrid, Spain; Hosp La Fe, Valencia, Spain; and<br />
8Hosp Univ Reina Sofia, Cordoba, Spain<br />
1063 High HIV DNA Intrahepatic Content Is Associated With a<br />
More Severe Liver Disease in HIV/HCV-co-infected Patients<br />
with High HIV Viremia than Aviremic HIV/HCV-co-infected<br />
Patients<br />
G Sitia1 , A De Bona1 , F Canducci2 , Caterina Uberti-Foppa* 1 ,<br />
M Marinozzi2 , L Galli1 , M Clementi2 , L Guidotti1 , and A Lazzarin1,2 1 2 San Raffaele Sci Inst, Milan, Italy and Univ Vita-Salute San Raffaele,<br />
Milan, Italy<br />
66 15th Conference on Retroviruses and Opportunistic Infections<br />
1064 Hepatic Venous Pressure Gradient Is Lower in HIV/HCV-coinfected<br />
than in HCV-mono-infected Cirrhotic Patients<br />
O Lo Lacono, Juan Berenguer*, D Rincon, P Miralles, A Hernando,<br />
M Sanchez-Conde, J Gomez, J Lopez, E Alvarez, and R Banares<br />
Hosp Gregorio Maranon, Madrid, Spain<br />
1065 Factors Associated with Lack of Serological Responses<br />
to HIV and HCV in Co-infected Patients with Profound<br />
Immunosuppression<br />
C Toro, A Simon, A Amor, V Jimenez, P Rios, and Vincent Soriano*<br />
Hosp Carlos III, Madrid, Spain<br />
1066 HCV Spreads among HIV + Men Who Have Sex with Men:<br />
Evidence of Separate Sexual Transmission Networks in<br />
Europe and Australia<br />
Thijs van de Laar* 1 , M Danta2,3 , S Bhagani2 , ML Chaix4 , G Dore3 ,<br />
M Nelson5 , M Prins1,6 , M Vogel7 , P White3 , R Coutinho1,6,8 , and HIV and<br />
Acute HCV Group<br />
1 2 Hlth Svc, Amsterdam, The Netherlands; Royal Free and Univ Coll<br />
London, UK; 3Univ of New South Wales, Sydney, Australia; 4Hosp Necker,<br />
Paris, France; 5Chelsea and Westminster Hosp, London, UK; 6Academic Med Ctr, Amsterdam, The Netherlands; 7Univ of Bonn, Germany; and<br />
8Natl Inst of Publ Hlth and the Environment, The Netherlands<br />
1067 CD4 T Lymphocyte Recovery with ART Is Not Directly<br />
Influenced by HCV-co-Infection Status<br />
Curtis Cooper* 1 , B Hutton1 , E Mills2 , and J Angel1 1 2 Univ of Ottawa and Ottawa Hlth Res Inst, Canada and BC Ctr for<br />
Excellence in HIV/AIDS, Vancouver, Canada<br />
1068 The Effect of Vicriviroc upon HCV Viral Load in HIV/<br />
HCV-co-infected Patients Receiving a Ritonavir-containing<br />
Protease Inhibitor Regimen<br />
Gerd Faetkenheuer* 1 , C Hoffmann2 , J Slim3 , R Rouzier4 ,<br />
A Sansone-Parsons5 , M Treitel5 , C Kasserra5 , A Keung5 , E O’Mara5 , and<br />
D Schurmann6 1 2 3 Univ of Cologne, Germany; Univ Kiel, Germany; St Michael’s Med Ctr,<br />
Newark, NJ, US; 4CentreCap, Montpellier, France; 5Schering-Plough Res<br />
Inst, Kenilworth, NJ, US; and 6Med Univ of Berlin, Germany<br />
1069 HCV Co-infection Does Not Influence the CD4 Cell Recovery<br />
in HIV-1-infected Patients with Maximum Virologic<br />
Suppression: EuroSIDA Cohort<br />
Lars Peters* 1 , A Mocroft2 , V Soriano3 , J Rockstroh4 , P Aldins5 ,<br />
M Losso6 , L Valerio7 , P Reiss8 , B Ledergerber9 , J Lundgren1 , and the<br />
EuroSIDA Study Group<br />
1 2 Copenhagen HIV Prgm, Univ of Copenhagen, Denmark; Royal Free and<br />
Univ Coll London Med Sch, UK; 3Hosp Carlos III, Madrid, Spain; 4Univ of Bonn, Germany; 5Infectology Ctr of Latvia, Riga; 6Hosp JM Ramos<br />
Mejia, Buenos Aires, Argentina; 7Ctr Hosp Univ Nice, Hosp de l’Archet,<br />
France; 8Academic Med Ctr, Amsterdam, The Netherlands; and 9Univ Hosp Zurich, Switzerland<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 173–Poster Abstracts<br />
Hepatitis C Co-infection: Treatment<br />
1070 Frequency of RVR and Its Utility as a Predictor of Treatment<br />
Outcome In HIV + and HIV- Individuals with Acute<br />
Hepatitis C<br />
Gail Matthews* 1 , M Hellard2 , P Haber3 , B Yeung1 , D Baker4 , A Lloyd5 ,<br />
W Rawlinson6 , J Sasadeusz7 , J Kaldor1 , and G Dore1 on behalf of the<br />
ATAHC Study Group<br />
1Natl Ctr for HIV Epidemiology and Clin Res, Univ of New South Wales,<br />
Australia; 2Macfarlane Inst for Med Res and Publ Hlth, Melbourne,<br />
Australia; 3Drug Hlth Svc, Royal Prince Alfred Hosp, Sydney, Australia;<br />
4 5 407 Doctors, Sydney, Australia; Univ of New South Wales, Sch of Med<br />
Sci, Sydney, Australia; 6SEALS Microbio, Prince of Wales Hosp, Sydney,<br />
Australia; and 7Royal Melbourne Hosp, Australia<br />
1071 The TGF-ß High-producer Genotype Is Associated with<br />
Response to HCV-specific Therapy in HIV + Patients with<br />
Acute Hepatitis C<br />
Jacob Nattermann*, M Vogel, H Nischalke, G Ahlenstiel, M Michalk,<br />
T Sauerbruch, J Rockstroh, U Spengler, and Kompetenznetz HIV/AIDS<br />
Univ of Bonn, Germany<br />
1072 High Rate of Sustained Virological Response to an Early<br />
Course of Anti-HCV Treatment for Acute HCV Hepatitis in<br />
HIV + Patients<br />
Stephanie Dominguez* 1 , S Bhagani2 , M Vogel3 , M Nelson4 , J Rockstroh3 ,<br />
E Low4 , A Azwa4 , MA Valantin1 , C Katlama1 , and M Guiguet5 1 2 Hosp Pitie-Salpetriere, Paris, France; Royal Free Infectious Disease<br />
Unit, London, UK; 3Univ of Bonn, Germany; 4Chelsea and Westminster<br />
Hosp, London, UK; and 5INSERM U720, Paris VI Univ, Paris, France
CROI 2008 Session 174<br />
1073 On-treatment Responses at Weeks 4 and 12 Can Be Used to<br />
Predict Sustained Virological Response Rates in HCV/HIVco-infected<br />
Patients Treated with Peg-Interferonα-2a and<br />
Ribavirin<br />
M Rodriguez-Torres1 , Jurgen Rockstroh* 2 , J Depamphilis3 , G Carosi4 ,<br />
D Dieterich5 , and F Torriani6 1 2 Fndn de Investigacion de Diego, Santurce, Puerto Rico; Univ of Bonn,<br />
Germany; 3Roche, Nutley, NJ, US; 4Univ Degli Studi di Brescia, Italy;<br />
5 6 Mt Sinai Sch of Med, New York, NY, US; and Univ of California, San<br />
Diego, US<br />
1074 Efficacy of Pegylated Interferon + Ribavirin Treatment<br />
in HIV/HCV-co-infected Patients Receiving Abacavir<br />
+ Lamivudine or Tenofovir + either Lamivudine or<br />
Emtricitabine as Nucleoside Analogue Backbone<br />
Jose Mira* 1 , L Lopez-Cortes2 , P Barreiro3 , C Tural4 , M Torres-Tortosa5 ,<br />
I de los Santos Gil6 , P Martin-Rico7 , M Rios-Villegas8 , J Macias1 , and<br />
J Pineda1 1 2 Hosp Univ de Valme, Seville, Spain; Hosp Univ Virgen del Rocio,<br />
Seville, Spain; 3Hosp Carlos III, Madrid, Spain; 4Hosp Univ Germans<br />
Trias i Pujol, Badalona, Spain; 5Hosp Punta Europa, Algeciras, Spain;<br />
6 7 Hosp Univ de la Princesa, Madrid, Spain; Hosp Univ Carlos Haya,<br />
Malaga, Spain; and 8Hosp Univ Virgen Macarena, Seville, Spain<br />
1075 Does the Choice of NRTI Have a Significant Influence on the<br />
Outcome of peg-IFN plus Ribavirin among HIV/HCV-coinfected<br />
Patients?<br />
Ana Moreno*, C Quereda, A Muriel, M Perez-Elias, J Casado,<br />
F Dronda, M Mateos, A Moreno, R Barcena, and S Moreno<br />
Hosp Ramon y Cajal, Madrid, Spain<br />
1076 The Use of Tenofovir + Lamivudine/Emtricitabine Is<br />
Associated with an Improved Response to Pegylated<br />
Interferon + Ribavirin in HIV/HCV-co-infected Patients<br />
Receiving HAART: The Gesida 50/06 Study<br />
Juan Gonzalez-Garcia* 1,2 , J Berenguer3 , E Condes4 , C Quereda5 ,<br />
P Labarga6 , M Laguno7 , M von Wichman8 , P Robres9 , I Santos10 ,<br />
B Moyano2 , and the GESIDA 50/06 Study Group<br />
1 2 Hosp La Paz, Madrid, Spain; Agencia de Ensayos Clinicos de Gesida,<br />
Spain; 3Hosp Gregorio Maranon, Madrid, Spain; 4Hosp de Mostoles,<br />
Madrid, Spain; 5Hosp Ramon y Cajal, Madrid, Spain; 6Hosp Carlos<br />
III, Madrid, Spain; 7Hosp Clinic i Provincial, Barcelona, Spain; 8Hosp Donostia, San Sebastian, Spain; 9Hosp de Bellvitge, Barcelona, Spain;<br />
and 10Hosp de la Princesa, Madrid, Spain<br />
1077 Race but Not HIV Status Affects Hepatitis C Early Viral<br />
Kinetics<br />
Mamta Jain* 1 , J Shelton1 , N Liston1 , B Adams-Huet1 , N Attar1 , HJ Yuan1 ,<br />
M Gale2 , and W Lee1 1 2 Univ of Texas Southwestern Med Ctr, Dallas, US and Univ of<br />
Washington, Seattle, US<br />
1078 Treatment Rates and Eligibility in HCV Mono-infected vs<br />
HCV/HIV Co-infected Persons<br />
A Butt1,2 , J Tsevat3 , O Shaikh1 , D McMahon1 , Uzma Khan* 4 ,<br />
Z Dorey-Stein5 , and V Lo Re5 1 2 Univ of Pittsburgh Med Ctr, PA, US; Ctr for Hlth Equity Res and<br />
Promotion, Pittsburgh, PA, US; 3Inst for the Study of Hlth, Univ of<br />
Cincinnati Med Ctr and Cincinnati VAMC, OH, US; 4Albany Med Ctr,<br />
NY, US; and 5Univ of Pennsylvania Med Ctr, Philadelphia, US<br />
1079 Utility and Predictors of Rapid Viral Response in HCV and<br />
HCV/HIV-co-infected Hemophiliacs<br />
Philippe Zamor* 1 , N Shire1 , S Rouster1 , E Eyster2 , K Sherman1 , and<br />
Multicenter Hemophilia Cohort HCV Study Group<br />
1 2 Univ of Cincinnati, OH, US and Penn State Med Ctr, Hershey, US<br />
1080 Analyzing Substrate Recognition in Terms of Drug<br />
Resistance in HCV NS3 Protease<br />
Keith Romano* and C Schiffer<br />
Univ of Massachusetts Med Sch, Worcester, US<br />
1081a A Novel HCV NS3/4A Protease Assay Using a Bacteriophage<br />
Lambda-based Genetic Screen<br />
Sandra Franco*, B Clotet, and M Martinez<br />
Fndn irsiCaixa, Spain<br />
1081b A Randomized Trial to Compare the Efficacy and Safety of<br />
PEG-interferon alfa-2b plus Ribavirin versus PEG-interferon<br />
alfa-2a plus Rivabirin for Treatment of Chronic Hepatitis C in<br />
HIV Co-infected Patients<br />
M Laguno1 , C Cifuentes2 , J Murillas3 , F Vidal4 , L Bonet3 , S Veloso4 ,<br />
C Tural5 , I Perez1 , J Gatell1 , and Josep Mallolas* 1<br />
1 2 Hosp Clin Barcelona, Spain; Hosp Son Llatzer, Palma de Mallorca,<br />
Spain; 3Hosp Son Dureta, Palma de Mallorca, Spain; 4Hosp Joan XXIII,<br />
Tarragona, Spain; and 5Hosp Univ Germans Trias i Pujol, Badalona, Spain<br />
b Tuesday, 1-4 pm; Hall B<br />
Session 174–Poster Abstracts<br />
Hepatitis Co-infection: Cardiovascular and<br />
Malignancy Association<br />
1082 Hepatitis Virus Co-infections and Risk of Diabetes Mellitus<br />
and Myocardial Infarction in HIV-infected Persons: The<br />
D:A:D Study<br />
Rainer Weber* 1 , C Sabin2 , P Reiss3 , S De Wit4 , S Worm5 , M Law6 ,<br />
F Dabis7 , A d’Arminio Monforte8 , E Fontas9 , J Lundgren5 , and the D:A:D<br />
Study Group<br />
1 2 Univ Hosp Zurich, Switzerland; Royal Free and Univ Coll London,<br />
UK; 3ATHENA, Academic Med Ctr, Amsterdam, The Netherlands; 4Ctr Hosp Univ St Pierre, Brussels, Belgium; 5Copenhagen HIV Prgm, Univ<br />
of Copenhagen, Denmark; 6Australian HIV Observational Database, Natl<br />
Ctr in HIV Epidemiology and Clin Res, Sydney; 7Univ Victor Segalen,<br />
Bordeaux, France; 8ICONA, Hosp San Paolo, Univ of Milan, Italy; and<br />
9Ctr Hosp Univ Nice, Hosp de l’Archet, France<br />
1083 HCV Is an Independent Risk Factor for Acute Myocardial<br />
Infarction among HIV-infected Veterans<br />
Roger Bedimo* 1,2 , A Westfall3 , M Mugavero3 , N Khanna2 , and M Saag3 1 2 VA North Texas Hlth Care System, US; Univ of Texas Southwestern Med<br />
Ctr, Dallas, US; and 3Univ of Alabama at Birmingham, US<br />
1084 HIV + Subjects Co-infected with HBV or HCV Have a Higher<br />
Risk of Developing AIDS-defining Malignancies<br />
Marco Bongiovanni* 1 , A Cozzi-Lepri2 , A Castagna3 , A Antinori4 ,<br />
A De Luca5 , C Mussini6 , S Lo Caputo7 , C Arici8 , M Puoti9 , A d’Arminio<br />
Monforte1 , and ICONA Fndn Study Group<br />
1 2 San Paolo Hosp, Univ of Milan, Italy; Royal Free and Univ Coll<br />
Med Sch, London, UK; 3Vita e Salute Univ, Milan, Italy; 4Natl Inst for<br />
Infectious Diseases “Lazzaro Spallanzani”, Rome, Italy; 5Catholic Univ,<br />
Rome, Italy; 6Univ of Modena, Italy; 7Santissima Annunziata Hosp, Bagno<br />
a Ripoli, Florence, Italy; 8Hosp Riuniti, Bergamo, Italy; and 9Univ of<br />
Brescia, Italy<br />
<strong>Program</strong> 67<br />
Poster Listings
CR I 2008<br />
DAY TIME TYPE AUDITORIUM BALLROOM B/C BALLROOM A 302-304 312 311<br />
SUNDAY 2/3/08<br />
MONDAY 2/4/08<br />
TUESDAY 2/5/08<br />
WEDNESDAY 2/6/08<br />
9 am -1:40 pm Workshop 1. <strong>Program</strong> <strong>Committee</strong><br />
Workshop for New<br />
Investigators and Trainees<br />
10 am-1 pm Workshop 2. Host Genomics Hands-on Computer Workshop (Rm 100-Computer Lab)<br />
2-4 pm Opening<br />
Symposium<br />
4-6 pm Opening<br />
Plenaries<br />
3. Scale-up of HIV Prevention<br />
and Treatment in the<br />
Developing World<br />
4. 13th Bernard Fields Lecture<br />
and<br />
2nd N’Galy-Mann Lecture<br />
6-8 pm Welcome Reception (Halls C and D)<br />
8:30-9 am Plenary 5. Morbidity and Mortality<br />
in the HAART Era<br />
9-9:30 am Plenary 6. Searching the Genome for<br />
Determinants of Response<br />
to HIV<br />
10 am-12 n Oral Abstract<br />
Sessions<br />
1-4 pm Poster Sessions<br />
2-3 pm Poster<br />
Discussions<br />
4-6 pm Symposia +<br />
Oral Abstract<br />
Sessions<br />
10. New Antiretrovirals and<br />
Clinical Trials<br />
Oral Abstract Session<br />
17. Hepatitis Co-infection<br />
8:30-9 am Plenary 18. Challenges in Pediatric and<br />
Adolescent HIV Care<br />
9-9:30 am Plenary 19. Natural Enhancers and<br />
Inhibitors of HIV Infection<br />
10-11:30 am Oral Abstract<br />
Sessions<br />
23. HIV Vaccines 22. New Mechanisms of<br />
Resistance and<br />
Virologic Failure<br />
11:30 am-12 n Plenary 24. <strong>Scientific</strong> Obstacles to an<br />
Effective HIV Vaccine<br />
12 n-12:30 pm Plenary 25. AIDS Vaccine<br />
at the Crossroads<br />
1-4 pm Poster Sessions<br />
2-3 pm Poster<br />
Discussions<br />
4-6 pm Symposia +<br />
Oral Abstract<br />
Session<br />
33. Targeting TB:<br />
New Opportunities<br />
and Challenges<br />
8:30-9 am Plenary 34. Advances in Management<br />
of Treatment-experienced<br />
Patients: A 2 nd Wave<br />
of HAART<br />
9-9:30 am Plenary 35. New Insights into<br />
Retrovirus-Hostcell<br />
Interactions<br />
10 am-12 n Oral Abstract<br />
Sessions<br />
1-4 pm Poster Sessions<br />
2-3 pm Poster<br />
Discussions<br />
39. Cardiovascular Risk,<br />
Mortality and TB<br />
Complicating HIV Infections<br />
4-6 pm Symposia 45. Individualizing Patient<br />
Management<br />
9. Prevention Strategies 8. Viral Pathogenesis and<br />
Immune Surveillance<br />
16. Curbing the US Epidemic 15. Voyages through the Cell:<br />
Imaging Viral Traffic<br />
7. Epidemiology of SIV/HIV<br />
Infection and AIDS-related<br />
Malignancies<br />
13. Emerging Patterns of<br />
Resistance to New<br />
Antiretrovirals<br />
Oral Abstract Session<br />
14. PMTCT<br />
21. HIV in Women and Children 20. Insights into<br />
Neuropathogenesis<br />
29. TB-associated<br />
Immune Reconstitution<br />
Inflammatory Syndrome<br />
32. Aging and AIDS Oral Abstract Session<br />
31. HIV Molecular Biology and<br />
Host Cell Interactions<br />
38. Drug Delivery, Interactions<br />
and Genetic Variability<br />
44. Frontiers in<br />
Vaccine Research<br />
<strong>Program</strong> at-a-Glance<br />
28. Novel PrEP Agents and<br />
Evaluation Strategies<br />
30. The Emerging Science of<br />
HIV Prevention in Women<br />
37. Epidemiology of HIV 36. New Insights into<br />
Infection and Scale-up of Mechanisms of<br />
ART in Developing Countries Viral Pathogenicity<br />
43. Accessory Proteins and<br />
Intrinsic Resistance<br />
42. Maternal ART and<br />
Feeding Practices: Impact<br />
on Infant Outcomes<br />
12. New Approaches to<br />
HIV Testing<br />
27. Risk Factors for<br />
Lost-to-Follow-up in<br />
Resource-limited Settings<br />
41. Molecular Epidemiology:<br />
The Americas<br />
11. Lymphocyte Depletion<br />
in the Gut<br />
26. Clinical Developments<br />
in Neuropathogenesis<br />
40. New Insights into<br />
APOBEC Proteins<br />
POSTER<br />
HALLS<br />
Poster<br />
Set-up<br />
8 am-8 pm<br />
Posters<br />
Open<br />
7 am-7 pm<br />
Posters<br />
Open<br />
7 am-7 pm<br />
Posters<br />
Open<br />
7 am-6 pm<br />
Poster<br />
Removal<br />
6 -9 pm<br />
ISBN 0-9793191-3-7